U.S. patent application number 14/387514 was filed with the patent office on 2015-03-19 for live, attenuated rubella vector to express vaccine antigens.
This patent application is currently assigned to The United States of America, as Represented by the Secretary, Dep. of Health and Human Services. The applicant listed for this patent is The United States of America, as Represented by the Secretary, Dep. of Health and Human Services. Invention is credited to Ira Berkower, Konstantin Virnik.
Application Number | 20150079123 14/387514 |
Document ID | / |
Family ID | 48183001 |
Filed Date | 2015-03-19 |
United States Patent
Application |
20150079123 |
Kind Code |
A1 |
Berkower; Ira ; et
al. |
March 19, 2015 |
LIVE, ATTENUATED RUBELLA VECTOR TO EXPRESS VACCINE ANTIGENS
Abstract
Disclosed herein are isolated rubella viral vector constructs
that include a rubella non-structural protein open reading frame
(ORF) without an in-frame deletion, a rubella structural protein
ORF, and a heterologous antigenic insert. In one example, the
heterologous antigenic insert is positioned within the rubella
structural protein ORF. In some examples, the heterologous
antigenic insert is positioned in the rubella structural protein
ORF in between a gene encoding structural protein E2 and a gene
encoding structural protein E1. Exemplary antigenic inserts include
HIV, SIV, RSV or hepatitis B surface antigens. In some examples,
the HIV antigenic insert is a Gag antigenic insert, a gp41
antigenic insert or a gp120 antigenic insert. Also disclosed are
uses of the isolated rubella viral vector, such as to induce an
immune response to a particular virus, such as HIV-1, testing
sensitivity to neutralizing antibodies, or screening antiviral
drugs (such as protease inhibitors).
Inventors: |
Berkower; Ira; (Washington,
DC) ; Virnik; Konstantin; (Fairfax, VA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The United States of America, as Represented by the Secretary, Dep.
of Health and Human Services |
Bethesda |
MD |
US |
|
|
Assignee: |
The United States of America, as
Represented by the Secretary, Dep. of Health and Human
Services
Bethesda
MD
|
Family ID: |
48183001 |
Appl. No.: |
14/387514 |
Filed: |
April 8, 2013 |
PCT Filed: |
April 8, 2013 |
PCT NO: |
PCT/US2013/035634 |
371 Date: |
September 23, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61621394 |
Apr 6, 2012 |
|
|
|
61642333 |
May 3, 2012 |
|
|
|
Current U.S.
Class: |
424/188.1 ;
435/235.1; 435/252.33; 435/320.1; 435/325; 435/352 |
Current CPC
Class: |
C12N 2770/36243
20130101; C12N 2770/36234 20130101; A61K 2039/54 20130101; C12N
2770/36271 20130101; C12N 2740/16034 20130101; A61K 2039/53
20130101; C12N 2740/15034 20130101; C12N 2740/16134 20130101; A61K
39/21 20130101; C12N 15/86 20130101; A61K 39/12 20130101; A61K
2039/545 20130101; C12N 2770/36221 20130101 |
Class at
Publication: |
424/188.1 ;
435/320.1; 435/252.33; 435/325; 435/352; 435/235.1 |
International
Class: |
A61K 39/21 20060101
A61K039/21; C12N 15/86 20060101 C12N015/86 |
Claims
1. An isolated rubella viral vector, comprising a rubella
non-structural protein open reading frame (ORF) without an in-frame
deletion, a rubella structural protein ORF, and a heterologous
antigenic insert.
2. The isolated rubella viral vector of claim 1, wherein the
heterologous antigenic insert is positioned within the rubella
structural protein ORF.
3. The isolated rubella viral vector of claim 1, wherein the
heterologous antigenic insert is positioned in the rubella
structural protein ORF in between a gene encoding structural
protein E2 and a gene encoding structural protein E1.
4. The isolated rubella viral vector of claim 1, wherein the
antigenic insert comprises an amino acid sequence set forth as SEQ
ID NO: 126, 127, 131-156 or 158-162.
5. The isolated rubella viral vector of claim 1, wherein the
antigenic insert consists of an amino acid sequence set forth as
SEQ ID NO: 126, 127, 131-156 or 158-162.
6. The isolated rubella viral vector of claim 1, wherein the
antigenic insert comprises an HIV antigenic insert.
7. The isolated rubella viral vector of claim 1, wherein the
antigenic insert comprises a Gag antigenic insert, a gp41 antigenic
insert, or a gp120 antigenic insert.
8. The isolated rubella viral vector of claim 7, wherein the Gag
antigenic insert comprises at least one cytotoxic T-lymphocyte
(CTL) Gag epitope with an amino acid sequence set forth by any one
of SEQ ID NOs: 82-88, 90-103, 132-135 and 138-142.
9. The isolated rubella viral vector of claim 7, wherein the
antigenic insert comprises a Gag antigenic insert, comprising the
amino acid sequence TABLE-US-00023 ((SEQ ID NO: 141)
LDRFGLAESLLENKEGCQKILSVLAPLVPTGSENLKSLYNTVCVIWCIH
AEEKVKHTEEAKQIVQRHLVVETGTTETMPKTSRPTAPSSGRGGNYPVQ
QIGGNYVHLPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDIN
QMLNCVGDHQAAMQIIRDIINEEAADWDLQHPQPAPQQGQLREPSGSDI
AGTTSSVDEQIQWMYRQQNPIPVGNIYRRWIQLGLQKCVRMYNPTNILD
VKQGPKEPFQSYVDRFYKSLRAEQTDAAVKNWMTQTLLIQNANPDCKLV
LKGLGVNPTLEEMLTACQGVGGPGQKARLMHTLAAFVLLVPWVLIFMVC
RRTCRRRGAAAALTAVVLQGYNPPAYG; (SEQ ID NO: 142)
LDRFGLAESLLENKEGCQKILSVLAPLVPTGSENLKSLYNTVCVIWCIH
AEEKVKHTEEAKQIVQRHLVVETGTTETMPKTSRPTAPSSGRGGNYPVQ
QIGGNYVHLPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDIN
QMLNCVGDHQAAMQIIRDIINEEAADWDLQHPQPAPQQGQLREPSGSDI
AGTTSSVDEQIQWMYRQQNPIPVGNIYRRWIQLGLQKCVRMYNPTNILD
VKQGPKEPFQSYVDRFYKSLRAEQTDAAVKNWMTQTLLIQNANPDCKLV
LKGLGVNPTLEEMLTACQGVGGPGQKARLMAEALKEALAPVPIPFAAAQ
QRGPRKPIMHTLAAFVLLVPWVLIFMVCRRTCRRRGAAAALTAVVLQGY NPPAYG; (SEQ ID
NO: 83) FQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA; or (SEQ ID NO: 82)
REGSQKILSVLAPLVPTGSENLKSLYNTVSVIWSIHAED.
10. The isolated rubella viral vector of claim 9, wherein the Gag
antigenic insert comprises the amino acids
FQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA (SEQ ID NO: 83).
11. The isolated rubella viral vector of claim 10, wherein the
antigenic insert further comprises the amino acids
LPLSPRTLNAWVKLIEEKKFGAEVVPG (residues 1 to 27 of SEQ ID NO:
84).
12. The isolated rubella viral vector of claim 11, wherein the
antigenic insert further comprises the amino acids SQKILSVLAPL
(residues 4-14 of SEQ ID NO: 82).
13. The isolated rubella viral vector of claim 7, wherein the
antigenic insert comprises a Gag antigenic insert, comprising the
amino acids GSENLKSLYNT (residues 4-13 of SEQ ID NO: 88).
14. The isolated rubella viral vector of claim 7, wherein the
antigenic insert comprises the amino acid sequence set forth as one
of SEQ ID NOs: 143-155; SEQ ID NO. 156; SEQ ID NOs: 158-162; or SEQ
ID NOs: 84-91.
15. The isolated rubella viral vector of claim 7, wherein the
antigenic insert consists of the amino acid sequence set forth as
one of SEQ ID NOs: 143-155; SEQ ID NO. 156; SEQ ID NOs:158-162; or
SEQ ID NOs: 84-91.
16. The isolated rubella viral vector of claim 1, wherein the
antigenic insert comprises a gp41 antigenic insert, comprising: a)
an antigenic polypeptide fragment of gp41 comprising the amino acid
sequence of SEQ ID NO: 1 (NEX.sub.1X.sub.2LLX.sub.3LDKWASLWN)
wherein the polypeptide fragment of gp41 is between 16 and 150
amino acids in length; and b) a transmembrane membrane region of
gp41 comprising the amino acid sequence set forth as SEQ ID NO: 25
(X.sub.4FIMIVGGLX.sub.5GLRIVFTX.sub.6LSIV), wherein the
transmembrane spanning region of gp41 is between 22 and 40 amino
acids in length and wherein the transmembrane spanning region of
gp41 is C-terminal to the antigenic polypeptide fragment of gp41,
wherein X.sub.1, X.sub.2 and X.sub.3 are any amino acid and
X.sub.4, X.sub.5, and X.sub.6 are any hydrophobic amino acid.
17. The isolated rubella viral vector of claim 1, wherein the
antigenic polypeptide comprises the amino acid sequence set forth
as one of: TABLE-US-00024 SEQ ID NO: 30 a) (PSAQEKNEKELLELDKWAS
LWN); SEQ ID NO: 2 b) (NEQELLALDKWASLWNWFDITNWLWYIK); SEQ ID NO: 3
c) (NEQDLLALDKWASLWNWFDITNWLWYIK); SEQ ID NO: 4 d)
(NEQDLLALDKWANLWNWFDISNWLWYIK); SEQ ID NO: 5 e)
(NEQDLLALDKWANLWNWFNITNWLWYIR); SEQ ID NO: 6 f)
(NEQELLELDKWASLWNWFDITNWLWYIK); SEQ ID NO: 7 g)
(NEKDLLALDSWKNLWNWFDITNWLWYIK); SEQ ID NO: 8 h)
(NEQDLLALDSWENLWNWFDITNWLWYIK); SEQ ID NO: 9 i)
(NEQELLELDKWASLWNWFSITQWLWYIK); SEQ ID NO: 10 j)
(NEQELLALDKWASLWNWFDISNWLWYIK); SEQ ID NO: 11 k)
(NEQDLLALDKWDNLWSWFTITNWLWYIK); SEQ ID NO: 12 l)
(NEQDLLALDKWASLWNWFDITKWLWYIK); SEQ ID NO: 13 m)
(NEQDLLALDKWASLWNWFSITNWLWYIK); SEQ ID NO: 14 n)
(NEKDLLELDKWASLWNWFDITNWLWYIK); SEQ ID NO: 15 o)
(NEQEILALDKWASLWNWFDISKWLWYIK); SEQ ID NO: 16 p)
(NEQDLLALDKWANLWNWFNISNWLWYIK); SEQ ID NO: 17 q)
(NEQDLLALDKWASLWSWFDISNWLWYIK); SEQ ID NO: 18 r)
(NEKDLLALDSWKNLWSWFDITNWLWYIK); SEQ ID NO: 19 s)
(NEQELLQLDKWASLWNWFSITNWLWYIK); SEQ ID NO: 20 t)
(NEQDLLALDKWASLWNWFDISNWLWYIK); SEQ ID NO: 21 u)
(NEQELLALDKWASLWNWFDISNWLWYIR); SEQ ID NO: 22 v)
(NEQELLELDKWASLWNWFNITNWLWYIK); SEQ ID NO: 81 w)
(QEKNEKELLELDKWASLWNWFDITNWLWYIRLFI); or SEQ ID NO: 89 x)
(PSWNWFDITNWLWYIRLDA).
18. The isolated rubella viral vector of claim 1, wherein the
antigenic peptide consists of the amino acid sequence set forth as
one of: TABLE-US-00025 SEQ ID NO: 30 a) (AQEKNEKELLELDKWASLWN); SEQ
ID NO: 2 b) (NEQELLALDKWASLWNWFDITNWLWYIK); SEQ ID NO: 3 c)
(NEQDLLALDKWASLWNWFDITNWLWYIK); SEQ ID NO: 4 d)
(NEQDLLALDKWANLWNWFDISNWLWYIK); SEQ ID NO: 5 e)
(NEQDLLALDKWANLWNWFNITNWLWYIR); SEQ ID NO: 6 f)
(NEQELLELDKWASLWNWFDITNWLWYIK); SEQ ID NO: 7 g)
(NEKDLLALDSWKNLWNWFDITNWLWYIK); SEQ ID NO: 8 h)
(NEQDLLALDSWENLWNWFDITNWLWYIK); SEQ ID NO: 9 i)
(NEQELLELDKWASLWNWFSITQWLWYIK); SEQ ID NO: 10 j)
(NEQELLALDKWASLWNWFDISNWLWYIK); SEQ ID NO: 11 k)
(NEQDLLALDKWDNLWSWFTITNWLWYIK); SEQ ID NO: 12 l)
(NEQDLLALDKWASLWNWFDITKWLWYIK); SEQ ID NO: 13 m)
(NEQDLLALDKWASLWNWFSITNWLWYIK); SEQ ID NO: 14 n)
(NEKDLLELDKWASLWNWFDITNWLWYIK); SEQ ID NO: 15 o)
(NEQEILALDKWASLWNWFDISKWLWYIK); SEQ ID NO: 16 p)
(NEQDLLALDKWANLWNWFNISNWLWYIK); SEQ ID NO: 17 q)
(NEQDLLALDKWASLWSWFDISNWLWYIK); SEQ ID NO: 18 r)
(NEKDLLALDSWKNLWSWFDITNWLWYIK); SEQ ID NO: 19 s)
(NEQELLQLDKWASLWNWFSITNWLWYIK); SEQ ID NO: 20 t)
(NEQDLLALDKWASLWNWFDISNWLWYIK); SEQ ID NO: 21 u)
(NEQELLALDKWASLWNWFDISNWLWYIR); SEQ ID NO: 22 v)
(NEQELLELDKWASLWNWFNITNWLWYIK); or SEQ ID NO: 81 w)
(QEKNEKELLELDKWASLWNWFDITNWLWYIRLFI).
19. The isolated rubella viral vector of claim 1, wherein the
transmembrane spanning region of gp41 comprises the amino acid
sequence set forth as one of: TABLE-US-00026 SEQ ID NO: 26 a)
(IFIMIVGGLIGLRIVFTVLSIV); SEQ ID NO: 27 b)
(LFIMIVGGLIGLRIVFTALSIV); or SEQ ID NO: 28 c)
(IFIMIVGGLVGLRIVFTALSIV).
20. The isolated rubella viral vector of claim 19, wherein the
membrane spanning region of gp41 consists of the amino acid
sequence set forth as one of: TABLE-US-00027 SEQ ID NO: 26 a)
(IFIMIVGGLIGLRIVFTVLSIV); SEQ ID NO: 27 b)
(LFIMIVGGLIGLRIVFTALSIV); or SEQ ID NO: 28 c)
(IFIMIVGGLVGLRIVFTALSIV).
21. The isolated rubella viral vector of claim 1, wherein the
antigenic insert comprises a gp120 antigenic insert comprising
amino acid sequence set forth by SEQ ID NOs: 63, 66, 67, 69, 71,
73, 74, 152, 153, 154, 155, 156, 158, 159 or 160.
22. The isolated rubella viral vector of claim 21, wherein the
gp120 antigenic insert comprises a variant gp120 polypeptide
comprising a deletion of at least 8 consecutive residues of the
fourth conserved loop (C4) between residues 423 and 433 of SEQ ID
NO: 63.
23. The isolated rubella viral vector of claim 22, wherein residues
424-432 of gp120 are deleted.
24. The isolated rubella viral vector of claim 22, wherein the
sequence consisting of the amino acid sequence INMWQKVGK (residues
424 to 432 of SEQ ID NO: 63) is deleted.
25. The isolated rubella viral vector of claim 1, wherein the
antigenic insert comprises the amino acid sequence according to SEQ
ID NO: 66.
26. The isolated rubella viral vector of claim 1, wherein the
vector comprises the amino acid sequence according to SEQ ID NO:
77-80.
27. A host cell transformed with the isolated rubella viral vector
of claim 1.
28. A viral-like particle produced by the isolated rubella viral
vector of claim 1.
29. The viral-like particle of claim 28, further comprising at
least one TLR ligand.
30. A composition comprising an effective amount of the viral-like
particle of claim 28.
31. A method for preventing, inhibiting or treating an HIV
infection in a subject, comprising administering an effective
amount of the composition of claim 30 to the subject in need
thereof, thereby inhibiting one or more signs or symptoms
associated with HIV infection.
32. A method for inducing an immune response to HIV in a subject,
comprising administering an effective amount of the composition of
claim 30 to the subject, thereby inducing the immune response.
33. The method of claim 32, wherein the immune response comprises
the induction of neutralizing antibodies to HIV or CTL.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Application Nos. 61/621,394, filed Apr. 6, 2012, and 61/642,333,
filed May 3, 2012, each of which is incorporated herein by
reference in its entirety.
FIELD
[0002] This disclosure relates to the field of viral vectors,
specifically to a live, attenuated rubella viral vector platform
capable of expressing a heterologous antigen, and the use of this
platform to induce an immune response.
BACKGROUND
[0003] The worldwide spread of human immunodeficiency
virus/acquired immunodeficiency syndrome (HIV/AIDS) has created an
urgent need for HIV immunogens that can elicit broad protection
against infection. Natural HIV infection in man and SIV infection
in monkeys often elicit a strong antibody-mediated (B cell) and T
cell-mediated immune response. A number of viral antigens targeted
by broadly reactive neutralizing antibodies and antigen specific T
cells have been identified. The challenge is to develop vaccines
with sufficient potency to stimulate an effective immune response
to these important viral antigens. Live viral vectors can enhance
both T cell and B cell responses by presenting antigens in the most
immunogenic way, in the context of an acute infection.
[0004] Weak immunogenicity of vaccine antigens is one of the main
problems in vaccine development. Several approaches have been tried
to improve presentation and enhance immunogenicity of these
antigens, including DNA vaccines, non-replicating vectors and live
viral vectors (FIG. 8). DNA vaccines have been used to immunize or
to prime for immunization. They have the advantage of flexibility
and safety, but often lack potency when used alone. By expressing
vaccine antigens in the cytoplasm, DNA vaccines may favor
endogenous antigen processing and presentation pathways, leading to
induction of MHC class I restricted T cells. Similarly,
non-replicating viral vectors deliver antigens directly into
cytoplasmic pathways needed to elicit a strong T cell response.
These vaccine platforms usually require a high immunizing dose, as
antigen expression is limited by vector dose. Live viral vectors
can immunize at the lowest dose of any vector, sufficient to
initiate infection; they immunize as they replicate. Some vectors
set up a chronic infection, while others persist for only a few
weeks.
[0005] Some of the most successful vaccines, such as oral polio
virus and measles, mumps, and rubella virus vaccine, consist of
live attenuated viruses. These are given at very low doses, so the
vaccine strain must grow in the host to produce sufficient viral
antigens to elicit an immune response. By simulating a viral
infection, they can elicit innate and adaptive immune responses,
resulting in antigen-specific T cells and antibody-producing B
cells. Through a process of attenuation, the vaccine strains have
retained the growth and immunogenicity of wild type virus while
losing its pathogenicity and virulence. However, for many
pathogenic viruses, such as HIV, SW, RSV and/or hepatitis, it has
not been possible to produce a live attenuated vaccine. Thus,
additional approaches for creating vaccines for pathogenic viruses
are needed.
SUMMARY
[0006] Disclosed herein is a live attenuated rubella viral vector
platform capable of stably expressing a heterologous antigen, such
as a vaccine antigen (e.g., an HIV antigen (for example, an
envelope glycoprotein antigen, such as, a gp41 or a gp120), a Gag
antigen (such as an HIV or SIV Gag antigen), hepatitis B surface
antigen (HBsAg), or an RSV antigen and the use of this platform to
induce an immune response. The inventors utilized the rubella
vaccine strain RA27/3 as a viral vector because of its safety and
immunogenicity. Its safety has been demonstrated in millions of
children around the world. If the rubella vector losses its insert,
it reverts to the vaccine strain. At the same time, it is
immunogenic and elicits both humoral and mucosal immunity. The
inventors surprisingly found that rubella viral vector can
accommodate foreign inserts at either of two sites, in the
nonstructural region or between two structural genes. Each site was
found to be controlled by a different viral promoter, resulting in
expression of the insert as an early or late antigen of rubella. At
the nonstructural site the insert was expressed as a fusion
protein, while at the structural site it was expressed with the
structural polyprotein and cleaved to a mature protein. The mature
protein was incorporated into virions and co-sedimented with viral
particles in sucrose density gradients. The vectors stably
expressed the insert, while replicating for at least eight to ten
passages in culture.
[0007] One advantage of rubella vectors for vaccine research is
their ability to infect rhesus macaques. This animal model allows
the testing of vector replication and immunogenicity in vivo.
Rhesus macaques are also the animal of choice for SW and SHIV
challenge studies; thus, the immune response can be evaluated for
durability and protection against SIV or SHIV challenge. Production
of rubella vectors is efficient, as they grow to high titer in cell
culture, yet they immunize at a low dose. Their one limitation,
eliciting antibodies to the vector, is overcome by combining a live
rubella vector with another vaccine delivery platform in a prime
and boost strategy.
[0008] The disclosed vectors are of interest to vaccine researchers
as they reprogram the rubella vaccine strain to present new vaccine
antigens. In the developed world, where virtually all rubella
infections are caused by design (vaccination), the disclosed
rubella vectors can be used to immunize against two or more
infectious agents instead of one. In the third world, where rubella
vaccine is not currently used, there is a window of opportunity for
the vector to be given prior to the age of natural rubella
infection, which ranges from two to six years old in most
countries. It is contemplated that the disclosed vectors can be
used against a variety of infectious diseases, including HIV, SIV,
RSV and hepatitis.
[0009] In some embodiments, an isolated rubella viral vector
includes a rubella non-structural protein open reading frame (ORF)
without an in-frame deletion, a rubella structural protein ORF, and
a heterologous antigenic insert. In some examples, the heterologous
antigenic insert is positioned within the rubella structural
protein ORF. In other examples, the heterologous antigenic insert
is positioned in between the genes encoding structural proteins E2
and E1. In some examples, the heterologous antigenic insert is
positioned between the genes encoding structural protein capsid and
E2. In some examples, the antigenic insert comprises an amino acid
sequence set forth as SEQ ID NO: 126, 127, 128, 129, 130, 131, 132,
133, 134, 135, 136, 137, 138, 138, 140, 141, 142, 143, 144, 145,
146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 159,
160, 161, or 162.
[0010] Exemplary antigenic inserts can include cytotoxic T
lymphocyte (CTL) epitopes, HIV envelope protein epitopes, RSV
antigen and HBsAg inserts. For example, an antigenic insert can
include a CTL epitope of HIV or SIV Gag, an epitope of HIV gp41,
including a membrane proximal region (MPER or MPR) or an epitope of
HIV gp120. The antigenic insert can include repeats of any one of
the disclosed antigenic epitopes, such as one to ten copies of one
or more of the disclosed antigenic envelope or CTL epitopes.
[0011] In some examples, an antigenic insert is a wildtype or
variant of a CTL epitope of a Gag polypeptide or a fragment
thereof. In some examples, the antigenic peptide includes one or
more major CTL epitopes of Gag, and can be from about 8 to about
350 amino acids in length, such from about 10 to about 280 amino
acids in length, such as 20 to about 270 amino acids in length,
such as from about 40 to about 250 amino acids in length, including
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,
42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 57, 60, 63, 65, 67, 70, 73,
75, 77, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135,
140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200,
205, 210, 215, 220, 225, 230, 231, 232, 233, 234, 235, 236, 237,
238, 239, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290,
295, 300, 305, 310, 315, 320, 321, 322, 323, 324, 325, 326, 327,
328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,
341, 342, 343, 344, 345, 346, 347, 348, 349 or 350. In some
examples, an antigenic insert includes one or more CTL epitopes,
such as one or more CTL HIV or SIV epitopes, including those set
forth as SEQ ID NOs: 77, 78, 79, 80, 92, 93, 94, 95, 96, 97, 98,
99, 100, 101, and 102. In some examples, an antigenic insert
includes one or more antigenic polypeptide fragments of Gag, such
as one or more antigenic polypeptides with an amino acid sequence
provided by SEQ ID NOs: 82-88, 90, 91, 132, 133, 134, 135, 138,
139, 140, 141 or 142.
[0012] In some examples, an antigenic insert is a wildtype or
variant gp41 polypeptide or a fragment thereof. In some examples, a
gp41 antigenic insert can include (a) an antigenic polypeptide
fragment of gp41 and (b) a transmembrane spanning region of gp41.
For example, the gp41 antigenic insert includes (a) an antigenic
polypeptide fragment, such as an antigenic polypeptide fragment
with the amino acid sequence set forth in SEQ ID NO:1 (in which
wherein X.sub.1, X.sub.2 and X.sub.3 are any amino acid) and the
polypeptide is between 8 and 400 amino acids in length, such as
between 10 and 300 amino acids in length, such as from about 12 to
about 250, such as from about 16 to about 160 amino acids, such as
from about 28 to about 150 amino acids in length, such as from
about 28 to about 140 amino acids in length, including 29, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 120,
125, 130, 135, 140, or 145 amino acids; and (b) a transmembrane
spanning gp41 region, such as a transmembrane spanning gp41 region
with the amino acid sequence set forth in SEQ ID NO: 25 (in which
X.sub.4, X.sub.5, and X.sub.6 are any hydrophobic amino acid) and
is between 22 and 40 amino acids in length, such as about 23 and 38
amino acids in length, including 24, 25, 26, 27, 28, 29, 30, 31,
32, 33, 34, 35, 36, 37, 38 amino acids. In certain examples, an
antigenic insert includes an antigenic polypeptide fragment of gp41
with an amino acid sequence provided by SEQ ID NOs: 1-22, 30, 81 or
89 and a transmembrane region of gp41 with an amino acid sequence
provided by SEQ ID NOs: 25-28.
[0013] In some examples, an antigenic insert is a wildtype or
variant gp120 polypeptide. In an example, a wildtype gp120
polypeptide has an amino acid provided by SEQ ID NO: 63 or a
fragment thereof. In other examples, a variant gp120 polypeptide
includes a gp120 polypeptide in which at least 8 consecutive
residues of the fourth conserved loop (C4) between residues 419 and
434 of gp120 according HXB2 numbering of SEQ ID NO: 63 are deleted.
This deletion within the .beta.20-21 loop of the gp120 polypeptide
exposes the CD4 binding site thereby providing improved antibody
binding and antibody induction. In one example, a variant gp120
polypeptide is a gp120 polypeptide in which at least 8 consecutive
residues, such as between 8-12, 8-11, 8-10, or 8-9 (for example, 9,
10, 11 or 12) consecutive residues of C4 between residues 419 and
434 of gp120 of SEQ ID NO: 63 have been deleted.
[0014] In a particular example, a variant gp120 polypeptide
includes a gp120 polypeptide in which residues 424-432 are deleted.
Additional variant gp120 polypeptides include deletions of
INMWQKVGK (residues 424-432 of SEQ ID NO: 63), INMWQKVGKA (residues
424-433 of SEQ ID NO: 63), INMWQKVGKAM (residues 424-434 of SEQ ID
NO: 63), RIKQIINMWQKVGK (residues 419-432 of SEQ ID NO: 63),
IKQIINMWQKVGK (residues 420-432 of SEQ ID NO: 63), KQIINMWQKVGK
(residues 421-432 of SEQ ID NO: 63), QIINMWQKVGK (residues 422-432
of SEQ ID NO: 63), or IINMWQKVGK (residues 423-432 of SEQ ID NO:
63). In other embodiments, variant gp120 polypeptides include
combinations of the amino and carboxyl ends between residues 419
and 434.
[0015] In some embodiments, a variant gp120 polypeptide does not
include a variant in which residues 419-428 of SEQ ID NO: 63 are
deleted. In other embodiments, a variant gp120 polypeptide does not
include a variant in which residues 437-452 of SEQ ID NO: 63 are
deleted. In certain examples, an antigenic insert includes an amino
acid sequence set forth by SEQ ID NOs: 63, 66, 67, 69, 71, 73 or
74.
[0016] In some embodiments, an isolated rubella viral vector
comprises an antigenic insert comprising an amino acid sequence set
forth as SEQ ID NO: 126, 127, 131-156 or 158-162.
[0017] In some embodiments, an isolated rubella viral vector
comprises an antigenic insert consisting of an amino acid sequence
set forth as SEQ ID NO: 126, 127, 131-156 or 158-162.
[0018] In some embodiments, a disclosed isolated rubella viral
vector comprises an antigenic insert comprising a Gag antigenic
insert, comprising the amino acid sequence as set forth by SEQ ID
NO: 141, SEQ ID NO. 142, SEQ ID NO: 82 or SEQ ID NO: 83.
[0019] In some embodiments, a disclosed isolated rubella viral
vector comprises an antigenic insert comprising the amino acid
sequence set forth as one of SEQ ID NOs: 143-155; SEQ ID NO. 156;
SEQ ID NOs: 158-162; or SEQ ID NOs: 84-91.
[0020] In some embodiments, a disclosed isolated rubella viral
vector comprises an antigenic insert consisting of the amino acid
sequence set forth as one of SEQ ID NOs: 143-155; SEQ ID NO. 156;
SEQ ID NOs: 158-162; or SEQ ID NOs: 84-91.
[0021] Viral-like particles including any of the disclosed isolated
viral vector constructs are provided herein. Compositions
comprising the viral-like particles are also provided.
[0022] The disclosed isolated viral vectors can be used to induce
an immune response, such as a protective immune response, when
introduced into a subject. The provided rubella viral vector
platforms can also be used in assays to diagnose a viral infection,
such as an HIV infection, an SIV infection, RSV infection or
hepatitis. Thus, methods are provided for inhibiting a viral
infection, such as an HIV infection in a subject, for inducing an
immune response to HIV in a subject, and for diagnosing HIV
infection in a subject. The disclosed viral vector platforms can
also be used for measuring host range, testing sensitivity to
neutralizing antibodies, or screening antiviral drugs. In one
example, methods of screening antiviral drugs including methods of
identifying protease inhibitors are disclosed.
[0023] The foregoing and other features of the disclosure will
become more apparent from the following detailed description, which
proceeds with reference to the accompanying sequence listing and
figures.
BRIEF DESCRIPTION OF SEQUENCES
[0024] The nucleic and amino acid sequences listed herein are shown
using standard letter abbreviations for nucleotide bases, and three
letter code for amino acids, as defined in 37 C.F.R. 1.822. Only
one strand of each nucleic acid sequence is shown, but the
complementary strand is understood as included by any reference to
the displayed strand. All sequence database accession numbers
referenced herein are understood to refer to the version of the
sequence identified by that accession number as it was available on
the designated date.
[0025] SEQ ID NO: 1 is a consensus amino acid sequence for the
membrane proximal region (MPR) of gp41 of HIV-1. An X represents
specific amino acids where alterations can be tolerated.
[0026] SEQ ID NO: 2 is a consensus amino acid sequence based on
each clade consensus sequence of the MPR region from HIV-1.
[0027] SEQ ID NO: 3 is the ancestral amino acid sequence of the
MPER region from HIV-1 clade M. This sequence is also the consensus
amino acid sequence of the MPR region from HIV-1 clade AG.
[0028] SEQ ID NO: 4 is the consensus amino acid sequence of the
MPER region from HIV-1 clade A1. This sequence is also the
ancestral amino acid sequence of the MPER region from HIV-1 clade
A1.
[0029] SEQ ID NO: 5 is the consensus amino acid sequence of the
MPER region from HIV-1 clade A2.
[0030] SEQ ID NO: 6 is the consensus amino acid sequence of the
MPER region from HIV-1 clade B. This sequence is also the ancestral
amino acid sequence of the MPER region from HIV-1 clade B.
[0031] SEQ ID NO: 7 is the consensus amino acid sequence of the
MPER region from HIV-1 clade C.
[0032] SEQ ID NO: 8 is the ancestral amino acid sequence of the
MPER region from HIV-1 clade C.
[0033] SEQ ID NO: 9 is the consensus amino acid sequence of the
MPER region from HIV-1 clade D.
[0034] SEQ ID NO: 10 is the consensus amino acid sequence of the
MPER region from HIV-1 clade F1.
[0035] SEQ ID NO: 11 is the consensus amino acid sequence of the
MPER region from HIV-1 clade F2.
[0036] SEQ ID NO: 12 is the consensus amino acid sequence of the
MPER region from HIV-1 clade G.
[0037] SEQ ID NO: 13 is the consensus amino acid sequence of the
MPER region from HIV-1 clade H.
[0038] SEQ ID NO: 14 is the consensus amino acid sequence of the
MPER region from HIV-1 clade AE.
[0039] SEQ ID NO: 15 is the consensus amino acid sequence of the
MPER region from HIV-1 clade AB.
[0040] SEQ ID NO: 16 is the consensus amino acid sequence of the
MPER region from HIV-1 clade 04CPX.
[0041] SEQ ID NO: 17 is the consensus amino acid sequence of the
MPER region from HIV-1 clade 06CPX.
[0042] SEQ ID NO: 18 is the consensus amino acid sequence of the
MPER region from HIV-1 clade 08BC.
[0043] SEQ ID NO: 19 is the consensus amino acid sequence of the
MPER region from HIV-1 clade 10CD.
[0044] SEQ ID NO: 20 is the consensus amino acid sequence of the
MPER region from HIV-1 clade 11CPX.
[0045] SEQ ID NO: 21 is the consensus amino acid sequence of the
MPER region from HIV-1 clade 12BF.
[0046] SEQ ID NO: 22 is the consensus amino acid sequence of the
MPER region from HIV-1 clade 14BG.
[0047] SEQ ID NOs: 23-24 are oligonucleotide primers used to
amplify a rubella sequence flanking a zGFP insert.
[0048] SEQ ID NO: 25 is a consensus amino acid sequence for the
transmembrane region of gp41. An X represents any hydrophobic amino
acid.
[0049] SEQ ID NOs: 26-28 are amino acid sequences for a
transmembrane spanning region of gp41.
[0050] SEQ ID NO: 29 is an amino acid sequence for a disclosed
isolated immunogen in which the first transmembrane domain of
hepatitis B surface antigen is replaced with the MPER and
transmembrane domain of gp41.
[0051] SEQ ID NO: 30 is an exemplary MPER region from HIV-1 amino
acid sequence.
[0052] SEQ ID NO: 31 is an exemplary wildtype amino acid sequence
of HBsAg.
[0053] SEQ ID NO: 32 is an example of a nucleotide sequence for a T
helper cell epitope.
[0054] SEQ ID NO: 33 is an example of an amino acid sequence for a
T helper cell epitope.
[0055] SEQ ID NO: 34 is the CAAX amino acid sequence, where C is
cystein, A is an aliphatic amino acid and X is any amino acid.
[0056] SEQ ID NO: 35 is the core amino acid sequence of the 2F5
epitope.
[0057] SEQ ID NO: 36 is the core amino acid sequence of the 4E10
epitope.
[0058] SEQ ID NO: 37 is the linker sequence GPGP.
[0059] SEQ ID NO: 38 (ggagctcgtcgacagcaa) is a forward primer for
amplification of the HBsAg.
[0060] SEQ ID NO: 39 (gctctagacccgatgtacaccca) is a reverse primer
for amplification of the HBsAg.
[0061] SEQ ID NO: 40 (gctctagaaacgagcaggagctgctg) is a forward
primer for amplification of MPER.
[0062] SEQ ID NO: 41 (cgcggatcctcaccccttgatgtaccacagccactt) is a
reverse primer for amplification of MPER.
[0063] SEQ ID NO: 42 (cgcggatcctcaatggtgatggtgatggtgggg) is a
reverse primer for amplification of MPER-Foldon.
[0064] SEQ ID NO: 43 (gctctagagccgtggagcggtacctg) is a forward
primer for amplification of C-heptad.
[0065] SEQ ID NO: 44 (ctcggatcctcaaatcatgatgaaaatcttgat) is a
reverse primer for amplification of MPER-Tm5.
[0066] SEQ ID NO: 45 (ctcggatcctcacaccaggccaccaacaat) is a reverse
primer for amplification of MPER-Tm10.
[0067] SEQ ID NO: 46 (ctcggatcctcacaccagcctcaggcccac) is a reverse
primer for amplification of MPER-Tm15.
[0068] SEQ ID NO: 47 (ctcggatcctcaggcgggcgc) is a reverse primer
for amplification of MPER-Tm23.
[0069] SEQ ID NO: 48
(ccctgcaagacctgcaccaccaccggtcagggcaactccaagttcccc) is a forward
primer for amplification of the MPER region with AgeI.
[0070] SEQ ID NO: 49
(ggggaacttggagttgccctgaccggtggtggtgcaggtcttgcaggg) is a reverse
primer for amplification of the MPER region with AgeI.
[0071] SEQ ID NO: 50 (ggcaccggtaacgagcaggagctgctg) is a forward
primer for amplification of the MPER region with AgeI.
[0072] SEQ ID NO: 51 (ggcaccggtccccttgatgtaccacagccactt) is a
reverse primer for amplification of the MPER region with AgeI.
[0073] SEQ ID NO: 52 (agcgaattcaacgagcaggagctgctg) is a forward
primer for amplification of the MPER region with HBsAg (MPER SAG or
MPER-N-term).
[0074] SEQ ID NO: 53 (cgcggatcctcacccgatgtacaccca) is a reverse
primer for amplification of the MPER region with HBsAg (MPER SAG or
MPER-N-term).
[0075] SEQ ID NO: 54 (caggaagccggaggtgatgaaccccttgatgtaccacagc
cactt) is a forward primer for amplification of SAGMPER-R1 (HBsAg
at the N-terminus of MPER).
[0076] SEQ ID NO: 55
(aagtggctgtggtacatcaaggggttcatcacctccggcttcctg) is a reverse primer
for amplification of SAGMPER-R1 (HBsAg at the N-terminus of
MPER).
[0077] SEQ ID NO: 56 is an nucleic acid sequence which encodes the
Gag antigenic insert with an amino acid sequence set forth as SEQ
ID NO: 103
[0078] SEQ ID NO: 57 (MKTIIALSYIFCLVFAQDLPGNDNNSEFNEKELLELDKWASL
WNWFDITNWLWYIRLFIMIVGGLIGLRIVFAVLSIPQSLDSWWTSLNFLGGSPVCLGQNSQS
PTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGP
CKTCTTPAQGNSKFPSCCCTKPTDGNCTCIPINEKELLELDKWASLWNWFDITNWLWYIRL
FIMIVGGLIGLRIVFAVLSIVVGLSPTVWLSAIWMMWYWGPSLYSIVSPFIPLLPIFFCLWVY IG)
is an amino acid sequence for a disclosed isolated immunogen in
which the first and third transmembrane domains of hepatitis B
surface antigen are each replaced with the MPER and transmembrane
domain of gp41.
[0079] SEQ ID NO: 58 is a nucleic acid sequence for a disclosed
isolated immunogen in which the third transmembrane domains of
HBsAg is replaced with the MPER and transmembrane domain of
gp41.
[0080] SEQ ID NO: 59 is an amino acid sequence for a disclosed
isolated immunogen in which the third transmembrane domain of
hepatitis B surface antigen is replaced with the MPER and
transmembrane domain of gp41.
[0081] SEQ ID NO: 60 (NEKELLELDKWASLW) is an amino acid sequence of
the MPER region in the TM32 or TM32F constructs.
[0082] SEQ ID NO: 61 (NEKELLELDKWASLWNWFDITNWLW) is an amino acid
sequence of the MPER region in the TM34 construct.
[0083] SEQ ID NO: 62 (MKTIIALSYIFCLVFAQDLPGNDNNSEFNEKELLELDKWASLW
NWFDITNWLWYIRLFIMIVGGLIGLRIVFAVLSIPQSLDSWWTSLNFLGGSPVCLGQNSQSP
TSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPC
KTCTTPAQGNSKFPSCCCTKPTDGNCTCISINEKELLELDKWASLWNWFDITNWLWSSLW
AIKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWGPSLYSIVSPFIPLLPI
FFCLWVYIG) is an amino acid sequence of a disclosed variant HbsAg
construct (TM16+34) in which the first domain is replaced with a
MPER and transmembrane domain of gp41 and an additional MPER is
inserted between a second and third domain in the variant
HBsAg.
[0084] SEQ ID NO: 63 is an amino acid sequence of a variant gp120
with a V1V2 deleted gp120.
[0085] SEQ ID NO: 64 (MKTIIALSYIFCLVFAQDLPGNDNNSEFNEKELLELDKWASL
WNWFDITNWLWYIRLFIMIVGGLIGLRIVFAVLSIPQSLDSWWTSLNFLGGSPVCLGQNSQS
PTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCIFLLVLLDYQGMLPVCPLIPGSTTTSTGPC
KTCTTPAQGNSKFPSCCCTKPTDGNCTCISINEKELLELDKWASLWAINEKELLELDKWAS
LWAINEKELLELDKWASLWAINEKELLELDKWASLWAIKYLWEWASVRFSWLSLLVPFV
QWFVGLSPTVWLSAIWMMWYWGPSLYSIVSPFIPLLPIFFCLWVYIG) is an amino acid
sequence of a disclosed variant HbsAg construct (TM16+32F) in which
the first domain is replaced with a MPER and transmembrane domain
of gp41 and four additional MPERs are inserted between a second and
third domain in the variant HBsAg.
[0086] SEQ ID NO: 65 (MKTIIALSYIFCLVFAQDLPGNDNNSEFITSGFLGPLLVLQAGF
FLLTRILTIPQSLDSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIF
LFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSKFPSCCCTKPTDGN
CTCISINEKELLELDKWASLWAINEKELLELDKWASLWAINEKELLELDKWASLWAINEKE
LLELDKWASLWAIKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWGPS
LYSIVSPFIPLLPIFFCLWVYIG) is an amino acid sequence of a disclosed
variant HbsAg construct (32F) in which four MPERs are inserted
between a second and third domain in the variant HBsAg.
[0087] SEQ ID NO: 66 is an amino acid sequence for a variant gp120
with a V1V2 deletion with a beta 20-21 loop deletion.
[0088] SEQ ID NO: 67 is an amino acid sequence for a variant gp120
from HIV isolate JR-FL.
[0089] SEQ ID NO: 68 is a nucleic acid sequence for a variant gp120
from HW isolate JR-FL.
[0090] SEQ ID NO: 69 is an amino acid sequence for a variant gp120
from HW isolate AD8.
[0091] SEQ ID NO: 70 is a nucleic acid sequence for a variant gp120
from HIV isolate AD8.
[0092] SEQ ID NO: 71 is an amino acid sequence for a variant gp120
from HIV isolate BaL.
[0093] SEQ ID NO: 72 is a nucleic acid sequence for a variant gp120
from HIV isolate BaL.
[0094] SEQ ID NO: 73 is an amino acid sequence for a variant gp120
from HIV isolate IIIB
[0095] SEQ ID NO: 74 is a nucleic acid sequence for a variant gp120
from HIV isolate IIB.
[0096] SEQ ID NOS: 75-76 are oligonucleotide primers used to
amplify Zoanthus sp. green fluorescent protein (zGFP).
[0097] SEQ ID NOS: 77-80 are amino acid sequences of disclosed
variant rubella constructs in which one MPER is inserted into the
structural open reading frame of the rubella construct.
[0098] SEQ ID NO: 81 is an amino acid sequence of MPER.sub.f which
contains the epitope recognized by neutralizing monoclonal antibody
2F5.
[0099] SEQ ID NOS: 82-88 are amino acid sequences of Gag antigenic
inserts.
[0100] SEQ ID NO: 89 is an amino acid sequence of MPER.sub.e which
contains the epitope recognized by neutralizing monoclonal antibody
4E1.
[0101] SEQ ID NOs: 90-91 are amino acid sequences of Gag antigenic
inserts.
[0102] SEQ ID NOs: 92-96 are amino acid sequences of CTL epitopes
of SIV Gag.
[0103] SEQ ID NOs: 97-102 are amino acid sequences of CTL epitopes
of HIV Gag.
[0104] SEQ ID NO: 103 is an amino acid sequence of a Gag antigenic
insert.
[0105] SEQ ID NOs: 104-125 are oligonucleotide primer
sequences.
[0106] SEQ ID NOs: 126-127 are amino acid sequences of MPER.sub.F
inserts.
[0107] SEQ ID NO: 128 is an amino acid sequence of MPER.sub.F
insert.
[0108] SEQ ID NO: 129 is an amino acid sequence of MPER.sub.E
insert.
[0109] SEQ ID NO: 130 is an amino acid sequence of MPER insert.
[0110] SEQ ID NO: 131 is an amino acid sequence of MPER-HIVTM
insert.
[0111] SEQ ID NO: 132 is an amino acid sequence of an SW Gag insert
(sGag-E2TM amino acids 41-211) expressed at the structural
site.
[0112] SEQ ID NO: 133 is an amino acid sequence of an SW Gag insert
(SGag-E2TM, amino acids 135-271) expressed at the structural
site.
[0113] SEQ ID NO: 134 is an amino acid sequence of an SW Gag insert
(full p28-sGag-E2TM) expressed at the structural site.
[0114] SEQ ID NO: 135 is an amino acid sequence of an SW Gag insert
(fullp28 plus-sGag-E2TM) expressed at the structural site.
[0115] SEQ ID NOS: 136 is an amino acid sequence of a disclosed
variant rubella constructs in which one MPER is inserted into the
structural open reading frame of the rubella construct.
[0116] SEQ ID NO: 137 is an amino acid sequence of an MPER
construct incorporating the gp41 trimerization domain (N and C
domains) before MPER, such arrangement can increase MPER valency
and size.
[0117] SEQ ID NOs: 138-140 are amino acid sequences of HIV Gag
inserts expressed at the rubella structural site.
[0118] SEQ ID NOs: 141-162 are sequences of inserts expressed at
the rubella structural site.
[0119] The Sequence Listing is submitted as an ASCII text file in
the form of the file named Sequence.txt, which was created on Apr.
8, 2013, and is 196,048 bytes, which is incorporated by reference
herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0120] FIG. 1A is a restriction map of a rubella cDNA plasmid in
which the two Not I sites are shown and the deletion between such
sites becomes the site of zGFP insertion.
[0121] FIG. 1B is a schematic drawing of the expressed
nonstructural proteins nsP150 and nsP90 and the structural proteins
C, E2 and E1. The zGFP insert is expressed as part of the nsP150
polyprotein.
[0122] FIG. 2 is a digital image of a Western blot illustrating
expression of rubella genes in Not I deletion/insertion mutants.
Each full length rubella cDNA was transcribed, capped, and
transfected into Vero cells. Expression of rubella structural
proteins was detected by western blot of the P.sub.0 cell lysates
on day 12. Wild type rubella expressed Capsid 33, E1 and E2
proteins (lane 5) at the same level as Not I deleted rubella (lane
4). Two clones with zGFP inserted at the Not I site expressed
normal levels of rubella proteins (lanes 1 and 2).
[0123] FIG. 3 is a graph of a time course illustrating rubella
vector growth over a number of months.
[0124] FIG. 4 is a schematic illustrating the arrangement of
various Gag epitopes expressed in a rubella vector.
[0125] FIG. 5 is a digital image illustrating growth of two rubella
vectors and rubella-GFP control as detected by western blot of
rubella proteins E1 and C:
[0126] FIG. 6 is a digital image of a western blot illustrating a
time course of MPER expression by rubella-MPER.sub.F vector as
detected with anti-MPER monoclonal 2F5 or anti-rubella polyclonal
antibodies.
[0127] FIG. 7 is a digital image of a western blot illustrating
growth of seven rubella-sGag vectors at passage 2, as detected with
antibodies to rubella capsid.
[0128] FIG. 8 is a schematic illustrating different vaccine
platforms. DNA vaccines, non-replicating vectors, and live viral
vectors are under development as vaccine platforms for viral
antigens. Due to transient expression and limited antigen
production, DNA vaccines and non-replicating vectors favor T cell
immunity. In contrast, a replicating viral vector, while immunizing
at the lowest dose of any vector, produces exponentially increasing
amounts of antigen to stimulate stronger T cell and B cell
responses. Live rubella vectors combine the safety of a licensed
vaccine with the targeted antigenicity of a vector. The disclosed
live rubella vectors provide a vaccine platform that can be used
alone or in combination with the other platforms in a prime and
boost strategy.
[0129] FIG. 9 is a schematic illustrating deletion/insertion
strategy for producing rubella vectors and composition of foreign
gene inserts. (A) Permissive deletion between two Not I restriction
sites in nonstructural protein P150 made room for insertion of
foreign genes at the same site. Vector replication was detected
with anti-rubella antibodies directed primarily to the structural
proteins C and E1. (B) Deletion at the Not I site was combined with
insertions in the structural region between envelope glycoproteins
E2 and E1. (C) HIV-1 gp41 inserts contained one or two epitopes of
the membrane-proximal external region (MPER) targeted by broadly
neutralizing antibodies 2F5 and 4E10. Alternatively, inserts at the
structural site included the transmembrane domain from rubella
proteins E1 (E1TM), E2 (E2TM) or HIV-1 gp41 (HIVTM), as well as the
E1 signal peptide sequence (E1SP) for proper processing and
potential anchoring in the viral envelope. As indicated, four MPER
vectors replicated strongly for at least seven passages. Vectors
containing MPER.sub.E or full length MPER inserts at the Not I
site, replicated poorly or not at all, respectively. (D) SW Gag
amino acids 41 to 211 contain five T cell epitopes denoted by
letters A through E. In constructs denoted by an asterisk (*) one
epitope at a time was added to the carboxyl end of sGag2L to
produce sGag2L-A, -B, or -C. All vectors were grown for several
passages, and the largest construct BC-sGag2 was grown for at least
eight passages.
[0130] FIG. 10 provides amino acid sequences of the HIV-1 MPER- and
SIV Gag-derived inserts expressed at the Not I and structural
sites. Underlined sequences show the core epitopes for broadly
neutralizing antibodies 2F5 and 4E10, T cell epitopes in SIV Gag,
or membrane-spanning domains in MPER inserts expressed at the
structural site.
[0131] FIGS. 11A-11D are digital images of Western blot analyses
illustrating replication of rubella vectors expressing HIV MPER and
SIV Gag inserts at the Not I site. Replication of rubella vectors
expressing HIV MPER and SIV Gag inserts at the Not I site. (A)
Growth of rubella vectors expressing HIV MPER- or SW Gag-derived
inserts at the Not I deletion site. Viral replication and protein
expression were detected by Western blot with goat polyclonal
antibodies specific for rubella structural proteins capsid C and
envelope glycoprotein E1. Vectors expressing MPER.sub.F and SW
Gag2L grew as well as a control vector expressing zGFP. Lane N
represents uninfected cells. (B) Western blots showing a time
course of HIV MPER.sub.F expression at the Not I site. MPER.sub.F
(at passage P.sub.3) was expressed as a high molecular-weight
fusion protein with nonstructural protein P150 (arrow). It was
detected with monoclonal antibody 2F5 (left panel). Maximal
expression of P150-MPER.sub.F fusion protein was observed from day
2 to 5 after infection, showing that p150 is an early gene under
control of the rubella genomic promoter. After 5 days,
P150-MPER.sub.F expression became undetectable. Rubella structural
proteins E1 and C (right panel) first appeared on day 5 or 6 and
were strongly expressed on days 7-10. Lane zGFP represents a
control infection with rubella expressing zGFP but no MPER
antigens, and lane N shows uninfected cells. (C) Growth of rubella
vectors expressing SIV Gag inserts at the Not I site. Vector
replication at passage P.sub.2 was detected by Western blot with
anti-rubella antibodies. Vectors replicated strongly while
expressing two, three or four Gag epitopes. Gag constructs and
epitopes are labeled as in FIG. 1D. Lane N represents a mock
infection. (D) Expression of the BC-sGag2 insert as a P150 fusion
protein was detected by Western blot with antibodies to P150. The
P150 band for each construct is indicated by arrowheads. Lane 1
shows the size of P150 with zGFP inserted at the Not I site. Lane 2
shows the size of P150 alone after Not I deletion. Lanes 3 and 4
show the size of the P150-BC-sGag2 fusion protein, which was
expressed on days 6 and 7, respectively, and then declined by day
10 (lane 5). The shift of the P150-BC-sGag2 band, as compared to
P150-NotI, indicates the presence of a BC-sGag-2 insert. The
BC-sGag2 insert was confirmed by sequencing the viral genome at
passage P.sub.6.
[0132] FIGS. 12A-12C are digital images of Western blot analyses
illustrating replication of rubella vectors expressing HIV MPER
antigens in the structural insertion site. Replication of rubella
vectors expressing HIV MPER antigens in the structural insertion
site. (A) Western blot showing replication of two rubella vectors
with inserts between envelope glycoproteins E2 and E1,
MPER.sub.F-E2TM and MPER.sub.F-E1TM (lanes 1 and 2) and a control
vector expressing zGFP. (B) Western blot of the same samples with
monoclonal antibody 2F5, showing high level expression of
MPER.sub.F as an 8.5 kDa protein when inserted between E2 and E1
(lanes 1 and 2). Additional bands at higher molecular weight
suggest incomplete cleavage of the structural polyprotein, leaving
MPER.sub.F fused to either E2 or E1. These bands were not observed
in uninfected cells (lane N). Lane SHIV represents a positive
control with aldrithiol-2-inactivated SIV/HIV chimeric virions
containing HIV-1 gp41. (C) Dual antigenicity of full length MPER
expressed in the structural site. Vero cells were infected with a
control rubella vector expressing zGFP (lanes 1, 3 and 5) or with a
vector expressing MPER-HIVTM at the structural site at passage
P.sub.8 (lanes 2, 4 and 6). Cell lysates were sedimented on a
10-40% sucrose gradient for 16.5 hours at 39,000 rpm in an SW41Ti
rotor to band the virus by density. Peak fractions of each gradient
were probed with antibodies specific for rubella structural
proteins (lanes 1 and 2) or MPER (monoclonal 2F5 in lanes 3 and 4
or monoclonal 4E10 in lanes 5 and 6). Expression of rubella
proteins was slightly greater in lane 2 than in control lane 1. The
10 kDa band for MPER-HIVTM showed nearly equal staining with 2F5 or
4E10 (lanes 4 and 6), indicating that both epitopes were expressed
equally. Neither monoclonal detected a band in vector control lanes
3 and 5, indicating specificity. A minor band above 62 kDa in lanes
4 and 6 may represent incomplete cleavage of the structural
polyprotein, resulting in an MPER-HIVTM-E1 fusion protein.
[0133] FIG. 13A is a schematic representation of processing of the
native structural polyprotein and one with MPER-derived inserts. In
unmodified rubella (upper panel), the structural proteins are
separated by transmembrane domains that provide a signal peptide
for the next protein. Signal peptidase cleaves the polyprotein at
two sites (arrows) to release three mature proteins: capsid, E2 and
E1. In rubella vectors with an MPER insert (FIG. 13A, lower panel),
the MPER insert is followed by an additional transmembrane domain
and signal peptide. Cleavage at three sites would produce the same
three rubella structural proteins plus MPER with membrane spanning
domains at a size of 8.5 to 10 kDa. Incomplete cleavage before or
after MPER gave additional bands corresponding to E2-MPER-HIVTM (50
to 57 kDa) or MPER-HIVTM-E1 (66 to 68 kDa). E2SP and E1SP denote
the E2 and E1 signal peptides, respectively. E2TM, E1TM, and HIVTM
denote the E2, E1, and HIV transmembrane domains, respectively. The
membrane spanning domains anchor rubella structural proteins in the
viral envelope.
[0134] FIGS. 14A and 14B are schematics illustrating exemplary
deletion/insertion strategies for producing rubella vectors. FIG.
14A illustrates a permissive deletion between two Not I restriction
sites in nonstructural protein p150 and an insertion of foreign
genes at the structural site between E1 and E2.
[0135] FIG. 15 shows digital images of Western blot analyses
illustrating MPER antigen incorporation into rubella virions.
[0136] FIG. 16 is a table illustrating titers of rubella vectors
carrying exemplary inserts.
[0137] FIG. 17 is a graph illustrating disclosed rubella vectors
are infectious in vivo and immunize subjects, such as macaques,
efficiently.
[0138] FIG. 18 is a digital image of PCR products separated by gel
electrophoresis showing rubella vectors lacking a Not I deletion
replicate efficiently in vivo.
[0139] FIG. 19 is graph illustrating the antibody response to the
BCsGag-2 insert.
[0140] FIGS. 20A and 20B is a table illustrating amino acid
sequences of exemplary SIV Gag inserts (SEQ ID NOs: 132-135).
[0141] FIGS. 21A-21E is a table illustrating amino acid sequences
of MPER-HIVTM-E1 or E2-MPER-HIVTM fusion proteins (SEQ ID NOs:
77-80 and 136).
[0142] FIG. 22 is a table illustrating the amino acid sequence of
an MPER construct incorporating the gp41 trimerization domain (N
and C domains) before MPER (SEQ ID NO: 137).
[0143] FIG. 23 is a table illustrating amino acid sequences of HIV
Gag inserts expressed at the rubella structural site (SEQ ID NOs:
138-140).
[0144] FIG. 24A is a schematic illustrating the general design of
rubella vectors with an insert in the structural site, located
between envelope glycoproteins E2 and E1. The detailed view shows
antigen flanked by two signal peptidase cleavage sites (E1 SP) and
followed by a transmembrane (TM) domain. This.TM. domain can vary
from the TM domain of rubella E2 to the TM domain of HW or other
viruses.
[0145] FIG. 24B is a digital image of replication of rubella
vectors bearing foreign antigens demonstrated by western blot with
antibodies to rubella structural proteins capsid and E1. Lanes 1, 3
and 4 show replicating virus, while lane 2 shows uninfected control
cells. Lanes 5 to 8 were stained with monoclonal antibody specific
for the MPER determinant of HIV. Only lane 7 generated a strong 10
kDa band for MPER, while rubella infected control lane 5 gave no
band. Lanes 9 to 12 were stained with human polyclonal antibodies
to HIV Gag. These antibodies detected SIV Gag antigen, called
BCsGag2, in lane, as well as a positive control for SIV Gag in lane
12, but did not give a band for rubella infected cells in lane
10.
[0146] FIG. 25 is a digital image of Western blots of rubella
expression of MPER or BCsGag2 antigens. MPER expression is shown
over time: it is optimal between day 5 and 10 of infection. On the
right, BCsGag2 is detected in lane 1 by polyclonal antibodies to SW
Gag obtained from a macaque immunized with a rubella vector
expressing Gag.
[0147] FIGS. 26A-26C are graphs illustrating the immune response to
the SIV Gag insert expressed by rubella vectors. FIG. 26A
illustrates sera from three macaques that received rubella-Gag 4 to
7 weeks earlier. FIG. 26B illustrates sera from three macaques that
received three doses of DNA vaccine, followed by rubella-Gag 4
weeks earlier. Both groups developed high tittered antibodies to
Gag. FIG. 26C compares three of these sera with five sera from SW
infected macaques. In each case, the antibody titers elicited by
rubella-Gag vectors were greater than or equal to SIV
infection.
[0148] FIGS. 27A and 27B are graphs illustrating the antibody
response to a single dose of Rubella-Gag vectors. Antibodies rose
steadily between 2 and 4 to 7 weeks after immunization with the
live vectors.
[0149] FIGS. 28A-28F are graphs illustrating persistence of
antibodies elicited by rubella vectors. All three animals in group
3 were followed over 9 months following their dose of live
rubella-Gag vectors. The decline in anti-Gag titers was compared to
the decline in anti-rubella antibodies at the same time points.
Both antibodies fell at nearly the same rate, indicating that
anti-Gag antibodies may be long-lived in these animals.
[0150] FIGS. 29A and 29B are graphs illustrating the immune
response to a live rubella-Gag vector boost. Group 1 (right panel)
and group 4 (left panel) macaques were rested for 6 to 9 months
after their first dose and then re-immunized with rubella vectors
expressing SIV Gag antigens. Group 4 macaques were unable to
respond, but the group 1 macaques responded strongly. Boosting
indicates that the initial vaccination with rubella-Gag had
successfully induced memory B cells specific for the Gag
insert.
[0151] FIG. 30 is a set of graphs illustrating the immune response
to the MPER insert expressed by rubella vectors. Macaques in groups
1 and 3 were exposed to two rubella vectors concurrently, one
expressing HIV MPER and the other expressing SIV Gag. As shown
above (FIGS. 26A and 27B), all six macaques made antibodies to the
Gag insert. In addition, this figure shows that five out of six
macaques developed strong antibody titers to MPER. These results
indicate that immunization with two rubella vectors at the same
time results in antibodies to both vaccine inserts.
[0152] FIG. 31 is a schematic illustrating the position of various
larger Gag antigens. The size of Gag inserts that were expressed in
the structural site of rubella expanded from 85 amino acids
(BCsGag2) to 170 amino acids (Gag 41-211) to 322 amino acids (Gag
41-363) and even to 350 amino acids (Gag 41-391) (see FIG. 32). The
last two constructs include the entire p27 Gag protein, with or
without p2.
[0153] FIG. 32 is a digital image illustrating the expression of
large Gag antigens was demonstrated by western blot, using
monoclonal antibody 2F12. Lanes 1 to 3 show the expression of Gag
protein 41-363 by rubella vectors at passages P3 and P6. Lanes 4 to
7 show expression of Gag 41-391 at passages P3 to P6. Lane 8 is a
positive control of recombinant p57 Gag protein. The sequences of
these constructs are provided in the Table 8, part A, large Gag
inserts. Known epitopes for T cell recognition including Class I
restricted epitopes are shown and are known targets of CTLs. Class
II restricted epitopes are also shown.
[0154] FIG. 33 is a set of digital images illustrating growth and
expression of rubella vectors with gp120 inserts. Vector growth was
detected by western blot with anti-rubella antibodies (left panel).
Expression of rubella proteins capsid and E1 indicate vector
growth. These vectors also expressed gp120 constructs with internal
deletions, lanes 1-3, or with amino acids 1-20 of rubella E1
protein attached at the amino end of gp120. Antigen expression was
detected by western blot, using monoclonal antibody 2G12. These
inserts are listed in Table 8, part C, HIV gp120 inserts.
[0155] FIG. 34 is a digital image of a western blot illustrating
expression of additional gp120 inserts, as detected by western blot
with monoclonal antibody 2G12. These gp120 constructs were
truncated at the amino end (amino acid (aa) 79, 88 or 93) or at the
carboxyl end (aa 484 or 506). The sequences of these inserts are
given in Table 8, part C, HIV gp120 inserts.
DETAILED DESCRIPTION OF SEVERAL EMBODIMENTS
I. Introduction
[0156] Many of the most successful vaccines are based on live
attenuated vaccine strains of pathogens. As they replicate, they
expose the host to exponentially increasing amounts of viral
antigens, while presenting the antigens in the most immunogenic
way, in the context of an acute infection. They combine innate and
adaptive immunity to elicit antigen specific T cells and
neutralizing antibodies. In the past, these strains were derived
from virulent viruses by repeated passage under selective
conditions, until virulence genes were mutated or lost, while
retaining the ability to replicate and elicit an immune response in
the host.
[0157] Human immunodeficiency virus (HIV) infection often elicits a
strong immune response, including T cell immunity and neutralizing
antibodies. Similarly, prior infection with nef deleted simian
immunodeficiency virus (SIV) can protect animals against a
subsequent challenge. However, it seems unlikely that HIV virus
could be attenuated sufficiently for vaccine use. In part, this is
due to the retroviral life cycle, with its obligatory integration
into host DNA. It is also due to the high rate of mutation, with
the risk of reversion to wild type. In addition, no virulence genes
have been identified that could be mutated or deleted to produce a
reliably attenuated vaccine strain.
[0158] Instead of classical attenuation, the inventors have
developed live attenuated rubella viral vectors to combine the
safety and immunogenicity of the vector with the antigenicity of
the HIV and SIV protein inserts. Previous vectors have included DNA
viruses, such as vaccinia virus and modified vaccinia Ankara,
adenovirus and cytomegalovirus (CMV). They also have included RNA
viruses, such as Venezuelan equine encephalomyelitis replicons,
attenuated vesicular stomatitis virus, and yellow fever vaccine.
Some vectors are defective and replicate poorly or not at all in
vivo, while others grow freely. Rubella virus has a number of
desirable properties for a live vector. The live attenuated rubella
vaccine strain is immunogenic in humans at a dose of just 5,000
PFU. The RA27/3 vaccine strain is a licensed product, and its
safety record has been established in millions of children around
the world. It is immunogenic: one dose protects for life (against
rubella infection), and it elicits mucosal as well as systemic
immunity. It has no DNA intermediate, cannot integrate into host
DNA, and does not persist after the acute infection. A full length,
infectious cDNA clone is available, both for wild type rubella and
for the RA27/3 vaccine strain, making it possible to manipulate
rubella genetically. Rubella readily infects rhesus macaques. These
are the animal model of choice for demonstrating protection against
SIV or simian-human immunodeficiency virus (SHIV) challenge.
[0159] Despite these desirable properties, the use of rubella virus
for a live vector has been unsuccessful because of the inability to
maintain stable expression of foreign genes in a live rubella
vector. Moreover, it has remained unclear which foreign genes could
be inserted, where to insert them, and how large an insert could be
accommodated in viral RNA and packaged into virions. For example,
if the insert exceeded the size limit, selective pressure resulted
in an unstable construct with loss of gene expression.
[0160] Disclosed herein is a rubella viral vector construct that is
capable of expressing foreign genes at a high level without
interfering with expression of essential rubella genes and
packaging of live virus. This vector construct maintains stable
expression of foreign genes for multiple passages. Thus, the
inventors have created a new way to use rubella vaccine as a viral
vector to express an additional protein antigen of a second virus.
In this way, the safety and immunogenicity of a rubella vaccine can
be combined with the antigenicity of another virus.
[0161] For example, previous vectors, with up to 1000 fold less
potency, have been tested for immunization with HIV antigens, and
they all failed to protect against HIV infection. The vector
constructs disclosed herein are believed to be capable of actually
immunizing against this pathogen. Further, unlike previous vectors,
the safety and immunogenicity of a live attenuated rubella vaccine
has been demonstrated in tens of millions of children throughout
the world. Vaccine potency is based on the fact that this is a
replicating vector that simulates infection. One dose protects for
life against rubella. The vaccine induces mucosal as well as
systemic immunity. Each of these properties would be desirable in a
vaccine against HIV or other pathogens, such as SIV, RSV or
hepatitis.
[0162] At the same time, a disclosed vector construct can also be
the lowest cost vector for virtually any viral pathogen, since the
immunizing dose is so low that one ml of culture fluid can make up
to 1,000 doses of vaccine. The market could be more than 100
million doses per year. Moreover, in the United States, the
disclosed vector construct can be used to generate a rubella
vaccine that could be substituted for the current rubella vaccine,
at almost zero cost, and used to immunize against rubella plus the
inserted antigen. Without vaccination, the average age of becoming
seropositive to rubella is about 9 years old in many parts of the
world. Thus, it could be given to 1-2 year olds with a boost at 9
years old, with a high likelihood of success in immunizing against
rubella as well as the foreign antigen (such as HBsAg or HIV, SIV
or RSV antigen).
II. Abbreviations and Terms
[0163] aa: amino acid [0164] AIDS: acquired immune deficiency
syndrome [0165] bp: base pair [0166] CTL: cytotoxic T lymphocyte
[0167] ELISA: enzyme linked immunosorbent assay [0168] Gag:
group-specific antigen [0169] GFP: green fluorescent protein [0170]
Gp41: glycoprotein 41 [0171] Gp120: glycoprotein 120 [0172] HBsAg:
hepatitis B surface antigen [0173] HIV: human immunodeficiency
virus [0174] MHC: major histocompatibility complex [0175] MPER or
[0176] MPR: membrane proximal region [0177] MW molecular weight
[0178] ORF: open reading frame [0179] PCR: polymerase chain
reaction [0180] TM: transmembrane [0181] VLP: viral like
particle
[0182] Unless otherwise noted, technical terms are used according
to conventional usage. Definitions of common terms in molecular
biology may be found in Benjamin Lewin, Genes V, published by
Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al.
(eds.), The Encyclopedia of Molecular Biology, published by
Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A.
Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive
Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN
1-56081-569-8).
[0183] Unless otherwise explained, all technical and scientific
terms used herein have the same meaning as commonly understood by
one of ordinary skill in the art to which this disclosure belongs.
The singular terms "a," "an," and "the" include plural referents
unless context clearly indicates otherwise. Similarly, the word
"or" is intended to include "and" unless the context clearly
indicates otherwise. It is further to be understood that all base
sizes or amino acid sizes, and all molecular weight or molecular
mass values, given for nucleic acids or polypeptides are
approximate, and are provided for description. Although methods and
materials similar or equivalent to those described herein can be
used in the practice or testing of this disclosure, suitable
methods and materials are described below. The term "comprises"
means "includes." All publications, patent applications, patents,
and other references mentioned herein are incorporated by reference
in their entirety. In case of conflict, the present specification,
including explanations of terms, will control. In addition, the
materials, methods, and examples are illustrative only and not
intended to be limiting.
[0184] To facilitate review of the various embodiments of this
disclosure, the following explanations of specific terms are
provided:
[0185] Amplification: Of a nucleic acid molecule (e.g., a DNA or
RNA molecule) refers to use of a technique that increases the
number of copies of a nucleic acid molecule in a specimen. An
example of amplification is the polymerase chain reaction (PCR), in
which a biological sample collected from a subject is contacted
with a pair of oligonucleotide primers, under conditions that allow
for the hybridization of the primers to a nucleic acid template in
the sample. The primers are extended under suitable conditions,
dissociated from the template, and then re-annealed, extended, and
dissociated to amplify the number of copies of the nucleic acid.
The product of amplification may be characterized by
electrophoresis, restriction endonuclease cleavage patterns,
oligonucleotide hybridization or ligation, and/or nucleic acid
sequencing using standard techniques. Other examples of
amplification include strand displacement amplification, as
disclosed in U.S. Pat. No. 5,744,311; transcription-free isothermal
amplification, as disclosed in U.S. Pat. No. 6,033,881; repair
chain reaction amplification, as disclosed in WO 90/01069; ligase
chain reaction amplification, as disclosed in EP-A-320 308; gap
filling ligase chain reaction amplification, as disclosed in U.S.
Pat. No. 5,427,930; and NASBA.TM. RNA transcription-free
amplification, as disclosed in U.S. Pat. No. 6,025,134.
[0186] Antibody: Immunoglobulin molecules and immunologically
active portions of immunoglobulin molecules, that is, molecules
that contain an antigen binding site that specifically binds
(immunoreacts with) an antigen.
[0187] A naturally occurring antibody (e.g., IgG, IgM, IgD)
includes four polypeptide chains, two heavy (H) chains and two
light (L) chains interconnected by disulfide bonds. However, it has
been shown that the antigen-binding function of an antibody can be
performed by fragments of a naturally occurring antibody. Thus,
these antigen-binding fragments are also intended to be designated
by the term "antibody." Specific, non-limiting examples of binding
fragments encompassed within the term antibody include (i) a Fab
fragment consisting of the V.sub.L, V.sub.H, C.sub.L and C.sub.H1
domains; (ii) an F.sub.d fragment consisting of the V.sub.H and
C.sub.H1 domains; (iii) an Fv fragment consisting of the V.sub.L
and V.sub.H domains of a single arm of an antibody, (iv) a dAb
fragment (Ward et al., Nature 341:544-546, 1989) which consists of
a V.sub.H domain; (v) an isolated complimentarity determining
region (CDR); and (vi) a F(ab').sub.2 fragment, a bivalent fragment
comprising two Fab fragments linked by a disulfide bridge at the
hinge region.
[0188] Methods of producing polyclonal and monoclonal antibodies
are known to those of ordinary skill in the art, and many
antibodies are available. See, e.g., Coligan, Current Protocols in
Immunology Wiley/Greene, NY, 1991; and Harlow and Lane, Antibodies:
A Laboratory Manual Cold Spring Harbor Press, NY, 1989; Stites et
al., (eds.) Basic and Clinical Immunology (4th ed.) Lange Medical
Publications, Los Altos, Calif., and references cited therein;
Goding, Monoclonal Antibodies: Principles and Practice (2d ed.)
Academic Press, New York, N.Y. 1986; and Kohler and Milstein,
Nature 256: 495-497, 1975. Other suitable techniques for antibody
preparation include selection of libraries of recombinant
antibodies in phage or similar vectors. See, Huse et al., Science
246: 1275-1281, 1989; and Ward et al., Nature 341: 544-546, 1989.
"Specific" monoclonal and polyclonal antibodies and antisera (or
antiserum) will usually bind with a K.sub.D of at least about 0.1
.mu.M, preferably at least about 0.01 .mu.M or better, and most
typically and preferably, 0.001 .mu.M or better.
[0189] Immunoglobulins and certain variants thereof are known and
many have been prepared in recombinant cell culture (e.g., see U.S.
Pat. No. 4,745,055; U.S. Pat. No. 4,444,487; WO 88/03565; EP
256,654; EP 120,694; EP 125,023; Faoulkner et al., Nature 298:286,
1982; Morrison, J. Immunol. 123:793, 1979; Morrison et al., Ann
Rev. Immunol 2:239, 1984). Detailed methods for preparation of
chimeric (humanized) antibodies can be found in U.S. Pat. No.
5,482,856. Additional details on humanization and other antibody
production and engineering techniques can be found in Borrebaeck
(ed), Antibody Engineering, 2.sup.nd Edition Freeman and Company,
NY, 1995; McCafferty et al., Antibody Engineering, A Practical
Approach, IRL at Oxford Press, Oxford, England, 1996, and Paul
Antibody Engineering Protocols Humana Press, Towata, N.J.,
1995.
[0190] Antigen: A compound, composition, or substance that can
stimulate the production of antibodies or a T cell response in an
animal, including compositions that are injected or absorbed into
an animal. An antigen reacts with the products of specific humoral
or cellular immunity, including those induced by heterologous
immunogens. The term is used interchangeably with the term
"immunogen." The term "antigen" includes all related antigenic
epitopes. An "antigenic polypeptide" is a polypeptide to which an
immune response, such as a T cell response or an antibody response,
can be stimulated. "Epitope" or "antigenic determinant" refers to a
site on an antigen to which B and/or T cells respond. In one
embodiment, T cells respond to the epitope when the epitope is
presented in conjunction with an MHC molecule. Epitopes can be
formed both from contiguous amino acids (linear) or noncontiguous
amino acids juxtaposed by tertiary folding of an antigenic
polypeptide (conformational). Epitopes formed from contiguous amino
acids are typically retained on exposure to denaturing solvents
whereas epitopes formed by tertiary folding are typically lost on
treatment with denaturing solvents. Normally, a B-cell epitope will
include at least about 5 amino acids but can be as small as 3-4
amino acids. A T-cell epitope, such as a CTL epitope, will include
at least about 7-9 amino acids, and a helper T-cell epitope at
least about 12-20 amino acids. Normally, an epitope will include
between about 5 and 15 amino acids, such as, 9, 10, 12 or 15 amino
acids. The amino acids are in a unique spatial conformation.
Methods of determining spatial conformation of epitopes include,
for example, x-ray crystallography and multi-dimensional nuclear
magnetic resonance spectroscopy. The term "antigen" denotes both
subunit antigens, (for example, antigens which are separate and
discrete from a whole organism with which the antigen is associated
in nature), as well as killed, attenuated or inactivated bacteria,
viruses, fungi, parasites or other microbes. Antibodies such as
anti-idiotype antibodies, or fragments thereof, and synthetic
peptide mimotopes, which can mimic an antigen or antigenic
determinant, are also captured under the definition of antigen as
used herein. Similarly, an oligonucleotide or polynucleotide which
expresses an antigen or antigenic determinant in vivo, such as in
gene therapy and DNA immunization applications, is also included in
the definition of antigen herein.
[0191] An "antigen," when referring to a protein, includes a
protein with modifications, such as deletions, additions and
substitutions (generally conservative in nature) to the native
sequence, so long as the protein maintains the ability to elicit an
immunological response, as defined herein. These modifications may
be deliberate, as through site-directed mutagenesis, or may be
accidental, such as through mutations of hosts which produce the
antigens.
[0192] Antigen Delivery Platform or Epitope Mounting Platform: In
the context of the present disclosure, the terms "antigen delivery
platform" and "epitope mounting platform" refer to a macromolecular
complex including one or more antigenic epitopes. Delivery of an
antigen (including one or more epitopes) in the context of an
epitope mounting platform enhances, increases, ameliorates or
otherwise improves a desired antigen-specific immune response to
the antigenic epitope(s). The molecular constituents of the antigen
delivery platform may be antigenically neutral or may be
immunologically active, that is, capable of generating a specific
immune response. Nonetheless, the term antigen delivery platform is
utilized to indicate that a desired immune response is generated
against a selected antigen that is a component of the
macromolecular complex other than the platform polypeptide to which
the antigen is attached. Accordingly, the epitope mounting platform
is useful for delivering a wide variety of antigenic epitopes,
including antigenic epitopes of pathogenic organisms such as
bacteria and viruses. The antigen delivery platform of the present
disclosure is particularly useful for the delivery of complex
peptide or polypeptide antigens, which may include one or many
distinct epitopes.
[0193] Antigenic polypeptide fragment: A polypeptide that is
antigenic. In an example, an antigenic polypeptide fragment
includes an HIV antigenic polypeptide fragment, such as a Gag, gp41
or gp120 antigenic polypeptide fragment or a HBsAg antigenic
polypeptide fragment.
[0194] Conservative variants: "Conservative" amino acid
substitutions are those substitutions that do not substantially
affect or decrease a desired activity of a protein or polypeptide.
For example, in the context of the present disclosure, a
conservative amino acid substitution does not substantially alter
or decrease the immunogenicity of an antigenic epitope. Similarly,
a conservative amino acid substitution does not substantially
affect the structure or, for example, the stability of a protein or
polypeptide. Specific, non-limiting examples of a conservative
substitution include the following examples:
TABLE-US-00001 Original Residue Conservative Substitutions Ala Ser
Arg Lys Asn Gln; His Asp Glu Cys Ser Gln Asn Glu Asp His Asn; Gln
Ile Leu, Val Leu Ile; Val Lys Arg; Gln; Glu Met Leu; Ile Phe Met;
Leu; Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp; Phe Val Ile; Leu
[0195] The term conservative variation also includes the use of a
substituted amino acid in place of an unsubstituted parent amino
acid, provided that antibodies raised to the substituted
polypeptide also immunoreact with the unsubstituted polypeptide.
Non-conservative substitutions are those that reduce an activity or
antigenicity or substantially alter a structure, such as a
secondary or tertiary structure, of a protein or polypeptide.
[0196] cDNA (complementary DNA): A piece of DNA lacking internal,
non-coding segments (introns) and regulatory sequences that
determine transcription. cDNA is typically synthesized in the
laboratory by reverse transcription from messenger RNA extracted
from cells.
[0197] Cytotoxic T lymphocyte (CTL): A type of lymphocyte (white
blood cell) that is involved in the immune defenses of the body.
Cytotoxic T cells are capable of inducing the death of inducing the
death of infected somatic or tumor cells. They are also capable of
killing cells infected with viruses (or other pathogens) or are
otherwise damaged or dysfunctional. Most CTLs express T-cell
receptors that can recognize a specific antigenic peptide bound to
Class I MHC molecules.
[0198] Deletion: Removal or loss of a sequence of nucleic or amino
acids. In one example, a deletion is an "in-frame deletion" (a
deletion of a number of base pairs that is a multiple of three and
thus constitutes a codon, and therefore does not disrupt the
triplet reading frame.)
[0199] Diagnostic: Identifying the presence or nature of a
pathologic condition, such as, but not limited to a condition
induced by a viral or other pathogen. Diagnostic methods differ in
their sensitivity and specificity. The "sensitivity" of a
diagnostic assay is the percentage of diseased individuals who test
positive (percent of true positives). The "specificity" of a
diagnostic assay is 1 minus the false positive rate, where the
false positive rate is defined as the proportion of those without
the disease who test positive. While a particular diagnostic method
may not provide a definitive diagnosis of a condition, it suffices
if the method provides a positive indication that aids in
diagnosis. "Prognostic" is the probability of development (or for
example, the probability of severity) of a pathologic condition,
such as a symptom induced by a viral infection or other pathogenic
organism, or resulting indirectly from such an infection.
[0200] Epitope: An antigenic determinant. These are particular
chemical groups or peptide sequences on a molecule that are
antigenic, that is, that elicit a specific immune response. An
antibody specifically binds a particular antigenic epitope on a
polypeptide. Epitopes can be formed both from contiguous amino
acids or noncontiguous amino acids juxtaposed by tertiary folding
of a protein. Epitopes formed from contiguous amino acids are
typically retained on exposure to denaturing solvents whereas
epitopes formed by tertiary folding are typically lost on treatment
with denaturing solvents. An epitope typically includes at least 3,
and more usually, at least 5, about 9, or 8-10 amino acids in a
unique spatial conformation. Methods of determining spatial
conformation of epitopes include, for example, x-ray
crystallography and multi-dimensional nuclear magnetic resonance
spectroscopy. See, e.g., "Epitope Mapping Protocols" in Methods in
Molecular Biology, Vol. 66, Glenn E. Morris, Ed (1996). In some
embodiments, an epitope binds an MHC molecule, e.g., an HLA
molecule or a DR molecule. In some embodiments, an epitope is a
cytotoxic T lymphocyte (CTL) epitope, such as a CTL epitope of
Gag.
[0201] Expression Control Sequences: Nucleic acid sequences that
regulate the expression of a heterologous nucleic acid sequence to
which it is operatively linked. Expression control sequences are
operatively linked to a nucleic acid sequence when the expression
control sequences control and regulate the transcription and, as
appropriate, translation of the nucleic acid sequence. Thus,
expression control sequences can include appropriate promoters,
enhancers, transcription terminators, a start codon (typically,
ATG) in front of a protein-encoding gene, splicing signal for
introns, maintenance of the correct reading frame of that gene to
permit proper translation of mRNA, and stop codons. The term
"control sequences" is intended to include, at a minimum,
components whose presence can influence expression, and can also
include additional components whose presence is advantageous, for
example, leader sequences and fusion partner sequences.
[0202] Glycoprotein 41 (gp41): An HIV-1 envelope glycoprotein that
mediates receptor binding and HIV entry into a cell. Gp41 includes
a membrane proximal region (MPR or MPER) and a transmembrane
spanning domain. Gp41 is immunogenic and induces a variety of
neutralizing antibodies, such as neutralizing antibodies directed
to 2F5, 4E10 and Z13. These three gp41 neutralizing antibodies
recognize the MPER of the HW-1 gp41 glycoprotein.
[0203] Gp41 antigenic insert: A peptide fragment that includes a
MPER of gp41 and a transmembrane spanning region of gp41. In an
example, the MPER (also referred to as the antigenic polypeptide
fragment) of gp41 includes the amino acid sequence of SEQ ID NO: 1
and a transmembrane spanning region of gp41 including the amino
acid sequence set forth as SEQ ID NO: 25
(X.sub.4FIMIVGGLX.sub.5GLRIVFTX.sub.6LSIV, X.sub.1, X.sub.2 and
X.sub.3 are any amino acid and X.sub.4, X.sub.5, and X.sub.6 are
any hydrophobic amino acid). For example, the antigenic polypeptide
fragment of gp41 is between 16 and 150 amino acids in length (such
as 28 and 150 amino acids in length) and the transmembrane spanning
region of gp41 is between 22 and 40 amino acids in length and
wherein the transmembrane spanning region of gp41 is C-terminal to
the antigenic polypeptide fragment of gp41.
[0204] Glycoprotein 120 (gp120): An envelope protein from Human
Immunodeficiency Virus (HIV). The envelope protein is initially
synthesized as a longer precursor protein of 845-870 amino acids in
size, designated gp160. Gp160 forms a homotrimer and undergoes
glycosylation within the Golgi apparatus. It is then cleaved by a
cellular protease into gp120 and gp41. Gp41 contains a
transmembrane domain and remains in a trimeric configuration; it
interacts with gp 120 in a non-covalent manner. Gp120 contains most
of the external, surface-exposed, domains of the envelope
glycoprotein complex, and it is gp120 which binds both to the
cellular CD4 receptor and to the cellular chemokine receptors (such
as CCR5).
[0205] Mature gp120 wildtype polypeptides have about 500 amino
acids in the primary sequence. Gp120 is heavily N-glycosylated
(approximately 20 to 25 sites) giving rise to an apparent molecular
weight of 120 kD. Exemplary sequence of wt gp160 polypeptides are
shown on GENBANK.RTM., for example accession numbers AAB05604 and
AAD12142 incorporated herein by reference in their entirety as
available on Oct. 16, 2009.
[0206] The gp120 core has a unique molecular structure, which
comprises two domains: an "inner" domain (which faces gp41) and an
"outer" domain (which is mostly exposed on the surface of the
oligomeric envelope glycoprotein complex). The two gp120 domains
are separated by a "bridging sheet" that is not part of either
domain. The gp120 core comprises 25 beta strands, 5 alpha helices,
and 10 defined loop segments. The 10 defined loop segments include
five conserved regions (C1-C5) and five regions of high variability
(V1-V5).
[0207] Gp120 polypeptides also include "gp120-derived molecules"
which encompasses analogs (non-protein organic molecules),
derivatives (chemically functionalized protein molecules obtained
starting with the disclosed protein sequences) or mimetics
(three-dimensionally similar chemicals) of the native gp120
structure, as well as proteins sequence variants (such as mutants,
for example deletions, such as loop deletions, insertions or point
mutation in any combination), genetic alleles, fusions proteins of
gp120, or combinations thereof.
[0208] The numbering used in gp120 polypeptides disclosed herein is
relative to the HXB2 numbering scheme as set forth in Numbering
Positions in HIV Relative to HXB2CG Bette Korber et al., Human
Retroviruses and AIDS 1998: A Compilation and Analysis of Nucleic
Acid and Amino Acid Sequences. Korber B, Kuiken C L, Foley B, Hahn
B, McCutchan F, Mellors J W, and Sodroski J, Eds. Theoretical
Biology and Biophysics Group, Los Alamos National Laboratory, Los
Alamos, N. Mex. which is incorporated by reference herein in its
entirety.
[0209] As used herein, a variant gp120 polypeptide is a gp120
polypeptide in which one or more amino acids have been altered
(e.g., deleted or substituted). In one example, a variant gp120
polypeptide is a gp120 polypeptide in which at least 8 consecutive
residues, such as 9, 10, 11 or 12 consecutive residues, of the
fourth conserved loop (C4) between residues 419 and 434 of gp120 of
SEQ ID NO: 63 has been deleted. In a particular example, a variant
gp120 polypeptide includes a gp120 polypeptide in which residues
424-432 are deleted. Additional variant gp120 polypeptides include
deletions of INMWQKVGK (residues 424-432 of SEQ ID NO:63),
INMWQKVGKA (residues 424-433 of SEQ ID NO: 63), INMWQKVGKAM
(residues 424-434 of SEQ ID NO: 63), RIKQIINMWQKVGK (residues
419-432 of SEQ ID NO: 63), IKQIINMWQKVGK (residues 420-432 of SEQ
ID NO: 63), KQIINMWQKVGK (residues 421-432 of SEQ ID NO: 63),
QIINMWQKVGK (residues 422-432 of SEQ ID NO: 63), IINMWQKVGK
(residues 423-432 of SEQ ID NO: 63). In other embodiments, variant
gp120 polypeptides include combinations of the amino and carboxyl
ends between residues 419 and 434.
[0210] Any of the disclosed variant gp120 polypeptide including
deletions in C4 can also include a deletion in the V1V2 loop region
(with an amino acid sequence set forth in SEQ ID NO: 63); see SR
Pollard and DC Wiley, EMBO J. 11:585-91, 1992 which is hereby
incorporated by reference in its entirety.
[0211] In some examples, an antigenic insert includes a gp120
polypeptide with an amino acid sequence set forth by SEQ ID NOs:
152, 153, 154, 155, 156, 158, 159 or 160.
[0212] Group-specific antigen (Gag): A gene which encodes core
structural proteins of HIV or SIV. In particular, Gag contains
approximately 1500 nucleotides and encodes four separate proteins
(capsid protein (p24), matrix protein (p17), nucleocapsid (p9) and
p6) which form the building blocks for the viral core. Gag forms a
spherical shell underlying the membrane of an immature viral
particle. After proteolytic maturation of Gag, the capsid (CA)
domain of Gag reforms into a conical shell enclosing the RNA
genome. This mature shell contains 1,000-1,500 CA proteins
assembled into a hexameric lattice with a spacing of 10 nm.
Exemplary nucleic acid and amino acid sequences are known to those
of skill in the art including the amino acid sequences provided for
Gag herein.
[0213] Hepatitis B Surface Antigen (HBsAg): HBsAg is composed of 3
polypeptides, preS1, preS2 and S that are produced from alternative
translation start sites. The surface proteins have many functions,
including attachment and penetration of the virus into hepatocytes
at the beginning of the infection process. The surface antigen is a
principal component of the hepatitis B envelope. HBsAg has four
membrane spanning domains. Exemplary nucleic acid and amino acid
sequences are known to those of skill in the art and are shown on
GENBANK.RTM., for example accession numbers NM.sub.--001166119,
NM.sub.--001130714, NM.sub.--001130713, NM.sub.--016269, BAF48754,
BAF48753, BAF48752, BAF48751, AAA35977, AAA35976, AAA35975,
AAA35974 and AAA35973 all of which are incorporated herein by
reference in their entirety as available on Oct. 16, 2009.
[0214] As used herein, a variant HBsAg can include natural variants
or recombinant variants such as a HBsAg that includes a MPER from
gp41. In a particular example, a variant HBsAg includes a MPER and
a membrane spanning domain from gp41.
[0215] Heterologous antigenic insert: An insert with an antigenic
sequence that is not normally (in the wild-type sequence) found
adjacent to a second sequence. In one embodiment, the antigenic
insert is from a different genetic source, such as a virus or
organism, than the second sequence. In one particular example, the
antigenic insert is an HIV envelope protein or an HIV Gag protein.
For example, the heterologous antigenic insert is a MPER of the
HIV-1 gp41 glycoprotein. In other examples, the heterologous
antigenic insert is not a rubella structural protein, such as a
capsid.
[0216] Host cells: Cells in which a polynucleotide, for example, a
polynucleotide vector or a viral vector, can be propagated and its
DNA expressed. The cell may be prokaryotic or eukaryotic. The term
also includes any progeny of the subject host cell. It is
understood that all progeny may not be identical to the parental
cell since there may be mutations that occur during replication.
However, such progeny are included when the term "host cell" is
used.
[0217] Human Immunodeficiency Virus (HIV): A virus, known to cause
AIDS, which includes HIV-1 and HIV-2. HIV-1 is composed of two
copies of single-stranded RNA enclosed by a conical capsid
including the viral protein p24, typical of lentiviruses. The
capsid is surrounded by a plasma membrane of host-cell origin.
[0218] The RNA genome has at least three genes, gag, pol, and env,
which contain information needed to make the structural proteins
for new virus particles. The envelope protein of HIV-1 is made up
of a glycoprotein called gp160. The mature, virion associated
envelope protein is a trimeric molecule composed of three gp120 and
three gp41 subunits held together by weak noncovalent interactions.
This structure is highly flexible and undergoes substantial
conformational changes upon gp120 binding with CD4 and chemokine
coreceptors, which leads to exposure of the fusion peptides of gp41
that insert into the target cell membrane and mediate viral entry.
Following oligomerization in the endoplasmic reticulum, the gp160
precursor protein is cleaved by cellular proteases and is
transported to the cell surface. During the course of HIV-1
infection, the gp120 and gp41 subunits are shed from virions and
virus-infected cells due to the noncovalent interactions between
gp120 and gp41 and between gp41 subunits.
[0219] The HIV-1 envelope glycoproteins (gp120-gp41), which mediate
receptor binding and entry, are major targets for neutralizing
antibodies. Although the envelope glycoproteins are immunogenic and
induce a variety of antibodies, the neutralizing antibodies that
are induced are strain-specific, and the majority of the immune
response is diverted to non-neutralizing determinants. Broadly
neutralizing monoclonal antibodies have been isolated only rarely
from natural HIV infection. For example, only three gp41-directed
neutralizing antibodies (2F5, 4E10 and Z13) and a few
gp120-directed neutralizing antibodies have been identified to
date.
[0220] Immune response: A response of a cell of the immune system,
such as a B cell, T cell, or monocyte, to a stimulus. In some
cases, the response is specific for a particular antigen (that is,
an "antigen-specific response"). In some cases, an immune response
is a T cell response, such as a CD4+ response or a CD8+ response.
Alternatively, the response is a B cell response, and results in
the production of specific antibodies. For purposes of the present
invention, a "humoral immune response" refers to an immune response
mediated by antibody molecules, while a "cellular immune response"
is one mediated by T-lymphocytes and/or other white blood cells. A
"protective immune response" is an immune response that inhibits a
detrimental function or activity (such as a detrimental effect of a
pathogenic organism such as a virus), reduces infection by a
pathogenic organism (such as, a virus), or decreases symptoms that
result from infection by the pathogenic organism. A protective
immune response can be measured, for example, by the inhibition of
viral replication or plaque formation in a plaque reduction assay
or ELISA-neutralization assay (NELISA), or by measuring resistance
to viral challenge in vivo.
[0221] An immunogenic composition can induce a B cell response. The
ability of a particular antigen to stimulate a B cell response can
be measured by determining if antibodies are present that bind the
antigen. In one example, neurtralizing antibodies are produced.
[0222] One aspect of cellular immunity involves an antigen-specific
response by cytolytic T-cells ("CTL"s). CTLs have specificity for
peptide antigens that are presented in association with proteins
encoded by the major histocompatibility complex (MHC) and expressed
on the surface of cells. CTLs help induce and promote the
destruction of intracellular microbes, or the lysis of cells
infected with such microbes. Another aspect of cellular immunity
involves an antigen-specific response by helper T-cells. Helper
T-cells act to help stimulate the function, and focus the activity
of, nonspecific effector cells against cells displaying peptide
antigens in association with MHC molecules on their surface. A
"cellular immune response" also refers to the production of
cytokines, chemokines and other such molecules produced by
activated T-cells and/or other white blood cells, including those
derived from CD4+ and CD8+ T-cells.
[0223] The ability of a particular antigen to stimulate a
cell-mediated immunological response may be determined by a number
of assays, such as by lymphoproliferation (lymphocyte activation)
assays, CTL cytotoxic cell assays, or by assaying for T-lymphocytes
specific for the antigen in a sensitized subject. Such assays are
well known in the art. See, for example, Erickson et al. (1993) J.
Immunol. 151:4189-4199; Doe et al. (1994) Eur. J. Immunol.
24:2369-2376. Recent methods of measuring cell-mediated immune
response include measurement of intracellular cytokines or cytokine
secretion by T-cell populations, or by measurement of epitope
specific T-cells (for example, by the tetramer technique) (reviewed
by McMichael and O'Callaghan (1998) J. Exp. Med. 187(9)1367-1371;
Mcheyzer-Williams et al. (1996) Immunol. Rev. 150:5-21; Lalvani et
al. (1997) J. Exp. Med. 186:859-865).
[0224] Thus, an immunological response as used herein may be one
which stimulates the production of CTLs, and/or the production or
activation of helper T-cells. The antigen of interest may also
elicit an antibody-mediated immune response. Hence, an
immunological response may include one or more of the following
effects: the production of antibodies by B-cells; and/or the
activation of suppressor T-cells and/or gamma-delta T-cells
directed specifically to an antigen or antigens present in the
composition or vaccine of interest. These responses may serve to
neutralize infectivity, and/or mediate antibody-complement, or
antibody dependent cell cytotoxicity (ADCC) to provide protection
to an immunized host. Such responses can be determined using
standard immunoassays and neutralization assays, well known in the
art.
[0225] Immunogenic composition: A composition comprising at least
one epitope of a virus, or other pathogenic organism, that induces
a measurable CTL response, or induces a measurable B cell response
(for example, production of antibodies that specifically bind the
epitope). It further refers to isolated nucleic acids encoding an
immunogenic epitope of virus or other pathogen that can be used to
express the epitope (and thus be used to elicit an immune response
against this polypeptide or a related polypeptide expressed by the
pathogen). For in vitro use, the immunogenic composition may
consist of the isolated nucleic acid, protein or peptide. For in
vivo use, the immunogenic composition will typically include the
nucleic acid, protein or peptide in pharmaceutically acceptable
carriers or excipients, and/or other agents, for example,
stabilizers. An immunogenic polypeptide (such as an antigenic
polypeptide), or nucleic acid encoding the polypeptide, can be
readily tested for its ability to induce a CTL or antibody response
by art-recognized assays.
[0226] Immunogenic peptide: A peptide which comprises an
allele-specific motif or other sequence such that the peptide will
bind an MHC molecule and induce a cytotoxic T lymphocyte ("CTL")
response, or a B cell response (e.g. antibody production) against
the antigen from which the immunogenic peptide is derived.
[0227] Inhibiting an infection: Inhibiting infection by a pathogen
such as a virus, such as a lentivirus, or other virus, refers to
inhibiting the full development of a disease either by avoiding
initial infection or inhibiting development of the disease process
once it is initiated. For example, inhibiting a viral infection
refers to lessening symptoms resulting from infection by the virus,
such as preventing the development of symptoms in a person who is
known to have been exposed to the virus, or to lessening virus
number or infectivity of a virus in a subject exposed to the
virus.
[0228] Isolated: An "isolated" biological component (such as a
nucleic acid or protein or organelle) has been substantially
separated or purified away from other biological components in the
cell of the organism in which the component naturally occurs, for
example, other chromosomal and extra-chromosomal DNA and RNA,
proteins and organelles. Nucleic acids and proteins that have been
"isolated" include nucleic acids and proteins purified by standard
purification methods. The term also embraces nucleic acids and
proteins prepared by recombinant expression in a host cell as well
as chemically synthesized nucleic acids.
[0229] Label: A detectable compound or composition that is
conjugated directly or indirectly to another molecule to facilitate
detection of that molecule. Specific, non-limiting examples of
labels include fluorescent tags, affinity tags, enzymatic linkages,
and radioactive isotopes. An affinity tag is a peptide or
polypeptide sequence capable of specifically binding to a specified
substrate, for example, an organic, non-organic or enzymatic
substrate or cofactor. A polypeptide including a peptide or
polypeptide affinity tag can typically be recovered, for example,
purified or isolated, by means of the specific interaction between
the affinity tag and its substrate. An exemplary affinity tag is a
poly-histidine (e.g., six-histidine) affinity tag which can
specifically bind to non-organic metals such as nickel and/or
cobalt. Additional affinity tags are well known in the art.
[0230] Linking peptide: A linking peptide (or linker sequence) is
an amino acid sequence that covalently links two polypeptide
domains. Linking peptides can be included between a polypeptide and
an antigenic epitope to provide rotational freedom to the linked
polypeptide domains and thereby to promote proper domain folding.
Linking peptides, which are generally between 2 and 25 amino acids
in length, are well known in the art and include, but are not
limited to the amino acid sequences glycine-proline-glycine-proline
(GPGP)(SEQ ID NO: 37) and glycine-glycine-serine (GGS), as well as
the glycine(4)-serine spacer described by Chaudhary et al., Nature
339:394-397, 1989. In some cases multiple repeats of a linking
peptide are present.
[0231] Lymphocytes: A type of white blood cell that is involved in
the immune defenses of the body. There are two main types of
lymphocytes: B cells and T cells. "T lymphocytes" or "T cells" are
non-antibody producing lymphocytes that constitute a part of the
cell-mediated arm of the immune system. T cells arise from immature
lymphocytes that migrate from the bone marrow to the thymus, where
they undergo a maturation process under the direction of thymic
hormones. Here, the mature lymphocytes rapidly divide increasing to
very large numbers. The maturing T cells become immunocompetent
based on their ability to recognize and bind a specific antigen.
Activation of immunocompetent T cells is triggered when an antigen
binds to the lymphocyte's surface receptors. T cells include, but
are not limited to, CD4.sup.+ T cells and CD8.sup.+ T cells. A
CD4.sup.+ T lymphocyte is an immune cell that carries a marker on
its surface known as "cluster of differentiation 4" (CD4). These
cells, also known as helper T cells, help orchestrate the immune
response, including antibody responses as well as killer T cell
responses. CD8.sup.+ T cells carry the "cluster of differentiation
8" (CD8) marker. In one embodiment, a CD8 T cell is a cytotoxic T
lymphocyte. In another embodiment, a CD8 cell is a suppressor T
cell.
[0232] Membrane proximal region (MPER) of gp41: A region that is
immediately N-terminal of the transmembrane region of gp41. The
MPER is also known and referred to herein as the MPER (Membrane
proximal external region). The MPER is highly hydrophobic (50% of
residues are hydrophobic) and is highly conserved across many HIV
clades (Zwick, M. B., et al., J Virol, 75 (22): p. 10892-905,
2001). The conserved MPER of HIV-1 gp41 is a target of two broadly
neutralizing human monoclonal antibodies, 2F5 and 4E10. The core of
the 2F5 epitope has been shown to be ELDKWAS (SEQ ID NO: 35). With
this epitope, the residues D, K, and W were found to be involved in
recognition by 2F5. The core of the 4E10 epitope, NWFDIT (SEQ ID
NO: 36), maps just C-terminal to the 2F5 epitope on the gp41
ectodomain.
[0233] Oligonucleotide: A linear polynucleotide sequence of up to
about 100 nucleotide bases in length.
[0234] Open reading frame ("ORF"): A series of nucleotide triplets
(codons) coding for amino acids without any internal termination
codons. These sequences are usually translatable into a polypeptide
(peptide or protein). In one example, an open reading frame is a
rubella non-structural protein open reading frame, such as one
coding amino acids that include two NotI restriction enzyme sites.
In other examples, an open reading frame is a rubella structural
protein open reading frame.
[0235] Operatively linked: A first nucleic acid sequence is
operatively linked with a second nucleic acid sequence when the
first nucleic acid sequence is placed in a functional relationship
with the second nucleic acid sequence. For instance, a promoter is
operatively linked to a coding sequence if the promoter affects the
transcription or expression of the coding sequence. Generally,
operatively linked DNA sequences are contiguous and, where
necessary to join two protein-coding regions, in the same reading
frame, for example, two polypeptide domains or components of a
fusion protein.
[0236] Pharmaceutically acceptable carriers and/or pharmaceutically
acceptable excipients: The pharmaceutically acceptable carriers or
excipients of use are conventional. Remingtons: The Science and
Practice of Pharmacy, University of the Sciences in Philadelphia,
Lippincott Williams & Wilkins, Philadelphia, Pa., 21st Edition
(2005), describes compositions and formulations suitable for
pharmaceutical delivery of the constructs disclosed herein.
[0237] In general, the nature of the carrier will depend on the
particular mode of administration being employed. For instance,
parenteral formulations usually comprise injectable fluids that
include pharmaceutically and physiologically acceptable fluids such
as water, physiological saline, balanced salt solutions, aqueous
dextrose, glycerol or the like as a vehicle. For solid compositions
(e.g., powder, pill, tablet, or capsule forms), conventional
non-toxic solid carriers can include, for example, pharmaceutical
grades of mannitol, lactose, starch or magnesium stearate. In
addition to biologically neutral carriers, pharmaceutical
compositions to be administered can contain minor amounts of
non-toxic auxiliary substances, such as wetting or emulsifying
agents, preservatives, and pH buffering agents and the like, for
example sodium acetate or sorbitan monolaurate.
[0238] A "therapeutically effective amount" is a quantity of a
composition used to achieve a desired effect in a subject. For
instance, this can be the amount of the composition necessary to
inhibit viral (or other pathogen) replication or to prevent or
measurably alter outward symptoms of viral (or other pathogenic)
infection. When administered to a subject, a dosage will generally
be used that will achieve target tissue concentrations (for
example, in lymphocytes) that has been shown to achieve an in vitro
effect.
[0239] Polynucleotide: The term polynucleotide or nucleic acid
sequence refers to a polymeric form of nucleotide at least 10 bases
in length. A recombinant polynucleotide includes a polynucleotide
that is not immediately contiguous with both of the coding
sequences with which it is immediately contiguous (one on the 5'
end and one on the 3' end) in the naturally occurring genome of the
organism from which it is derived. The term therefore includes, for
example, a recombinant DNA which is incorporated into a vector;
into an autonomously replicating plasmid or virus; or into the
genomic DNA of a prokaryote or eukaryote, or which exists as a
separate molecule (e.g., a cDNA) independent of other sequences.
The nucleotides can be ribonucleotides, deoxyribonucleotides, or
modified forms of either nucleotide. The term includes single- and
double-stranded forms of DNA.
[0240] Polypeptide: Any chain of amino acids, regardless of length
or post-translational modification (for example, glycosylation or
phosphorylation), such as a protein or a fragment or subsequence of
a protein. The term "peptide" is typically used to refer to a chain
of amino acids of between 3 and 30 amino acids in length. For
example an immunologically relevant peptide may be between about 7
and about 25 amino acids in length, e.g., between about 8 and about
10 amino acids.
[0241] In the context of the present disclosure, a polypeptide can
be a fusion protein comprising a plurality of constituent
polypeptide (or peptide) elements. Typically, the constituents of
the fusion protein are genetically distinct, that is, they
originate from distinct genetic elements, such as genetic elements
of different organisms or from different genetic elements (genomic
components) or from different locations on a single genetic
element, or in a different relationship than found in their natural
environment. Nonetheless, in the context of a fusion protein the
distinct elements are translated as a single polypeptide. The term
monomeric fusion protein (or monomeric fusion protein subunit) is
used synonymously with such a single fusion protein polypeptide to
clarify reference to a single constituent subunit where the
translated fusion proteins assume a multimeric tertiary
structure.
[0242] Probes and primers: A probe comprises an isolated nucleic
acid attached to a detectable label or reporter molecule. Primers
are short nucleic acids, preferably DNA oligonucleotides, for
example, a nucleotide sequence of about 15 nucleotides or more in
length. Primers may be annealed to a complementary target DNA
strand by nucleic acid hybridization to form a hybrid between the
primer and the target DNA strand, and then extended along the
target DNA strand by a DNA polymerase enzyme. Primer pairs can be
used for amplification of a nucleic acid sequence, for example, by
the polymerase chain reaction (PCR) or other nucleic-acid
amplification methods known in the art. One of skill in the art
will appreciate that the specificity of a particular probe or
primer increases with its length. Thus, for example, a primer
comprising 20 consecutive nucleotides will anneal to a target with
a higher specificity than a corresponding primer of only about 15
nucleotides. Thus, in order to obtain greater specificity, probes
and primers may be selected that comprise 20, 25, 30, 35, 40, 50 or
more consecutive nucleotides.
[0243] Promoter: A promoter is a minimal sequence sufficient to
direct transcription. Also included are those promoter elements
which are sufficient to render promoter-dependent gene expression
controllable for cell-type specific, tissue-specific, or inducible
by external signals or agents; such elements may be located in the
5' or 3' regions of the gene. Both constitutive and inducible
promoters are included (see e.g., Bitter et al., Methods in
Enzymology 153:516-544, 1987). For example, when cloning in
bacterial systems, inducible promoters such as pL of bacteriophage
lambda, plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like
may be used. In one embodiment, when cloning in mammalian cell
systems, promoters derived from the genome of mammalian cells (for
example, metallothionein promoter) or from mammalian viruses (for
example, the retrovirus long terminal repeat; the adenovirus late
promoter; the vaccinia virus 7.5K promoter) can be used. Promoters
produced by recombinant DNA or synthetic techniques may also be
used to provide for transcription of the nucleic acid
sequences.
[0244] Purified: The term "purified" does not require absolute
purity; rather, it is intended as a relative term. Thus, for
example, a purified nucleic acid is one in which the nucleic acid
is more enriched than the nucleic acid in its natural environment
within a cell. Similarly, a purified peptide preparation is one in
which the peptide or protein is more enriched than the peptide or
protein is in its natural environment within a cell. In one
embodiment, a preparation is purified such that the protein or
peptide represents at least 50% (such as, but not limited to, 70%,
80%, 90%, 95%, 98% or 99%) of the total peptide or protein content
of the preparation.
[0245] Recombinant: A recombinant nucleic acid is one that has a
sequence that is not naturally occurring or has a sequence that is
made by an artificial combination of two otherwise separated
segments of sequence, for example, a polynucleotide encoding a
fusion protein. This artificial combination is often accomplished
by chemical synthesis or, more commonly, by the artificial
manipulation of isolated segments of nucleic acids, e.g., by
genetic engineering techniques.
[0246] Respiratory syncytial virus (RSV): A virus which is a
leading cause of acute upper and lower respiratory tract infection
in adults, young children and infants. Serological evidence
indicates that in the western world approximately 95% of all
children have been infected with RSV by the age of two and 100% of
children have been exposed by the time they reach adulthood. In
most cases the RSV infections will only cause minor upper
respiratory illness with symptoms resembling that of the common
cold. However, severe infection with the virus may result in
bronchiolitis or pneumonia which may result in hospitalization or
death. In a given year, around 91,000 infants are hospitalized with
RSV infection in the United States. Infants who have been born
prematurely or have a pre-existing lung disease are a high risk of
severe infection and complications. These infections are
responsible for 40 to 50% of hospitalizations for pediatric
bronchiolitis and 25% of hospitalizations for pediatric pneumonia.
Since the immune response to RSV infection is not protective, RSV
infections reoccur throughout adulthood. In adults and older
children, RSV infection has been associated with upper respiratory
infection, tracheobronchitis, and otitis media. However, RSV in the
institutionalized elderly can be more serious and is characterized
by severe pneumonia and mortality rates of up to 20 and 78%,
respectively. Adults with a previous history of heart or lung
conditions are at a high risk for RSV infection. The infection has
been linked to exacerbation of patients with chronic obstructive
pulmonary disease. Significant mortality has been observed in
immunocompromised patients, particularly those undergoing bone
marrow transplantation.
[0247] RSV is a member of the order Mononegavira{umlaut over ()}es,
which includes the non-segmented negative strand RNA viruses in the
Families Paramyxoviridae, Rhandoviridae and Filoviridae. RSV of
humans (often also termed RSV or HRSV) is a member of the
Pneumovirus genus of the sub-family Pneumovirinae within the Family
Paramyxoviridae. Based on genetic and antigenic variations in the
structural proteins, RSV is classified into two subgroups, A and B
(Mufson, M. et al., J. Gen. Virol. 66:2111-2124). Other members of
the Pneumovirus genus include viruses such as bovine RSV (BRSV),
ovine RSV (ORSV) and pneumonia virus of mice (PVM) amongst others.
The sub-family Pneumovirinae also includes the genus
Metapneumovirus which contains the human pathogen human
metapneumovirus (hMPV).
[0248] hMPV causes respiratory illness ranging from mild upper
respiratory symptoms to severe lower respiratory disease such as
bronchiolitis and pneumonia. Depending on the patient population
sampled, between 5 and 15% of respiratory infections in young
children may be attributable to hMPV infection. hMPV is also
associated with 12 to 50% of otitis media in children. In the
Netherlands, 55% of tested individuals were seropositive for hMPV
by age 2, and almost all individuals 5 years and older were
seropositive.
[0249] In addition to the genome features described above, Family
characteristics include a lipid envelope containing one or more
glycoprotein species considered to be associated with attachment
and entry of the host cell. Entry is considered to require a
process by which the viral envelope fuses with the membrane of the
host cell. Fusion of infected cells with, for example, their
neighbors, can also result in the formation of fused multinucleate
cells known as syncytia in some cases. The fusion process is
believed to be glycoprotein mediated and is a feature shared with
diverse enveloped viruses in other taxonomic groups. In the case of
the Parctmyxoviridae viruses of all genera characteristically
express a fusion glycoprotein (F) which mediates membrane
fusion.
[0250] Rubella: A small, quasi-spherical, enveloped, nonsegmented,
plus-strand RNA virus that is a member of the rubivirus genus of
the togavirus family (Togaviridae). Molecular biology of rubella
virus is summarized by Frey, T. K. in Adv. Virus Res. 44:69-160
(1994) which is hereby incorporated by reference in its entirety.
The rubella virion (virus particle) includes a single-stranded RNA
encapsidated in an icosahedral nucleocapsid surrounded by a lipid
envelope. This virion has at least two RdRp nonstructural proteins
(nsP150 and nsP90) and three structural proteins (Capsid (C), E2
and E1). Multiple copies of a viral protein, designated the C
protein (molecular weight (MW)=32,000-38,000 daltons), make up the
nucleocapsid. Two types of viral glycoprotein, designated E1 and E2
(MW=53,000-58,000 daltons and 42,000-48,000 daltons, respectively),
are embedded in the envelope. The E2 glycoprotein has been further
subdivided into two subgroups, designated E2a and E2b, by their
ability to migrate differently when resolved by polyacrylamide gel
electrophoresis. E1 is the viral hemagglutinin. Neutralizing
epitopes have been found on both E1 and E2. In one example, MPER
and other HIV antigenic determinants are linked to E2 and E1 to
elicit similar neutralizing antibodies against HIV.
[0251] The rubella genome consists of RNA of positive polarity that
is roughly 10,000 nucleotides long and is capped and
polyadenylated. In infected cells, three viral RNA species are
synthesized: the genomic RNA, which also is the mRNA for
translation of the nonstructural proteins (whose function is in
viral RNA synthesis) from a long open reading frame (ORF) at the 5'
end of the genome; a complementary genome-length RNA of minus
polarity which is the template for synthesis of plus-strand RNA
species; and a subgenomic (SG) RNA which is initiated internally
and contains the sequences of the 3'-terminal one-third of the
genome (3327 nucleotides) and serves as the mRNA for the
translation of the structural proteins. The structural proteins are
proteolytically processed from a polyprotein precursor during
translation. The order of these proteins in the polyprotein is
NH2-C-E2-E1-COOH.
[0252] Sequence identity: The similarity between amino acid (and
polynucleotide) sequences is expressed in terms of the similarity
between the sequences, otherwise referred to as sequence identity.
Sequence identity is frequently measured in terms of percentage
identity (or similarity); the higher the percentage, the more
similar are the primary structures of the two sequences. In
general, the more similar the primary structures of two amino acid
sequences, the more similar are the higher order structures
resulting from folding and assembly. However, the converse is not
necessarily true, and polypeptides with low sequence identity at
the amino acid level can nonetheless have highly similar tertiary
and quaternary structures.
[0253] Methods of determining sequence identity are well known in
the art. Various programs and alignment algorithms are described
in: Smith and Waterman, Adv. Appl. Math. 2:482, 1981; Needleman and
Wunsch, J. Mol. Biol. 48:443, 1970; Higgins and Sharp, Gene 73:237,
1988; Higgins and Sharp, CABIOS 5:151, 1989; Corpet et al., Nucleic
Acids Research 16:10881, 1988; and Pearson and Lipman, Proc. Natl.
Acad. Sci. USA 85:2444, 1988. Altschul et al., Nature Genet. 6:119,
1994, presents a detailed consideration of sequence alignment
methods and homology calculations.
[0254] The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul
et al., J. Mol. Biol. 215:403, 1990) is available from several
sources, including the National Center for Biotechnology
Information (NCBI, Bethesda, Md.) and on the internet, for use in
connection with the sequence analysis programs blastp, blastn,
blastx, tblastn and tblastx. A description of how to determine
sequence identity using this program is available on the NCBI
website on the internet.
[0255] Another indicia of sequence similarity between two nucleic
acids is the ability to hybridize. The more similar are the
sequences of the two nucleic acids, the more stringent the
conditions at which they will hybridize. The stringency of
hybridization conditions are sequence-dependent and are different
under different environmental parameters. Thus, hybridization
conditions resulting in particular degrees of stringency will vary
depending upon the nature of the hybridization method of choice and
the composition and length of the hybridizing nucleic acid
sequences. Generally, the temperature of hybridization and the
ionic strength (especially the Na.sup.+ and/or Mg.sup.+
concentration) of the hybridization buffer will determine the
stringency of hybridization, though wash times also influence
stringency. Generally, stringent conditions are selected to be
about 5.degree. C. to 20.degree. C. lower than the thermal melting
point (T.sub.m) for the specific sequence at a defined ionic
strength and pH. The T.sub.m is the temperature (under defined
ionic strength and pH) at which 50% of the target sequence
hybridizes to a perfectly matched probe. Conditions for nucleic
acid hybridization and calculation of stringencies can be found,
for example, in Sambrook et al., Molecular Cloning: A Laboratory
Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
N.Y., 2001; Tijssen, Hybridization With Nucleic Acid Probes, Part
I: Theory and Nucleic Acid Preparation, Laboratory Techniques in
Biochemistry and Molecular Biology, Elsevier Science Ltd., NY, NY,
1993. and Ausubel et al. Short Protocols in Molecular Biology,
4.sup.th ed., John Wiley & Sons, Inc., 1999.
[0256] For purposes of the present disclosure, "stringent
conditions" encompass conditions under which hybridization will
only occur if there is less than 25% mismatch between the
hybridization molecule and the target sequence. "Stringent
conditions" may be broken down into particular levels of stringency
for more precise definition. Thus, as used herein, "moderate
stringency" conditions are those under which molecules with more
than 25% sequence mismatch will not hybridize; conditions of
"medium stringency" are those under which molecules with more than
15% mismatch will not hybridize, and conditions of "high
stringency" are those under which sequences with more than 10%
mismatch will not hybridize. Conditions of "very high stringency"
are those under which sequences with more than 6% mismatch will not
hybridize. In contrast nucleic acids that hybridize under "low
stringency conditions include those with much less sequence
identity, or with sequence identity over only short subsequences of
the nucleic acid.
[0257] For example, a specific example of progressively higher
stringency conditions is as follows: 2.times.SSC/0.1% SDS at about
room temperature (hybridization conditions); 0.2.times.SSC/0.1% SDS
at about room temperature (low stringency conditions);
0.2.times.SSC/0.1% SDS at about 42.degree. C. (moderate stringency
conditions); and 0.1.times.SSC at about 68.degree. C. (high
stringency conditions). One of skill in the art can readily
determine variations on these conditions (e.g., Molecular Cloning:
A Laboratory Manual, 2nd ed., vol. 1-3, ed. Sambrook et al., Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).
Washing can be carried out using only one of these conditions,
e.g., high stringency conditions, or each of the conditions can be
used, e.g., for 10-15 minutes each, in the order listed above,
repeating any or all of the steps listed. However, as mentioned
above, optimal conditions will vary, depending on the particular
hybridization reaction involved, and can be determined
empirically.
[0258] Subject: Living multi-cellular vertebrate organisms, a
category that includes both human and veterinary subjects,
including human and non-human mammals.
[0259] Therapeutically active polypeptide: An agent, such as an
epitope of a virus or other pathogen that causes induction of an
immune response, as measured by clinical response (for example
increase in a population of immune cells, increased cytolytic
activity against the epitope). Therapeutically active molecules can
also be made from nucleic acids. Examples of a nucleic acid based
therapeutically active molecule is a nucleic acid sequence that
encodes an epitope of a protein of a virus or other pathogen,
wherein the nucleic acid sequence is operatively linked to a
control element such as a promoter.
[0260] Therapeutically Effective Amount: An amount of a composition
that alone, or together with an additional therapeutic agent(s)
(for example nucleoside/nucleotide reverse transcriptase
inhibitors, a non-nucleoside reverse transcriptase inhibitors,
protease inhibitors, fusion/entry inhibitors or integrase
inhibitors) induces the desired response (e.g., prevention,
inhibition, or reduction in a virus, such as inhibition or
reduction of viral infection or replication). In one example, a
desired response is to inhibit or reduce HIV replication in a cell
to which the therapy is administered. HIV replication does not need
to be completely eliminated for the composition to be effective.
For example, a composition can decrease HIV replication by a
desired amount, for example by at least 10%, at least 20%, at least
50%, at least 60%, at least 70%, at least 80%, at least 90%, at
least 95%, at least 98%, or even at least 100% (elimination of
HIV), as compared to HIV replication in the absence of the
composition.
[0261] In another example, a desired response is to inhibit HIV
infection. The HIV infected cells do not need to be completely
eliminated for the composition to be effective. For example, a
composition can decrease the number of HIV infected cells by a
desired amount, for example by at least 10%, at least 20%, at least
50%, at least 60%, at least 70%, at least 80%, at least 90%, at
least 95%, at least 98%, or even at least 100% (elimination of
detectable HIV infected cells), as compared to the number of HIV
infected cells in the absence of the composition.
[0262] A therapeutically effective amount of a composition can be
administered in a single dose, or in several doses, for example
daily, during a course of treatment. However, the therapeutically
effective amount can depend on the subject being treated, the
severity and type of the condition being treated, and the manner of
administration. For example, a therapeutically effective amount of
such agent can vary from about 1 .mu.g-10 mg per 70 kg body weight
if administered intravenously.
[0263] Transformed or Transfected: A transformed cell is a cell
into which a nucleic acid molecule has been introduced by molecular
biology techniques. As used herein, the term introduction or
transformation encompasses all techniques by which a nucleic acid
molecule might be introduced into such a cell, including
transfection with viral vectors, transformation with plasmid
vectors, and introduction of naked DNA by electroporation,
lipofection, and particle gun acceleration.
[0264] Transmembrane spanning region or membrane spanning domain of
gp41: A region or domain of gp41 that is immediately C-terminal to
the membrane proximal region of gp41. An example of a transmembrane
spanning region is provided in SEQ ID NO: 25.
[0265] Treating a disease: "Treatment" refers to a therapeutic
intervention that ameliorates a sign or symptom of a disease or
other pathological condition, such as an infection, for example a
sign or symptom of HIV. Treatment can also induce remission or cure
of a condition, such as elimination of detectable HIV infected
cells. In particular examples, treatment includes preventing a
disease, for example by inhibiting the full development of a
disease, such as HIV, by inhibiting HIV replication or infection or
the development of AIDS. Prevention of a disease does not require a
total absence of disease. For example, a decrease of at least 50%
can be sufficient.
[0266] Vaccine: A vaccine is a pharmaceutical composition that
elicits a prophylactic or therapeutic immune response in a subject.
In some cases, the immune response is a protective immune response.
Typically, a vaccine elicits an antigen-specific immune response to
an antigen of a pathogen, for example, a bacterial or viral
pathogen, or to a cellular constituent correlated with a
pathological condition. A vaccine may include a polynucleotide, a
peptide or polypeptide, a virus, a bacteria, a cell or one or more
cellular constituents. In some cases, the virus, bacteria or cell
may be inactivated or attenuated to prevent or reduce the
likelihood of infection, while maintaining the immunogenicity of
the vaccine constituent.
[0267] Vector: A nucleic acid molecule as introduced into a host
cell, thereby producing a transformed host cell. A vector may
include nucleic acid sequences that permit it to replicate in a
host cell, such as an origin of replication. A vector may also
include one or more selectable marker gene and other genetic
elements known in the art.
[0268] Virus: Microscopic infectious organism that reproduces
inside living cells. A virus consists essentially of a core of a
single nucleic acid surrounded by a protein coat, and has the
ability to replicate only inside a living cell. "Viral replication"
is the production of additional virus by the occurrence of at least
one viral life cycle. A virus may subvert the host cells' normal
functions, causing the cell to behave in a manner determined by the
virus. For example, a viral infection may result in a cell
producing a cytokine, or responding to a cytokine, when the
uninfected cell does not normally do so.
[0269] "Retroviruses" are RNA viruses wherein the viral genome is
RNA. When a host cell is infected with a retrovirus, the genomic
RNA is reverse transcribed into a DNA intermediate which is
integrated very efficiently into the chromosomal DNA of infected
cells. The integrated DNA intermediate is referred to as a
provirus. The term "lentivirus" is used in its conventional sense
to describe a genus of viruses containing reverse transcriptase.
The lentiviruses include the "immunodeficiency viruses" which
include human immunodeficiency virus (HIV) type 1 and type 2 (HIV-1
and HIV-2), simian immunodeficiency virus (SIV), and feline
immunodeficiency virus (FIV). HIV-1 is a retrovirus that causes
immunosuppression in humans (HIV disease), and leads to a disease
complex known as AIDS. "HIV infection" refers to the process in
which HIV enters macrophages and CD4+ T cells by the adsorption of
glycoproteins on its surface to receptors on the target cell
followed by fusion of the viral envelope with the cell membrane and
the release of the HIV capsid into the cell. "HIV disease" refers
to a well-recognized constellation of signs and symptoms (including
the development of opportunistic infections) in persons who are
infected by an HIV virus, as determined by antibody or western blot
studies. Laboratory findings associated with this disease are a
progressive decline in T cells.
[0270] Virus-like particle or VLP: A nonreplicating, viral shell,
derived from any of several viruses. VLPs are generally composed of
one or more viral proteins, such as, but not limited to, those
proteins referred to as capsid, coat, shell, surface and/or
envelope proteins, or particle-forming polypeptides derived from
these proteins. VLPs can form spontaneously upon recombinant
expression of the protein in an appropriate expression system.
Methods for producing particular VLPs are known in the art. The
presence of VLPs following recombinant expression of viral proteins
can be detected using conventional techniques known in the art,
such as by electron microscopy, biophysical characterization, and
the like. See, for example, Baker et al. (1991) Biophys. J.
60:1445-1456; Hagensee et al. (1994) J. Virol. 68:4503-4505. For
example, VLPs can be isolated by density gradient centrifugation
and/or identified by characteristic density banding. Alternatively,
cryoelectron microscopy can be performed on vitrified aqueous
samples of the VLP preparation in question, and images recorded
under appropriate exposure conditions.
III. Overview of Several Embodiments
[0271] Rubella vectors expressing a variety of antigens, such as
SIV, HIV, RSV or hepatitis antigens are demonstrated herein to be
useful for evaluating new immunogens and for developing prime and
boost strategies for eliciting protective immunity.
[0272] The inventors have discovered that rubella virus can be
adapted for protein expression by making a permissive deletion in
the nonstructural p150 gene (Not I deletion), to make room for the
insert or by inserting positioning an insert in between two
structural proteins within the rubella virus without making a
deletion in the nonstructural p150 gene. The resulting rubella
vectors replicate with kinetics similar to wild type virus, while
stably expressing a reporter gene coding for Zoanthus sp. green
fluorescent protein (zGFP) for at least 12 passages in cell
culture. The inventors also report herein live rubella vectors
expressing heterologous antigens, such as HIV and SIV vaccine
antigens. These vectors express the HIV membrane-proximal external
region (MPER) or SIV Gag antigens at either of two insertion sites:
the Not I site or an insertion site in the structural gene region.
The foreign antigens are controlled by early or late rubella
promoters, depending on the insertion site. At the structural
insertion site, HIV MPER was highly expressed as part of the
structural polyprotein, processed to a free protein, and
incorporated into virions. The vectors are based on rubella vaccine
strain RA27/3 and grow to high titers in vitro. These vectors
provide an ideal vaccine platform for testing vector replication
and immunogenicity in vivo, as well as protection against SW or
SHIV challenge.
[0273] In some embodiments, an isolated rubella viral vector
construct includes a rubella non-structural protein ORF with an
in-frame deletion, a rubella structural protein ORF, and a
heterologous antigenic insert. In one example, the in-frame
deletion within the rubella non-structural protein ORF is an
in-frame deletion between two NotI restriction enzyme sites. In
some examples, the heterologous antigenic insert is positioned
within the rubella non-structural protein ORF. In other examples,
the heterologous antigenic insert is positioned within the rubella
structural protein ORF.
[0274] In some embodiments, an isolated rubella viral vector
includes a rubella non-structural protein open reading frame (ORF)
without an in-frame deletion, a rubella structural protein ORF, and
a heterologous antigenic insert. In some examples, the heterologous
antigenic insert is positioned within the rubella structural
protein ORF. In other examples, the heterologous antigenic insert
is positioned in between the genes encoding structural proteins E2
and E1.
[0275] In some examples, the antigenic insert comprises an amino
acid sequence set forth as SEQ ID NO: 126, 127, 128, 129, 130, 131,
132, 133, 134, 135, 136, 138, 139, 140, 141, 142, 143, 144, 145,
146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 159,
160, 161 or 162.
[0276] Exemplary antigenic inserts include an HIV antigenic insert
(such as a Gag antigenic insert, a gp41 antigenic insert or a gp120
antigenic insert) or a hepatitis B antigenic insert. In some
examples, a Gag antigenic insert includes an antigenic polypeptide
fragment with an amino acid sequence provided by SEQ ID NOs: 82,
83, 84, 85, 86, 87, 88, 90, 91, 132, 133, 134, 135, 138, 139, 140,
141, or 142. In some examples, a gp41 antigenic insert includes an
antigenic polypeptide fragment of gp41 with an amino acid sequence
provided by SEQ ID NOs: 1-22, 30, 81 or 89 and a transmembrane
region of gp41 with an amino acid sequence provided by SEQ ID NOs:
25-28. In certain examples, a gp120 antigenic insert includes an
amino acid sequence set forth by SEQ ID NOs: 63, 66, 67, 69, 71,
73, 74, 152, 153, 154, 155, 156, 158, 159 or 160. For example, the
gp120 antigenic insert includes a variant gp120 polypeptide
comprising a deletion of at least 8 consecutive residues of the
fourth conserved loop (C4) between residues 423 and 433 of SEQ ID
NO: 63. In some examples, an antigenic insert includes one or more
CTL epitopes, such as one or more CTL HIV or SIV epitopes,
including those set forth as SEQ ID NOs: 77, 78, 79, 80, 92, 93,
94, 95, 96, 97, 98, 99, 100, 101, and 102.
[0277] Viral-like particles including the isolated viral vector
construct are provided herein. Compositions comprising the
viral-like particles are also provided.
[0278] Also disclosed are methods of using the disclosed isolated
viral vectors to induce an immune response, such as a protective
immune response, when introduced into a subject or to diagnose an
HIV infection. For example, methods are provided for inhibiting HIV
infection in a subject, for inducing an immune response to HIV in a
subject, and for diagnosing HIV infection in a subject. Also
disclosed are methods for measuring host range, testing sensitivity
to neutralizing antibodies, or screening antiviral drugs, such as
protease inhibitors.
A. Rubella Viral Vector Constructs
[0279] Disclosed herein are rubella viral vector constructs. In one
example, an isolated rubella viral vector construct is disclosed
that includes a rubella non-structural ORF with an in-frame
deletion, a rubella structural protein ORF, and a heterologous
antigenic insert. In some examples, an isolated rubella viral
vector includes a sub genomic promoter. For example, the sub
genomic promoter can control the expression of the structural
proteins.
[0280] In one example, an in-frame deletion is within the rubella
non-structural protein ORF. For example, the in-frame deletion is
within nsP150. In one particular example, the in-frame deletion is
an in-frame deletion between two NotI restriction enzyme sites
located in nsP150, such as between base pairs (bp) 1685 and 2192.
For example, the heterologous antigenic insert can be positioned
within the rubella non-structural protein ORF. For example, the
heterologous antigenic insert is positioned into nsP150, such as
into the site of the Not I deletion (see FIG. 1A).
[0281] In other examples, the heterologous antigenic insert is
positioned at either end of the three rubella structural proteins,
capsid (C), E2 and E1 in a rubella viral construct that does not
include a deletion, such as a Not I deletion, in the non-structural
protein ORF.
[0282] In some embodiments of this example, the heterologous
antigenic insert is positioned in between the genes encoding
structural proteins C, E2 and E1. For example, the heterologous
antigenic insert is positioned in between the genes encoding
structural protein E2 and E1.
[0283] In some examples, the antigenic insert comprises an amino
acid sequence set forth as SEQ ID NO: 77, 78, 79, 80, 126, 127,
128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140,
141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153,
154, 155, 156, 158, 159, 160, 161 or 162.
[0284] In one example, the heterologous antigenic insert sequence
is expressed at the carboxyl end of rubella capsid protein without
a deletion being made, such as an in-frame deletion within nsP150,
in the non-structural protein ORF. For example, the heterologous
antigenic insert sequence is expressed at the amino end of envelope
protein E2 and no deletion is present, such as an in-frame deletion
within nsP150, in the non-structural protein ORF. In another
exemplary construct, the heterologous antigenic insert is expressed
at the carboxyl end of E2 and no deletion is present, such as an
in-frame deletion within nsP150, in the non-structural protein ORF.
In another example, the heterologous antigenic insert sequence is
expressed at the amino end of envelope protein E1.
[0285] In some examples, the MPER sequence is expressed at the
carboxyl end of rubella capsid protein. In other examples, the MPER
sequence is expressed at the amino end of envelope protein E2. In
another exemplary construct, MPER is expressed at the carboxyl end
of E2. In another example, the MPER sequence is expressed at the
amino end of envelope protein E1.
[0286] In additional examples, a deletion is made within the P150
of the rubella construct, such as in the middle in a size
comparable to the Not I deletion to allow for the insertion and
expression of genes coding for heterologous antigens, such as one
or more HIV envelope protein. In one particular example, a deletion
comparable to the Not I deletion is present in the middle of the
P150 of the rubella vaccine strain RA27/3. Various heterologous
antigens, including any of those described herein are inserted into
either the nonstructural ORF or structural ORF in this strain known
to be safe and immunogenic in humans.
[0287] For use, the disclosed vector constructs are chemically
introduced into susceptible culture cells, for example, E. coli,
for amplification and production of large amounts of the cDNA clone
by methods known to those of ordinary skill in the art, including
chemical introduction. In one particular example, the purified
infectious clone is digested with an restriction endonuclease such
as EcoRI (New England Biolabs, Beverly, Mass.) for linearization at
the termination of the rubella virus cDNA sequences. The linearized
plasmid is then transcribed in vitro with an RNA polymerase such as
SP6 RNA polymerase, which results in production of RNA transcripts.
The resulting RNA transcripts are used to transfect the cells by
transfection procedures known to those skilled in the art. The
cells, in turn, will produce both the native structural proteins of
the rubella virus and the protein encoded by the foreign gene (such
as HIV antigens, SIV antigens or HBsAgs). The replication of the
RNA sequences and the expression of the encoded protein by the
cells may be monitored by various means known to the ones skilled
in the art. In some examples, the cells will further produce
recombinant virus particles which, in turn, may be used to infect
cells or organisms.
[0288] The recombinant virus particles can be recovered in quantity
using any purification process known to those of skill in the art,
such as a nickel (NTA-agarose) affinity chromatography purification
procedure. These particles can be combined with a pharmaceutically
acceptable carrier to provide a safe, effective vaccine, such as a
HIV, SIV, RSV or Hepatitis B vaccine. The carrier can be oil,
water, saline, phosphate buffer, polyethylene glycol, glycerine,
propylene glycol, and combinations thereof, or other vehicles
routinely used by the pharmaceutical industry for these purposes
(as described in detail below). The vaccine is usually provided in
lyophilized form and therefore is free of preservatives.
[0289] The disclosed recombinant virus particles can also be used
to identify antibodies, such as antibodies within a subject. The
immunogenic compositions of this disclosure can be employed to
generate antibodies that recognize the antigens disclosed herein
and the antigen from which the disclosed antigen was derived. The
methods include administering to a subject an immunogenic
composition including a disclosed antigen or administering to the
subject a polynucleotide encoding a disclosed antigen to generate
antibodies that recognize the disclosed antigen. The subject
employed in this embodiment is one typically employed for antibody
production. Mammals, such as, rodents, rabbits, goats, sheep, etc.,
are preferred.
[0290] The antibodies generated can be either polyclonal or
monoclonal antibodies. Polyclonal antibodies are raised by
injecting (for example subcutaneous or intramuscular injection)
antigenic polypeptides into a suitable animal (for example, a mouse
or a rabbit). The antibodies are then obtained from blood samples
taken from the animal. The techniques used to produce polyclonal
antibodies are extensively described in the literature. Polyclonal
antibodies produced by the subjects can be further purified, for
example, by binding to and elution from a matrix that is bound with
the polypeptide against which the antibodies were raised. Those of
skill in the art will know of various standard techniques for
purification and/or concentration of polyclonal, as well as
monoclonal, antibodies. Monoclonal antibodies can also be generated
using techniques known in the art.
i. Wildtype and Variant Gp41 Antigenic Inserts
[0291] In some examples, isolated rubella viral vectors disclosed
herein include an antigenic insert that is a wildtype or variant
gp41 polypeptide. In an example, an antigenic insert is a wildtype
gp41 polypeptide or a fragment thereof. Exemplary sequence of
wildtype gp41 polypeptides are shown on GENBANK.RTM., for example
accession number CAD23678 incorporated herein by reference in its
entirety as available on Oct. 15, 2009. In other examples, a gp41
antigenic insert can include (a) an antigenic polypeptide fragment
of gp41 and (b) a transmembrane spanning region of gp41.
[0292] In an example, the gp41 antigenic insert includes (a) an
antigenic polypeptide fragment, such as an antigenic polypeptide
fragment with the amino acid sequence set forth in SEQ ID NO:1 and
is between 8 and 400 amino acids in length, including 10 and 300
amino acids in length, such as from about 10 to about 150, such as
about 16 to about 160 amino acids, such as from about 28 to about
150 amino acids in length, such as from about 28 to about 140 amino
acids in length, including 29, 30, 35, 40, 45, 50, 55, 60, 65, 70,
75, 80, 85, 90, 95, 100, 105, 110, 120, 125, 130, 135, 140, 141,
142, 143, 144 or 145 amino acids; and (b) a transmembrane spanning
gp41 region, such as a transmembrane spanning gp41 region with the
amino acid sequence set forth in SEQ ID NO: 25 (in which wherein
X.sub.1, X.sub.2 and X.sub.3 are any amino acid; and X.sub.4,
X.sub.5, and X.sub.6 are any hydrophobic amino acid) and is between
22 and 40 amino acids in length, such as about 23 and 38 amino
acids in length, including 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38 amino acids.
[0293] In one example, the antigenic polypeptide includes the amino
acid sequence of NEX.sub.1X.sub.2LLX.sub.3LDKWASLWN (SEQ ID NO: 1).
In this sequence, X.sub.1, X.sub.2 and X.sub.3 are any amino acid.
The antigenic epitope can include repeats of this sequence, such as
one to five copies of SEQ ID NO: 1. As noted above, the antigenic
peptide includes one or more antigenic epitopes, such as one or
more envelope proteins of HIV-1, and, including SEQ ID NO: 1, can
be from about 10 to about 200 amino acids in length, such as from
about 16 to about 160 amino acids, such as from about 28 to about
150 amino acids in length, such as from about 28 to about 140 amino
acids in length, including 29, 30, 35, 40, 45, 50, 55, 60, 65, 70,
75, 80, 85, 90, 95, 100, 105, 110, 120, 125, 130, 135, 140, 141,
142, 143, 144 or 145 amino acids.
[0294] In several examples, the antigenic polypeptide includes one
or more of the amino acid sequences set forth below:
TABLE-US-00002 SEQ ID NO: 2 a) (NEQELLALDKWASLWNWFDITNWLWYIK); SEQ
ID NO: 3 b) (NEQDLLALDKWASLWNWFDITNWLWYIK); SEQ ID NO: 4 c)
(NEQDLLALDKWANLWNWFDISNWLWYIK); SEQ ID NO: 5 d)
(NEQDLLALDKWANLWNWFNITNWLWYIR); SEQ ID NO: 6 e)
(NEQELLELDKWASLWNWFDITNWLWYIK); SEQ ID NO: 7 f)
(NEKDLLALDSWKNLWNWFDITNWLWYIK); SEQ ID NO: 8 g)
(NEQDLLALDSWENLWNWFDITNWLWYIK); SEQ ID NO: 9 h)
(NEQELLELDKWASLWNWFSITQWLWYIK); SEQ ID NO: 10 i)
(NEQELLALDKWASLWNWFDISNWLWYIK); SEQ ID NO: 11 j)
(NEQDLLALDKWDNLWSWFTITNWLWYIK); SEQ ID NO: 12 k)
(NEQDLLALDKWASLWNWFDITKWLWYIK); SEQ ID NO: 13 l)
(NEQDLLALDKWASLWNWFSITNWLWYIK); SEQ ID NO: 14 m)
(NEKDLLELDKWASLWNWFDITNWLWYIK); SEQ ID NO: 15 n)
(NEQEILALDKWASLWNWFDISKWLWYIK); SEQ ID NO: 16 o)
(NEQDLLALDKWANLWNWFNISNWLWYIK); SEQ ID NO: 17 p)
(NEQDLLALDKWASLWSWFDISNWLWYIK); SEQ ID NO: 18 q)
(NEKDLLALDSWKNLWSWFDITNWLWYIK); SEQ ID NO: 19 r)
(NEQELLQLDKWASLWNWFSITNWLWYIK); SEQ ID NO: 20 s)
(NEQDLLALDKWASLWNWFDISNWLWYIK); SEQ ID NO: 21 t)
(NEQELLALDKWASLWNWFDISNWLWYIR); SEQ ID NO: 22 u)
(NEQELLELDKWASLWNWFNITNWLWYIK); SEQ ID NO: 30 v)
(PSAQEKNEKELLELDKWASLWN); SEQ ID NO: 81 w)
(QEKNEKELLELDKWASLWNWFDITNWLWYIRLFI); or SEQ ID NO: 89 x)
(PSWNWFDITNWLWYIRLDA).
[0295] In some examples, the antigenic polypeptide can include one
of the amino acid sequences set forth as SEQ ID NOs: 2-22, 30, 81,
89, 126-131, 136 or 137. A single copy of one of SEQ ID NOs: 2-22,
30, 81, 89 or 137 can be included as the antigenic polypeptide.
Alternatively, multiple copies of one of SEQ ID NOs: 2-22, 30, 81,
89, 126-131, 136 or 137 can be included as the antigenic
polypeptide. Thus, one, two, three, four or five copies of one of
the amino acid sequences set forth as SEQ ID NOs: 2-22, 30, 81, 89,
126-131, 136 or 137 can be included as the antigenic
polypeptide.
[0296] In additional embodiments, more than one of these sequences
can be included in the antigenic polypeptide. Thus, in several
examples, two, three, four or five of the amino acid sequences set
forth as SEQ ID NOs: 2-22, 30, 81, 89, 126-131, 136 or 137 can be
included as the antigenic polypeptide in tandem. Each amino acid
sequence included in the antigenic polypeptide can be present only
a single time, or can be repeated.
[0297] In some embodiments, the transmembrane spanning gp41 region
includes the amino acid sequence set forth in SEQ ID NO: 25. In
this sequence, X.sub.1, X.sub.2 and X.sub.3 are any amino acid and
X.sub.4, X.sub.5, and X.sub.6 are any hydrophobic amino acid and
the transmembrane spanning gp41 region is between 22 and 40 amino
acids in length, such as 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,
33, 34, 35, 36, 37, 38, 39 or 40 amino acids. In several examples,
the antigenic polypeptide includes one or more of the amino acid
sequences set forth below:
TABLE-US-00003 SEQ ID NO: 26 a) (IFIMIVGGLIGLRIVFTVLSIV) SEQ ID NO:
27 b) (LFIMIVGGLIGLRIVFTALSIV); or SEQ ID NO: 28 c)
(IFIMIVGGLVGLRIVFTALSIV)
[0298] A gp41 polypeptide can be covalently linked to a carrier,
which is an immunogenic macromolecule to which an antigenic
molecule can be bound. When bound to a carrier, the bound
polypeptide becomes more immunogenic. Carriers are chosen to
increase the immunogenicity of the bound molecule and/or to elicit
higher titers of antibodies against the bound molecule which are
diagnostically, analytically, and/or therapeutically beneficial.
Covalent linking of a molecule to a carrier can confer enhanced
immunogenicity and T cell dependence (see Pozsgay et al., PNAS
96:5194-97, 1999; Lee et al., J. Immunol. 116:1711-18, 1976;
Dintzis et al., PNAS 73:3671-75, 1976). Useful carriers include
polymeric carriers, which can be natural (for example,
polysaccharides, polypeptides or proteins from bacteria or
viruses), semi-synthetic or synthetic materials containing one or
more functional groups to which a reactant moiety can be attached.
Bacterial products and viral proteins (such as HBsAg and core
antigen) can also be used as carriers, as well as proteins from
higher organisms such as keyhole limpet hemocyanin, horseshoe crab
hemocyanin, edestin, mammalian serum albumins, and mammalian
immunoglobulins. Additional bacterial products for use as carriers
include bacterial wall proteins and other products (for example,
streptococcal or staphylococcal cell walls and lipopolysaccharide
(LPS)).
ii. Wildtype and Variant Gp120 Antigenic Inserts
[0299] In some examples, isolated rubella viral vectors disclosed
herein include an antigenic insert that is a wildtype or variant
gp120 polypeptide. In an example, a wildtype gp120 polypeptide has
an amino acid provided by SEQ ID NO: 63 or a fragment thereof. In
other examples, a variant gp120 polypeptide includes a gp120
polypeptide in which at least 8 consecutive residues of the fourth
conserved loop (C4) between residues 419 and 434 of gp120 according
HXB2 numbering of SEQ ID NO: 63 are deleted. This deletion within
the .beta.20-21 loop of the gp120 polypeptide exposes the CD4
binding site thereby providing improved antibody binding and
antibody induction. In one example, a variant gp120 polypeptide is
a gp120 polypeptide in which at least 8 consecutive residues, such
as between 8-12, 8-11, 8-10, or 8-9 (for example, 9, 10, 11 or 12)
consecutive residues of C4 between residues 419 and 434 of gp120 of
SEQ ID NO: 63 have been deleted.
[0300] In a particular example, a variant gp120 polypeptide
includes a gp120 polypeptide in which residues 424-432 are deleted.
Additional variant gp120 polypeptides include deletions of
INMWQKVGK (residues 424-432 of SEQ ID NO: 63), INMWQKVGKA (residues
424-433 of SEQ ID NO: 63), INMWQKVGKAM (residues 424-434 of SEQ ID
NO: 63), RIKQIINMWQKVGK (residues 419-432 of SEQ ID NO: 63),
IKQIINMWQKVGK (residues 420-432 of SEQ ID NO: 63), KQIINMWQKVGK
(residues 421-432 of SEQ ID NO: 63), QIINMWQKVGK (residues 422-432
of SEQ ID NO: 63), or IINMWQKVGK (residues 423-432 of SEQ ID NO:
63). In other embodiments, variant gp120 polypeptides include
combinations of the amino and carboxyl ends between residues 419
and 434.
[0301] In some embodiments, a variant gp120 polypeptide does not
include a variant in which residues 419-428 of SEQ ID NO: 63 are
deleted. In other embodiments, a variant gp120 polypeptide does not
include a variant in which residues 437-452 of SEQ ID NO: 63 are
deleted.
[0302] Any of the disclosed variant gp120 polypeptide including
deletions in C4 can also include a deletion in the V1V2 loop region
(spanning from amino acids 125 to 205 of wild-type gp120, such as
demonstrated in SEQ ID NO: 63); see SR Pollard and DC Wiley, EMBO
J. 11:585-91, 1992 which is hereby incorporated by reference in its
entirety.
[0303] The gp120 polypeptides disclosed herein can be chemically
synthesized by standard methods, or can be produced recombinantly.
An exemplary process for polypeptide production is described in Lu
et al., Federation of European Biochemical Societies Letters.
429:31-35, 1998. They can also be isolated by methods including
preparative chromatography and immunological separations.
[0304] Exemplary sequences for the amino acid sequence for
full-length gp120 can be found on Genbank, EMBL and SwissProt
websites. Exemplary non-limiting sequence information can be found
for example, as SwissProt Accession No. P04578, (includes gp41 and
gp120, initial entry Aug. 13, 1987, last modified on Jul. 15, 1999)
and Genbank Accession No. AAF69493 (Oct. 2, 2000, gp120), all of
which are incorporated herein by reference.
[0305] In other embodiments, the antigenic insert is a fusion
protein. For example, fusion proteins are provided including a
first and second polypeptide moiety in which one of the protein
moieties includes a variant gp120 polypeptide such as a variant
gp120 polypeptide with an amino acid sequence in which INMWQKVGK
(residues 424-432 of SEQ ID NO:63), INMWQKVGKA (residues 424-433 of
SEQ ID NO: 63), INMWQKVGKAM (residues 424-434 of SEQ ID NO: 63),
RIKQIINMWQKVGK (residues 419-432 of SEQ ID NO: 63), IKQIINMWQKVGK
(residues 420-432 of SEQ ID NO: 63), KQIINMWQKVGK (residues 421-432
of SEQ ID NO: 63), QIINMWQKVGK (residues 422-432 of SEQ ID NO: 63),
or IINMWQKVGK (residues 423-432 of SEQ ID NO: 63) has been deleted.
The other moiety is a heterologous protein such as a carrier
protein and/or an immunogenic protein. Such fusions also are useful
to evoke an immune response against gp120. In certain embodiments
the gp120 polypeptides disclosed herein are covalent or
non-covalent addition of toll like receptor (TLR) ligands or
dendritic cell or B cell targeting moieties to produce
self-adjuvanting proteins (e.g., IL-21).
[0306] In certain embodiments, a variant gp120 includes a V1V2
deletion without a beta 20-21 loop deletion with an amino acid
sequence as set forth as:
TABLE-US-00004 (SEQ ID NO: 63)
VPVWREATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLGNVT
ENFNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLSVQACPKVSFQPIP
IHYCVPAGFAMLKCNNKTFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNG
SLAEEDIVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRRRLSIGPG
RAFYARRNIIGDIRQAHCNISRAKWNNTLQQIVIKLREKFRNKTIAFNQ
SSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTEGNDIITL
QCRIKQIINMWQKVGKAMYAPPITGQIRCSSNITGLLLTRDGGNSTETE
TEIFRPGGGDMRDNWRSELYKYKVVRIEPIGVAPTRAKR.
[0307] In some embodiments, a variant gp120 includes a V1V2
deletion with a beta 20-21 loop deletion with an amino acid
sequence as set forth as:
VPVWREATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLGNVTENFNMWKNN
MVDQMHEDIISLWDESLKPCVKLTPLSVQACPKVSFQPIPIHYCVPAGFAMLKCNNKTFNG
SGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEDIVIRSENFTDNAKTIIVQLNESVVINCTR
PNNNTRRRLSIGPGRAFYARRNIIGDIRQAHCNISRAKWNNTLQQIVIKLREKFRNKTIAFN
QSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTEGNDIITLQCRIKQLAMYA
PPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMRDNWRSELYKYKVVRIEPIGVAP
TRAKR (SEQ ID NO: 66). Sequences for deletion to generate gp120
variant with an amino acid sequence set forth in SEQ ID NO: 66 are
shown in bold.
[0308] In other embodiments, a variant gp120 from a HIV isolate
JRFL includes an amino acid sequence as set forth in SEQ ID NO: 67
and nucleic acid sequence set forth in SEQ ID NO: 68:
TABLE-US-00005 (SEQ ID NO: 67)
IIHTVPPSGADPGPKRAEFKGLRRQQKQGIILLTMKTIIALSYILCLVLAQKLPGNDNNSEFITSGFLGPLLVL-
QAGFFLLTRILTIPQSL
DSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVC-
PLIPGSTTTSTGPCKTC
TTPAQGNSKFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMM-
WYWGPSLYSIVSPFIPL
LPIFFCLWVYIGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLENVTEHFNMWKNNMVEQ-
MQEDIISLWDQSLKPCV
KLTPLQACPKISFEPIPIHYCAPAGFAILKCNDKTFNGKGPCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVV-
IRSDNFTNNAKTIIVQL
KESVEINCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNISRAKWNDTLKQIVIKLREQFENKTIVFNHS-
SGGDPEIVMHSFNCGGE
FFYCNSTQLFNSTWNNNTEGSNNTEGNTITLPCRIKQLAMYAPPIRGQIRCSSNITGLLLTRDGGINENGTEIF-
RPGGGDMRDNWRSELYK YKVVKIEPLGVAPTKAKR*LVAAAFESR. (SEQ ID NO: 68)
ggattattcataccgtcccaccatcgggcgcggatcccggtccgaagcgcgcggaattcaaaggcctacgtcga-
cagcaaaagcaggggat
aattctattaaccatgaagactatcattgctttgagctacattttatgtctggttctcgctcaaaaacttcccg-
gaaatgacaacaacagc
gaattcatcacctccggcttcctgggccccctgctggtgctgcaggccggcttcttcctgctgacccgcatcct-
gaccatcccccagtccc
tggactcctggtggacctccctgaacttcctgggcggctcccccgtgtgcctgggccagaactcccagtccccc-
acctccaaccactcccc
cacctcctgcccccccatctgccccggctaccgctggatgtgcctgcgccgcttcatcatcttcctgttcatcc-
tgctgctgtgcctgatc
ttcctgctggtgctgctggactaccagggcatgctgcccgtgtgccccctgatccccggctccaccaccacctc-
caccggcccctgcaaga
cctgcaccacccccgcccagggcaactccaagttcccctcctgctgctgcaccaagcccaccgacggcaactgc-
acctgcatccccatccc
ctcctcctgggccttcgccaagtacctgtgggagtgggcctccgtgcgcttctcctggctgtccctgctggtgc-
ccttcgtgcagtggttc
gtgggcctgtcccccaccgtgtggctgtccgccatctggatgatgtggtactggggcccctccctgtactccat-
cgtgtcccccttcatcc
ccctgctgcccatcttcttctgcctgtgggtgtacatcggggtacctgtgtggaaagaagcaaccaccactcta-
ttttgtgcatcagatgc
taaagcatatgatacagaggtacataatgtttgggccacacatgcctgtgtacccacagaccccaacccacaag-
aagtagtattggaaaat
gtaacagaacattttaacatgtggaaaaataacatggtagaacagatgcaggaggatataatcagtttatggga-
tcaaagcctaaagccat
gtgtaaaattaaccccactccaggcctgtccaaagatatcctttgagccaattcccatacattattgtgccccg-
gctggttttgcgattct
aaagtgtaatgataagacgttcaatggaaaaggaccatgtaaaaatgtcagcacagtacaatgtacacatggaa-
ttaggccagtagtatca
actcaactgctgctaaatggcagtctagcagaagaagaggtagtaattagatctgacaatttcacgaacaatgc-
taaaaccataatagtac
agctgaaagaatctgtagaaattaattgtacaagacccaacaacaatacaagaaaaagtatacatataggacca-
gggagagcattttatac
tacaggagaaataataggagatataagacaagcacattgtaacattagtagagcaaaatggaatgacactttaa-
aacagatagttataaaa
ttaagagaacaatttgagaataaaacaatagtctttaatcactcctcaggaggggacccagaaattgtaatgca-
cagttttaattgtggag
gagaatttttctactgtaattcaacacaactgtttaatagtacttggaataataatactgaagggtcaaataac-
actgaaggaaatactat
cacactcccatgcagaataaaacagctagcaatgtatgcccctcccatcagaggacaaattagatgttcatcaa-
atattacagggctgcta
ttaacaagagatggtggtattaatgagaatgggaccgagatcttcagacctggaggaggagatatgagggacaa-
ttggagaagtgaattat
ataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagatgactagtcgcggcc-
gctttcgaatctaga
[0309] In other embodiments, a variant gp120 from a HIV isolate AD8
includes an amino acid sequence as set forth in SEQ ID NO: 69 or
nucleic acid sequence set forth in SEQ ID NO: 70:
TABLE-US-00006 (SEQ ID NO: 69)
IIHTVPPSGADPGPKRAEFKGLRRQQKQGIILLTMKTIIALSYILCLVLAQKLPGNDNNSEFITSGFLGPLLVL-
QAGFFLLTRILTIPQSL
DSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPV-
CPLIPGSTTTSTGPCKT
CTTPAQGNSKFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWM-
MWYWGPSLYSIVSPFIP
LLPIFFCLWVYIGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVELENVTENFNMWKNNMVE-
QMHEDIISLWDQSLKPC
VKLTPLQACPKVSFEPIPIHYCTPAGFAILKCKDKKFNGTGPCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEEV-
VIRSSNFTDNAKNIIVQ
LKESVEINCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNISRTKWNNTLNQIATKLKEQFGNNKTIVFN-
QSSGGDPEIVMHSFNCG
GEFFYCNSTQLFNSTWNFNGTWNLTQSNGTEGNDTITLPCRIKQLAMYAPPIRGQIRCSSNITGLILTRDGGNN-
HNNDTETFRPGGGDMRD NWRSELYKYKVVKIEPLGVAPTKAKR*LV. (SEQ ID NO: 70)
ggattattcataccgtcccaccatcgggcgcggatcccggtccgaagcgcgcggaattcaaaggcctacgtcga-
cagcaaaagcaggggat
aattctattaaccatgaagactatcattgctttgagctacattttatgtctggttctcgctcaaaaacttcccg-
gaaatgacaacaacagc
gaattcatcacctccggcttcctgggccccctgctggtgctgcaggccggcttcttcctgctgacccgcatcct-
gaccatcccccagtccc
tggactcctggtggacctccctgaacttcctgggcggctcccccgtgtgcctgggccagaactcccagtccccc-
acctccaaccactcccc
cacctcctgcccccccatctgccccggctaccgctggatgtgcctgcgccgcttcatcatcttcctgttcatcc-
tgctgctgtgcctgatc
ttcctgctggtgctgctggactaccagggcatgctgcccgtgtgccccctgatccccggctccaccaccacctc-
caccggcccctgcaaga
cctgcaccacccccgcccagggcaactccaagttcccctcctgctgctgcaccaagcccaccgacggcaactgc-
acctgcatccccatccc
ctcctcctgggccttcgccaagtacctgtgggagtgggcctccgtgcgcttctcctggctgtccctgctggtgc-
ccttcgtgcagtggttc
gtgggcctgtcccccaccgtgtggctgtccgccatctggatgatgtggtactggggcccctccctgtactccat-
cgtgtcccccttcatcc
ccctgctgcccatcttcttctgcctgtgggtgtacatcggggtacctgtgtggaaagaagcaaccaccactcta-
ttttgtgcatcagatgc
taaagcatatgatacagaggtacataatgtttgggccacacatgcctgtgtacccacagaccccaacccacaag-
aagtagtattggaaaat
gtgacagaaaattttaacatgtggaaaaataacatggtagaacagatgcatgaggatataatcagtttatggga-
tcaaagcctaaagccat
gtgtaaaattaaccccactccaggcctgtccaaaggtatcctttgagccaattcccatacattattgtaccccg-
gctggttttgcgattct
aaagtgtaaagacaagaagttcaatggaacagggccatgtaaaaatgtcagcacagtacaatgtacacatggaa-
ttaggccagtagtgtca
actcaactgctgttaaatggcagtctagcagaagaagaggtagtaattagatctagtaatttcacagacaatgc-
aaaaaacataatagtac
agttgaaagaatctgtagaaattaattgtacaagacccaacaacaatacaaggaaaagtatacatataggacca-
ggaagagcattttatac
aacaggagaaataataggagatataagacaagcacattgcaacattagtagaacaaaatggaataacactttaa-
atcaaatagctacaaaa
ttaaaagaacaatttgggaataataaaacaatagtctttaatcaatcctcaggaggggacccagaaattgtaat-
gcacagttttaattgtg
gaggggaatttttctactgtaattcaacacaactgtttaatagtacttggaattttaatggtacttggaattta-
acacaatcgaatggtac
tgaaggaaatgacactatcacactcccatgtagaataaaacagctagcaatgtatgcccctcccatcagaggac-
aaattagatgctcatca
aatattacagggctaatattaacaagagatggtggaaataaccacaataatgataccgagacctttagacctgg-
aggaggagatatgaggg
acaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggca-
aaaagatgactagtc.
[0310] In other embodiments, a variant gp120 from a HIV isolate BaL
includes an amino acid sequence as set forth in SEQ ID NO: 71 or a
nucleic acid sequence as set forth in SEQ ID NO: 72:
TABLE-US-00007 (SEQ ID NO: 71)
IIHTVPPSGADPGPKRAEFKGLRRQQKQGIILLTMKTIIALSYILCLVLAQKLPGNDNNSEFITSGFLGPLLVL-
QAGFFLLTRILTIPQSL
DSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPV-
CPLIPGSTTTSTGPCKT
CTTPAQGNSKFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWM-
MWYWGPSLYSIVSPFIP
LLPIFFCLWVYIGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVELENVTENFNMWKNNMVE-
QMHEDIISLWDQSLKPC
VKLTPLQACPKISFEPIPIHYCAPAGFAILKCKDKKFNGKGPCSNVSTVQCTHGIRPVVSTQLLLNGSLAEEEV-
VIRSENFADNAKTIIVQ
LNESVEINCTRPNNNTRKSIHIGPGRALYTTGEIIGDIRQAHCNLSRAKWNDTLNKIVIKLREQFGNKTIVFKH-
SSGGDPEIVTHSFNCGG
EFFYCNSTQLFNSTWNVTEESNNTVENNTITLPCRIKQLAMYAPPIRGQIRCSSNITGLLLTRDGGPEDNKTEV-
FRPGGGDMRDNWRSELY KYKVVKIEPLGVAPTKAKR*LVAAAFESR. (SEQ ID NO: 72)
ggattattcataccgtcccaccatcgggcgcggatcccggtccgaagcgcgcggaattcaaaggcctacgtcga-
cagcaaaagcaggggat
aattctattaaccatgaagactatcattgctttgagctacattttatgtctggttctcgctcaaaaacttcccg-
gaaatgacaacaacagc
gaattcatcacctccggcttcctgggccccctgctggtgctgcaggccggcttcttcctgctgacccgcatcct-
gaccatcccccagtccc
tggactcctggtggacctccctgaacttcctgggcggctcccccgtgtgcctgggccagaactcccagtccccc-
acctccaaccactcccc
cacctcctgcccccccatctgccccggctaccgctggatgtgcctgcgccgcttcatcatcttcctgttcatcc-
tgctgctgtgcctgatc
ttcctgctggtgctgctggactaccagggcatgctgcccgtgtgccccctgatccccggctccaccaccacctc-
caccggcccctgcaaga
cctgcaccacccccgcccagggcaactccaagttcccctcctgctgctgcaccaagcccaccgacggcaactgc-
acctgcatccccatccc
ctcctcctgggccttcgccaagtacctgtgggagtgggcctccgtgcgcttctcctggctgtccctgctggtgc-
ccttcgtgcagtggttc
gtgggcctgtcccccaccgtgtggctgtccgccatctggatgatgtggtactggggcccctccctgtactccat-
cgtgtcccccttcatcc
ccctgctgcccatcttcttctgcctgtgggtgtacatcggggtacctgtgtggaaagaagcaaccaccactcta-
ttttgtgcatcagatgc
taaagcatatgatacagaggtacataatgtttgggccacacatgcctgtgtacccacagaccccaacccacaag-
aagtagaattggaaaat
gtgacagaaaattttaacatgtggaaaaataacatggtagaacagatgcatgaggatataatcagtttatggga-
tcaaagcctaaagccat
gtgtaaaattaactccactccaggcctgtccaaagatatcctttgagccaattcccatacattattgtgccccg-
gctggttttgcgattct
aaagtgtaaagataagaagttcaatggaaaaggaccatgttcaaatgtcagcacagtacaatgtacacatggga-
ttaggccagtagtatca
actcaactgctgttaaatggcagtctagcagaagaagaggtagtaattagatccgaaaatttcgcggacaatgc-
taaaaccataatagtac
agctgaatgaatctgtagaaattaattgtacaagacccaacaacaatacaagaaaaagtatacatataggacca-
ggcagagcattatatac
aacaggagaaataataggagatataagacaagcacattgtaaccttagtagagcaaaatggaatgacactttaa-
ataagatagttataaaa
ttaagagaacaatttgggaataaaacaatagtctttaagcattcctcaggaggggacccagaaattgtgacgca-
cagttttaattgtggag
gggaatttttctactgtaattcaacacaactgtttaatagtacttggaatgttactgaagagtcaaataacact-
gtagaaaataacacaat
cacactcccatgcagaataaaacagctagcaatgtatgcccctcccatcagaggacaaattagatgttcatcaa-
atattacagggctgcta
ttaacaagagatggtggtccagaggacaacaagaccgaggtcttcagacctggaggaggagatatgagggacaa-
ttggagaagtgaattat
ataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagatgactagtcgcggcc-
gctttcgaatctaga.
[0311] In other embodiments, a variant gp120 from a HIV isolate
IIIB includes an amino acid sequence as set forth in SEQ ID NO: 73
or a nucleic acid sequence as set forth in SEQ ID NO: 74:
TABLE-US-00008 (SEQ ID NO: 73)
IIHTVPPSGADPGPKRAEFKGLRRQQKQGIILLTMKTIIALSYILCLVLAQKLPGNDNNSEFITSGFLGPLLVL-
QAGFFLLTRILTIPQSL
DSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPV-
CPLIPGSTTTSTGPCKT
CTTPAQGNSKFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWM-
MWYWGPSLYSIVSPFIP
LLPIFFCLWVYIGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVE-
QMHEDIISLWDQSLKPC
VKLTPLSVQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEE-
EVVIRSVNFTDNAKTII
VQLNTSVEINCTRPSVNFTDNAKTIIVQLNTSVEINCTRPMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTI-
IFKQSSGGDPEIVTHSF
NCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQSIAMYAPPISGQIRCSSNITGLLLTRDG-
GNSNNESEIFRPGGGDM RDNWRSELYKYKVVKIEPLGVAPTKAKR. (SEQ ID NO: 74)
ggattattcataccgtcccaccatcgggcgcggatcccggtccgaagcgcgcggaattcaaaggcctacgtcga-
cagcaaaagcaggggat
aattctattaaccatgaagactatcattgctttgagctacattttatgtctggttctcgctcaaaaacttcccg-
gaaatgacaacaacagc
gaattcatcacctccggcttcctgggccccctgctggtgctgcaggccggcttcttcctgctgacccgcatcct-
gaccatcccccagtccc
tggactcctggtggacctccctgaacttcctgggcggctcccccgtgtgcctgggccagaactcccagtccccc-
acctccaaccactcccc
cacctcctgcccccccatctgccccggctaccgctggatgtgcctgcgccgcttcatcatcttcctgttcatcc-
tgctgctgtgcctgatc
ttcctgctggtgctgctggactaccagggcatgctgcccgtgtgccccctgatccccggctccaccaccacctc-
caccggcccctgcaaga
cctgcaccacccccgcccagggcaactccaagttcccctcctgctgctgcaccaagcccaccgacggcaactgc-
acctgcatccccatccc
ctcctcctgggccttcgccaagtacctgtgggagtgggcctccgtgcgcttctcctggctgtccctgctggtgc-
ccttcgtgcagtggttc
gtgggcctgtcccccaccgtgtggctgtccgccatctggatgatgtggtactggggcccctccctgtactccat-
cgtgtcccccttcatcc
ccctgctgcccatcttcttctgcctgtgggtgtacatcggggtacctgtgtggaaggaagcaaccaccactcta-
ttttgtgcatcagatgc
taaagcatatgatacagaggtacataatgtttgggccacacatgcctgtgtacccacagaccccaacccacaag-
aagtagtattggtaaat
gtgacagaaaattttaacatgtggaaaaatgacatggtagaacagatgcatgaggatataatcagtttatggga-
tcaaagcctaaagccat
gtgtaaaattaaccccactctcggtccaggcctgtccaaaggtatcctttgagccaattcccatacattattgt-
gccccggctggttttgc
gattctaaaatgtaataataagacgttcaatggaacaggaccatgtacaaatgtcagcacagtacaatgtacac-
atggaattaggccagta
gtatcaactcaactgctgttaaatggcagtctagcagaagaagaggtagtaattagatctgtcaatttcacgga-
caatgctaaaaccataa
tagtacagctgaacacatctgtagaaattaattgtacaagaccctctgtcaatttcacggacaatgctaaaacc-
ataatagtacagctgaa
cacatctgtagaaattaattgtacaagacccatgagacaagcacattgtaacattagtagagcaaaatggaata-
acactttaaaacagata
gctagcaaattaagagaacaatttggaaataataaaacaataatctttaagcaatcctcaggaggggacccaga-
aattgtaacgcacagtt
ttaattgtggaggggaatttttctactgtaattcaacacaactgtttaatagtacttggtttaatagtacttgg-
agtactgaagggtcaaa
taacactgaaggaagtgacacaatcaccctcccatgcagaataaaacaatcgatagcaatgtatgcccctccca-
tcagtggacaaattaga
tgttcatcaaatattacagggctgctattaacaagagatggtggtaatagcaacaatgagtccgagatcttcag-
acctggaggaggagata
tgagggacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccacc-
aaggcaaagagataa.
[0312] A gp120 polypeptide can be covalently linked to a carrier,
which is an immunogenic macromolecule to which an antigenic
molecule can be bound. When bound to a carrier, the bound
polypeptide becomes more immunogenic. Carriers are chosen to
increase the immunogenicity of the bound molecule and/or to elicit
higher titers of antibodies against the bound molecule which are
diagnostically, analytically, and/or therapeutically beneficial.
Covalent linking of a molecule to a carrier can confer enhanced
immunogenicity and T cell dependence (see Pozsgay et al., PNAS
96:5194-97, 1999; Lee et al., J. Immunol. 116:1711-18, 1976;
Dintzis et al., PNAS 73:3671-75, 1976). Useful carriers include
polymeric carriers, which can be natural (for example,
polysaccharides, polypeptides or proteins from bacteria or
viruses), semi-synthetic or synthetic materials containing one or
more functional groups to which a reactant moiety can be attached.
Bacterial products and viral proteins (such as HBsAg and core
antigen) can also be used as carriers, as well as proteins from
higher organisms such as keyhole limpet hemocyanin, horseshoe crab
hemocyanin, edestin, mammalian serum albumins, and mammalian
immunoglobulins. Additional bacterial products for use as carriers
include bacterial wall proteins and other products (for example,
streptococcal or staphylococcal cell walls and lipopolysaccharide
(LPS)).
iii. Wildtype and Variant Gag Antigenic Inserts
[0313] In some examples, isolated rubella viral vectors disclosed
herein include an antigenic insert that is a wildtype or variant
CTL epitope, such as a CTL epitope from HIV or SW. In some
examples, a HIV or SIV CTL epitope is a CTL epitope of Gag or a
fragment thereof. In some examples, the antigenic peptide includes
one or more major CTL epitopes of Gag, and can be from about 5 to
about 400 amino acids in length, including about 8 to about 350
amino acids in length, such from about 10 to about 280 amino acids
in length, such as 20 to about 270 amino acids in length, such as
from about 40 to about 250 amino acids in length, including 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,
44, 45, 46, 47, 48, 49, 50, 55, 57, 60, 63, 65, 67, 70, 73, 75, 77,
80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145,
150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210,
215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275,
280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 340, 341,
342, 343, 344, 345, 346, 347, 348, 349 or 350.
[0314] Exemplary sequences of wildtype CTL epitopes are publically
available such as those provided on the World Wide Web
addresshiv.1an1.gov/content/immunology/tables/ctl_summary which is
incorporated herein by reference in its entirety as available on
Oct. 15, 2010. In some examples, the antigenic peptide is more than
5 amino acids in length and is encoded by SIVagm Gag (1566 bp,
GenBank Accession No. M30931), SIVmac239 gag (1533 bp, GenBank
Accession No. M33262) or HIV-1 gag (1491 bp; CRF02_AG), each of
which is hereby incorporated in reference in its entirety as of
Apr. 6, 2012. In some examples, the antigenic peptide is more than
5 amino acids in length, such as from about 5 to about 400 amino
acids in length, including about 8 to about 350 amino acids in
length, such as from about 10 to about 280 amino acids in length,
such as 20 to about 270 amino acids in length, such as from about
40 to about 250 amino acids in length, including 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46,
47, 48, 49, 50, 55, 57, 60, 63, 65, 67, 70, 73, 75, 77, 80, 85, 90,
95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155,
160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220,
225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285,
290, 295, 300, 305, 310, 315, 320, 325, 330, 340, 341, 342, 343,
344, 345, 346, 347, 348, 349 or 350 amino acids and is encoded by
SIVagm Gag (1566 bp, GenBank Accession No. M30931), SIVmac239 gag
(1533 bp, GenBank Accession No. M33262), HIV-1 gag (1491 bp;
CRF02_AG) or any of the SIV or HIV Gag sequences disclosed herein.
In some examples, the antigenic peptide is between 135 and 180
amino acids and is encoded by SIVagm Gag (1566 bp, GenBank
Accession No. M30931), SIVmac239 gag (1533 bp, GenBank Accession
No. M33262) or HIV-1 gag (1491 bp; CRF02_AG). In some examples, the
antigenic peptide has an amino acid sequence corresponding to amino
acids 41-211 and/or amino acids 135-269 encoded by SIVmac239 gag
(1533 bp, GenBank Accession No. M33262). In some examples, the
antigenic peptide is approximately 250 amino acids and corresponds
to p27 which is encoded by SIVmac239 gag (1533 bp, GenBank
Accession No. M33262).
[0315] In some examples, a CTL epitope is a CTL epitope of Gag
listed in Tables 1 and 2 below.
TABLE-US-00009 TABLE 1 CTL epitope sequence table for SIV-Gag
epitopes. MCH Class I or SEQ Name Class II Gag Epitope Residues
Location Sequence ID NO: D A01 CM9 181-189 p27 gag CTPYDINQM 92 B
A02 GY9 71-79 P17MA GSENLKSLY 93 A DP.sub.B1-06 KP11 59-70 P17 MA
KILSVLAPLVP 94 C DR.sub.B-W606 TE15/KT15 97-111 TEEAKQIVQRHLVVET 95
E DR.sub.B1-0306 ME11 200-210 p27 gag MQIIRDIINEE 96
TABLE-US-00010 TABLE 2 CTL epitope sequence table for HIV-Gag
epitopes. HXB2 SEQ Epitope Protein location Subtype ID NO:
TRANSPTRR Gag_Pol_TF 21-29 B 97 NSPTRREL Gag_Pol_TF 24-31 B 98
PTRRELQVW Gag_Pol_TF 26-34 B 99 PTSRELQVW Gag_Pol_TF 26-34 A1 100
AGAERQGTL Gag_Pol_TF 44-52 C 101 FSFPQITLW Gag_Pol_TF 54-6 B
102
[0316] In some examples, an antigenic polypeptide includes one or
more of CTL epitopes of Gag, such as one or more of the epitopes
listed in Table 1 or 2 or provided in present FIGS., including
FIGS. 20 and 23. In some examples, an antigenic polypeptide
includes one or more of the amino acid sequences set forth by any
one of SEQ ID NOs: 82-102, 132, 133, 134, 135, 138, 139, 140, 141,
142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154,
155, 156, 158, 159, 160, 161 or 162. The antigenic epitope can
include repeats of any one of these sequences, such as at least two
repeats, such as between two to ten copies, such as three to five
copies, such as one, two, three, four, five, six, seven, eight,
nine or ten copies of SEQ ID NOs: 82-102, 132, 133, 134, 135, 138,
139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151,
152, 153, 154, 155, 156, 158, 159, 160, 161 or 162 or combinations
thereof.
[0317] In some examples, an antigenic polypeptide includes the
amino acid sequence FQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA (SEQ ID
NO: 83) or REGSQKILSVLAPLVPTGSENLKSLYNTVSVIWSIHAED (SEQ ID NO: 82).
For example, the isolated rubella viral vector includes a Gag
antigenic insert including the amino acids
FQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA (SEQ ID NO: 83). In some
examples, the Gag antigenic insert includes the amino acids
LPLSPRTLNAWVKLIEEKKFGAEVVPG (residues 1 to 27 of SEQ ID NO: 84). In
additional examples, the Gag antigenic insert includes the amino
acids SQKILSVLAPL (residues 4-14 of SEQ ID NO: 82). In some
examples, the antigenic insert includes a Gag antigenic insert,
comprising the amino acids GSENLKSLYNT (residues 4-14 of SEQ ID NO:
88).
[0318] The antigenic epitope can include repeats of any one of
these sequences, such as at least two repeats, such as between two
to ten copies, such as three to five copies, such as one, two,
three, four, five, six, seven, eight, nine or ten copies of SEQ ID
NOs: 82-88 or combinations thereof (e.g., one or more copies of
FQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA (SEQ ID NO: 83);
LPLSPRTLNAWVKLIEEKKFGAEVVPG (residues 1 to 27 of SEQ ID NO: 84).
SQKILSVLAPL (residues 4-14 of SEQ ID NO: 82); or GSENLKSLYNT
(residues 4-14 of SEQ ID NO: 88)).
[0319] In several examples, the antigenic polypeptide includes one
or more of the amino acid sequences set forth below:
TABLE-US-00011 (SEQ ID NO: 82)
REGSQKILSVLAPLVPTGSENLKSLYNTVSVIWSIHAED; (SEQ ID NO: 83)
FQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA; (SEQ ID NO: 84)
LPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNC VGDHQAAMQIIRDIINEEA;
(SEQ ID NO: 85) LPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNC
VGDHQAAMQIIRDIINEEATRSQKILSVLAPLVPT; (SEQ ID NO: 86)
LPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNC
VGDHQAAMQIIRDIINEEATRTGSENLKSLYNT; (SEQ ID NO: 87)
LPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNC
VGDHQAAMQIIRDIINEEATRHTEEAKQIVQRHLVVETGTT; (SEQ ID NO: 88)
VPTGSENLKSLYNTVTRVKHTEEAKQIVQRHLVVETGTTSDAFQAL
SEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA; (SEQ ID NO: 90)
LDRFGLAESLLENKEGSQKILSVLAPLVPTGSENLKSLYNTVTRVK
HTEEAKQIVQRHLVVETGTTETSDAFQALSEGCTPYDINQMLNCVG DHQAAMQIIRDIINEEA;
or (SEQ ID NO: 91) LDRFGLAESLLENKEGSQKILSVLAPLVPTGSENLKSLYNTVTRVK
HTEEAKQIVQRHLVVETGTTETRLPLSPRTLNAWVKLIEEKKFGAE
VVPGFQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA.
[0320] The antigenic polypeptide can include one of the amino acid
sequences set forth as SEQ ID NOs: 82-88, 90 and 91. A single copy
of one of SEQ ID NOs: 82-88, 90 and 91 can be included as the
antigenic polypeptide. Alternatively, multiple copies of one of SEQ
ID NOs: 82-88, 90 and 91 can be included as the antigenic
polypeptide. Thus, one, two, three, four, five, six, seven, eight,
nine or more copies of one of the amino acid sequences set forth as
SEQ ID NOs: 82-88, 90 and 91 can be included as the antigenic
polypeptide.
[0321] In additional embodiments, more than one of these sequences
can be included in the antigenic polypeptide. Thus, in several
examples, two, three, four or five of the amino acid sequences set
forth as SEQ ID NOs: 82-88, 90 and 91, can be included as the
antigenic polypeptide in tandem. Each amino acid sequence included
in the antigenic polypeptide can be present only a single time, or
can be repeated.
[0322] In some examples, an antigenic polypeptide includes an amino
acid sequence set forth as
LDRFGLAESLLENKEGCQKILSVLAPLVPTGSENLKSLYNTVCVIWCIHAEEKVKHTEEAK
QIVQRHLVVETGTTETMPKTSRPTAPSSGRGGNYPVQQIGGNYVHLPLSPRTLNAWVKLIE
EKKFGAEVVPGFQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA (SEQ ID NO: 103)
and is encoded by a nucleic acid sequence set forth as
ATTAGATAGATTTGGATTAGCAGAAAGCCTGTTGGAGAACAAAGAAGGATGTCAAAA
AATACTTTCGGTCTTAGCTCCATTAGTGCCAACAGGCTCAGAAAATTTAAAAAGCCTTT
ATAATACTGTCTGCGTCATCTGGTGCATTCACGCAGAAGAGAAAGTGAAACACACTGA
GGAAGCAAAACAGATAGTGCAGAGACACCTAGTGGTGGAAACAGGAACAACAGAAA
CTATGCCAAAAACAAGTAGACCAACAGCACCATCTAGCGGCAGAGGAGGAAATTACC
CAGTACAACAAATAGGTGGTAACTATGTCCACCTGCCATTAAGCCCGAGAACATTAAA
TGCCTGGGTAAAATTGATAGAGGAAAAGAAATTTGGAGCAGAAGTAGTGCCAGGATT
TCAGGCACTGTCAGAAGGTTGCACCCCCTATGACATTAATCAGATGTTAAATTGTGTG
GGAGACCATCAAGCGGCTATGCAGATTATCAGAGATATTATAAACGAGGAGGCTG (SEQ ID NO:
56).
[0323] An antigenic insert of a CTL epitope of a Gag polypeptide
can be covalently linked to a carrier, which is an immunogenic
macromolecule to which an antigenic molecule can be bound. When
bound to a carrier, the bound polypeptide becomes more immunogenic.
Carriers are chosen to increase the immunogenicity of the bound
molecule and/or to elicit higher titers of antibodies against the
bound molecule which are diagnostically, analytically, and/or
therapeutically beneficial. Covalent linking of a molecule to a
carrier can confer enhanced immunogenicity and T cell dependence
(see Pozsgay et al., PNAS 96:5194-97, 1999; Lee et al., J. Immunol.
116:1711-18, 1976; Dintzis et al., PNAS 73:3671-75, 1976). Useful
carriers include polymeric carriers, which can be natural (for
example, polysaccharides, polypeptides or proteins from bacteria or
viruses), semi-synthetic or synthetic materials containing one or
more functional groups to which a reactant moiety can be attached.
Bacterial products and viral proteins (such as HBsAg and core
antigen) can also be used as carriers, as well as proteins from
higher organisms such as keyhole limpet hemocyanin, horseshoe crab
hemocyanin, edestin, mammalian serum albumins, and mammalian
immunoglobulins. Additional bacterial products for use as carriers
include bacterial wall proteins and other products (for example,
streptococcal or staphylococcal cell walls and lipopolysaccharide
(LPS)).
iv. Wildtype and Variant HBsAgs
[0324] In an example, a disclosed isolated rubella viral vector
includes a wildtype or variant HBsAg. Suitable amino acid sequences
for HBsAg are known in the art, and are disclosed, for example, in
PCT Publication No. WO 2002/079217, which is incorporated herein by
reference. Additional sequences for hepatitis B surface antigen can
be found, for example, in PCT Publication No. 2004/113369 and PCT
Publication No. WO 2004/09849. An exemplary HBsAg amino acid
sequence, and the sequence of a nucleic acid encoding HBsAg, is
shown in Berkower et al., Virology 321: 74-86, 2004, which is
incorporated herein by reference in its entirety. An amino acid
sequence of an exemplary HBsAg is set forth as follows:
TABLE-US-00012 (SEQ ID NO: 31)
EFITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGSPVCLG
QNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLD
YQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSKFPSCCCTKPTDGNCT
CISIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWM
MWYWGPSLYSIVSPFIPLLPIFFCLWVYIG.
[0325] Naturally occurring variants of HBsAg are found in other
hepadnaviruses and also self assemble. These include: woodchuck
hepatitis, ground squirrel hepatitis and duck hepatitis virus
variants. Any of these naturally occurring HBsAg variants can be
included within the disclosed constructs.
[0326] By itself, HBsAg assembles into approximately 22 nm
virus-like particles. When expressed together with an HIV-1
antigenic epitope, the HBsAg fusion proteins assemble spontaneously
and efficiently into virus-like particles (see Berkower et al.,
Virology 321: 75-86, 2004, which is incorporated herein by
reference). Without being bound by theory, the multimeric form
expresses the one or more antigenic epitopes at the lipid-water
interface. These epitopes can be used to induce an immune response,
such as to induce the production of neutralizing antibodies.
[0327] The preparation of HBsAg is well documented. See, for
example, Harford et al. (1983) Develop. Biol. Standard 54:125; Greg
et al. (1987) Biotechnology 5:479; EP-A-0 226 846; and EP-A-0 299
108.
[0328] Fragments and variants of HBsAgs as disclosed herein are
fragments and variants that retain the ability to spontaneously
assemble into virus-like particles. By "fragment" of an HBsAg is
intended a portion of a nucleotide sequence encoding a HBsAg, or a
portion of the amino acid sequence of the protein. By "homologue"
or "variant" is intended a nucleotide or amino acid sequence
sufficiently identical to the reference nucleotide or amino acid
sequence, respectively.
[0329] It is recognized that the gene or cDNA encoding a
polypeptide can be considerably mutated without materially altering
one or more the polypeptide's functions. The genetic code is well
known to be degenerate, and thus different codons encode the same
amino acids. Even where an amino acid substitution is introduced,
the mutation can be conservative and have no material impact on the
essential functions of a protein (see Stryer, Biochemistry 4th Ed.,
W. Freeman & Co., New York, N.Y., 1995). Part of a polypeptide
chain can be deleted without impairing or eliminating all of its
functions. Sequence variants of a protein, such as a 5' or 3'
variant, can retain the full function of an entire protein.
Moreover, insertions or additions can be made in the polypeptide
chain for example, adding epitope tags, without impairing or
eliminating its functions (Ausubel et al., Current Protocols in
Molecular Biology, Greene Publ. Assoc. and Wiley-Intersciences,
1998). Specific substitutions include replacing one or more
transmembrane spanning domains of HBsAg with a gp41 transmembrane
spanning domain, such as replacing the first domain and/or third
domain of HBsAg with a gp41 transmembrane spanning domain. Other
modifications that can be made without materially impairing one or
more functions of a polypeptide include, for example, in vivo or in
vitro chemical and biochemical modifications or the incorporation
of unusual amino acids. Such modifications include, for example,
acetylation, carboxylation, phosphorylation, glycosylation,
ubiquitination, labeling, such as with radionucleides, and various
enzymatic modifications, as will be readily appreciated by those
well skilled in the art. A variety of methods for labeling
polypeptides and labels useful for such purposes is well known in
the art, and includes radioactive isotopes such as .sup.125I or
.sup.3H, ligands that bind to or are bound by labeled specific
binding partners (such as antibodies), fluorophores,
chemiluminescent agents, enzymes, and antiligands or crosslinkers
to produce dimers or multimers.
[0330] Functional fragments and variants of HBsAg include those
fragments and variants that are encoded by nucleotide sequences
that retain the ability to spontaneously assemble into virus-like
particles. Functional fragments and variants can be of varying
length. For example, a fragment may consist of 10 or more, 25 or
more, 50 or more, 75 or more, 100 or more, or 200 or more amino
acid residues of a HBsAg amino acid sequence.
[0331] A functional fragment or variant of HBsAg is defined herein
as a polypeptide that is capable of spontaneously assembling into
virus-like particles and/or self-aggregating into stable multimers.
This includes, for example, any polypeptide six or more amino acid
residues in length that is capable of spontaneously assembling into
virus-like particles. Methods to assay for virus-like particle
formation are well known in the art (see, for example, Berkower et
al. (2004) Virology 321:75-86, herein incorporated by reference in
its entirety).
[0332] "Homologues" or "variants" of a HBsAg are encoded by a
nucleotide sequence sufficiently identical to a nucleotide sequence
of hepatitis B surface antigen, examples of which are described
above. By "sufficiently identical" is intended an amino acid or
nucleotide sequence that has at least about 60% or 65% sequence
identity, about 70% or 75% sequence identity, about 80% or 85%
sequence identity, about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98% or 99% sequence identity over its full length as compared to a
reference sequence, for example using the NCBI Blast 2.0 gapped
BLAST set to default parameters. Alignment may also be performed
manually by inspection. For comparisons of amino acid sequences of
greater than about 30 amino acids, the Blast 2 sequences function
is employed using the default BLOSUM62 matrix set to default
parameters (gap existence cost of 11, and a per residue gap cost of
1). When aligning short peptides (fewer than around 30 amino
acids), the alignment should be performed using the Blast 2
sequences function, employing the PAM30 matrix set to default
parameters (open gap 9, extension gap 1 penalties). In one
embodiment, the HBsAg protein is at least about 85%, at least about
90%, at least about 95%, at least about 96%, at least about 97%, at
least about 98%, at least about 99% identical to the polypeptide
set forth as SEQ ID NO: 31.
[0333] One or more conservative amino acid modifications can be
made in the HBsAg amino acid sequence, whether an addition,
deletion or modification, that does not substantially alter the
3-dimensional structure of the polypeptide. For example, a
conservative amino acid substitution does not affect the ability of
the HBsAg polypeptide to self-aggregate into stable multimers.
HBsAg proteins having deletions of a small number of amino acids,
for example, less than about 20% (such as less than about 18%, less
than about 15%, less than about 10%, less than about 8%, less than
about 5%, less than about 2%, or less than about 1%) of the total
number of amino acids in the wild type HBsAg protein can also be
included in the fusion proteins described herein. The deletion may
be a terminal deletion, or an internal deletion, so long as the
deletion does not substantially affect the structure or aggregation
of the fusion protein.
[0334] In certain embodiments, a variant HBsAg can include a linker
sequence. This peptide is a short amino acid sequence providing a
flexible linker that permits attachment of an antigenic
polypeptide, such as an HIV antigen (such as a gp41 or gp120
polypeptide), without disruption of the structure, aggregation
(multimerization) or activity of the self-aggregating polypeptide
component. Typically, a linear linking peptide consists of between
two and 25 amino acids. Usually, the linear linking peptide is
between two and 15 amino acids in length. In one example, the
linker polypeptide is two to three amino acids in length, such as a
serine and an arginine, or two serine residues and an arginine
residue, or two arginine residues and a serine residue. In other
examples, the linear linking peptide can be a short sequence of
alternating glycines and prolines, such as the amino acid sequence
glycine-proline-glycine-proline. A linking peptide can also consist
of one or more repeats of the sequence glycine-glycine-serine.
Alternatively, the linear linking peptide can be somewhat longer,
such as the glycine(4)-serine spacer described by Chaudhary et al.,
Nature 339:394-397, 1989.
[0335] Directly or indirectly adjacent to the remaining end of the
linear linking peptide (that is, the end of the linear linking
peptide not attached to the self-aggregating polypeptide component
of the fusion protein) is a polypeptide sequence including at least
one antigenic epitope of HIV-1, such as an epitope of gp41, such as
at least one antigenic epitope of the membrane proximal region. The
antigenic polypeptide can be a short peptide sequence including a
single epitope. For example the antigenic polypeptide can be a
sequence of amino acids as short as eight or nine amino acids,
sufficient in length to provide an antigenic epitope in the context
of presentation by a cellular antigen presenting complex, such as
the major histocompatibility complex (MHC). The antigenic
polypeptide can also be of sufficient in length to induce
antibodies, such as neutralizing antibodies. Larger peptides, in
excess of 10 amino acids, 20 amino acids or 30 amino acids are also
suitable antigenic polypeptides, as are much larger polypeptides
provided that the antigenic polypeptide does not disrupt the
structure or aggregation of the HBsAg polypeptide component.
[0336] In some examples, the variant HBsAg includes one or more
epitopes of the envelope protein of HIV-1 or major CTLs of HIV or
SIV Gag, and is about 20 to about 200 amino acids in length, such
as about 25 to about 150 amino acids in length, such as about 25 to
about 100 amino acids in length. In several additional examples,
the antigenic polypeptide includes one or more antigenic epitopes
of HIV-1 gp41, such as the membrane proximal region (MPER) of
gp41.
[0337] Exemplary sequences for HIV-1, as well as the amino acid
sequence for full-length gp41 and gp120 and CTLs of Gag can be
found on Genbank, EMBL and SwissProt websites. Exemplary
non-limiting sequence information can be found for example, as
SwissProt Accession No. P04578, (includes gp41 and gp120, initial
entry Aug. 13, 1987, last modified on Jul. 15, 1999); Genbank
Accession No. HIVHXB2CG (full length HIV-1, including RNA sequence
and encoded proteins, Oct. 21, 2002); Genbank Accession No.
CAD23678 (gp41, Apr. 15, 2005); Genbank Accession No. CAA65369
(Apr. 18, 2005); all of which are incorporated herein by reference.
Similar information is available for HIV-2.
[0338] Suitable Env proteins are known in the art and include, for
example, gp160, gp120, gp41, and gp140. Any clade of HIV is
appropriate for antigen selection, including HIV clades A, B, C,
and the like. HIV Gag, Pol, Nef and/or Env proteins from HIV clades
A, B, C, as well as nucleic acid sequences encoding such proteins
and methods for the manipulation and insertion of such nucleic acid
sequences into vectors, are known (see, for example, HIV Sequence
Compendium, Division of AIDS, National Institute of Allergy and
Infectious Diseases, 2003, HIV Sequence Database (on the world wide
web at hiv-web.1an1.gov/content/hiv-db/mainpage.html), Sambrook et
al., Molecular Cloning, a Laboratory Manual, 2d edition, Cold
Spring Harbor Press, Cold Spring Harbor, N.Y., 1989, and Ausubel et
al., Current Protocols in Molecular Biology, Greene Publishing
Association. Exemplary Env polypeptides, for example, corresponding
to clades A, B and C are represented by the sequences of
Genbank.RTM. Accession Nos. U08794, K03455 and AF286227,
respectively.
[0339] Variant HBsAgs can form a self-aggregating multimeric
spherical or rod-shaped structure upon expression in a host cell.
Similarly, the variant HBsAgs can assemble spontaneously
(self-aggregate) when placed in suspension in a solution of
physiological pH (for example, a pH of about 7.0 to 7.6). Thus, in
the present disclosure, wherever a single or monomeric variant
HBsAg is disclosed, polymeric forms are also considered to be
described.
[0340] In some embodiments, an isolated rubella viral vector
includes a variant HBsAg with one or more transmembrane domains of
the HBsAg replaced with a gp41 antigenic insert. The gp41 antigenic
insert can include (a) an antigenic polypeptide fragment of gp41
and (b) a transmembrane spanning region of gp41. In an example, the
gp41 antigenic insert includes (a) an antigenic polypeptide
fragment, such as an antigenic polypeptide fragment with the amino
acid sequence set forth in SEQ ID NO:1 and is between 28 and 350
amino acids in length and (b) a transmembrane spanning gp41 region,
such as a transmembrane spanning gp41 region with the amino acid
sequence set forth in SEQ ID NO: 25 (in which wherein X.sub.1,
X.sub.2 and X.sub.3 are any amino acid; and X.sub.4, X.sub.5, and
X.sub.6 are any hydrophobic amino acid) and is between 22 and 40
amino acids in length.
[0341] In one example, the antigenic polypeptide includes the amino
acid sequence of NEX.sub.1X.sub.2LLX.sub.3LDKWASLWN (SEQ ID NO: 1).
In this sequence, X.sub.1, X.sub.2 and X.sub.3 are any amino acid.
The antigenic epitope can include repeats of this sequence, such as
one to five copies of SEQ ID NO: 1. As noted above, the antigenic
peptide includes one or more epitopes of the envelope protein of
HIV-1, and, including SEQ ID NO: 1, about 10 to about 300 amino
acids in length, such as from about 16 to about 160 amino acids,
such as from about 28 to about 150 amino acids in length, such as
from about 28 to about 140 amino acids in length.
[0342] In several examples, the antigenic polypeptide includes one
or more of the amino acid sequences set forth in SEQ ID NOs: 2-22,
30, 81-102, 126-156 and 158-162. A single copy of one of SEQ ID
NOs: 2-22, 30, 81-102, 126-156 and 158-162 can be included as the
antigenic polypeptide. Alternatively, multiple copies of one of SEQ
ID NOs: 2-22, 30, 81 or 89 can be included as the antigenic
polypeptide. Thus, one, two, three, four or five copies of one of
the amino acid sequences set forth as SEQ ID NOs: 2-22, 30, 81 or
89 can be included as the antigenic polypeptide.
[0343] In additional embodiments, more than one of these sequences
can be included in the antigenic polypeptide. Thus, in several
examples, two, three, four or five of the amino acid sequences set
forth as SEQ ID NOs: 2-22, 30, 81 and 89 can be included as the
antigenic polypeptide in tandem. Each amino acid sequence included
in the antigenic polypeptide can be present only a single time, or
can be repeated.
[0344] The HBsAg variants can include one or more transmembrane
spanning domains that include one of the amino acid sequences set
forth as SEQ ID NOs: 26-28. A single gp41 transmembrane can be
included in the variant HBsAg. Alternatively, multiple gp41
transmembrane domains with amino acid sequences set forth as SEQ ID
NOs: 26-28 can be included within the variant HBsAg. Thus, one,
two, three, four or five gp41 transmembrane domains with one of the
amino acid sequences set forth as SEQ ID NOs: 26-28 can be included
in the variant HBsAg.
[0345] In one particular embodiment, an isolated rubella viral
construct includes a variant HBsAg in which the first transmembrane
spanning domain of the HBsAg is replaced by a gp41 antigenic
insert. For example, the gp41 antigenic insert replaces at least
the first 29 amino acid residues of SEQ ID NO:20, for example amino
acid residues 1-35 of SEQ ID NO: 31. In another example, the gp41
antigenic insert replaces amino acid residues 1-32 of SEQ ID NO:
31. In yet another example, the gp41 antigenic insert replaces
amino acid residues 1-29 of SEQ ID NO: 31. In a particular example,
an isolated construct includes a variant HBsAg in which the first
transmembrane spanning domain of the HBsAg is replaced by a gp41
antigenic insert that has the amino acid sequence set forth as SEQ
ID NO: 29.
[0346] In another particular embodiment, an isolated construct
includes a variant HBsAg in which the third transmembrane spanning
domain of the HBsAg is replaced by a gp41 antigenic insert. For
example, the gp41 antigenic insert replaces at least 29 amino acids
residues of SEQ ID NO: 31, for example amino acid residues 150-190
of SEQ ID NO: 31. In another example, the gp41 antigenic insert
replaces amino acid residues 153-187 of SEQ ID NO: 31. In yet
another example, the gp41 antigenic insert replaces amino acid
residues 156-185 of SEQ ID NO: 31. In a particular example, an
isolated construct includes a variant HBsAg in which the third
transmembrane spanning domain of the HBsAg is replaced by a gp41
antigenic insert has the amino acid sequence set forth as SEQ ID
NO: 59.
[0347] In an even more particular embodiment, an isolated rubella
viral construct includes a variant HBsAg in which more than one
transmembrane spanning domains of HBsAg have been replaced with an
antigenic insert. In one example, an isolated construct includes a
variant HBsAg in which the first and the third transmembrane
spanning domains of the HBsAg are replaced by a gp41 antigenic
insert. For example, the gp41 antigenic insert replaces amino acid
residues 1-35 and 150-190 of SEQ ID NO: 31. In another example, the
gp41 antigenic insert replaces amino acid residues 1-32 and 153-187
of SEQ ID NO: 31. In yet another example, the gp41 antigenic insert
replaces amino acid residues 1-29 and 156-185 of SEQ ID NO: 31. In
a particular example, an isolated construct including a variant
HBsAg in which the third transmembrane spanning domain of the HBsAg
is replaced by a gp41 antigenic insert has the amino acid sequence
set forth as:
TABLE-US-00013 (SEQ ID NO: 59)
MKTIIALSYIFCLVFAQDLPGNDNNSEFITSGFLGPLLVLQAGFFLLTR
ILTIPQSLDSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYR
WMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCK
TCTTPAQGNSKFPSCCCTKPTDGNCTCININEKELLELDKWASLWNWFD
ITNWLWYIRLFIMIVGGLIGLRIVFAVLSIVVGLSPTVWLSAIWMMWYW
GPSLYSIVSPFIPLLPIFFCLWVYIG.
[0348] In one example of an isolated construct, in which the first
transmembrane domain of HBsAg is replaced with the MPER and
transmembrane domain of gp41 has the amino acid sequence set forth
as:
TABLE-US-00014 (SEQ ID NO: 29)
MKTIIALSYIFCLVFAQDLPGNDNNSEFNEKELLELDKWASLWNWFDIT
NWLWYIRLFIMIVGGLIGLRIVFAVLSIPQSLDSWWTSLNFLGGSPVCL
GQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLL
DYQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSKFPSCCCTKPTDGNC
TCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIW
MMWYWGPSLYSIVSPFIPLLPIFFCLWVYIG.
[0349] In one example of the isolated construct, the third
transmembrane domain of HBsAg is replaced with the MPER and
transmembrane domain of gp41 has the amino acid sequence set forth
as:
TABLE-US-00015 (SEQ ID NO: 59)
MKTIIALSYIFCLVFAQDLPGNDNNSEFITSGFLGPLLVLQAGFFLLTR
ILTIPQSLDSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYR
WMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCK
TCTTPAQGNSKFPSCCCTKPTDGNCTCININEKELLELDKWASLWNWFD
ITNWLWYIRLFIMIVGGLIGLRIVFAVLSIVVGLSPTVWLSAIWMMWYW
GPSLYSIVSPFIPLLPIFFCLWVYIG.
[0350] In an example, an isolated construct is provided in which
the first transmembrane domain and third domain of HBsAG is each
replaced with the MPER and transmembrane domain of gp41 and has the
amino acid sequence set forth as:
TABLE-US-00016 (SEQ ID NO: 58)
MKTIIALSYIFCLVFAQDLPGNDNNSEFNEKELLELDKWASLWNWFDIT
NWLWYIRLFIMIVGGLIGLRIVFAVLSIPQSLDSWWTSLNFLGGSPVCL
GQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLL
DYQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSKFPSCCCTKPTDGNC
TCIPINEKELLELDKWASLWNWFDITNWLWYIRLFIMIVGGLIGLRIVF
AVLSIVVGLSPTVWLSAIWMMWYWGPSLYSIVSPFIPLLPIFFCLWVYIG.
[0351] In one example, an isolated construct is provided in which
the first transmembrane domain of HBsAg is replaced with the MPER
and transmembrane domain of gp41 and an additional MPER is inserted
just proximal to the third membrane spanning domain of HBsAg. In
another example, an isolated construct is provided in which
multiple MPERs are inserted within the HBsAg, such as two, three,
four or more MPERs are inserted just proximal to the third membrane
spanning domain of HBsAg. In yet another example, an isolated
construct is provided in which a MPER and transmembrane domain of
gp41 is inserted following the fourth HBsAg membrane spanning
domain.
[0352] The variant HBsAg can optionally include additional
elements, such as a leader sequence or a suitable T cell epitope.
Generally, a T cell epitope is about eight to about ten amino acids
in length, such as about nine amino acid in length, and binds major
histocompatibility complex (MHC), such as HLA 2, for example, HLA
2.2. Examples of suitable T cell epitopes include, but are not
limited to, ASLWNWFNITNWLWY (SEQ ID NO: 32) and IKLFIMIVGGLVGLR
(SEQ ID NO: 33).
[0353] The variant HBsAg may also include a CAAX (SEQ ID NO: 34)
sequence, for isoprenyl addition in vivo. In this sequence, C is
cysteine, A is an aliphatic amino acid and X is any amino acid. The
X residue determines which isoprenoid will be added to the
cysteine. When X is a methionine or serine, the
farnesyl-transferase transfers a farnesyl, and when X is a leucine
or isoleucine, the geranygeranyl-transferase I transfers a
geranylgeranyl group. In general, aliphatic amino acids have
protein side chains containing only carbon or hydrogen atoms.
Aliphatic amino acids include proline (P), glycine (G), alanine
(A), valine (V), leucine (L), and isoleucine (I), presented in
order from less hydrophobic to more hydrophobic. Although
methionine has a sulphur atom in its side-chain, it is largely
non-reactive, meaning that methionine effectively substitutes well
with the true aliphatic amino acids.
B. Therapeutic Methods and Pharmaceutical Compositions
[0354] The disclosed isolated rubella viral vector constructs
including antigenic inserts, such as HIV polypeptides (e.g., Gag,
gp41 or gp120), RSV polypeptides or HBsAgs polypeptides (natural
and recombinant) described herein can be used to produce
pharmaceutical compositions, including compositions suitable for
prophylactic and/or therapeutic administration. These compositions
can be used to induce an immune response to HIV, SIV, RSV or
Hepatitis B, such as a protective immune response. However, the
compositions can also be used in various assays, such as in assays
designed to detect an HIV-1 or Hepatitis B infection.
[0355] The disclosed isolated rubella viral constructs including
can be administered to a subject in order to generate an immune
response to HIV-1, SIV or Hepatitis B. In one example, the immune
response is a protective immune response. Thus, the constructs
disclosed herein can be used in a vaccine, such as a vaccine to
inhibit subsequent infection with HIV, SIV or Hepatitis B. In some
examples the disclosed constructs are administered as a virus like
particle.
[0356] A therapeutically effective amount of a rubella viral
construct, a virus-like particle including this construct, or a
composition including the construct or virus-like particle can be
administered to a subject to prevent, inhibit or to treat a
condition, symptom or disease, such as AIDS. As such, the
constructs can be administered as vaccines to prophylactically or
therapeutically induce or enhance an immune response. For example,
the pharmaceutical compositions described herein can be
administered to stimulate a protective immune response against HIV,
such as a HIV-1, SIV or Hepatitis B. In some examples, a disclosed
composition is administered to a subject either alone or in
combination with other HIV, SIV or Hepatitis B therapeutic agents.
A single administration can be utilized to prevent or treat an HIV
or Hepatitis B infection, or multiple sequential administrations
can be performed.
[0357] In exemplary applications, compositions are administered to
a subject infected with HIV or Hepatitis B, or likely to be exposed
to an infection, in an amount sufficient to raise an immune
response to HIV or Hepatitis B. Administration induces a sufficient
immune response to reduce viral load, to prevent or lessen a later
infection with the virus, or to reduce a sign or a symptom of HIV
or Hepatitis B infection. Amounts effective for this use will
depend upon various clinical parameters, including the general
state of the subject's health, and the robustness of the subject's
immune system, amongst other factors. A therapeutically effective
amount of the compound is that which provides either subjective
relief of one or more symptom(s) of HIV or Hepatitis B infection,
an objectively identifiable improvement as noted by the clinician
or other qualified observer, a decrease in viral load, an increase
in lymphocyte count, such as an increase in CD4 cells, or
inhibition of development of symptoms associated with infection. In
one particular example, the administration of the composition will
result in in vivo protein expression of the proteins encoded by the
open reading frames contained in the expression vector construct.
For example, the administration of the composition will result in
the induction of immunity against the viruses whose proteins are
encoded by the open reading frames.
[0358] The compositions can be administered by any means known to
one of skill in the art (see Banga, A., "Parenteral Controlled
Delivery of Therapeutic Peptides and Proteins," in Therapeutic
Peptides and Proteins, Technomic Publishing Co., Inc., Lancaster,
Pa., 1995) such as by intramuscular, subcutaneous, or intravenous
injection, but even oral, nasal, or anal administration is
contemplated.
[0359] In some examples, the compositions are administered in a
formulation including a carrier or excipient. A wide variety of
suitable excipients are known in the art, including physiological
phosphate buffered saline (PBS), and the like. Optionally, the
formulation can include additional components, such as aluminum
hydroxylphophosulfate, alum, diphtheria CRM.sub.197, or liposomes.
To extend the time during which the peptide or protein is available
to stimulate a response, the peptide or protein can be provided as
an implant, an oily injection, or as a particulate system. The
particulate system can be a microparticle, a microcapsule, a
microsphere, a nanocapsule, or similar particle. A particulate
carrier based on a synthetic polymer has been shown to act as an
adjuvant to enhance the immune response, in addition to providing a
controlled release. Aluminum salts may also be used to produce an
immune response.
[0360] In a specific example, the composition is administered as a
vaccine subcutaneously at a concentration range from 102 to 104
TCID.sub.50/person (TCID is an abbreviation for tissue culture
infectious doses). For example, the vaccine is provided to the
physician in a lyophilized form, reconstituted in an appropriate
solvent such as deionized water or saline, and administered as a
single injection.
[0361] In one embodiment, the construct is mixed with two or more
of a stabilizing detergent, a micelle-forming agent, and an oil.
Suitable stabilizing detergents, micelle-forming agents, and oils
are detailed in U.S. Pat. No. 5,585,103; U.S. Pat. No. 5,709,860;
U.S. Pat. No. 5,270,202; and U.S. Pat. No. 5,695,770, all of which
are incorporated by reference. A stabilizing detergent is any
detergent that allows the components of the emulsion to remain as a
stable emulsion. Such detergents include polysorbate, 80 (TWEEN)
(Sorbitan-mono-9-octadecenoate-poly(oxy-1,2-ethanediyl;
manufactured by ICI Americas, Wilmington, Del.), TWEEN 40.TM.,
TWEEN 20.TM., TWEEN 60.TM., ZWITTERGENT.TM. 3-12, TEEPOL HB7.TM.,
and SPAN 85.TM.. These detergents are usually provided in an amount
of approximately 0.05 to 0.5%, such as at about 0.2%. A micelle
forming agent is an agent which is able to stabilize the emulsion
formed with the other components such that a micelle-like structure
is formed. Such agents generally cause some irritation at the site
of injection in order to recruit macrophages to enhance the
cellular response. Examples of such agents include polymer
surfactants described by BASF Wyandotte publications, for example,
Schmolka, J. Am. Oil. Chem. Soc. 54:110, 1977; and Hunter et al.,
J. Immunol 129:1244, 1981, PLURONIC.TM. L62LF, L101, and L64,
PEG1000, and TETRONIC.TM. 1501, 150R1, 701, 901, 1301, and 130R1.
The chemical structures of such agents are well known in the art.
In one embodiment, the agent is chosen to have a
hydrophile-lipophile balance (HLB) of between 0 and 2, as defined
by Hunter and Bennett, J. Immun. 133:3167, 1984. The agent can be
provided in an effective amount, for example between 0.5 and 10%,
or in an amount between 1.25 and 5%.
[0362] The oil included in the composition is chosen to promote the
retention of the antigen in oil-in-water emulsion, such as to
provide a vehicle for the desired antigen, and preferably has a
melting temperature of less than 65.degree. C. such that emulsion
is formed either at room temperature (about 20.degree. C. to
25.degree. C.), or once the temperature of the emulsion is brought
down to room temperature. Examples of such oils include squalene,
Squalane, EICOSANE.TM., tetratetracontane, glycerol, and peanut oil
or other vegetable oils. In one specific, non-limiting example, the
oil is provided in an amount between 1 and 10%, or between 2.5 and
5%. The oil should be both biodegradable and biocompatible so that
the body can break down the oil over time, and so that no adverse
effects, such as granulomas, are evident upon use of the oil.
[0363] An adjuvant can be included in the composition. In one
example, the adjuvant is a water-in-oil emulsion in which antigen
solution is emulsified in mineral oil (such as Freund's incomplete
adjuvant or montanide-ISA). In one embodiment, the adjuvant is a
mixture of stabilizing detergents, micelle-forming agent, and oil
available under the name PROVAX.RTM. (IDEC Pharmaceuticals, San
Diego, Calif.). Other examples of suitable adjuvants are listed in
the terms section of this specification.
[0364] Actual methods for preparing administrable compositions will
be known or apparent to those skilled in the art and are described
in more detail in such publications as Remington: The Science and
Practice of Pharmacy, University of the Sciences in Philadelphia,
Lippincott Williams & Wilkins, Philadelphia, Pa., 21st Edition
(2005). The compositions can be administered, either systemically
or locally, for therapeutic treatments, such as to treat an HIV
infection. In therapeutic applications, a therapeutically effective
amount of the composition is administered to a subject infected
with HIV, such as, but not limited to, a subject exhibiting signs
or symptoms of AIDS. Single or multiple administrations of the
compositions can be administered depending on the dosage and
frequency as required and tolerated by the subject. In one
embodiment, the dosage is administered once as a bolus, but in
another embodiment can be applied periodically until a therapeutic
result is achieved. Generally, the dose is sufficient to treat or
ameliorate symptoms or signs of the HIV infection without producing
unacceptable toxicity to the subject.
[0365] Controlled release parenteral formulations can be made as
implants, oily injections, or as particulate systems. For a broad
overview of protein delivery systems, see Banga, Therapeutic
Peptides and Proteins: Formulation, Processing, and Delivery
Systems, Technomic Publishing Company, Inc., Lancaster, Pa. (1995).
Particulate systems include microspheres, microparticles,
microcapsules, nanocapsules, nanospheres, and nanoparticles.
Microcapsules contain the therapeutic protein as a central core. In
microspheres, the therapeutic agent is dispersed throughout the
particle. Particles, microspheres, and microcapsules smaller than
about 1 .mu.m are generally referred to as nanoparticles,
nanospheres, and nanocapsules, respectively. Capillaries have a
diameter of approximately 5 .mu.m so that only nanoparticles are
administered intravenously. Microparticles are typically around 100
.mu.m in diameter and are administered subcutaneously or
intramuscularly (see Kreuter, Colloidal Drug Delivery Systems, J.
Kreuter, ed., Marcel Dekker, Inc., New York, N.Y., pp. 219-342
(1994); Tice & Tabibi, Treatise on Controlled Drug Delivery, A.
Kydonieus, ed., Marcel Dekker, Inc. New York, N.Y., pp. 315-339
(1992)). In one example, virus like particles are in the range of
10-30 nm.
[0366] Polymers can be used for ion-controlled release. Various
degradable and nondegradable polymeric matrices for use in
controlled drug delivery are known in the art (Langer, Accounts
Chem. Res. 26:537, 1993). For example, the block copolymer,
polaxamer 407 exists as a viscous yet mobile liquid at low
temperatures but forms a semisolid gel at body temperature. It has
shown to be an effective vehicle for formulation and sustained
delivery of recombinant interleukin-2 and urease (Johnston et al.,
Pharm. Res. 9:425, 1992; and Pec, J. Parent. Sci. Tech. 44(2):58,
1990). Alternatively, hydroxyapatite has been used as a
microcarrier for controlled release of proteins (Ijntema et al.,
Int. J. Pharm. 112:215, 1994). In yet another aspect, liposomes are
used for controlled release as well as drug targeting of the
lipid-capsulated drug (Betageri et al., Liposome Drug Delivery
Systems, Technomic Publishing Co., Inc., Lancaster, Pa., 1993).
Numerous additional systems for controlled delivery of therapeutic
proteins are known (e.g., U.S. Pat. No. 5,055,303; U.S. Pat. No.
5,188,837; U.S. Pat. No. 4,235,871; U.S. Pat. No. 4,501,728; U.S.
Pat. No. 4,837,028; U.S. Pat. No. 4,957,735; and U.S. Pat. No.
5,019,369; U.S. Pat. No. 5,055,303; U.S. Pat. No. 5,514,670; U.S.
Pat. No. 5,413,797; U.S. Pat. No. 5,268,164; U.S. Pat. No.
5,004,697; U.S. Pat. No. 4,902,505; U.S. Pat. No. 5,506,206; U.S.
Pat. No. 5,271,961; U.S. Pat. No. 5,254,342; and U.S. Pat. No.
5,534,496).
C. Immunodiagnostic Reagents and Kits
[0367] In addition to the therapeutic methods provided above, any
of the disclosed rubella viral constructs herein can be utilized to
produce antigen specific immunodiagnostic reagents, for example,
for serosurveillance. Immunodiagnostic reagents can be designed
from any of the constructs including antigenic polypeptides
described herein. For example, the presence of serum antibodies to
HIV, SIV, RSV or Hepatitis B can be monitored using the isolated
immunogens disclosed herein, such as to detect an HIV, SIV, RSV or
Hepatitis B infection. Generally, the method includes contacting a
sample from a subject, such as, but not limited to a blood, serum,
plasma, urine or sputum sample from the subject with one or more of
the variant molecules disclosed herein and detecting binding of
antibodies in the sample to the variant molecule. For example, the
method can include contacting a sample from a subject, such as, but
not limited to a blood, serum, plasma, urine or sputum sample from
the subject with one or more of the constructs disclosed herein and
detecting binding of antibodies in the sample to the antigenic
insert. The binding can be detected by any means known to one of
skill in the art, including the use of labeled secondary antibodies
that specifically bind the antibodies from the sample. Labels
include radiolabels, enzymatic labels, and fluorescent labels.
[0368] Any such immunodiagnostic reagents can be provided as
components of a kit. Optionally, such a kit includes additional
components including packaging, instructions and various other
reagents, such as buffers, substrates, antibodies or ligands, such
as control antibodies or ligands, and detection reagents.
[0369] Methods are further provided for a diagnostic assay to
monitor a particular disease and/or to monitor the response of the
subject to immunization by a particular vaccine, such as HIV, SIV,
RSV or Hepatitis B vaccine. In one example, a diagnostic assay is
to monitor an HIV-1 induced disease in a subject and/or to monitor
the response of the subject to immunization by an HIV vaccine. By
"HIV-1 induced disease" is intended any disease caused, directly or
indirectly, by HIV. An example of an HIV-1 induced disease is
acquired autoimmunodeficiency syndrome (AIDS). The method includes
contacting a disclosed construct with a sample of bodily fluid from
the subject, and detecting binding of antibodies in the sample to
the disclosed antigens. In addition, the detection of the HIV-1
binding antibody also allows the response of the subject to
immunization by a HIV vaccine to be monitored. In still other
embodiments, the titer of the HIV-1 binding antibodies is
determined. The binding can be detected by any means known to one
of skill in the art, including the use of labeled secondary
antibodies that specifically bind the antibodies from the sample.
Labels include radiolabels, enzymatic labels, and fluorescent
labels. In other embodiments, a disclosed construct is used to
isolate antibodies present in a subject or biological sample
obtained from a subject.
[0370] The provided isolated viral vectors can also be used in
screening antiviral drugs. In one example, methods of screening
antiviral drugs including methods of identifying protease
inhibitors are disclosed. Viral inhibitory peptides correspond to
the sequence of a protease target site for rubella. Inhibitory
peptides contain synthetic amino acids, such as dehydro-alanine, on
either side of the expected cleavage site. When these groups are
attacked by the active site cysteine of the protease, they react
with it and form a covalent bond. This attaches irreversibly to the
free SH-group of the active site of the enzyme and results in
non-competitive inhibition of the protease.
[0371] In one particular example, a method of identifying protease
inhibitors is provided that utilizes a disclosed rubella-GFP
construct to detect the effect of protease inhibition. Typically,
in the absence of a protease inhibitor, GFP is expressed well by
days 3 to 7 of infection. However, when an inhibitory peptide is
added, the virus fails to cleave its nonstructural protein
precursor into two fragments: P150 and active RNA polymerase.
Without this cleavage, no RNA transcription can occur, either of
the negative strand template RNA, or of the positive strand RNA
coding for the nonstructural and structural proteins. In
particular, protease inhibition prevents expression of GFP linked
to P150, as manifested by a loss of green fluorescence. Therefore,
a protease inhibitor is identified by detecting a decrease or
inhibition of GFP expression or a decrease or inhibition in
expression of one or more of the rubella nonstructural and
structural proteins, such as a 10%, 20%, 30% 40%, 50%, 60%, 70%,
80%, 90% or more reduction in expression. In one particular
example, a method of identifying a protease inhibitor includes
contacting a cell expressing one or more of the disclosed
rubella-GFP viral constructs with one or more test agents and with
an amount of an agent capable of inhibiting protease activity.
Expression of GFP or one or more of the rubella nonstructural
and/or structural proteins is subsequently measured, whereby a
decrease in expression of one or more of this proteins indicates
that the agent is a protease inhibitor.
[0372] Besides reducing GFP expression, protease inhibitors disrupt
the localization of P150-GFP to viral replicating centers in the
cytoplasm. P150-GFP preserves the normal functions of P150 and
localizes correctly to sites of viral RNA synthesis as noted by
P150-GFP localizing to these centers as intensely fluorescent dots
in the cytoplasm. When protease is inhibited, even partially, this
is detected as a reduction in replicating centers. It is believed
that rubella will be just as sensitive to protease inhibitors as is
HIV as both viruses work by similar mechanisms. Additionally, other
alphaviruses, such as VEE, have a similar requirement for protease
activation of RNA replication, and their inhibitory peptides can be
designed similarly, based on the known targets for viral
protease.
[0373] The disclosure is illustrated by the following non-limiting
Examples.
EXAMPLES
Example 1
Materials and Methods
[0374] This example describes the materials and methods used in
Example 2.
[0375] Construction of Rubella Expression Plasmids and Mutant
Viruses.
[0376] A full length, infectious cDNA clone coding for wild type
rubella of the Therien strain (GenBank accession M15240), called
Robo 302, was kindly provided by Dr. Teryl Frey of Georgia State
University (Pugachev et. al., J. Virol. 71, 562-568, 1999). For the
generation of pRub.DELTA.Not 1, Robo 302 was digested with Not I
and re-ligated, resulting in deletion of a 507 by fragment from the
non-structural region (bp 3661-4168 of the plasmid), without
disruption of the reading frame. For the generation of
pRub.DELTA.Not 1-GFP, a 3807 by Hind III-Sca 1 fragment from
pRub.DELTA.Not 1 was cloned into pBR322, resulting in plasmid
pBR322-3818.DELTA.Not1.
[0377] This construct contained a single Not I site. Zoanthus sp.
green fluorescent protein (zGFP) was PCR-amplified from
pZsGreen1-C1 (Cat. No. 632447, Clontech Laboratories, Inc. Mountain
View, Calif.) using upstream primer 5'
CGGCGGCCGCACCGGTCGCCACCATGGCCCAGTCCAAGCACGGCCTGACC-3' (SEQ ID NO:
75) and downstream primer
5'-TGGCGGCCGCTCTAGATCCGGTGGATCCCGGGCCCGCGGTACCGTCG-3' (SEQ ID NO:
76) and the resulting 804 by product was digested with Not I and
ligated into the Not 1 site of pBR322-3818 .DELTA.Not 1in frame
with the non structural sequence, generating
pBR322-3818.DELTA.Not1-GFP. A 4096 by Bsu36 I-Sca 1 restriction
fragment from pBR322-3818.DELTA.Not1-GFP, comprising GFP cloned
into the Not I deletion in Rub non-structural coding sequences, was
cloned into corresponding sites of Robo302 to generate
pRub-.DELTA.Not1-GFP.
[0378] Vero Cell Culture.
[0379] African Green monkey kidney (Vero) cells were maintained in
DMEM containing L-Glutamine, penicillin/streptomycin (MediaTech,
Inc. Herndon Va.) and 10% fetal bovine serum at 37.degree. C. and
5% CO.sub.2 in a humidified incubator. All microscopy was carried
out using an inverted Nikon Diaphot microscope equipped for
fluorescence detection and digital image capture.
[0380] Generation of Capped, Infectious Rubella Virus RNA and Cell
Transfection.
[0381] In each of the pRub plasmids, the viral genome is located
downstream of an SP6 promoter. The plasmids were linearized by
digestion with Spe I and transcribed using the RiboMAX Large scale
RNA Production System (Promega Corp., Madison Wis.). The
transcription reaction contained 1.times. SP6 transcription buffer,
0.8U RNAsin, 5 mM rATP, 5 mM rCTP, 5 mM rUTP, 1 mM rGTP, 2 mM Ribo
m7G(5')ppp(5')G cap analog, 5-10 .mu.g linear ds-DNA template and 1
.mu.L of SP6 RNA polymerase. The reaction mixture was incubated at
37.degree. C. for 3 hours, followed by another hour in the presence
of 1 .mu.l of RNAse-free DNAse. Capped infectious rubella RNA was
transfected into Vero cells as follows. The RNA was combined with 1
mL of OptiMEM, while 14 .mu.L of DMRIEC lipid reagent (Invitrogen
Corporation Carlsbad, Calif.) was added to 1 mL of OptiMEM. The two
mixtures were combined and mixed gently. Cells were seeded 12-18
hours before and were washed twice with OptiMEM before being
overlaid with the transfection mixture and incubated for 6-12 hours
at 37.degree. C. and 5% CO.sub.2 in a humidified incubator.
[0382] Western Blot Analyses.
[0383] Rubella structural proteins were detected by western blot.
Vero cell lysates in RIPA buffer were sonicated for 30 seconds and
then electrophoresed on a denaturing Nupage 4-12% acrylamide
Bis-Tris gel (Invitrogen Corporation, Carlsbad, Calif.). Proteins
were transferred to 0.2 .mu.m Nitrocellulose filters followed by
blocking for 30 min in TBS with 3% bovine serum albumin at room
temperature on a rocking platform. Primary antibody binding was
performed with polyclonal goat anti-rubella antibodies at a 1:400
dilution (Fitzgerald Industries International, Inc. Concord, Mass.
Cat#20-RG04) in TBS with 0.2% Tween, 0.3% BSA at 4.degree. C.
overnight on a rocking platform. Blots were washed 3 times with 10
ml TBS with 0.2% Tween for 10 minutes each on an orbital shaker.
Horseradish peroxidase-conjugated rabbit anti-goat IgG at a
dilution of 1:5000 (Santa Cruz Biotechnology, Santa Cruz, Calif.)
was added in TBS with 0.2% Tween for 40 minutes at room temperature
on a rocking platform, followed by the same washing procedure as
above. Proteins were visualized by enhanced chemiluminescence
(Amersham Biosciences, Buckinghamshire, England) and
autoradiography.
Analysis of the zGFP Insert in Viral RNA.
[0384] Viral RNA was extracted by treating infected cells or
pelleted virus with TRIzol (Invitrogen Corporation, Carlsbad,
Calif.) and purified according to the manufacturer's instructions.
Reverse transcription was performed using a SuperScript III kit
(Invitrogen Corporation, Carlsbad, Calif.) and random hexamers. The
cDNA was PCR amplified using an Advantage-GC PCR kit (Clonetech
Laboratories, Mountain View, Calif.) and primers specific for
rubella sequences flanking the insert. The 5' primer Robo-55 was
5'-CCATTAAGCGGTTCCTCGGTAGC (SEQ ID NO: 23), and the 3' primer was
5'-GAGTGCCGCGAGCGTCCGAGTGC (SEQ ID NO: 24), resulting in a product
of 1.2 Kb. Amplified cDNA was analyzed by gel electrophoresis,
purified using a Qiagen kit, and sequenced using the same PCR
primers. To analyze zGFP function, the amplified cDNA was cloned
into E. coli and each colony was examined for fluorescence. The
cDNA was PCR amplified using a puReTaq Ready-To-Go PCR kit (GE
Healthcare) and 5' primers containing an NcoI restriction site and
3' primers containing an EcoRI restriction site. The purified PCR
products and a pZsGreen plasmid (Clontech Laboratories, Mountain
View, Calif.) were cleaved using NcoI and EcoRI restriction
endonucleases (NEB), gel purified, and ligated together to produce
a functional zGFP plasmid. The products were transformed into
competent DH5-.alpha. cells (Invitrogen Corporation, Carlsbad,
Calif.), plated overnight in LB/Amp medium containing 100 uM IPTG,
and visualized in an inverted fluorescent Nikon Diaphot microscope.
Fifty five to 76 colonies per passage were analyzed for green
fluorescence. Representative colonies of either type were grown in
LB/Amp medium, and the plasmid was isolated (Qiagen Mini-prep kit)
and sequenced (FDA core facility).
Example 2
Stable Expression of GFP Insert in a Rubella Vector
[0385] This example illustrates that a foreign gene, zGFP, can be
inserted into the Not I site in the nonstructural gene nsP150 of a
rubella vector, resulting in an infectious rubella hybrid that
expresses the foreign protein for many generations. Although this
example utilizes the foreign gene zGFP, it is contemplated that
other foreign genes such as HIV antigens, SIV antigens, RSV
antigens or HBsAgs can also be incorporated in a similar
manner.
[0386] FIG. 1A provides an illustration of the pRobo 302 plasmid
coding for full length, infectious rubella virus. Rubella
nonstructural proteins (nsPs) are expressed as a polyprotein
precursor, which is cleaved to produce nsP150 and nsP90. The
structural proteins, capsid, E2 and E1, are expressed from a
subgenomic promoter and cleaved to produce proteins that assemble
into mature virions. Two Not I restriction sites are located in
nsP150 at by 1685 and 2192 (FIG. 1B).
[0387] To determine if a deletion of 507 by between two Not I
restriction sites was permissive for subgenomic transcription and
viral replication, each full length rubella cDNA was transcribed,
capped, and transfected into Vero cells as described above.
Expression of rubella structural proteins was detected by western
blot of the P.sub.0 cell lysates on day 12. Wild type rubella
expressed capsid, E2 and E1 proteins (FIG. 2, lane 5) at the same
level as Not I deleted rubella (FIG. 2, lane 4).
[0388] Normal expression of the structural proteins indicated that
viral RNA polymerase made negative strand template RNA, followed by
plus strand subgenomic RNA coding for the structural proteins. The
deletion was located in a region of unknown function, and created a
potential space for insertion of a foreign gene without interfering
with essential viral functions. The reporter gene zGFP was inserted
into the site of the Not I deletion. This added 792 by of DNA, for
a net increase of 285 bp, and preserved the open reading frame.
Vero cells were transfected with capped viral RNA, and viral
supernatants were transferred onto fresh cultures. The rubella-GFP
hybrid virus expressed normal levels of rubella structural
proteins, as shown by western blot (FIG. 2, lanes 1 and 2 showing
two independent clones). zGFP expression was detected as
fluorescence of infected Vero cells. The initial transfection with
infectious RNA resulted in multiple foci of bright fluorescence.
The supernatants of these cultures contained infectious virus that
produced bright fluorescent foci on Vero cells.
[0389] Stability of GFP expression was tested during serial passage
of culture supernatants on Vero cells. GFP expression was
manifested by multiple bright fluorescent foci that appeared by day
4 and spread throughout the culture by day 7 to 10. Each
intermediate passage showed GFP expression, and there was no
fluorescence from an uninfected control run in parallel.
[0390] Genetic stability of zGFP was examined by recovering viral
RNA from culture supernatants or infected cells after passages 5,
6, 10, and 11 and generating cDNA by RT-PCR of the insert. The
overall GFP sequence was unchanged at passages 5 and 6, but showed
a deletion of 27 by at passages 10 and 11. This finding contrasted
with fluorescence observed at later passages and suggested the
possibility of a mixed population of wild type viruses giving
fluorescence and mutants giving the observed sequence. To test
this, the cDNAs were cloned into E. coli and individual colonies
were examined for GFP expression. At passage 5, 76% of colonies (42
out of 55) were fluorescent, but by passages 10 and 11 only 5% of
colonies (5 out of 100) expressed functional GFP.
[0391] Several clones of each phenotype were sequenced. At passage
5, four non-fluorescing clones constituted a swarm of different
mutants. Two clones had point mutations Leu 46 to Pro or Phe 83 to
Ser, while two others had deletions of 9 or 54 by coding for amino
acids Ile 79-Asp 81 or Lys 39-Phe 56. The deletion mutant that
predominated at later passages was not detected at this passage. By
passage 11, all five non-fluorescing clones had deletions ranging
from 9 to 27 bp. Three had the predominant 27 by deletion coding
for amino acids Phe 83-Tyr 91 that was identical to the bulk
culture. Two others had deletions coding for Asp 78-Val 80 or Thr
73-Asp 81. In contrast, two fluorescent clones at passage 11 showed
the full wild type zGFP sequence. The loss of 9, 27, or 54 by
suggests persistent selective pressure to reduce the size of the
zGFP insert. However, the emergence after 10 passages of a
predominant clone with a 27 by deletion that preserves the reading
frame suggests that zGFP may achieve stability at a size of about
765 bp.
[0392] Rubella-GFP allowed the host range and sensitivity to
interferon to be examined. FIG. 3 shows that infection was limited
to Vero cells, as the virus did not grow well or at all on
fibroblasts, osteocytes, epithelial cells, or a glioma. This
finding may be due to cells that do not support infection lacking
receptors for rubella. Alternatively, since rubella replication
proceeds via a double stranded RNA intermediate that strongly
elicits interferon, the growth pattern may reflect the inability of
Vero cells to produce interferon, while the other cells resist
infection by producing interferon.
[0393] These studies support the notion that rubella can be a
vector for delivering vaccine antigens, since it can express genes
as large as most viral antigens, while growing to high enough
titers for vaccine production and immunization. For example, the
current insert size of 792 by (or 765 by after deletion) is larger
than hepatitis B surface antigen (680 bp) and most HIV antigens,
including p24 (660 bp) and the gp41 ectodomain (570 bp). In
addition, rubella hybrids can achieve sufficiently high titers for
efficient vaccine production. After four passages on Vero cells,
the titer reached 4.times.10.sup.6 fluorescent foci per ml. Live
attenuated rubella is one of the most efficient vaccines, with a
recommended human dose of 5,000 PFU (Plotkin et al., Rubella
Vaccine. In: Plotkin, S. A., and Orenstein W. A. (Eds.), Vaccines,
4.sup.th ed. Saunders, Philadelphia, pp. 707-7432004), so this
culture supernatant could provide 800 doses per ml.
Example 3
Treatment or Prevention of HIV in a Human Subject
[0394] This example describes a particular method that can be used
to prevent or treat HIV in a human subject by administration of one
or more compositions that includes an effective amount of any of
the disclosed isolated immunogens. Although particular methods,
dosages, and modes of administrations are provided, one skilled in
the art will appreciate that variations can be made without
substantially affecting the treatment.
[0395] Based upon the teaching disclosed herein, a virus, such as
HIV, such as HIV type 1, can be prevented and/or treated by
administering a therapeutically effective amount of a composition
that includes a viral-like particle produced by an isolated rubella
viral vector with an HIV antigenic insert to prevent, reduce or
eliminate HIV infection, replication or a combination thereof. The
method can include screening subjects to determine if they are HIV
sero-positive, for example infected with HIV-1. Subjects having HIV
infection are selected. In one example, subjects having increased
levels of HIV antibodies in their blood (as detected with an
enzyme-linked immunosorbent assay, Western blot, immunofluorescence
assay, or nucleic acid testing, including viral RNA or proviral DNA
amplification methods) are selected. In one example, a clinical
trial would include half of the subjects following the established
protocol for treatment of HIV (such as a highly active
antiretroviral therapy). The other half would follow the
established protocol for treatment of HIV (such as treatment with
highly active antiretroviral compounds) in combination with
administration of the compositions including an isolated rubella
viral vector with an HIV antigenic insert (as described herein). In
another example, a clinical trial would include half of the
subjects following the established protocol for treatment of HIV
(such as a highly active antiretroviral therapy). The other half
would receive a composition including the isolated rubella viral
vector with an HIV antigenic insert.
[0396] In another example, a population of subjects at high risk of
HIV infection would be screened for rubella antibodies. The
seronegative subjects would be randomized to receive conventional
rubella vaccine without an insert or the rubella vectors with HIV
inserts. The subjects would be observed over time for protection
against rubella or HIV. If the vectors elicit protective immunity
to HIV, the number of HIV infections in the rubella control group
would greatly exceed the number in the rubella vector group. The
cohort size and risk per year would be large enough to produce at
least 30 infections in the control group. Under these conditions, a
reduction of 50% or greater would be statistically significant
protection.
Screening Subjects
[0397] In particular examples, the subject is first screened to
determine if they are infected with HIV. Examples of methods that
can be used to screen for HIV infection include a combination of
measuring a subject's CD4+ T cell count and the level of HIV in
serum blood levels or determine whether a subject is sero-positive
for HIV antibodies.
[0398] In some examples, HIV testing consists of initial screening
with an enzyme-linked immunosorbent assay (ELISA) to detect
antibodies to HW, such as to HIV-1. Specimens with a nonreactive
result from the initial ELISA are considered HIV-negative unless
new exposure to an infected partner or partner of unknown HIV
status has occurred. Specimens with a reactive ELISA result are
retested in duplicate. If the result of either duplicate test is
reactive, the specimen is reported as repeatedly reactive and
undergoes confirmatory testing with a more specific supplemental
test (e.g., Western blot or an immunofluorescence assay (IFA)).
Specimens that are repeatedly reactive by ELISA and positive by IFA
or reactive by Western blot are considered HIV-positive and
indicative of HIV infection. Specimens that are repeatedly
ELISA-reactive and occasionally provide an indeterminate Western
blot result, which may be either an incomplete antibody response to
HIV in an infected subject, or nonspecific reactions in an
uninfected person. IFA can be used to confirm infection in these
ambiguous cases. In some instances, a second specimen will be
collected more than a month later and retested for subjects with
indeterminate Western blot results. In additional examples, nucleic
acid testing (e.g., viral RNA or proviral DNA amplification method)
can also help diagnosis in certain situations.
[0399] The detection of HIV in a subject's blood is also indicative
that the subject has HIV and is a candidate for receiving the
therapeutic compositions disclosed herein. Moreover, detection of a
CD4+ T cell count below 350 per microliter, such as 200 cells per
microliter, suggests that the subject is likely to have HIV.
However, lack of HIV antibodies could indicate that the subject is
not infected and is a candidate for HIV prevention by the rubella
vector treatment.
[0400] Pre-screening is not required prior to administration of the
therapeutic compositions disclosed herein.
Pre-Treatment of Subjects
[0401] In particular examples, the subject is treated prior to
administration of a therapeutic composition that includes one or
more of the disclosed viral constructs. However, such pre-treatment
is not always required, and can be determined by a skilled
clinician. For example, the subject can be treated with an
established protocol for treatment of HIV (such as a highly active
antiretroviral therapy).
Administration of Therapeutic Compositions
[0402] Following subject selection, a therapeutic effective dose of
the composition including one or more of the disclosed rubella
viral constructs including an HIV antigen is administered to the
subject (such as an adult human or a newborn infant either at risk
for contracting HIV or known to be infected with HIV).
Administration induces a sufficient immune response to reduce viral
load, to prevent or lessen a later infection with the virus, or to
reduce a sign or a symptom of HIV infection. Additional agents,
such as anti-viral agents, can also be administered to the subject
simultaneously or prior to or following administration of the
disclosed compositions. Administration can be achieved by any
method known in the art, such as oral administration, intranasal
administration, inhalation, intravenous, intramuscular,
intraperitoneal, or subcutaneous.
[0403] The amount of the composition administered to prevent,
reduce, inhibit, and/or treat HIV or a condition associated with it
depends on the subject being treated, the severity of the disorder,
and the manner of administration of the therapeutic composition.
Ideally, a therapeutically effective amount of an agent is the
amount sufficient to prevent, reduce, and/or inhibit, and/or treat
the condition (e.g., HIV) in a subject without causing a
substantial cytotoxic effect in the subject. An effective amount
can be readily determined by one skilled in the art, for example
using routine trials establishing dose response curves. In
addition, particular exemplary dosages are provided above. The
therapeutic compositions can be administered in a single dose
delivery, via continuous delivery over an extended time period, in
a repeated administration protocol (for example, by a daily,
weekly, or monthly repeated administration protocol). In one
example, therapeutic compositions that include rubella viral vector
constructs including an HIV antigenic insert, such as a Gag, gp41
or gp120 antigenic insert are administered intramuscularly to a
human. As such, these compositions may be formulated with an inert
diluent or with a pharmaceutically acceptable carrier.
[0404] In one specific example, a composition including an isolated
rubella viral vector with an HIV antigenic insert is administered
intravenously from 0.1 pg to about 100 mg per kg per day. In an
example, the composition is administered continuously.
Administration of the therapeutic compositions can be taken long
term (for example over a period of months or years). In another
example, the composition is administered at 50 .mu.g per kg given
twice a week for 2 to 3 weeks. In another example, the composition
is administered at a dose of 1 pg to 10 ng and given at 0, 1, and 6
months to achieve a maximum immune response. It may also be given
at escalating doses of 1 to 10 pg for the first dose, 100 pg to 1
ng for the second dose, and 10 ng to 100 ng for the third dose.
This will allow immunity to the carrier virus to be overcome and to
boost immunity to the heterologous antigen, including MPER.
Assessment
[0405] Following the administration of one or more therapies,
subjects having HIV (for example, HIV-1 or HIV-2) can be monitored
for reductions in HIV levels, increases in a subjects CD4+ T cell
count, or reductions in one or more clinical symptoms associated
with HIV. In particular examples, subjects are analyzed one or more
times, starting 7 days following treatment. Subjects can be
monitored using any method known in the art. For example,
biological samples from the subject, including blood, can be
obtained and alterations in HW or CD4+ T cell levels evaluated.
[0406] For uninfected subjects, HIV antibodies and neutralizing
antibodies elicited by the vectors can have provide protection
against subsequent HIV infection, particularly if the overall level
of antibodies, or the level of neutralizing antibodies, exceeds
some protective level.
Additional Treatments
[0407] In particular examples, if subjects are stable or have a
minor, mixed or partial response to treatment, they can be
re-treated after re-evaluation with the same schedule and
preparation of agents that they previously received for the desired
amount of time, including the duration of a subject's lifetime. A
partial response is a reduction, such as at least a 10%, at least
20%, at least 30%, at least 40%, at least 50%, or at least 70% in
HIV infection, HIV replication or combination thereof. A partial
response may also be an increase in CD4+ T cell count such as at
least 350 T cells per microliter.
Example 4
Method of Monitoring Serum Antibodies to HIV or Hepatitis B
[0408] This example illustrates the methods of monitoring serum
antibodies to HIV or Hepatitis B.
[0409] Based upon the teachings disclosed herein, the presence of
serum antibodies to HIV or Hepatitis B can be monitored using the
isolated rubella viral vector construct platforms disclosed herein,
such as to detect an HIV or Hepatitis B infection. Generally, the
method includes contacting a sample from a subject, such as, but
not limited to a blood, serum, plasma, urine or sputum sample from
the subject with one or more of the disclosed compositions
including one or more rubella viral vector constructs with an HIV
or Hepatitis B antigenic insert and detecting binding of antibodies
in the sample to the one or more constructs. The binding can be
detected by any means known to one of skill in the art, including
the use of labeled secondary antibodies that specifically bind the
antibodies from the sample. Labels include radiolabels, enzymatic
labels, and fluorescent labels.
Example 5
Binding of HIVIgG and Human Sera from HIV-1 Positive Patients to
Disclosed Rubella Viral Vector Constructs
[0410] Based upon the teaching herein, the utility of a rubella
viral vector construct with an HIV antigenic insert to identify
sera that contain neutralizing antibodies against the HIV antigenic
insert included with the rubella viral vector construct can be
determined by screening a set of weakly and broadly neutralizing
human HIV-1 positive sera and HW-IgG for binding to one or more of
the disclosed constructs or virus like particles that include one
or more disclosed viral constructs. Human sera from HIV-1 positive
patients and antibodies specific for HIV antigens can be serially
diluted and analyzed for binding to HIV antigens and particles
containing such polypeptides in ELISA format.
Example 6
Immunization of Subjects Against HIV or of Animals Against SIV or
SHIV
[0411] Based upon the teaching herein, subjects are immunized with
a dose of 1 pg to 100 ng and given at 0, 1, and 6 months of the
disclosed rubella viral vector including one or more HIV antigens
or virus-like particles containing the disclosed vector including
one or more of such antigens by intramuscular route. Sera from the
subject is analyzed for binding to one or more of the HIV
antibodies by ELISA.
[0412] In addition, the sera can be checked for their neutralizing
ability in a viral neutralization assay using luciferase-based HIV
entry assay. If the neutralizing titers are high enough, the
subject is challenged with SHIV virus bearing the same envelope
glycoproteins as HIV. Alternatively, SIV antigens can be
incorporated into the disclosed viral vector, monkeys can be
immunized with rubella-SIV, and challenged with virulent SIV
strains. In one particular example, the subject is a rhesus
monkey.
Example 7
Stable Expression of SIV and HIV Antigens in a Rubella Vector
[0413] This example illustrates that SW and HIV antigens can be
inserted into the Not I site of a rubella vector, resulting in an
infectious rubella hybrid that expresses the foreign protein for
multiple generations.
[0414] In a first set of studies, full length RNA coding for the
rubella vector plus the insert was transcribed, capped, and the
vector genes were transfected into Vero cells (passage 0) as
described previously in Example 1. Growth of vector with the insert
was then determined by measuring rubella proteins by Western blot
analysis. Alternatively, expression of the insert gene product was
determined by Western blot using antibodies specific for the
insert. For example, this could be the Gag genes of SIV or the MPER
antigen of HIV.
[0415] In a second set of studies, Vero cells were transfected as
in the original method with rubella viral constructs containing SIV
or HIV sequences inserted at the Not I site. These cells were
called passage P0. After 7 days, virus and cells were transferred
together as a cell suspension. The suspension was made by scraping
a quarter of the cell monolayer, and then diluting the cell
suspension to 2 ml, followed by transferring 0.1 to 0.2 ml directly
onto a new monolayer of Vero cells to make passage P1. This
procedure was repeated for multiple passages.
[0416] FIG. 3 illustrates the number of vectors expressed within
cells that were able to grow over a period of months by using the
second rubella viral cell culture method. FIG. 4 illustrates the
size and position of various Gag epitopes expressed in live rubella
vectors. Table 3 provides the amino acid sequences, insert name and
size of inserts which were expressed in live rubella vectors.
Western blot analyses presented in FIGS. 7-9 illustrate successful
vector growth and expression of rubella proteins when the vector
includes various Gag and MPER epitopes with both cell culture
methods.
TABLE-US-00017 TABLE 3 SIV Gag and HIV MPER sequences expressed in
live rubella vectors SEQ Insert name Bp Insert Amino acid sequence
ID NO. SGAG1-1 111 REGSQKILSVLAPLVPTGSENLKSLYNTVSVIWSIHAED 82 SGAG2
114 FQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA 83 SGAG2L 204
LPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNC 84
VGDHQAAMQIIRDIINEEA SGAG2L-A 249
LPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNC 85
VGDHQAAMQIIRDIINEEATRSQKILSVLAPLVPT SGAG2L-B 243
LPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNC 86
VGDHQAAMQIIRDIINEEATRTGSENLKSLYNT SGAG2L-C 267
LPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNC 87
VGDHQAAMQIIRDIINEEATRHTEEAKQIVQRHLVVETGTT BC-SGAG2 252
VPTGSENLKSLYNTVTRVKHTEEAKQIVQRHLVVETGTTSDAFQAL 88
SEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA MPER-E PSWNWFDITNWLWYIRLDA 89
MPER-F 70 PSAQEKNEKELLELDKWASLWN 30 ABC-SGAG2 335
LDRFGLAESLLENKEGSQKILSVLAPLVPTGSENLKSLYNTVTRVK 90
HTEEAKQIVQRHLVVETGTTETSDAFQALSEGCTPYDINQMLNCVG DHQAAMQIIRDIINEEA
ABC-SGAG2L 411 LDRFGLAESLLENKEGSQKILSVLAPLVPTGSENLKSLYNTVTRVK 91
HTEEAKQIVQRHLVVETGTTETRLPLSPRTLNAWVKLIEEKKFGAE
VVPGFQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEA
[0417] For example, FIG. 5 illustrates growth of two rubella
vectors (made by the first method) and rubella-GFP control detected
by western blot of rubella proteins E1 and C. As illustrated in
FIG. 5, two different epitopes of SW gag were expressed (SGAG2L and
SGAG.sub.0). SGAG.sub.O has the same amino acid sequence as wild
type SGAG; its RNA sequence is different, since it has been codon
optimized. Besides giving better expression, the codon optimized
insert appeared more like the GC rich rubella RNA surrounding
it.
[0418] Further, FIG. 6 shows the time course of MPER expression in
which MPER.sub.f was expressed as part of an early gene of the
rubella virus, from days 2 to 5 of infection.
[0419] FIG. 7 illustrates successful expression of seven
rubella-sGag vectors at passage 2 (made by the second method) vs. a
rubella-GFP control in second lane from the right and uninfected
cells in last lane, as detected by western blot with antibodies to
rubella capsid. Arrow indicates the capsid band (Lane 1, Molecular
weight; Lane 2, SGAG2; Lane 3, SGAG2L; Lane 4, SGAG2L-A; Lane 5,
SGAG2L-B; Lane 6, SGAG2L-C; Lane 7, BC-SGAG2; Lane 8, SGAG1-1; Lane
9, GFP insert; Lane 10, uninfected control).
[0420] These studies show stable expression of SIV and HIV epitopes
in a rubella vector resulting in an infectious rubella hybrid that
expresses the foreign protein for sufficient generations to allow
expansion in a fermentor, followed by propagation and expression as
a vaccine antigen in the immunized host.
Example 8
Materials and Methods
[0421] This example describes the materials and methods used in
Example 9.
[0422] Analysis of Insert Stability.
[0423] To verify stability of the inserts in rubella, the rubella
flanking regions, as well as the entire insert, was sequenced.
Cells were infected with the vector for seven days and then treated
with TRIzol (Invitrogen). RNA was purified from the aqueous phase
with RNeasy Mini Kit, according to the manufacture's protocol
(Qiagen GmbH, Germany). Reverse transcription was performed using a
High Capacity RNA-to-cDNA Kit (Applied Biosystems), followed by PCR
amplification using illustra puReTaq Ready-to-Go PCR beads (GE
Healthcare). Oligonucleotide primers specific for rubella sequences
flanking the Not I insertion site: Robo-seq67 (forward primer:
5'-gatgacgaggcgctcatcc, SEQ ID NO: 104) and Robo-seq6A (reverse
primer: 5'-gagtgccgcgggcgtccgagtgc, SEQ ID NO: 105); or Robo-seq25
(forward primer: 5'-cgaactggtgagccccatgg, SEQ ID NO: 106) and
Robo-seqSbfDn4 (reverse primer: 5'-gatctcgcaaatgcaggctccagtg, SEQ
ID NO: 107) for inserts in the structural region. The PCR products
were analyzed by gel electrophoresis, purified from the gel using
MinElute Gel Extraction Kit (Qiagen) and sequenced using the same
primers.
[0424] Antibodies and Antigens.
[0425] Antibodies were obtained from the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID. Monoclonals 2F5
and 4E10 were obtained from Dr. Hermann Katinger. Polyclonal goat
antibodies to rubella structural proteins were purchased from
Fitzgerald Industries International, Inc. (Concord, Mass.). Rabbit
antibodies to rubella nonstructural protein P150 were provided by
Dr. Tero Ahola (University of Helsinki, Finland). Aldrithiol-2
inactivated SHIV virions with 89.6 envelope and SIV Gag proteins
were a gift of Drs. Larry Arthur and Jeffrey Lifson at the AIDS
Vaccine Program, NCI.
[0426] Construction of cDNA Plasmids Coding for Infectious RNA.
[0427] Plasmid p10RA coding for full-length infectious cDNA of the
RA27/3 vaccine strain of rubella and plasmid pRobo302, coding for
cDNA of the Therien strain of wild type rubella, were provided by
Dr. T. Frey (Georgia State University, Atlanta). Wild type rubella
cDNA was cloned into pBR322 to produce plasmid pBRobo3226.
Infectious rubella virus RNA was generated by transcribing from the
SP6 promoter, followed by RNA capping.
[0428] For cloning purposes, a sub-clone of p10RA (from Hind III to
Bgl II), pBR322-Hind-Bgl-RA was created in pBR322. To create space
for potential inserts, a deletion was made between the two Not I
sites at positions 3661 and 4168 in the non-structural protein
region, as reported for wild type rubella. Hind III-Cla I fragment
from the sub-clone carrying the Not I deletion was cloned back to
p10RA, giving pBRA3226-dNotI plasmid. The constructs were verified
by sequencing.
[0429] Construction of Vectors with Insertions in the Nonstructural
Gene Region.
[0430] Recognition sequences for Avr II and Nsi I restriction
enzymes were cloned into the Not I deletion site. These unique
restriction sites were then used for directional cloning of inserts
into the Not I-deletion site.
[0431] In the case of MPER.sub.F, MPER.sub.E, SGag2L-A, SGag2L-B,
SGag2L-C, and BC-SGag2, cloning was done using SpeI and Nsi I
sites. Spe I and Avr II have compatible sticky ends. Each insert
was PCR amplified using primers listed in Table 4 and HIV-1 89.6
gp160 or SIV mac239 gag DNA as templates, cut with restriction
enzymes, and ligated into the matching restriction sites. The amino
acid sequences of these inserts are listed in FIG. 10.
[0432] Construction of Vectors with Insertions in the Structural
Region.
[0433] For cloning purposes, a sub-clone of pBRobo3226 plasmid
coding for wild type rubella was created. The new plasmid
pBR322-NotI-BamHI contained rubella cDNA from the Not I site to
BamH I in the structural protein region. DNA inserts coding for
MPER.sub.F-E2TM and MPER.sub.F-E1TM, containing the 2F5 epitope,
transmembrane domains of E2 and E1 rubella proteins, respectively,
and E1 signal peptide sequence were synthesized by GeneArt
(Regensburg, Germany). The inserts were flanked by Sbf I and Kpn I
restriction sites, which were used to clone them into
pBR322-NotI-BamHI. These plasmids were cut with Sbf I and BamH I
restriction enzymes, and the products were cloned into plasmid
pBRobo3226-dNotI, resulting in plasmids, which combined inserts in
the structural genes with the deletion in the non-structural region
at Not I. A similar construct on the RA27/3 background was made by
inserting synthetic DNA coding for MPER, the transmembrane domain
of HW-1 gp41 and the E1 signal peptide, flanked by Sbf I
restriction sites, into the plasmid pBRA3226-dNotI coding for
RA27/3 vaccine strain of rubella with the Not I deletion. All
constructs were verified by sequencing. The amino acid sequences of
these inserts are given in FIG. 10.
[0434] Generation of Rubella Virus.
[0435] The protocol for generation of capped, infectious rubella
virus RNA from plasmid DNA and subsequent transfection of Vero
cells was described previously. Virus was propagated on Vero cells
maintained in DMEM containing L-glutamine, penicillin/streptomycin
(MediaTech, Inc., Herndon, Va.) and 10% heat-inactivated fetal
bovine serum at 37.degree. C. in a humidified incubator with 5%
CO2.
[0436] After 7-10 days of infection, culture supernatant (P.sub.0)
was centrifuged to produce cell-free supernatant and 0.1 mL of the
supernatant was transferred onto fresh Vero cells to begin the next
passage P.sub.1. Alternatively, in early passages, it was found
that passing infected cells from the previous culture along with
virus, helped in propagating new viral vectors. Infected cells were
continued to be passed for the first four passages, after that
cell-free virus was just as efficient. Infected cells were tested
for expression of rubella structural proteins, as a measure of
vector replication, and insert expression was evaluated by Western
blot, using specific antibodies. To expand a viral stock, virus
from passage 4 or 5 was grown for 7 to 10 days on a Vero cell
monolayer in a T75 flask, and multiple aliquots were frozen.
[0437] Detection of Rubella Proteins and MPER Inserts by Western
Blot.
[0438] Infected Vero cells were lysed in RIPA buffer (Thermo
Scientific, Rockford, Ill.) with addition of BD BaculoGold Protease
inhibitor cocktail (BD Biosciences, San Jose, Calif.). Cell lysates
were sonicated, run on a NuPAGE 4-12% polyacrylamide Bis-Tris gel
(Invitrogen, Carlsbad, Calif.), transferred to nitrocellulose, and
blocked with 2% BSA in TBS. Primary antibody was incubated in TBS
with 0.2% Tween20, 0.2% BSA for 11/2 hours at room temperature.
Expression of rubella structural proteins was detected with goat
anti-rubella polyclonal antibodies at 1:700 dilution, while rubella
non-structural protein P150 was detected using rabbit polyclonal
antibodies at a dilution of 1:1000 (30). Expression of MPER-derived
inserts was detected with human monoclonal antibodies 2F5 or 4E10
at 1 .mu.g/ml. Blots were washed three times with TBS/0.2% Tween20,
followed by incubation with secondary antibody diluted in the same
buffer for 60 min at room temperature on a rocking platform. The
second antibody was either horseradish peroxidase-conjugated rabbit
anti-goat IgG, goat anti-rabbit IgG or goat anti-human IgG at
1:5000 dilutions (Santa Cruz Biotechnology, CA). After the same
washing procedure as above, blots were visualized with enhanced
chemiluminescence (GE Healthcare).
TABLE-US-00018 TABLE 4 PCR primers used to generate inserts for
rubella viral vectors. The inserts were generated using HIV-1 89.6
gp160 or SIV mac239 gag DNAs Insert PCR primers MPER (89.6) F:
5'-gaagcacctaggtcagcccaagaaaagaatgaaaaagaattattggaattggataaatgg
(SEQ ID NO: 108) R:
5'-tgatctagatgcatctatgaatagtcttatataccacagccagtttgtta (SEQ ID NO:
109) MPER.sub.F (89.6) F:
5'-gaacagactagtgcccaagaaaagaatgaaaaagaattattggaattggataaatgg (SEQ
ID NO: 110) R:
5'-ccagcagatgcatcattccacaaacttgcccatttatccaattccaataattctttttc (SEQ
ID NO: 111) MPER.sub.E (89.6) F:
5'-gaacagactagttggaattggtttgacataacaaactggctgtggtatat (SEQ ID NO:
112) R: 5'-ccagcagatgcatctagtcttatataccacagccagtttgttatgtc (SEQ ID
NO: 113) sGag1 F:
5'-agatagcgcctagggaaggaagccaaaaaatactttcggtcttagctccattag (SEQ ID
NO: 114) R:
5'-tggcgatgatgcatcttctgcgtgaattgaccagatgaccgagacagtattataaaggct
(SEQ ID NO: 115) sGag2 F:
5'-agatagcgcctaggtttcaggcactgtcagaaggttgcac (SEQ ID NO: 116) R:
5'-tgtaatgatgcatcagcctcctcgtttataatatctctgat (SEQ ID NO: 117)
sGag2L F: 5'-agatagcgcctaggctgccattaagcccgagaacattaaatg (SEQ ID NO:
118) R: 5'-tggcgatgatgcatcactagtagcctcctcgtttataatatctctgat (SEQ ID
NO: 119) sGag2L-A F:
5'-gatagcgcctaggagccagaagatcctgagcgtgctggcccctctggt (SEQ ID NO:
120) R: 5'-tgcgatgatgcatcactagtgggcaccagaggggccagcacgctcag (SEQ ID
NO: 121) sGag2L-B F:
5'-gatagcgcctaggaccggcagcgagaacctgaagagcctgtacaa (SEQ ID NO: 122)
R: 5'-tgcgatgatgcatcactagtgttgtacaggctcttcaggttctcgct (SEQ ID NO:
123) sGag2L-C, F:
5'-gatagcgcctagggtgaagcacaccgaggaggccaagcagatcgtgcagcgccacctggtggtg
BC-sGag2 (SEQ ID NO: 124) R:
5'-tgcgatgatgcatcactagtggtgccggtctccaccaccaggtggcgctgcacgatct (SEQ
ID NO: 125)
TABLE-US-00019 TABLE 5 MPER.sub.F inserts expressed between
structural proteins of rubella SEQ Inser name Bp Insert Amino acid
sequence ID NO. MPER.sub.F-E2TM 219
FEEPRQEKNEKELLELDKWASLWNWFDMHTLAAFVLLVPWVLIFM 126
VCRRTCRRRGAAAALTAVVLQGYNPPAYG MPER.sub.F-E1TM 231
GEEPRQEKNEKELLELDKWASLWNWFDMHWWQLTGATCALPLAGL 127
LACCARRTCRRRGAAAALTAVVLQGYNPPAYG MPER-HIVTM
GEEPRQEKNEKELLELDKWASLWNWFDITNWLWYIRLFIMIVGGL 131
IGLRIVFAVLSIVCRRTCRRRGAAAALTAVVLQGYNPPAYG
Example 9
Insertion of Foreign Genes into Rubella Viral Constructs
[0439] This example illustrates deletion/insertion strategies to
construct rubella viral vectors carrying a foreign gene.
[0440] FIG. 9A illustrates a disclosed rubella viral construct
which was created by a deletion and insertion at the same Not I
site (FIG. 9A). FIG. 9B illustrates a construct including a
deletion at the Not I site and insertion between the structural
genes (FIG. 9B). As an example of the first strategy, a 507 by
deletion was made between two Not I restriction sites in the
nonstructural region and then inserted a zGFP reporter gene (792
bp) into the same site. The product was a live vector that
expressed zGFP (25 kDa) as a fusion protein with nonstructural
protein P150. Viral replication kinetics and titer were nearly the
same as for wild type rubella. The P150-zGFP fusion protein
performed essential P150 functions during RNA replication and
localized correctly to viral replication centers in the cytoplasm,
as shown by fluorescence microscopy. Ten additional vectors of this
type, bearing HIV and SIV inserts at the Not I site (FIGS. 9C and
9D) were created. Seven vectors expressed SIV Gag antigens (called
sGag) and three vectors contained HIV MPER-derived inserts. The
full length MPER insert coded for 33 amino acids and included
epitopes recognized by human neutralizing monoclonal antibodies 2F5
and 4E10 (FIG. 9C, FIG. 10). An MPER insert containing 19 amino
acids from the amino end was called MPER.sub.F, corresponding to
the epitope recognized by monoclonal 2F5. An insert coding for 15
amino acids from the carboxyl end of MPER was called MPER.sub.E,
corresponding to the 4E10 epitope. The MPER inserts were much
shorter (60 to 111 bp) than the Not I deletion (507 bp), so the
vector RNA should fit well within the size limits for rubella RNA
packaging.
[0441] The sGag inserts were derived from SIV Gag amino acids
41-211 (FIG. 9D). This region codes for the carboxyl half of matrix
protein p17 and the amino half of capsid protein p27. It is rich in
epitopes (at least 5) targeted by T cells during the immune
response to SIV infection in rhesus macaques (Table 6). Small
inserts coding for two epitopes were first used, such as sGag1 and
sGag2, and then added epitopes stepwise (FIG. 9D). Vector sGag1
contained T cell epitopes KP11 and GY9 within amino acids 54-91 of
MA protein p17. Vectors sGag2 (amino acids 173-211) and sGag2L
(amino acids 147-211) contained T cell epitopes CM9 and ME11 from
CA protein p27. One epitope at a time was added to the carboxyl end
of sGag2L to produce sGag2L-A (KP11), -B (GY9), or -C (TE15).
Alternatively, two epitopes were added to the amino end of sGag2 to
produce BC-sGag2. The sequences of these inserts are shown in FIG.
10. Together, these constructs code for a series of rubella vectors
expressing sGag inserts of increasing size and antigenic
complexity.
[0442] Each insert was ligated into the Not I site of the rubella
vaccine strain RA27/3, as shown in FIG. 9A. Following transcription
of plasmid DNA and capping, full length, infectious RNA was
transfected into Vero cells to create passage zero (P.sub.o). After
7 to 10 days in culture, the resulting virus was passed onto fresh
Vero cells, either as clarified culture supernatant or as infected
cells, for passage 1 (P.sub.1). After each subsequent passage,
vector replication was monitored by Western blot of the rubella
structural proteins C and E1. For the largest vectors and those
that were considered vaccine candidates, such as BC-sGag2 and
MPER.sub.F, stability of the inserts was verified by sequencing
viral RNA after four to six passages in culture.
[0443] Replication of rubella vectors expressing MPER.sub.F,
MPER.sub.E and sGag2L at passage P.sub.o was detected by Western
blot (FIG. 11A), using goat polyclonal antibodies to the rubella
structural proteins, capsid C and envelope protein E1. The vector
expressing MPER.sub.F (FIG. 11A, lane 1) replicated strongly for at
least seven passages, while the MPER.sub.E construct (lane 2)
replicated poorly at first and then became undetectable. Similarly,
rubella virus bearing full length MPER (with both 2F5 and 4E10
epitopes) at the Not I site did not replicate. At this site, MPER
was expressed as a fusion protein with P150 (FIG. 9A), and this
placed constraints on the insert. P150 plays a role as a cofactor
for both plus and minus strand RNA synthesis. The MPER-P150 fusion
protein preserves P150 folding, stability, and function. Anything
that reduced levels of functional P150 could be lethal for the
virus. Similarly, a vector expressing SIV Gag antigens, sGag2L,
replicated and expressed rubella structural proteins (FIG. 11A,
lane 3) as well as the MPER.sub.F vector and nearly as well as a
control vector expressing zGFP (lane 4). These estimates of viral
replication, based on expression of rubella proteins, were
generally borne out by measuring viral RNA titers (see below).
[0444] Expression of the MPER.sub.F insert was detected by Western
blot with monoclonal antibody 2F5 (FIG. 11B). It was found in a
high molecular weight band corresponding to a fusion protein with
nonstructural protein P150 (P150-MPER.sub.F indicated by an arrow).
A time course of MPER.sub.F expression showed that the
P150-MPER.sub.F protein was expressed strongly by day 2 of
infection, and expression continued at a high level until day 5.
After that, MPER.sub.F expression quickly became undetectable.
These results indicate that MPER.sub.F is expressed as an early
antigen under control of the rubella genomic promoter. In contrast,
rubella structural proteins C and E1, which are under control of
the subgenomic promoter, appeared as late antigens on day 6 or 7
and increased steadily until day 10 post infection.
[0445] The seven vectors with sGag inserts included four of the
five major epitopes from this region of Gag that are known targets
of T cell immunity against SIV. Their replication was monitored by
Western blot of rubella structural proteins (FIG. 11C). Each vector
replicated strongly, as shown by expression of rubella proteins C
and E1. The vector BC-sGag2 with four epitopes on the RA27/3
vaccine background, replicated nearly as well as a control vector
expressing zGFP on a wild type rubella background (FIG. 11C, lanes
BC-sGag2 and zGFP, respectively).
[0446] Due to lack of a monoclonal antibody specific for the T cell
epitopes of SIV Gag, expression of BC-sGag2 at the Not I site was
detected indirectly, by measuring a shift in the P150 band due to
the size of the p150-BCs-Gag2 fusion protein (FIG. 11D). Polyclonal
antibodies to P150 (30) showed the reduced size of P150 after Not I
deletion (FIG. 11D, lane 2, arrowhead). Its size was shifted to a
larger molecular weight by insertion of zGFP (lane 1, arrowhead) or
BC-sGag2 (lanes 3 and 4, arrowheads). The size difference between
P150 bands in lanes 3 and 4 vs. lane 2 was due to the BC-sGag2
insert. The P150-BC-sGag2 fusion protein was the major species of
P150 in these cells. The P150-BC-sGag2 fusion protein showed a
typical time course for the genomic promoter, since it was
expressed early (lanes 3 and 4) and then was virtually undetectable
by day 10 (FIG. 11D, lane 5). Viral RNA sequencing of the BC-sGag2
insert after six passages confirmed its stability: all four sGag
epitopes were present and in the correct reading frame.
[0447] In some cases, vectors appeared to be replicating after the
initial RNA transfection (P.sub.0) but failed to propagate further
by passing clarified culture supernatants. In these early passages,
propagation efficiency was increased by transferring virus via
infected cells, rather than culture supernatants. After passage
P.sub.4, cell-free passage was performed. This method helped to
propagate vectors with inserts as large as BC-sGag2.
[0448] FIG. 9B shows the second strategy used to create rubella
vectors with an insertion site in the structural region. To find a
permissive site of insertion, the Not I deletion was kept constant
and moved MPER.sub.F to different sites as a probe that could be
readily expressed by rubella. Insertions were made between capsid C
and envelope E2 genes, as well as between E2 and E1. The insertion
site between C and E2 was not permissive for viral replication.
However, MPER.sub.F, combined with a membrane spanning domain and
E1 signal peptide, was readily accepted between structural genes E2
and E1. The composition and sequence of each insert are given in
FIG. 9C and FIG. 10. As before, vector replication and insert
expression was monitored by Western blot.
[0449] FIGS. 12A and 12B show replication of two rubella vectors
bearing MPER.sub.F at the structural site and expression of the
inserts, respectively. MPER.sub.F was fused with the membrane
spanning domain of rubella E2 (lane 1) or E1 (lane 2) protein and
inserted between envelope proteins E2 and E1. These vectors, based
on wild type rubella, grew and expressed rubella proteins as well
as the control vector carrying zGFP (lane zGFP). Both replicating
vectors expressed MPER.sub.F fusion proteins (approximately 8.5
kDa), as detected by monoclonal 2F5 (FIG. 12B, lanes 1 and 2).
MPER.sub.F-E2TM gave consistently stronger MPER.sub.F expression
than MPER.sub.F-E1TM (lane 1 vs. lane 2). MPER.sub.F expression at
the structural site (FIG. 12B) was stronger than at the Not I site
(FIG. 11B). This is typical of rubella structural proteins, which
are over-expressed by the strong subgenomic promoter as compared to
the rubella genomic promoter. At the structural site, MPER.sub.F
was expressed as part of the structural polyprotein, and its
release from the polyprotein as a membrane-anchored 8.5 kDa protein
depended on signal peptidase. Incomplete cleavage at either end of
MPER.sub.F would produce MPER.sub.F linked to E2 or E1, and this
could explain minor bands of MPER.sub.F found at higher molecular
weight in FIG. 12B (lanes 1 and 2), which were not observed in
uninfected cells (lane N).
[0450] In addition, the insert was expanded to full length MPER,
which included both the 2F5 and 4E10 epitopes, and anchored it to
the membrane with the transmembrane domain of HIV gp41 linked to
the E1 signal peptide (FIG. 9C and FIG. 10). The MPER-HIVTM vector
replicated well and expressed MPER at about 10 kDa. To demonstrate
its dual antigenicity for both monoclonals, the virus was purified
by banding overnight in a 10-40% sucrose density gradient to remove
cell proteins and reduce background binding. Monoclonal antibody
binding was compared to the vector expressing MPER-HIVTM vs. a
control vector expressing zGFP (FIG. 12C). Both MPER epitopes were
detected equally as a 10 kDa band (FIG. 12C, lanes 4 and 6),
indicating its dual antigenicity.
[0451] These bands were not observed with a control vector
expressing zGFP (lanes 3 and 5), indicating their specificity. A
less prominent band above 62 kDa may represent partially
unprocessed MPER-HIVTM linked to E1. The sequence of the MPER-HIVTM
insert was confirmed by viral RNA sequencing.
[0452] A schematic of inserts at the structural site is shown in
FIG. 13A. In the native structural polyprotein (FIG. 13A, upper
panel), the transmembrane domains following capsid C and E2 protein
include signal peptides (E2SP and E1SP) for the next protein. E2
and E1 proteins have additional transmembrane domains, E2TM and
E1TM that anchor them to the membrane. Normally, the polyprotein is
cleaved by signal peptidase at two sites (arrows), to release three
mature proteins, capsid C, E2 and E1. In the MPER vectors (FIG.
13A, lower panel), to anchor the insert to a membrane, an
additional transmembrane domain (E2TM, E1TM or the HIV-1
transmembrane domain, HIVTM) was added and a signal peptide (E1SP)
after the MPER sequence. This polyprotein was cut three times to
release three structural proteins plus the MPER insert. The mature
8.5 kDa to 10 kDa proteins containing MPER inserts were observed on
Western blots (FIGS. 12B and C), as well as a minor band at about
68 kDa that may represent incomplete cleavage between MPER and
E1.
[0453] Since MPER was expressed with the rubella structural
proteins, it was examined whether it could be incorporated into
virions. After banding MPER-HIVTM virus (P.sub.8) in sucrose
density gradients, each fraction was analyzed for rubella viral
proteins (FIG. 13B) and MPER antigen (FIG. 13C). As shown in FIG.
13B, the virus banded primarily in fractions 2 to 6, as shown by
the presence of all three rubella structural proteins C (33 kDa),
E2 (42-47 kDa), and E1 (58 kDa). The E1 band extended from
fractions 2 to 8. Similarly, there was a strong MPER band in
fractions 2 to 8 (FIG. 13C), and the relative intensity of each
fraction followed that of E1. Little or no MPER was found at the
top of the gradient, indicating the absence of free MPER. In
addition to the expected MPER-HIVTM band at 10 kDa, a second MPER
band was observed at about 68 kDa, corresponding to the combined
size of an MPER-HIVTM-E1 fusion protein. This could be the product
of incomplete cleavage by signal peptidase of the structural
polyprotein between MPER-HIVTM and E1. The fact that nearly all
MPER-HIVTM co-sedimented with the viral band, indicates a strong
association with virions. Virion-associated MPER could contribute
to immunogenicity by presenting an array of MPER antigens on the
viral particle. A 38 kDa band reacting with 2F5 was observed in
fractions 15 through 19 of the gradient. This band was also found
in a Western blot of uninfected cells (FIG. 12B, lane N), and it
may represent one of the self proteins recognized by monoclonal
2F5.
[0454] Rubella vectors would not be practical as a vaccine platform
unless they could achieve high enough titers for vaccine
production. Twenty ml stocks of rubella vectors were produced on
the vaccine strain background (RA27/3). The vectors had MPER.sub.F
or BC-sGag2 inserts at the Not I site, or an MPER-HIVTM insert in
the structural site. Viral RNA content of the stocks were measured
by real time RT-PCR, as described previously. As shown in Table 7,
culture supernatants of MPER.sub.F contained 3.1.times.10.sup.7 RNA
copies/ml, BC-sGag2 grew to 2.5.times.10.sup.6 RNA copies/ml, and
MPER-HIVTM reached 1.3.times.10.sup.7 RNA copies/ml. Comparing
these vectors to a sample of rubella vaccine of known titer, titers
were estimated of about 5.0.times.10.sup.6 PFU/ml,
4.1.times.10.sup.5 PFU/ml and 2.2.times.10.sup.6 PFU/ml,
respectively.
[0455] These studies identified two insertion sites where rubella
can accommodate inserts into the viral genome: one is located
between two Not I restriction sites in the nonstructural genes,
while the other is located between the structural genes. When a
protein antigen (zGFP, BC-sGag2 or MPER.sub.F) is expressed at the
Not I site, it forms a fusion protein with rubella nonstructural
protein P150. It is expressed as an early viral antigen, under
control of the rubella genomic promoter, with maximal expression
between days 2 to 5 of infection. Based on the results with
P150-zGFP and prior studies of P150, the P150 fusion protein
localizes to the cytoplasm, where it participates in viral
replicative centers. This location is near the entry point for
proteasomal processing and could deliver SIV Gag antigen to the
main processing pathway leading to antigen presentation with MHC
class I for induction of T cell immunity. However, expression as a
fusion protein with P150 also places constraints on the insert, as
P150 function must be preserved. Within viral replication centers,
P150 acts as an essential cofactor in RNA synthesis, both for plus
and minus strand RNA. Loss of P150 function would be a lethal event
for the virus. This could occur if an insert prevented normal P150
folding, interfered with its interaction with RNA polymerase, or
caused instability through proteolytic degradation or
aggregation.
[0456] The second insertion site is located in the structural
region of rubella, between genes coding for envelope glycoproteins
E2 and E1. An MPER insert at this site was expressed as a late
viral protein, under control of the strong subgenomic promoter. The
ability to express the full MPER determinant at this site, but not
at the Not I site, suggested greater flexibility in protein
expression at the structural site. MPER expression was maximal
between days 5 and 10 after infection. It was expressed as part of
the structural polyprotein and then processed to free MPER antigen.
Sedimentation in sucrose gradients showed that most of the MPER was
incorporated into virions, and almost none remained as a free
protein. As shown in the schematic (FIG. 13A), MPER-HIVTM has a
transmembrane domain and signal peptide similar to envelope
glycoproteins E2 and E1, and its incorporation into virions may
follow the same path as the structural proteins. Positioning
MPER-derived antigens at the structural site contributes to
immunogenicity by high level of expression, incorporation into
viral particles, and by display on a membrane surface that
resembles the natural milieu on HIV virions. In addition, some of
the unprocessed MPER-HIVTM remains attached to envelope
glycoprotein E1 (FIG. 13C). Such a fusion protein enhances MPER
immunogenicity by linking it to a carrier protein E1.
[0457] The antigens expressed by recombinant rubella vectors
include the MPER determinant of HW transmembrane protein gp41 and
SIV Gag sequences, which are rich in T cell determinants. The MPER
region is a target of broadly reactive neutralizing antibodies
against HIV, such as monoclonal antibodies 2F5, 4E10, and Z13e.
However, despite many attempts to elicit antibodies to MPER, there
has been little success, presumably because MPER is a weak
immunogen by itself, lacks the native conformation, or resembles
self antigens. Its expression as part of a live, replicating viral
vector may enhance the immune response to MPER by eliciting T cell
help for MPER-specific B cells. Rubella vectors expressing MPER
could also be combined with another vector in a prime and boost
strategy or they could precede a boost with virus-like particles
expressing MPER.
[0458] The SIV Gag determinants were derived from a region of Gag
(aa 41-211) that is rich in targets of T cell immunity, including
five T cell epitopes. Two epitopes, CM9 and GY9, are restricted by
Mamu A01 and A02, respectively, and they have been identified as
predominant targets of CTLs early after SIV infection. For these
epitopes, virus escape occurs late, if at all. However, when it
does occur, escape mutants at CM9 have been associated with loss of
control of viremia and disease progression. These sites may be slow
to mutate because they perform viral functions for SIV that require
compensatory mutations before they can escape. By eliciting T cells
specific for these epitopes prior to infection, the BC-sGag2 vector
could potentially control a subsequent SIV infection.
[0459] Rubella's biological properties favor its use as a vaccine
platform. Its safety has been demonstrated in millions of children
around the world. The SIV Gag and HIV-1 MPER inserts at the Not I
site were made with the RA27/3 vaccine strain, and our inserts at
the structural site have been re-derived on this background. The
vectors replicate to high titers during vaccine production, and the
inserted genes are stably expressed for at least eight to ten
passages in cell culture. The vaccine strain can be used safely in
the host without further attenuation. Even if a vector loses its
insert, it reverts to the vaccine strain. Rubella virus possesses
little risk of viral persistence, has no DNA intermediates and does
not integrate into host genomes as retroviral vectors do. Also,
there is no interference with antigen processing and presentation,
as with CMV and adenovirus vectors. While growing to high titers in
cell culture, rubella vaccine immunizes at a low dose. Since the
minimum recommended dose of the RA27/3 strain is 10.sup.3 PFU for
humans, the titers obtained with rubella vectors (Table 7)
correspond to between 410 and 5,000 human doses per milliliter. At
this level, without further optimization, the entire US birth
cohort of four million children could be immunized with the product
of a 10 L fermentor.
[0460] Live attenuated rubella vaccine is immunogenic, and it
elicits mucosal as well as systemic immunity. A live vector can
immunize with a much lower dose than a non-replicating vector;
through exponential growth, it exposes the host to more antigen
over time. Rubella has low cytotoxicity, so infected cells can
present antigen for 5 days at the Not I site and up to 10 days at
the structural site. Persistent expression may help the induction
of antigen specific T cells and B cells. Antigen presented in the
context of an acute infection may combine innate and adaptive
immunity to elicit a stronger immune response.
TABLE-US-00020 TABLE 6 T cell epitopes in SIV Gag (amino acids
41-211) sGag Amino Gag MHC MHC SEQ insert Gag epitope Sequence
acids protein Class Type ID NO. A KP11 KILSVLAPLVP 59-70 p17 MA II
DP.sub.BI-06 94 B GY9 GSENLKSLY 71-79 p17 MA I A02 93 C TE15/KT15
TEEAKQIVQRHLVVE 97-111 p17 MA II DR.sub.B-W606 95 D CM9 CTPYDINQM
181-189 p27 CA I A01 92 E ME11 MQIIRDIINEE 200-210 p27 CA II
DR.sub.B1-0306 96
TABLE-US-00021 TABLE 7 Titers of rubella vector stocks of potential
vaccine candidates Estimated titer, Viral vector RNA copies/ml*
PFU/ml MPER.sub.F in NotI site (P.sub.6) 3.1 .times. 10.sup.7 5.0
.times. 10.sup.6 BC-sGag2 in NotI site (P.sub.6) 2.5 .times.
10.sup.6 4.1 .times. 10.sup.5 MPER-HIVTM in structural region 1.3
.times. 10.sup.7 2.2 .times. 10.sup.6 (P.sub.5) *The viral RNA
content of each vector was determined by real time RT-PCR. The
titer was estimated by comparison to a vaccine standard of known
infectious titer. Sequences for inserts of the viral stocks were
verified by viral genome sequencing.
Example 10
Characterization of Rubella Viral Constructs without a Deletion at
the Not I Site within the Non-Structural Site
[0461] This example characterizes rubella viral vector constructs
carrying a foreign gene within the structural site without a
deletion at the Not I site within the non-structural site.
[0462] As shown in FIG. 14 rubella vectors were made with inserts
at the structural site but without any deletion in the Not I site.
These vectors were made initially with the same MPER-HIVTM and
BC-sGag2 inserts as described above. The vectors grew well, as
shown in FIG. 15, left panel. For example, as shown in FIG. 15, the
first lane is the RA27/3 vaccine strain of rubella, and the second
lane shows uninfected cells. Lanes 3 and 4 show rubella vectors
with MPER-HIVTM or BC-sGag 2 inserts, respectively, which grew as
well as the vaccine strain they were derived from (lane 1). The
right panel in FIG. 15 shows strong expression of an MPER insert by
the non-deleted vector (lane 7), but not by the empty vector (lane
5) or uninfected control (lane 6). Monoclonal antibody detected
mature MPER protein as a 10 kDa protein, comparable in amount to
the HIV gp41 control. These vectors were grown for at least 6
passages and stably expressed the MPER insert at each passage.
These studies support the finding that vectors including inserts in
the structural site without any deletion in the Not I site were
viable.
[0463] Not only were the vector constructs viable, but such rubella
vectors grew to high titers in vitro as illustrated in FIG. 16.
FIG. 16 shows the titers obtained for rubella vectors bearing MPER
and Gag inserts at the structural site. Titers were based on real
time RT-PCR of rubella stocks, as compared to a rubella vaccine
standard with a known plaque-forming titer. Comparison of sections
B and C of the table shows that comparable titers were obtained
when the same insert was expressed with or without a Not I
deletion. Rubella immunization is highly efficient and requires
only 1,000 PFU of virus. The titers of these vectors correspond to
between 2300 and 5800 doses per ml. At this rate, the products of a
20 L fermentor could immunize the entire birth cohort of the US (4
million children) each year.
[0464] Subsequent studies were performed to determine if these
rubella vector constructs were infectious in vivo and effective at
immunizing subjects. FIG. 17 shows four attempted immunizations of
a group of macaques with rubella vectors that have the same inserts
but at different sites. The first two doses consisted of rubella
vectors with inserts at the structural site and deletions at the
Not I site. Despite giving 2 to 10 times the human dose, there was
no virus replication or "take", as shown by the absence of
antibodies to the vector (circles). The third dose consisted of
vectors with inserts at the Not I site in place of a nonstructural
protein deletion. One of three animals developed antibodies to the
vector, suggesting an occasional take. The fourth dose, however,
was a highly successful immunization, resulting in antibodies to
the vector in 3 out of 3 animals tested (circle). The new vectors
had inserts at the structural site but no deletions at the Not I
site. The rate and titer of antibody formation was greater than or
equal to the licensed rubella vaccine strain, given as a
control.
[0465] The difference between vectors that did or did not grow in
vivo was apparently due to the Not I deletion. The missing gene is
probably required to deal with host defenses, most likely
interferon. It was found that Not I deleted rubella viruses with a
structural site insertion can only grow in cell lines, such as Vero
cells, that are unable to make interferon. They do not grow in
MRC-5 or WI-38 cells that are classic hosts for rubella and produce
interferon. In contrast, vectors with the same structural insert
but without a Not I deletion grow well in these cells. Thus, a
vector's ability to grow in MRC-5 or WI-38 cells correlates well
with successful immunization of monkeys and man. Thus, these
studies demonstrate that rubella vectors lacking a Not I deletion
are infectious in vivo and immunize macaques efficiently.
[0466] Further studies were performed which also demonstrated
rubella vectors lacking a Not I deletion replicate well in vivo, as
detected by PCR of oral swabs. FIG. 18 shows a PCR study performed
to detect rubella replication in macaques. Each monkey was
vaccinated intramuscularly in the thigh with two rubella vectors:
one containing MPER and the other containing BCsGag-2, but lacking
deletions at Not I. The virus normally grows well in the mouth and
pharynx and is spread by droplets. Oral samples were taken for
detection of replicating virus on days 0, 7, and 14 after
immunization. RT-PCR was used to detect virus in oral samples. The
upper panel used primer pairs specific for the MPER insert, while
the lower panel used primers specific for the BCsGag-2 insert. Lane
7 was a plasmid control, showing the expected band for each insert.
As shown in lanes 1-3 of FIG. 18, all three monkeys were negative
for rubella vectors on day 0. By day 7, (lanes 4-6) two macaques
were positive of rubella-MPER and two were positive for rubella
BCsGag-2. By day 14 (lanes 8-10), one animal was positive for
rubella-MPER, and all were negative for rubella expressing
BCsGag-2. In one animal (lane 5), BC-sGag2 appeared first, followed
a week later by rubella-MPER. In another, (lane 6) both vectors
appeared at the same time. In one animal (lane 4), rubella-MPER was
detected, but no rubella-BCsGag-2. This result, combined with the
results above, indicates that rubella vectors lacking a Not I
deletion produced by the current method were infectious in 6 out of
6 animals and produced a vaccine take at a very low dose,
comparable to conventional rubella vaccine.
[0467] Additional studies were performed to determine if the
rubella vectors could elicit an immune response to the vaccine
insert. FIG. 19 shows the antibody response to the BCsGag-2 insert.
Antibodies were measured by ELISA, using plates coated with
recombinant SIV Gag protein. Two controls were a pre-bleed of one
macaque (J6L) and the serum of a macaque immunized with an empty
rubella vector (CL6A). Both showed no antibodies to SW Gag.
Subsequent studies demonstrated that all three macaques used in the
experiment were negative for antibodies to the insert at the start
of the study. As shown in FIG. 19, the vaccine elicited high
titered antibodies to the insert in 3 out of 3 animals tested. In
two animals, this was 7 weeks after the fourth dose of vaccine, but
this was the first dose producing a vaccine take in these animals.
In one case, DCVV was added to the group as a replacement for the
animal that had a take from an earlier dose. Thus, for DCVV, this
was the first dose of any rubella vector, and it elicited a strong
antibody response to the BC-sGag-2 insert after a single dose.
Importantly, the antibody response to rubella proteins was the same
in the tested vectors as in a rubella control. Thus, the immune
response to the insert does not detract from the response to
rubella vector. This means that a rubella vector can be used to
immunize against two viruses at the same time: the one in the
insert and itself.
[0468] A set of studies was performed which determined that rubella
constructs lacking a deletion at the Not I site were more robust
and could accommodate much larger inserts at the structural site
when compared to those including a deletion. As shown in FIG. 20, a
series of large sGag inserts at the structural site in vectors
lacking a Not I deletion were made. These grew well in culture, as
shown by western blot of rubella proteins. They stably retained the
insert, as shown by viral RNA sequencing. The maximum allowable
insert size has grown dramatically from 255 by in our largest
previous vector (which included the Not I deletion) to 405 by in
sGag-E2TM (135-271), 510 by in sGag-E2TM (41-211), 711 by in
fullp28-sGag-E2TM, and 795 by in full p28plus-sGag-E2TM. These new
inserts are a significant improvement, both by increasing the
number of sGag epitopes present and by allowing us to express
complete native proteins such as Gag p27. Native proteins are more
stable than fragments, and in the case of sGag, they have the well
documented ability to assemble into virus like particles, which
will further enhance immunogenicity. The larger insert size allows
the expression of additional viral antigens. For example, native
HIV gp120 can be expressed with selected deletions, ranging in size
from 900 to 1100 base pairs. These are important immunogens, with
the potential to elicit broadly crossreacting neutralizing
antibodies that depend on the native conformation.
Example 11
Rubella Vectors Stably Express SIV Gag and HIV MPER Determinants at
the Structural Site
[0469] This example illustrates rubella vectors stably express SIV
Gag and HIV MPER determinants at the structural site.
[0470] FIG. 24A shows the design of a typical rubella vector with
an insert at the structural site. The structural insertion site is
located between envelope glycoproteins E2 and E1 (FIG. 24A). The
inserted sequences code for the membrane proximal external region
(MPER) of HIV (18, 19, 27, 31) or for an SIV Gag construct
containing four T cell epitopes linked together (called BC-sGag2)
(18, 19, 32, 33). Each antigenic insert is preceded by the
transmembrane domain of E2 (E2TM) and the signal peptidase site of
E1 (E1SP), and it is followed by another transmembrane domain (TM)
and E1SP peptidase site. Signal peptidase cleavage at three sites
in the structural polyprotein (FIG. 24A, arrows) would release the
three rubella structural proteins plus the vaccine insert. Unlike
earlier constructs (18, 19), the type 3 vectors used in the example
have no compensatory deletion at the Not I site.
[0471] Vector replication in Vero cells was shown by Western blot
with antibodies to the rubella structural proteins C and E1 (FIG.
24B, left panel). Rubella vectors expressing HIV MPER (lane 3) or
SIV Gag antigen (lane 4) grew just as well as the vaccine strain
without an insert (lane 1). Expression of the MPER-HIVTM insert was
detected with monoclonal antibody 2F5 (FIG. 24B, middle panel). The
MPER insert was strongly expressed as a 10 kDa band (lane 7, yellow
arrowhead), which was absent in the empty rubella control (lane 5),
and it was comparable to gp41 in the inactivated virus control
(lane 8, red arrowhead). Expression of the SIV Gag insert was
detected by cross-reaction with HIV immune globulin (FIG. 24B,
right panel). The BC-sGag2 insert was expressed as a 14 kDa band
(lane 9, green arrowhead), which was absent in the empty rubella
control (lane 10) and was comparable to the control band for
recombinant p57 Gag (lane 12). After 5 passages in cell culture, we
expanded each vector to create viral stocks expressing MPER or SIV
Gag inserts.
[0472] Rubella vector stocks for the monkey studies were produced
and characterized rubella vector stocks for monkey studies. For
each vector type, we made one vector with an MPER insert and the
other with a Gag insert. The MPER insert at the structural site
consisted of the complete membrane proximal external region,
followed by the HIV transmembrane domain and an E1 SP signal
sequence. The Gag insert consisted of four known T cell epitopes
linked in tandem (called BC-sGag2), followed by the E2TM domain of
rubella and the E1 SP signal peptide. For each vector stock, we
demonstrated insert expression by Western blot.
[0473] Viral titers were determined by quantitative RT-PCR. The
titers were estimated by comparison to a rubella reference sample
of known PFU titer. Viral titers were 7.7.times.10.sup.6 PFU/ml, or
greater, which is equivalent to about 1500 human doses per ml.
Viral sequencing showed that the insert was stable and in reading
frame after at least five passages. The vector doses given to
macaques, based on viral titer, were between two and ten times the
typical human dose of rubella vaccine (about 5,000 PFU/dose).
[0474] FIG. 25 illustrates the time course of MPER expression by
rubella-MPER vectors. The MPER antigen appeared at day 5 and
persists at least until day 10. The right panel shows expression of
the BCsGag2 antigen by rubella vectors, as detected with a
polyclonal antibody from a vaccinated macaque (V584). The 14 kD
band was not observed in control lanes from empty rubella infected
cells (lane 2) or uninfected cells (lane 3). These studies indicate
that illustrates rubella vectors stably express SIV Gag and HIV
MPER determinants at the structural site.
Example 12
Rubella Vectors Bearing Gag and MPER Determinants are Highly
Immunogenic
[0475] This example demonstrates that Rubella vectors bearing Gag
and MPER determinants are highly immunogenic.
[0476] Monkeys were immunized according to a protocol. Group 1
macaques received three doses of DNA vaccine first, followed by a
rubella vector boost at week 25. Group 3 macaques received three
doses of non-replicating rubella vectors first, as we searched for
a replication competent vector. They finally received replicating
vectors at week 18, and this was followed by DNA vaccine given at
weeks 25 and 31. A successful vaccine "take" was detected as the
appearance of antibodies to the structural proteins of the rubella
vector. All six macaques made antibodies to the replicating vector,
as shown by ELISA assay on plates coated with rubella antigens.
(These plates are used for diagnosis of human infections.)
[0477] Antibodies to the SIV Gag insert were shown. As shown in
FIGS. 26A and 26B, all six macaques made high titered antibody
responses to the Gag insert, regardless of whether they received
DNA vaccine first. These antibodies were not found in prebleeds,
nor were they found in control animals immunized with rubella
vaccine lacking any inserts. Antibody titers elicited by vaccine in
three macaques were compared with the anti-Gag titers elicited by
natural SIV infection of five macaques (FIG. 26C). The anti-Gag
antibodies elicited by rubella-Gag vaccination were greater than or
equal to those elicited by natural SIV infection.
[0478] The kinetics of the response to SIV Gag are shown for
individual macaques in FIGS. 27A and 27B. Two animals, DCVV (group
3) and V584 (group 1), demonstrate the sustained response elicited
by a single dose of live rubella vectors. For DCVV, anti-Gag
antibodies rose between 2 and 4 weeks and reached a peak 7 weeks
post immunization (FIG. 27A). For macaque V584, which received
three priming doses of DNA vaccine, a good anti-Gag titer was
elicited by the DNA vaccine. This was followed by an even stronger
anti-Gag response to the live vector that increased steadily
between 2 and 4 weeks post immunization (FIG. 27B). The specificity
of these antibodies for SIV Gag was shown by Western blot (FIG.
25).
Example 13
Antibodies Elicited by Rubella Vectors are Persistent and
Boostable
[0479] This example demonstrates that antibodies elicited by
rubella vectors are persistent and boostable.
[0480] The persistence of anti-Gag antibodies in Group 3 macaques
for nine months after immunization was measured. This was compared
to the persistence of anti-rubella antibodies in the same animals
(FIGS. 28A-F). Anti-rubella titers in all three macaques (FIGS.
28A, 28C and 28E) peaked 4 to 7 weeks after immunization. They
declined about 3-fold by 15 weeks for DCVV and CL67 and then
remained constant until 38 weeks. The decline was greater for CL49,
about 9-fold by 15 weeks and another 3-fold by 38 weeks.
[0481] Anti-Gag antibodies were measured in the same macaques at
the same time points (FIGS. 28B, 28D, and 28F). Anti-Gag antibodies
peaked 4 to 7 weeks post immunization and then declined 3-fold or
less by 15 weeks. By 38 weeks, they declined another 3-fold or less
in two macaques (DCVV and CL49) and 5-fold in the other (CL67). In
two macaques, the durability of anti-Gag titers was greater than or
equal to anti-rubella titers, and in one case, anti-Gag titers were
less durable over a 9 month period. This indicates persistence of
the anti-Gag antibodies, as anti-rubella immunity is
long-lasting.
[0482] The inventors waited up to a year for rubella antibodies to
decline to a level where they could boost with rubella vectors
bearing new antigens. For group 4 macaques, which were primed with
rubella vaccine without an insert, these antibodies declined about
2.5-fold after 6 months, and then remained constant or rose
slightly by 1 year. After one year (group 4) or 6 months (group 1),
we boosted the macaques with rubella vectors expressing MPER and
SIV Gag antigens (week 57 of the study). All five animals showed a
prompt rise in antibodies to rubella.
[0483] The anti-SIV Gag antibody response was measured four weeks
after the boost (week 61 of the study, FIGS. 29A and 29B). For
group 4 animals primed with empty rubella vaccine, the BC-sGag2
boost represented new antigens that were not seen previously.
Neither macaque made anti-Gag antibodies (FIG. 29A), indicating
that boosting could not elicit a new response in an unprimed
animal. The group 1 animals were quite different: they still had
antibody titers to SIV Gag that were primed six months earlier
(FIG. 29B). In addition, they responded to the live vector boost
with a strong increase in anti-Gag titers. In this group, the boost
consisted of novel type 3 vectors expressing Gag as a combined
MPER-BC-sGag2 antigen or as the complete Gag protein p27. The
results indicate that the first dose of live rubella vectors
elicited memory B cells specific for SIV Gag antigens, and these B
cells were strongly boosted upon re-exposure to the vectors. In
contrast, once the control animals failed to make anti-Gag memory B
cells after the first rubella immunization, they could not be
boosted by a subsequent exposure to the rubella Gag vector.
[0484] With other vaccines and vectors, the immune response to SIV
and HIV antigens has been short-lived and lacked memory B cells.
Transient antibody responses are considered one of the major
obstacles to HIV vaccine development. Using live rubella vectors,
it is shown herein that anti-Gag antibodies persist for over nine
months and decline with nearly the same half-life as antibodies to
rubella proteins. In general, persistent antibody titers are
thought to depend on long-lived plasma cells, while boosting
depends on memory B cells, and both of these are signs of germinal
center function during immunization. The primary immune response to
these vectors produced memory B cells, as shown by boosting 6
months later. The secondary response depended on successful
priming, as control animals that were not primed to SIV Gag lacked
memory B cells and could not respond to the boost. Potentially, two
doses of live rubella vectors, given several years apart, could
boost and update immunity to circulating strains of HIV. In
addition, the ability to prime and boost memory B cells would allow
us to combine rubella vectors with other viral vectors bearing
similar HIV vaccine inserts.
Example 14
Immunization with Two Rubella Vectors at the Same Time Elicits
Antibodies to Both Inserts
[0485] This example demonstrates immunization with two rubella
vectors at the same time elicits antibodies to both inserts.
[0486] Macaques of groups 1 and 3 were immunized with two rubella
vectors concurrently. One vector expressed SIV Gag, and the other
expressed HIV MPER with a transmembrane domain from HW. Antibodies
to the MPER determinant were detected by ELISA assay on plates
coated with gp140 trimers. As shown in FIG. 30, five out of six
macaques from both groups made strong antibody responses to MPER.
The antibodies appear to be specific for the trimeric form of
gp140: they did not bind monomeric MPER peptides or to a peptide
called T20 that has the complete sequence of our MPER insert. There
was no binding to recombinant gp120 (right panel of FIG. 30).
[0487] When two rubella vectors were given simultaneously, they
both replicated side by side, as shown by RT-PCR, and they elicited
antibodies to both inserts. This means that rubella vectors can be
used to immunize against two or more antigens at the same time.
Example 15
Immunization with MPER Determinants to Elicit Broadly Crossreactive
Neutralizing Antibodies
[0488] This example demonstrates that immunization with MPER
determinants elicits broadly crossreactive neutralizing
antibodies.
[0489] Additional MPER constructs are listed in the Table 8, part
B. These are intended to improve signal peptidase cleavage, or to
enhance immunogenicity by linkage to the SIV Gag sequence or by
duplicating important epitopes recognized by neutralizing
antibodies 2F5 and 10E8. The MPER determinants perform an essential
viral function during membrane fusion and cell entry, and they are
conserved sequences. They are also the target of broadly
neutralizing antibodies. If MPER can be made more immunogenic, the
resulting antibodies should have broadly crossreactive neutralizing
activity.
TABLE-US-00022 TABLE 8 Inserts in the rubella structural site A.
Large Gag inserts SGAG(41-363)-E2TM (SEQ ID NO: 141)
LDRFGLAESLLENKEGCQKILSVLAPLVPTGSENLKSLYNTVCVIWCIHAEEKVKHTEEAKQIVQRHLVVE
TGTTETMPKTSRPTAPSSGRGGNYPVQQIGGNYVHLPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCT
PYDINQMLNCVGDHQAAMQIIRDIINEEAADWDLQHPQPAPQQGQLREPSGSDIAGTTSSVDEQIQWMYRQ
QNPIPVGNIYRRWIQLGLQKCVRMYNPTNILDVKQGPKEPFQSYVDRFYKSLRAEQTDAAVKNWMTQTLLI
QNANPDCKLVLKGLGVNPTLEEMLTACQGVGGPGQKARLMHTLAAFVLLVPWVLIFMVCRRTCRRRGAAAA
LTAVVLQGYNPPAYG (E2TM, underlined; E1SP, bolded). SGAG(41-391)-E2TM
(SEQ ID NO: 142)
LDRFGLAESLLENKEGCQKILSVLAPLVPTGSENLKSLYNTVCVIWCIHAEEKVKHTEEAKQIVQRHLVVE
TGTTETMPKTSRPTAPSSGRGGNYPVQQIGGNYVHLPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCT
PYDINQMLNCVGDHQAAMQIIRDIINEEAADWDLQHPQPAPQQGQLREPSGSDIAGTTSSVDEQIQWMYRQ
QNPIPVGNIYRRWIQLGLQKCVRMYNPTNILDVKQGPKEPFQSYVDRFYKSLRAEQTDAAVKNWMTQTLLI
QNANPDCKLVLKGLGVNPTLEEMLTACQGVGGPGQKARLMAEALKEALAPVPIPFAAAQQRGPRKPIMHTL
AAFVLLVPWVLIFMVCRRTCRRRGAAAALTAVVLQGYNPPAYG (E2TM, underlined;
E1SP, bolded). B. MPER inserts MPER-E2TM (SEQ ID NO: 143)
EEPRQEKNEKELLELDKWASLWNWFDITNWLWYIRMHTLAAFVLLVPWVLIFMVCRRTCRRRGAAAALTAV
VLQGYNPPAYG (E2TM, underlined; E1SP, bolded). MPER-E1TM (SEQ ID NO:
144)
EEPRQEKNEKELLELDKWASLWNWFDITNWLWYIRMHWWQLTLGATCALPLAGLLACCARRTCRRRGAAAA
LTAVVLQGYNPPAYG (E1TM, underlined; E1SP, bolded). MPER-HIVTM-E2SP
(SEQ ID NO: 145)
EEPRQEKNEKELLELDKWASLWNWFDITNWLWYIRLFIMIVGGLIGLRIVFAVLSIVCRRTCRRRFGAPQA
FLAGLLLAAVAVGTARAG (HIVTM, underlined; E2SP, bolded).
BC-SGAG2-MPER-HIVTM (SEQ ID NO: 146)
EEPRVPTGSENLKSLYNTVTRVKHTEEAKQIVQRHLVVETGTTSDAFQALSEGCTPYDINQMLNCVGDHQA
AMQIIRDIINEEAQEKNEKELLELDKWASLWNWFDITNWLWYIRLFIMIVGGLIGLRIVFAVLSIVCRRTC
RRRGAAAALTAVVLQGYNPPAYG (HIVTM, underlined; E1SP, bolded).
MPER-BC-SGAG2-E2TM (SEQ ID NO: 147)
EEPRQEKNEKELLELDKWASLWNWFDITNWLVPTGSENLKSLYNTVTRVKHTEEAKQIVQRHLVVETGTTS
DAFQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEEASLDLHTLAAFVLLVPWVLIFMVCRRTCRRRG
AAAALTAVVLQGYNPPAYG (E2TM, underlined; E1SP, bolded).
10e8-MPER-HIVTM (SEQ ID NO: 148)
EEPSLWNWFDITNWLWYIRLNEKELLELDKWASLWNWFDITNWLWYIRLFIMIVGGLIGLRIVFAVLSIVC
RRTCRRRGAAAALTAVVLQGYNPPAYG (HIVTM, underlined; E1SP, bolded).
10e8-MPER-E2TM (SEQ ID NO: 149)
EEPSLWNWFDITNWLWYIRLNEKELLELDKWASLWNWFDITNWLWYIRMHTLAAFVLLVPWVLIFMVCRRT
CRRRGAAAALTAVVLQGYNPPAYG (E2TM, underlined; E1SP, bolded).
MPERF-MPER-HIVTM (SEQ ID NO: 150)
EEKELLELDKWASLWNEKELLELDKWASLWNWFDITNWLWYIRLFIMIVGGLIGLRIVFAVLSIVCRRTCR
RRGAAAALTAVVLQGYNPPAYG (HIVTM, underlined; E1SP, bolded).
MPERF-MPER-E2TM (SEQ ID NO: 151)
EEKELLELDKWASLWNEKELLELDKWASLWNWFDITNWLWYIRMHTLAAFVLLVPWVLIFMVCRRTCRRRG
AAAALTAVVLQGYNPPAYG (E2TM, underlined; E1SP, bolded). C. HIV gp120
inserts. Outer domain of gp120 on a deleted inner domain scaffold
CC2(79-213-SIGG-252-506)dV1V2V3-G4S-E2TM (SEQ ID NO: 152)
EEPRNPQEVVLENVTENFNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLSVQACPKVSFQPISIGGGIRP
VVSTQLLLNGSLAEEDIVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRGRRGDIRQAHCNISRAKWNN
TLQQIVIKLREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTEGNDIITL
QCRIKQLAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMRDNWRSELYKYKVVRIEPIG
VAPTRAKRGGGGSMHTLAAFVLLVPWVLIFMVCRRTCRRRGAAAALTAVVLQGYNPPAYG (E2TM,
underlined; E1SP, bolded).
CC2(79-213-SIGG-252-506)dV1V2V3-G4S-SVE2TM (SEQ ID NO: 153)
EEPRNPQEVVLENVTENFNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLSVQACPKVSFQPISIGGGIRP
VVSTQLLLNGSLAEEDIVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRGRRGDIRQAHCNISRAKWNN
TLQQIVIKLREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTEGNDIITL
QCRIKQLAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMRDNWRSELYKYKVVRIEPIG
VAPTRAKRGGGGSMHVYTILAVASATVAMMIGVTVAVLCACRRTCRRRGAAAALTAVVLQGYNPPAYG
(E1SP, bolded). CC2(79-213-SIGG-252-506)dV1V2V3-G4S-HIVTM (SEQ ID
NO: 154)
EEPRNPQEVVLENVTENFNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLSVQACPKVSFQPISIGGGIRP
VVSTQLLLNGSLAEEDIVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRGRRGDIRQAHCNISRAKWNN
TLQQIVIKLREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTEGNDIITL
QCRIKQLAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMRDNWRSELYKYKVVRIEPIG
VAPTRAKRGGGGSMHLFIMIVGGLIGLRIVFAVLSIVCRRTCRRRGAAAALTAVVLQGYNPPAYG
(HIVTM, underlined; E1SP, bolded).
CC2(79-213-SIGG-252-506)dV1V2V3-G4S-VSVGTM (SEQ ID NO: 155)
EEPRNPQEVVLENVTENFNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLSVQACPKVSFQPISIGGGIRP
VVSTQLLLNGSLAEEDIVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRGRRGDIRQAHCNISRAKWNN
TLQQIVIKLREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTEGNDIITL
QCRIKQLAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMRDNWRSELYKYKVVRIEPIG
VAPTRAKRGGGGSMHSSIASFFFIIGLIIGLFLVLCRRTCRRRGAAAALTAVVLQGYNPPAYG
(E1SP, bolded). Outer domain on a Truncated inner domain scaffold
E2-CC2(79-506)dV1V2V3-G4S-E2TM (SEQ ID NO: 156)
EEPRNPQEVVLENVTENFNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLTSVQACPKVSFQPIPIHYCVP
AGFAMLKCNDKKFNGSGPCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEDIVIRSENFTDNAKTIIVQLNES
VVINCTRPNNNTRGRRGDIRQAHCNISRAKWNNTLQQIVIKLREKFRNKTIAFNQSSGGDPEIVMHSFNCG
GEFFYCNTAQLFNSTWNVTGGTNGTEGNDIITLQCRIKQLAMYAPPITGQIRCSSNITGLLLTRDGGNSTE
TETEIFRPGGGDMRDNWRSELYKYKVVRIEPIGVAPTRAKRGGGGSMHTLAAFVLLVPWVLIFMVCRRTCR
RRGAAAALTAVVLQGYNPPAYG (E2TM, underlined; E1SP, bolded).
E2-CC2(79-506)dV1V2V3-G4S-E2TM (Nucleotide sequence, SEQ ID NO:
157)
gaagaacctagGAACCCACAAGAAGTAGTATTGGAGAATGTGACAGAAAATTTTAACATGTGGAAAAATAA
CATGGTAGATCAGATGCAcGAGGATATAATCAGTTTATGGGACGAAAGTCttaaGCCATGTGTAAAATTAA
CCCCGCTCACTAGTGTCCAGGCCTGTCCAAAGGTATCCTTTCAGCCAATTCCCATACATTATTGTGTCCCA
GCAGGGTTCGCGATGCTAAAGTGTAACGATAAGAAATTCAATGGATCAGGACCATGCAAGAATGTGAGCAC
AGTACAATGTACCCATGGAATTAGGCCAGTGGTGTCAACTCAGCTGCTGTTAAATGGCAGTCTAGCAGAAG
AAGACATAGTAATTAGATCTGAAAATTTCACAGACAATGCTAAAACCATAATAGTACAGCTAAATGAATCT
GTAGTAATTAATTgtacAAGACCCAACAACAATACAAGAGGAAGAAGGGGAGATATAAGACAAGCACATTG
TAACATTTCCCGGGCAAAATGGAATAACACTTTACAACAGATAGTTATAAAATTAAGAGAAAAATTTAGGA
ATAAAACAATAGCCTTTAATCAATCCTCAGGAGGGGACCCAGAAATTGTAATGCACAGTTTTAATTGTGGA
GGGGAATTTTTCTACTGTAATACAGCACAACTGTTTAATAGCACGTGGAATGTTACTGGAGGGACAAATGG
CACTGAAGGAAATGACATAATCACACTCCAATGCAGAATAAAACAGCTAGCAATGTATGCCCCTCCCATCA
CCGGTCAAATTAGATGTTCATCAAATATTACAGGGCTGCTACTAACGCGTGATGGAGGTAATAGTACTGAG
ACTGAGACTGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAGCTCTATAAATA
TAAAGTAGTAAGAATTGAACCAATAGGAGTAGCACCCACCAGGGCAAAGAGAGGAGGCGGAGGAAGCAtgc
ataccctggccgcgttcgtgctcctcgtgccatgggtgctcatctttatggtctgtcggaggacctgcaga
cggaggggagctgccgctgcccttacagcagtggtcctgcaggggtacaacccccccgcctatggc
E2-CC2(88-506)dV1V2V3-G4S-E2TM (SEQ ID NO: 158)
EEPRVTENFNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLTSVQACPKVSFQPIPIHYCVPAGFAMLKCN
DKKFNGSGPCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEDIVIRSENFTDNAKTIIVQLNESVVINCTRPN
NNTRGRRGDIRQAHCNISRAKWNNTLQQIVIKLREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTA
QLFNSTWNVTGGTNGTEGNDIITLQCRIKQLAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPG
GGDMRDNWRSELYKYKVVRIEPIGVAPTRAKRGGGGSMHTLAAFVLLVPWVLIFMVCRRTCRRRGAAAALT
AVVLQGYNPPAYG (E2TM, underlined; E1P, bolded).
E2-CC2(93-506)dV1V2V3-G4S-E2TM (SEQ ID NO: 159)
EEPRNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLTSVQACPKVSFQPIPIHYCVPAGFAMLKCNDKKFN
GSGPCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEDIVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRG
RRGDIRQAHCNISRAKWNNTLQQIVIKLREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNS
TWNVTGGTNGTEGNDIITLQCRIKQLAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMR
DNWRSELYKYKVVRIEPIGVAPTRAKRGGGGSMHTLAAFVLLVPWVLIFMVCRRTCRRRGAAAALTAVVLQ
GYNPPAYG (E2TM, underlined; E1SP, bolded).
E2-CC2(93-484)dV1V2V3-G4S-E2TM (SEQ ID NO: 160)
EEPRNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLTSVQACPKVSFQPIPIHYCVPAGFAMLKCNDKKFN
GSGPCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEDIVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRG
RRGDIRQAHCNISRAKWNNTLQQIVIKLREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNS
TWNVTGGTNGTEGNDIITLQCRIKQLAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMR
DNWRSELYGGGGSMHTLAAFVLLVPWVLIFMVCRRTCRRRGAAAALTAVVLQGYNPPAYG (E2TM,
underlined; E1SP, bolded). Seamless E1 or E2 sequence at amino end
of gp120 E1(1-20)-CC2(40-506)dV1V2V3C-G4S-E2TM (SEQ ID NO: 161)
EEAFTYLCTAPGCATQAPVPVWREATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLENVTENFN
MWKNNMVDQMHEDIISLWDESLKPCVKLTPLTSVQACPKVSFQPIPIHYCVPAGFAMLKCNDKKFNGSGPC
KNVSTVQCTHGIRPVVSTQLLLNGSLAEEDIVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRGRRGDI
RQAHCNISRAKWNNTLQQIVIKLREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVT
GGTNGTEGNDIITLQCRIKQLAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMRDNWRS
ELYKYKVVRIEPIGVAPTRAKRGGGGSMHTLAAFVLLVPWVLIFMVCRRTCRRRGAAAALTAVVLQGYNPP
AYG (E2TM, underlined; E1SP, bolded). Non-HIV envelope
glycoproteins: E2-WNVE(FVR)-TM1 (SEQ ID NO: 162)
EEPRFNCLGMSNRDFLEGVSGATWVDLVLEGDSCVTIMSKDKPTIDVKMMNMEAANLAEVRSYCYLATVSD
LSTKAACPTMGEAHNDKRADPAFVCRQGVVDRGWGNGCGFFGKGSIDTCAKFACSTKAIGRTILKENIKYE
VAIFVHGPTTVESHGNYSTQVGATQAGRLSITPAAPSYTLKLGEYGEVTVDCEPRSGIDTNAYYVMTVGTK
TFLVHREWFMDLNLPWSSAGSTVWRNRETLMEFEEPHATKQSVIALGSQEGALHQALAGAIPVEFSSNTVK
LTSGHLKCRVKMEKLQLKGTTYGVCSKAFKFLGTPVDTGHGTVVLELQYTGTDGPCKVPISSVASLNDLTP
VGRLVTVNPFVSVATANAKVLIELEPPFGDSYIVVGRGEQQINHHWHKSGSSIGKAFTTTLKGAQRLAALG
DTAWDFGSVGGVFTSVGRAVHQVFGGAFRSLFGGMSWITQGLLGALLLWMGINACRRTCRRRGAAAALTAV
VLQGYNPPAYG (E1SP, bolded).
Example 16
Expression of Large Gag Inserts for Induction of CTLs
[0490] This example demonstrates expression of large Gag inserts
for the induction of CTLs.
[0491] Rubella is a small RNA virus that replicates exclusively in
the cytoplasm. This location is ideal for eliciting T cell
immunity, since it delivers antigens directly into the proteasomal
pathway leading to antigen presentation with MHC class I. The Gag
proteins are important targets of CTLs during infection. The
inventors have discovered that priming with DNA vaccine and
boosting with the rubella-BCsGag2 vector gave high levels of Gag
specific CD8+ T cells, ranging from 1 to 8% of all T cells. The
inventors have also discovered that the structural insertion site
can accommodate much larger Gag inserts than before. The large Gag
inserts are shown schematically in FIG. 31, and their sequences are
given in Table 8, part A. The known T cell epitopes are shown for
MHC class I and MHC class II restricted epitopes. Each construct
contains 7 to 9 epitopes for T cell induction.
[0492] Expression of two large Gag inserts was demonstrated by
western blot in FIG. 32. Gag construct 41-363 combined part of Gag
P17 and all of Gag protein P27. This antigen was stably expressed
at passages P3 and P6 (lanes 1 to 3). The other construct, coding
for amino acids 41-391, had all of the above plus P2, and it was
stably expressed for at least six passages (lanes 4 to 6).
Example 17
Expression of the Outer Domain of Gp120 Scaffolded on Parts of the
Inner Domain
[0493] This example illustrates the expression of the outer domain
of gp120 scaffolded on parts of the inner domain
[0494] HIV envelope gp 120 is an important target of neutralizing
antibodies. These depend on the native conformation of gp120. Gp120
has inner and outer domains. The main target of neutralizing
antibodies binding is located in the outer domain, but its folding
depends on the inner domain. The inventors have developed a variety
of gp120 constructs for use as vaccine inserts. In each of these,
the outer domain is preserved, but the inner domain is deleted at
either end. Deletion at the amino end produces a truncated gp120. A
deletion at the carboxyl end of the inner domain would produce an
internal deletion in gp120.
[0495] Four examples of internally deleted gp120 are shown in Table
8, part C. These all have amino acids 79-213, followed by an SIGG
linker, followed by 252-506. In the examples given, they are
followed by different transmembrane domains, from rubella E2
protein, HIV gp41, sindbis virus, or VSV. Expression of the first
three of these inserts by rubella vectors are shown in FIG. 33,
right panel, lanes 1 to 3. The fourth insert is also expressed well
in rubella.
[0496] Four examples of truncated gp120 are also given: these are
amino acids 79-506, 88-506, 93-506, and 93-484. The amino acid
sequences are given in Table 8, part C. Expression of these
truncated forms of gp120 by rubella vectors are shown in FIG. 34,
lanes 1, 2, 4, and 5. These constructs are intended to be small
enough for expression in rubella and yet large enough to fold
correctly and form the native CD4 binding site. The inventors have
also expressed gp120 with a short E1 sequence (20 amino acids)
inserted seamlessly at the amino end of gp120. The sequence is
given in Table 8. Expression of this seamless form of gp120 by a
rubella vector is shown by western blot in FIG. 33, lane 5. This
facilitates signal peptidase cleavage, and improves the release of
mature rubella proteins. This may also reduce selective pressure
against the insert, allowing stable expression for many passages.
The envelope glycoprotein of West Nile virus has also been
expressed at the structural site to make a novel rubella vector.
The sequence is indicated in Table 8.
[0497] In view of the many possible embodiments to which the
principles of the disclosed invention may be applied, it should be
recognized that the illustrated embodiments are only examples of
the invention and should not be taken as limiting the scope of the
invention. Rather, the scope of the invention is defined by the
following claims. We therefore claim as my invention all that comes
within the scope and spirit of these claims.
Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID
NOS: 162 <210> SEQ ID NO 1 <211> LENGTH: 16 <212>
TYPE: PRT <213> ORGANISM: Human immunodeficiency virus
<220> FEATURE: <221> NAME/KEY: misc_feature <222>
LOCATION: (3)..(4) <223> OTHER INFORMATION: Xaa can be any
naturally occurring amino acid <220> FEATURE: <221>
NAME/KEY: misc_feature <222> LOCATION: (7)..(7) <223>
OTHER INFORMATION: Xaa can be any naturally occurring amino acid
<400> SEQUENCE: 1 Asn Glu Xaa Xaa Leu Leu Xaa Leu Asp Lys Trp
Ala Ser Leu Trp Asn 1 5 10 15 <210> SEQ ID NO 2 <211>
LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 2 Asn Glu Gln Glu Leu
Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp Phe Asp
Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 3
<211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 3 Asn Glu Gln
Asp Leu Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp
Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ
ID NO 4 <211> LENGTH: 28 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 4 Asn
Glu Gln Asp Leu Leu Ala Leu Asp Lys Trp Ala Asn Leu Trp Asn 1 5 10
15 Trp Phe Asp Ile Ser Asn Trp Leu Trp Tyr Ile Lys 20 25
<210> SEQ ID NO 5 <211> LENGTH: 28 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 5 Asn Glu Gln Asp Leu Leu Ala Leu Asp Lys Trp Ala Asn Leu
Trp Asn 1 5 10 15 Trp Phe Asn Ile Thr Asn Trp Leu Trp Tyr Ile Arg
20 25 <210> SEQ ID NO 6 <211> LENGTH: 28 <212>
TYPE: PRT <213> ORGANISM: Human immunodeficiency virus
<400> SEQUENCE: 6 Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp
Ala Ser Leu Trp Asn 1 5 10 15 Trp Phe Asp Ile Thr Asn Trp Leu Trp
Tyr Ile Lys 20 25 <210> SEQ ID NO 7 <211> LENGTH: 28
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 7 Asn Glu Lys Asp Leu Leu Ala Leu Asp
Ser Trp Lys Asn Leu Trp Asn 1 5 10 15 Trp Phe Asp Ile Thr Asn Trp
Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 8 <211>
LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 8 Asn Glu Gln Asp Leu
Leu Ala Leu Asp Ser Trp Glu Asn Leu Trp Asn 1 5 10 15 Trp Phe Asp
Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 9
<211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 9 Asn Glu Gln
Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp
Phe Ser Ile Thr Gln Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ
ID NO 10 <211> LENGTH: 28 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 10 Asn
Glu Gln Glu Leu Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10
15 Trp Phe Asp Ile Ser Asn Trp Leu Trp Tyr Ile Lys 20 25
<210> SEQ ID NO 11 <211> LENGTH: 28 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 11 Asn Glu Gln Asp Leu Leu Ala Leu Asp Lys Trp Asp Asn
Leu Trp Ser 1 5 10 15 Trp Phe Thr Ile Thr Asn Trp Leu Trp Tyr Ile
Lys 20 25 <210> SEQ ID NO 12 <211> LENGTH: 28
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 12 Asn Glu Gln Asp Leu Leu Ala Leu Asp
Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp Phe Asp Ile Thr Lys Trp
Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 13 <211>
LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 13 Asn Glu Gln Asp Leu
Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp Phe Ser
Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 14
<211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 14 Asn Glu Lys
Asp Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp
Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ
ID NO 15 <211> LENGTH: 28 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 15 Asn
Glu Gln Glu Ile Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10
15 Trp Phe Asp Ile Ser Lys Trp Leu Trp Tyr Ile Lys 20 25
<210> SEQ ID NO 16 <211> LENGTH: 28 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 16 Asn Glu Gln Asp Leu Leu Ala Leu Asp Lys Trp Ala Asn
Leu Trp Asn 1 5 10 15 Trp Phe Asn Ile Ser Asn Trp Leu Trp Tyr Ile
Lys 20 25 <210> SEQ ID NO 17 <211> LENGTH: 28
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 17 Asn Glu Gln Asp Leu Leu Ala Leu Asp
Lys Trp Ala Ser Leu Trp Ser 1 5 10 15 Trp Phe Asp Ile Ser Asn Trp
Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 18 <211>
LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 18 Asn Glu Lys Asp Leu
Leu Ala Leu Asp Ser Trp Lys Asn Leu Trp Ser 1 5 10 15 Trp Phe Asp
Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 19
<211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 19 Asn Glu Gln
Glu Leu Leu Gln Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp
Phe Ser Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ
ID NO 20 <211> LENGTH: 28 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 20 Asn
Glu Gln Asp Leu Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10
15 Trp Phe Asp Ile Ser Asn Trp Leu Trp Tyr Ile Lys 20 25
<210> SEQ ID NO 21 <211> LENGTH: 28 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 21 Asn Glu Gln Glu Leu Leu Ala Leu Asp Lys Trp Ala Ser
Leu Trp Asn 1 5 10 15 Trp Phe Asp Ile Ser Asn Trp Leu Trp Tyr Ile
Arg 20 25 <210> SEQ ID NO 22 <211> LENGTH: 28
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 22 Asn Glu Gln Glu Leu Leu Glu Leu Asp
Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp Phe Asn Ile Thr Asn Trp
Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 23 <211>
LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 23 Cys Cys Ala Thr Thr
Ala Ala Gly Cys Gly Gly Thr Thr Cys Cys Thr 1 5 10 15 Cys Gly Gly
Thr Ala Gly Cys 20 <210> SEQ ID NO 24 <211> LENGTH: 23
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 24 Gly Ala Gly Thr Gly Cys Cys Gly Cys
Gly Ala Gly Cys Gly Thr Cys 1 5 10 15 Cys Gly Ala Gly Thr Gly Cys
20 <210> SEQ ID NO 25 <211> LENGTH: 22 <212>
TYPE: PRT <213> ORGANISM: Human immunodeficiency virus
<220> FEATURE: <221> NAME/KEY: misc_feature <222>
LOCATION: (1)..(1) <223> OTHER INFORMATION: Xaa can be any
naturally occurring amino acid <220> FEATURE: <221>
NAME/KEY: MISC_FEATURE <222> LOCATION: (3)..(3) <223>
OTHER INFORMATION: Xaa can be any hydrophobic amino acid.
<220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222>
LOCATION: (10)..(10) <223> OTHER INFORMATION: Xaa can be any
hydrophobic amino acid. <220> FEATURE: <221> NAME/KEY:
MISC_FEATURE <222> LOCATION: (18)..(18) <223> OTHER
INFORMATION: Xaa can be any hydrophobic amino acid. <400>
SEQUENCE: 25 Xaa Phe Ile Met Ile Val Gly Gly Leu Xaa Gly Leu Arg
Ile Val Phe 1 5 10 15 Thr Xaa Leu Ser Ile Val 20 <210> SEQ ID
NO 26 <211> LENGTH: 22 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 26 Ile
Phe Ile Met Ile Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe 1 5 10
15 Thr Val Leu Ser Ile Val 20 <210> SEQ ID NO 27 <211>
LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 27 Leu Phe Ile Met Ile
Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe 1 5 10 15 Thr Ala Leu
Ser Ile Val 20 <210> SEQ ID NO 28 <211> LENGTH: 22
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 28 Ile Phe Ile Met Ile Val Gly Gly Leu
Val Gly Leu Arg Ile Val Phe 1 5 10 15 Thr Ala Leu Ser Ile Val 20
<210> SEQ ID NO 29 <211> LENGTH: 276 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 29 Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Phe Cys Leu
Val Phe Ala 1 5 10 15 Gln Asp Leu Pro Gly Asn Asp Asn Asn Ser Glu
Phe Asn Glu Lys Glu 20 25 30 Leu Leu Glu Leu Asp Lys Trp Ala Ser
Leu Trp Asn Trp Phe Asp Ile 35 40 45 Thr Asn Trp Leu Trp Tyr Ile
Arg Leu Phe Ile Met Ile Val Gly Gly 50 55 60 Leu Ile Gly Leu Arg
Ile Val Phe Ala Val Leu Ser Ile Pro Gln Ser 65 70 75 80 Leu Asp Ser
Trp Trp Thr Ser Leu Asn Phe Leu Gly Gly Ser Pro Val 85 90 95 Cys
Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn His Ser Pro Thr 100 105
110 Ser Cys Pro Pro Ile Cys Pro Gly Tyr Arg Trp Met Cys Leu Arg Arg
115 120 125 Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu Cys Leu Ile Phe
Leu Leu 130 135 140 Val Leu Leu Asp Tyr Gln Gly Met Leu Pro Val Cys
Pro Leu Ile Pro 145 150 155 160 Gly Ser Thr Thr Thr Ser Thr Gly Pro
Cys Lys Thr Cys Thr Thr Pro 165 170 175 Ala Gln Gly Asn Ser Lys Phe
Pro Ser Cys Cys Cys Thr Lys Pro Thr 180 185 190 Asp Gly Asn Cys Thr
Cys Ile Pro Ile Pro Ser Ser Trp Ala Phe Ala 195 200 205 Lys Tyr Leu
Trp Glu Trp Ala Ser Val Arg Phe Ser Trp Leu Ser Leu 210 215 220 Leu
Val Pro Phe Val Gln Trp Phe Val Gly Leu Ser Pro Thr Val Trp 225 230
235 240 Leu Ser Ala Ile Trp Met Met Trp Tyr Trp Gly Pro Ser Leu Tyr
Ser 245 250 255 Ile Val Ser Pro Phe Ile Pro Leu Leu Pro Ile Phe Phe
Cys Leu Trp 260 265 270 Val Tyr Ile Gly 275 <210> SEQ ID NO
30 <211> LENGTH: 22 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 30 Pro
Ser Ala Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys 1 5 10
15 Trp Ala Ser Leu Trp Asn 20 <210> SEQ ID NO 31 <211>
LENGTH: 226 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 31 Glu Phe Ile Thr Ser
Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala 1 5 10 15 Gly Phe Phe
Leu Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser Leu Asp 20 25 30 Ser
Trp Trp Thr Ser Leu Asn Phe Leu Gly Gly Ser Pro Val Cys Leu 35 40
45 Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn His Ser Pro Thr Ser Cys
50 55 60 Pro Pro Ile Cys Pro Gly Tyr Arg Trp Met Cys Leu Arg Arg
Phe Ile 65 70 75 80 Ile Phe Leu Phe Ile Leu Leu Leu Cys Leu Ile Phe
Leu Leu Val Leu 85 90 95 Leu Asp Tyr Gln Gly Met Leu Pro Val Cys
Pro Leu Ile Pro Gly Ser 100 105 110 Thr Thr Thr Ser Thr Gly Pro Cys
Lys Thr Cys Thr Thr Pro Ala Gln 115 120 125 Gly Asn Ser Lys Phe Pro
Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly 130 135 140 Asn Cys Thr Cys
Ile Ser Ile Pro Ser Ser Trp Ala Phe Ala Lys Tyr 145 150 155 160 Leu
Trp Glu Trp Ala Ser Val Arg Phe Ser Trp Leu Ser Leu Leu Val 165 170
175 Pro Phe Val Gln Trp Phe Val Gly Leu Ser Pro Thr Val Trp Leu Ser
180 185 190 Ala Ile Trp Met Met Trp Tyr Trp Gly Pro Ser Leu Tyr Ser
Ile Val 195 200 205 Ser Pro Phe Ile Pro Leu Leu Pro Ile Phe Phe Cys
Leu Trp Val Tyr 210 215 220 Ile Gly 225 <210> SEQ ID NO 32
<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 32 Ala Ser Leu
Trp Asn Trp Phe Asn Ile Thr Asn Trp Leu Trp Tyr 1 5 10 15
<210> SEQ ID NO 33 <211> LENGTH: 15 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 33 Ile Lys Leu Phe Ile Met Ile Val Gly Gly Leu Val Gly
Leu Arg 1 5 10 15 <210> SEQ ID NO 34 <211> LENGTH: 4
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <220> FEATURE: <221> NAME/KEY: misc_feature
<222> LOCATION: (4)..(4) <223> OTHER INFORMATION: Xaa
can be any naturally occurring amino acid <400> SEQUENCE: 34
Cys Ala Ala Xaa 1 <210> SEQ ID NO 35 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 35 Glu Leu Asp Lys Trp Ala Ser 1 5
<210> SEQ ID NO 36 <211> LENGTH: 6 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 36 Asn Trp Phe Asp Ile Thr 1 5 <210> SEQ ID NO 37
<211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 37 Gly Pro Gly
Pro 1 <210> SEQ ID NO 38 <211> LENGTH: 18 <212>
TYPE: DNA <213> ORGANISM: Artificial sequence <220>
FEATURE: <223> OTHER INFORMATION: Synthetic neucleic acid
primer. <400> SEQUENCE: 38 ggagctcgtc gacagcaa 18 <210>
SEQ ID NO 39 <211> LENGTH: 23 <212> TYPE: DNA
<213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 39 gctctagacc cgatgtacac cca 23 <210>
SEQ ID NO 40 <211> LENGTH: 26 <212> TYPE: DNA
<213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 40 gctctagaaa cgagcaggag ctgctg 26
<210> SEQ ID NO 41 <211> LENGTH: 36 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 41 cgcggatcct caccccttga tgtaccacag ccactt 36
<210> SEQ ID NO 42 <211> LENGTH: 33 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 42 cgcggatcct caatggtgat ggtgatggtg ggg 33
<210> SEQ ID NO 43 <211> LENGTH: 26 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 43 gctctagagc cgtggagcgg tacctg 26
<210> SEQ ID NO 44 <211> LENGTH: 33 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 44 ctcggatcct caaatcatga tgaaaatctt gat 33
<210> SEQ ID NO 45 <211> LENGTH: 30 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 45 ctcggatcct cacaccaggc caccaacaat 30
<210> SEQ ID NO 46 <211> LENGTH: 30 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 46 ctcggatcct cacaccagcc tcaggcccac 30
<210> SEQ ID NO 47 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 47 ctcggatcct caggcgggcg c 21 <210> SEQ
ID NO 48 <211> LENGTH: 48 <212> TYPE: DNA <213>
ORGANISM: Artificial sequence <220> FEATURE: <223>
OTHER INFORMATION: Synthetic neucleic acid primer. <400>
SEQUENCE: 48 ccctgcaaga cctgcaccac caccggtcag ggcaactcca agttcccc
48 <210> SEQ ID NO 49 <211> LENGTH: 48 <212>
TYPE: DNA <213> ORGANISM: Artificial sequence <220>
FEATURE: <223> OTHER INFORMATION: Synthetic neucleic acid
primer. <400> SEQUENCE: 49 ggggaacttg gagttgccct gaccggtggt
ggtgcaggtc ttgcaggg 48 <210> SEQ ID NO 50 <211> LENGTH:
27 <212> TYPE: DNA <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Synthetic
neucleic acid primer. <400> SEQUENCE: 50 ggcaccggta
acgagcagga gctgctg 27 <210> SEQ ID NO 51 <211> LENGTH:
33 <212> TYPE: DNA <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Synthetic
neucleic acid primer. <400> SEQUENCE: 51 ggcaccggtc
cccttgatgt accacagcca ctt 33 <210> SEQ ID NO 52 <211>
LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial
sequence <220> FEATURE: <223> OTHER INFORMATION:
Synthetic neucleic acid primer. <400> SEQUENCE: 52 agcgaattca
acgagcagga gctgctg 27 <210> SEQ ID NO 53 <211> LENGTH:
27 <212> TYPE: DNA <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Synthetic
neucleic acid primer. <400> SEQUENCE: 53 cgcggatcct
cacccgatgt acaccca 27 <210> SEQ ID NO 54 <211> LENGTH:
45 <212> TYPE: DNA <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Synthetic
neucleic acid primer. <400> SEQUENCE: 54 caggaagccg
gaggtgatga accccttgat gtaccacagc cactt 45 <210> SEQ ID NO 55
<211> LENGTH: 45 <212> TYPE: DNA <213> ORGANISM:
Artificial sequence <220> FEATURE: <223> OTHER
INFORMATION: Synthetic neucleic acid primer. <400> SEQUENCE:
55 aagtggctgt ggtacatcaa ggggttcatc acctccggct tcctg 45 <210>
SEQ ID NO 56 <211> LENGTH: 515 <212> TYPE: DNA
<213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Neucleic acid sequence for
recombinant antigenic insert peptide. <400> SEQUENCE: 56
attagataga tttggattag cagaaagcct gttggagaac aaagaaggat gtcaaaaaat
60 actttcggtc ttagctccat tagtgccaac aggctcagaa aatttaaaaa
gcctttataa 120 tactgtctgc gtcatctggt gcattcacgc agaagagaaa
gtgaaacaca ctgaggaagc 180 aaaacagata gtgcagagac acctagtggt
ggaaacagga acaacagaaa ctatgccaaa 240 aacaagtaga ccaacagcac
catctagcgg cagaggagga aattacccag tacaacaaat 300 aggtggtaac
tatgtccacc tgccattaag cccgagaaca ttaaatgcct gggtaaaatt 360
gatagaggaa aagaaatttg gagcagaagt agtgccagga tttcaggcac tgtcagaagg
420 ttgcaccccc tatgacatta atcagatgtt aaattgtgtg ggagaccatc
aagcggctat 480 gcagattatc agagatatta taaacgagga ggctg 515
<210> SEQ ID NO 57 <211> LENGTH: 295 <212> TYPE:
PRT <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert peptide
construct. <400> SEQUENCE: 57 Met Lys Thr Ile Ile Ala Leu Ser
Tyr Ile Phe Cys Leu Val Phe Ala 1 5 10 15 Gln Asp Leu Pro Gly Asn
Asp Asn Asn Ser Glu Phe Asn Glu Lys Glu 20 25 30 Leu Leu Glu Leu
Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile 35 40 45 Thr Asn
Trp Leu Trp Tyr Ile Arg Leu Phe Ile Met Ile Val Gly Gly 50 55 60
Leu Ile Gly Leu Arg Ile Val Phe Ala Val Leu Ser Ile Pro Gln Ser 65
70 75 80 Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly Gly Ser
Pro Val 85 90 95 Cys Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn
His Ser Pro Thr 100 105 110 Ser Cys Pro Pro Ile Cys Pro Gly Tyr Arg
Trp Met Cys Leu Arg Arg 115 120 125 Phe Ile Ile Phe Leu Phe Ile Leu
Leu Leu Cys Leu Ile Phe Leu Leu 130 135 140 Val Leu Leu Asp Tyr Gln
Gly Met Leu Pro Val Cys Pro Leu Ile Pro 145 150 155 160 Gly Ser Thr
Thr Thr Ser Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro 165 170 175 Ala
Gln Gly Asn Ser Lys Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr 180 185
190 Asp Gly Asn Cys Thr Cys Ile Pro Ile Asn Glu Lys Glu Leu Leu Glu
195 200 205 Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr
Asn Trp 210 215 220 Leu Trp Tyr Ile Arg Leu Phe Ile Met Ile Val Gly
Gly Leu Ile Gly 225 230 235 240 Leu Arg Ile Val Phe Ala Val Leu Ser
Ile Val Val Gly Leu Ser Pro 245 250 255 Thr Val Trp Leu Ser Ala Ile
Trp Met Met Trp Tyr Trp Gly Pro Ser 260 265 270 Leu Tyr Ser Ile Val
Ser Pro Phe Ile Pro Leu Leu Pro Ile Phe Phe 275 280 285 Cys Leu Trp
Val Tyr Ile Gly 290 295 <210> SEQ ID NO 58 <211>
LENGTH: 1730 <212> TYPE: DNA <213> ORGANISM: Artificial
sequence <220> FEATURE: <223> OTHER INFORMATION:
Recombinant antigenic insert peptide. <400> SEQUENCE: 58
ggtaccgtcg acagcaaaag caggggataa ttctattaac catgaagact atcattgctt
60 ccatggcagc tgtcgttttc gtcccctatt aagataattg gtacttctga
tagtaacgaa 120 tgagctacat tttctgtctg gttttcgccc aagaccttcc
aggaaatgac aacaacagcg 180 actcgatgta aaagacagac caaaagcggg
ttctggaagg tcctttactg ttgttgtcgc 240 aattcatcac ctccggcttc
ctgggccccc tgctggtcct gcaggccggg ttcttcctgc 300 ttaagtagtg
gaggccgaag gacccggggg acgaccagga cgtccggccc aagaaggacg 360
tgacccgcat cctcaccatc ccccagtccc tggactcgtg gtggacctcc ctcaactttc
420 actgggcgta ggagtggtag ggggtcaggg acctgagcac cacctggagg
gagttgaaag 480 tggggggctc ccccgtgtgt ctgggccaga actcccagtc
ccccacctcc aaccactccc 540 accccccgag ggggcacaca gacccggtct
tgagggtcag ggggtggagg ttggtgaggg 600 ccacctcctg cccccccatc
tgccccggct accgctggat gtgcctgcgc cgcttcatca 660 ggtggaggac
gggggggtag acggggccga tggcgaccta cacggacgcg gcgaagtagt 720
tcttcctgtt catcctgctg ctgtgcctga tcttcctgct ggtgctgctg gactaccagg
780 agaaggacaa gtaggacgac gacacggact agaaggacga ccacgacgac
ctgatggtcc 840 gcatgctgcc cgtgtgcccc ctgatccccg gctccaccac
cacctccacc ggcccctgca 900 cgtacgacgg gcacacgggg gactaggggc
cgaggtggtg gtggaggtgg ccggggacgt 960 agacctgcac cacccccgcc
cagggcaact ccaagttccc ctcctgctgc tgcaccaagc 1020 tctggacgtg
gtgggggcgg gtcccgttga ggttcaaggg gaggacgacg acgtggttcg 1080
ccaccgacgg caactgcacc tgcatcaata ttaatgaaaa agaattattg gaattggata
1140 ggtggctgcc gttgacgtgg acgtagttat aattactttt tcttaataac
cttaacctat 1200 aatgggcaag tttgtggaat tggtttgaca taacaaactg
gctgtggtat ataagattat 1260 ttacccgttc aaacacctta accaaactgt
attgtttgac cgacaccata tattctaata 1320 tcataatgat agtaggaggc
ttgataggtt taagaatagt ttttgctgta ctttctatag 1380 agtattacta
tcatcctccg aactatccaa attcttatca aaaacgacat gaaagatatc 1440
tagtgggcct gtcccccacc gtgtggctgt ccgccatctg gatgatgtgg tactggggcc
1500 atcacccgga cagggggtgg cacaccgaca ggcggtagac ctactacacc
atgaccccgg 1560 cctccctgta ctccatcgtg tcccccttca tccccctgct
gcccatcttc ttctgcctgt 1620 ggagggacat gaggtagcac agggggaagt
agggggacga cgggtagaag aagacggaca 1680 gggtgtacat ctgactagtg
agctccccac atgtagactg atcactcgag 1730 <210> SEQ ID NO 59
<211> LENGTH: 271 <212> TYPE: PRT <213> ORGANISM:
Artificial sequence <220> FEATURE: <223> OTHER
INFORMATION: Recombinant antigenic insert peptide construct.
<400> SEQUENCE: 59 Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile
Phe Cys Leu Val Phe Ala 1 5 10 15 Gln Asp Leu Pro Gly Asn Asp Asn
Asn Ser Glu Phe Ile Thr Ser Gly 20 25 30 Phe Leu Gly Pro Leu Leu
Val Leu Gln Ala Gly Phe Phe Leu Leu Thr 35 40 45 Arg Ile Leu Thr
Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu 50 55 60 Asn Phe
Leu Gly Gly Ser Pro Val Cys Leu Gly Gln Asn Ser Gln Ser 65 70 75 80
Pro Thr Ser Asn His Ser Pro Thr Ser Cys Pro Pro Ile Cys Pro Gly 85
90 95 Tyr Arg Trp Met Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile
Leu 100 105 110 Leu Leu Cys Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr
Gln Gly Met 115 120 125 Leu Pro Val Cys Pro Leu Ile Pro Gly Ser Thr
Thr Thr Ser Thr Gly 130 135 140 Pro Cys Lys Thr Cys Thr Thr Pro Ala
Gln Gly Asn Ser Lys Phe Pro 145 150 155 160 Ser Cys Cys Cys Thr Lys
Pro Thr Asp Gly Asn Cys Thr Cys Ile Asn 165 170 175 Ile Asn Glu Lys
Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp 180 185 190 Asn Trp
Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Arg Leu Phe Ile 195 200 205
Met Ile Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe Ala Val Leu 210
215 220 Ser Ile Val Val Gly Leu Ser Pro Thr Val Trp Leu Ser Ala Ile
Trp 225 230 235 240 Met Met Trp Tyr Trp Gly Pro Ser Leu Tyr Ser Ile
Val Ser Pro Phe 245 250 255 Ile Pro Leu Leu Pro Ile Phe Phe Cys Leu
Trp Val Tyr Ile Gly 260 265 270 <210> SEQ ID NO 60
<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 60 Asn Glu Lys
Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp 1 5 10 15
<210> SEQ ID NO 61 <211> LENGTH: 25 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 61 Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser
Leu Trp Asn 1 5 10 15 Trp Phe Asp Ile Thr Asn Trp Leu Trp 20 25
<210> SEQ ID NO 62 <211> LENGTH: 300 <212> TYPE:
PRT <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert peptide
construct. <400> SEQUENCE: 62 Met Lys Thr Ile Ile Ala Leu Ser
Tyr Ile Phe Cys Leu Val Phe Ala 1 5 10 15 Gln Asp Leu Pro Gly Asn
Asp Asn Asn Ser Glu Phe Asn Glu Lys Glu 20 25 30 Leu Leu Glu Leu
Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile 35 40 45 Thr Asn
Trp Leu Trp Tyr Ile Arg Leu Phe Ile Met Ile Val Gly Gly 50 55 60
Leu Ile Gly Leu Arg Ile Val Phe Ala Val Leu Ser Ile Pro Gln Ser 65
70 75 80 Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly Gly Ser
Pro Val 85 90 95 Cys Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn
His Ser Pro Thr 100 105 110 Ser Cys Pro Pro Ile Cys Pro Gly Tyr Arg
Trp Met Cys Leu Arg Arg 115 120 125 Phe Ile Ile Phe Leu Phe Ile Leu
Leu Leu Cys Leu Ile Phe Leu Leu 130 135 140 Val Leu Leu Asp Tyr Gln
Gly Met Leu Pro Val Cys Pro Leu Ile Pro 145 150 155 160 Gly Ser Thr
Thr Thr Ser Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro 165 170 175 Ala
Gln Gly Asn Ser Lys Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr 180 185
190 Asp Gly Asn Cys Thr Cys Ile Ser Ile Asn Glu Lys Glu Leu Leu Glu
195 200 205 Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr
Asn Trp 210 215 220 Leu Trp Ser Ser Leu Trp Ala Ile Lys Tyr Leu Trp
Glu Trp Ala Ser 225 230 235 240 Val Arg Phe Ser Trp Leu Ser Leu Leu
Val Pro Phe Val Gln Trp Phe 245 250 255 Val Gly Leu Ser Pro Thr Val
Trp Leu Ser Ala Ile Trp Met Met Trp 260 265 270 Tyr Trp Gly Pro Ser
Leu Tyr Ser Ile Val Ser Pro Phe Ile Pro Leu 275 280 285 Leu Pro Ile
Phe Phe Cys Leu Trp Val Tyr Ile Gly 290 295 300 <210> SEQ ID
NO 63 <211> LENGTH: 382 <212> TYPE: PRT <213>
ORGANISM: Artificial sequence <220> FEATURE: <223>
OTHER INFORMATION: Recombinant antigenic insert peptide construct.
<400> SEQUENCE: 63 Val Pro Val Trp Arg Glu Ala Thr Thr Thr
Leu Phe Cys Ala Ser Asp 1 5 10 15 Ala Lys Ala Tyr Asp Thr Glu Val
His Asn Val Trp Ala Thr His Ala 20 25 30 Cys Val Pro Thr Asp Pro
Asn Pro Gln Glu Val Val Leu Gly Asn Val 35 40 45 Thr Glu Asn Phe
Asn Met Trp Lys Asn Asn Met Val Asp Gln Met His 50 55 60 Glu Asp
Ile Ile Ser Leu Trp Asp Glu Ser Leu Lys Pro Cys Val Lys 65 70 75 80
Leu Thr Pro Leu Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln Pro 85
90 95 Ile Pro Ile His Tyr Cys Val Pro Ala Gly Phe Ala Met Leu Lys
Cys 100 105 110 Asn Asn Lys Thr Phe Asn Gly Ser Gly Pro Cys Thr Asn
Val Ser Thr 115 120 125 Val Gln Cys Thr His Gly Ile Arg Pro Val Val
Ser Thr Gln Leu Leu 130 135 140 Leu Asn Gly Ser Leu Ala Glu Glu Asp
Ile Val Ile Arg Ser Glu Asn 145 150 155 160 Phe Thr Asp Asn Ala Lys
Thr Ile Ile Val Gln Leu Asn Glu Ser Val 165 170 175 Val Ile Asn Cys
Thr Arg Pro Asn Asn Asn Thr Arg Arg Arg Leu Ser 180 185 190 Ile Gly
Pro Gly Arg Ala Phe Tyr Ala Arg Arg Asn Ile Ile Gly Asp 195 200 205
Ile Arg Gln Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr 210
215 220 Leu Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn Lys
Thr 225 230 235 240 Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu
Ile Val Met His 245 250 255 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr
Cys Asn Thr Ala Gln Leu 260 265 270 Phe Asn Ser Thr Trp Asn Val Thr
Gly Gly Thr Asn Gly Thr Glu Gly 275 280 285 Asn Asp Ile Ile Thr Leu
Gln Cys Arg Ile Lys Gln Ile Ile Asn Met 290 295 300 Trp Gln Lys Val
Gly Lys Ala Met Tyr Ala Pro Pro Ile Thr Gly Gln 305 310 315 320 Ile
Arg Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly 325 330
335 Gly Asn Ser Thr Glu Thr Glu Thr Glu Ile Phe Arg Pro Gly Gly Gly
340 345 350 Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys
Val Val 355 360 365 Arg Ile Glu Pro Ile Gly Val Ala Pro Thr Arg Ala
Lys Arg 370 375 380 <210> SEQ ID NO 64 <211> LENGTH:
337 <212> TYPE: PRT <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Recombinant
antigenic insert peptide construct. <400> SEQUENCE: 64 Met
Lys Thr Ile Ile Ala Leu Ser Tyr Ile Phe Cys Leu Val Phe Ala 1 5 10
15 Gln Asp Leu Pro Gly Asn Asp Asn Asn Ser Glu Phe Asn Glu Lys Glu
20 25 30 Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe
Asp Ile 35 40 45 Thr Asn Trp Leu Trp Tyr Ile Arg Leu Phe Ile Met
Ile Val Gly Gly 50 55 60 Leu Ile Gly Leu Arg Ile Val Phe Ala Val
Leu Ser Ile Pro Gln Ser 65 70 75 80 Leu Asp Ser Trp Trp Thr Ser Leu
Asn Phe Leu Gly Gly Ser Pro Val 85 90 95 Cys Leu Gly Gln Asn Ser
Gln Ser Pro Thr Ser Asn His Ser Pro Thr 100 105 110 Ser Cys Pro Pro
Ile Cys Pro Gly Tyr Arg Trp Met Cys Leu Arg Arg 115 120 125 Phe Ile
Ile Phe Leu Phe Ile Leu Leu Leu Cys Leu Ile Phe Leu Leu 130 135 140
Val Leu Leu Asp Tyr Gln Gly Met Leu Pro Val Cys Pro Leu Ile Pro 145
150 155 160 Gly Ser Thr Thr Thr Ser Thr Gly Pro Cys Lys Thr Cys Thr
Thr Pro 165 170 175 Ala Gln Gly Asn Ser Lys Phe Pro Ser Cys Cys Cys
Thr Lys Pro Thr 180 185 190 Asp Gly Asn Cys Thr Cys Ile Ser Ile Asn
Glu Lys Glu Leu Leu Glu 195 200 205 Leu Asp Lys Trp Ala Ser Leu Trp
Ala Ile Asn Glu Lys Glu Leu Leu 210 215 220 Glu Leu Asp Lys Trp Ala
Ser Leu Trp Ala Ile Asn Glu Lys Glu Leu 225 230 235 240 Leu Glu Leu
Asp Lys Trp Ala Ser Leu Trp Ala Ile Asn Glu Lys Glu 245 250 255 Leu
Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Ala Ile Lys Tyr Leu 260 265
270 Trp Glu Trp Ala Ser Val Arg Phe Ser Trp Leu Ser Leu Leu Val Pro
275 280 285 Phe Val Gln Trp Phe Val Gly Leu Ser Pro Thr Val Trp Leu
Ser Ala 290 295 300 Ile Trp Met Met Trp Tyr Trp Gly Pro Ser Leu Tyr
Ser Ile Val Ser 305 310 315 320 Pro Phe Ile Pro Leu Leu Pro Ile Phe
Phe Cys Leu Trp Val Tyr Ile 325 330 335 Gly <210> SEQ ID NO
65 <211> LENGTH: 313 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 65 Met
Lys Thr Ile Ile Ala Leu Ser Tyr Ile Phe Cys Leu Val Phe Ala 1 5 10
15 Gln Asp Leu Pro Gly Asn Asp Asn Asn Ser Glu Phe Ile Thr Ser Gly
20 25 30 Phe Leu Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu
Leu Thr 35 40 45 Arg Ile Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp
Trp Thr Ser Leu 50 55 60 Asn Phe Leu Gly Gly Ser Pro Val Cys Leu
Gly Gln Asn Ser Gln Ser 65 70 75 80 Pro Thr Ser Asn His Ser Pro Thr
Ser Cys Pro Pro Ile Cys Pro Gly 85 90 95 Tyr Arg Trp Met Cys Leu
Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu 100 105 110 Leu Leu Cys Leu
Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln Gly Met 115 120 125 Leu Pro
Val Cys Pro Leu Ile Pro Gly Ser Thr Thr Thr Ser Thr Gly 130 135 140
Pro Cys Lys Thr Cys Thr Thr Pro Ala Gln Gly Asn Ser Lys Phe Pro 145
150 155 160 Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly Asn Cys Thr Cys
Ile Ser 165 170 175 Ile Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp
Ala Ser Leu Trp 180 185 190 Ala Ile Asn Glu Lys Glu Leu Leu Glu Leu
Asp Lys Trp Ala Ser Leu 195 200 205 Trp Ala Ile Asn Glu Lys Glu Leu
Leu Glu Leu Asp Lys Trp Ala Ser 210 215 220 Leu Trp Ala Ile Asn Glu
Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala 225 230 235 240 Ser Leu Trp
Ala Ile Lys Tyr Leu Trp Glu Trp Ala Ser Val Arg Phe 245 250 255 Ser
Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe Val Gly Leu 260 265
270 Ser Pro Thr Val Trp Leu Ser Ala Ile Trp Met Met Trp Tyr Trp Gly
275 280 285 Pro Ser Leu Tyr Ser Ile Val Ser Pro Phe Ile Pro Leu Leu
Pro Ile 290 295 300 Phe Phe Cys Leu Trp Val Tyr Ile Gly 305 310
<210> SEQ ID NO 66 <211> LENGTH: 373 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 66 Val Pro Val Trp Arg Glu Ala Thr Thr Thr Leu Phe Cys
Ala Ser Asp 1 5 10 15 Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val
Trp Ala Thr His Ala 20 25 30 Cys Val Pro Thr Asp Pro Asn Pro Gln
Glu Val Val Leu Gly Asn Val 35 40 45 Thr Glu Asn Phe Asn Met Trp
Lys Asn Asn Met Val Asp Gln Met His 50 55 60 Glu Asp Ile Ile Ser
Leu Trp Asp Glu Ser Leu Lys Pro Cys Val Lys 65 70 75 80 Leu Thr Pro
Leu Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln Pro 85 90 95 Ile
Pro Ile His Tyr Cys Val Pro Ala Gly Phe Ala Met Leu Lys Cys 100 105
110 Asn Asn Lys Thr Phe Asn Gly Ser Gly Pro Cys Thr Asn Val Ser Thr
115 120 125 Val Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr Gln
Leu Leu 130 135 140 Leu Asn Gly Ser Leu Ala Glu Glu Asp Ile Val Ile
Arg Ser Glu Asn 145 150 155 160 Phe Thr Asp Asn Ala Lys Thr Ile Ile
Val Gln Leu Asn Glu Ser Val 165 170 175 Val Ile Asn Cys Thr Arg Pro
Asn Asn Asn Thr Arg Arg Arg Leu Ser 180 185 190 Ile Gly Pro Gly Arg
Ala Phe Tyr Ala Arg Arg Asn Ile Ile Gly Asp 195 200 205 Ile Arg Gln
Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr 210 215 220 Leu
Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn Lys Thr 225 230
235 240 Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met
His 245 250 255 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr
Ala Gln Leu 260 265 270 Phe Asn Ser Thr Trp Asn Val Thr Gly Gly Thr
Asn Gly Thr Glu Gly 275 280 285 Asn Asp Ile Ile Thr Leu Gln Cys Arg
Ile Lys Gln Leu Ala Met Tyr 290 295 300 Ala Pro Pro Ile Thr Gly Gln
Ile Arg Cys Ser Ser Asn Ile Thr Gly 305 310 315 320 Leu Leu Leu Thr
Arg Asp Gly Gly Asn Ser Thr Glu Thr Glu Thr Glu 325 330 335 Ile Phe
Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu 340 345 350
Leu Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile Gly Val Ala Pro 355
360 365 Thr Arg Ala Lys Arg 370 <210> SEQ ID NO 67
<211> LENGTH: 664 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 67 Ile Ile His
Thr Val Pro Pro Ser Gly Ala Asp Pro Gly Pro Lys Arg 1 5 10 15 Ala
Glu Phe Lys Gly Leu Arg Arg Gln Gln Lys Gln Gly Ile Ile Leu 20 25
30 Leu Thr Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Val
35 40 45 Leu Ala Gln Lys Leu Pro Gly Asn Asp Asn Asn Ser Glu Phe
Ile Thr 50 55 60 Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala
Gly Phe Phe Leu 65 70 75 80 Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser
Leu Asp Ser Trp Trp Thr 85 90 95 Ser Leu Asn Phe Leu Gly Gly Ser
Pro Val Cys Leu Gly Gln Asn Ser 100 105 110 Gln Ser Pro Thr Ser Asn
His Ser Pro Thr Ser Cys Pro Pro Ile Cys 115 120 125 Pro Gly Tyr Arg
Met Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile 130 135 140 Leu Leu
Leu Cys Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln Gly 145 150 155
160 Met Leu Pro Val Cys Pro Leu Ile Pro Gly Ser Thr Thr Thr Ser Thr
165 170 175 Gly Pro Cys Lys Thr Cys Thr Thr Pro Ala Gln Gly Asn Ser
Lys Phe 180 185 190 Pro Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly Asn
Cys Thr Cys Ile 195 200 205 Pro Ile Pro Ser Ser Trp Ala Phe Ala Lys
Tyr Leu Trp Glu Trp Ala 210 215 220 Ser Val Arg Phe Ser Trp Leu Ser
Leu Leu Val Pro Phe Val Gln Trp 225 230 235 240 Phe Val Gly Leu Ser
Pro Thr Val Trp Leu Ser Ala Ile Trp Met Met 245 250 255 Trp Tyr Trp
Gly Pro Ser Leu Tyr Ser Ile Val Ser Pro Phe Ile Pro 260 265 270 Leu
Leu Pro Ile Phe Phe Cys Leu Trp Val Tyr Ile Gly Val Pro Val 275 280
285 Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala
290 295 300 Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys
Val Pro 305 310 315 320 Thr Asp Pro Asn Pro Gln Glu Val Val Leu Glu
Asn Val Thr Glu His 325 330 335 Phe Asn Met Trp Lys Asn Asn Met Val
Glu Gln Met Gln Glu Asp Ile 340 345 350 Ile Ser Leu Trp Asp Gln Ser
Leu Lys Pro Cys Val Lys Leu Thr Pro 355 360 365 Leu Gln Ala Cys Pro
Lys Ile Ser Phe Glu Pro Ile Pro Ile His Tyr 370 375 380 Cys Ala Pro
Ala Gly Phe Ala Ile Leu Lys Cys Asn Asp Lys Thr Phe 385 390 395 400
Asn Gly Lys Gly Pro Cys Lys Asn Val Ser Thr Val Gln Cys Thr His 405
410 415 Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser
Leu 420 425 430 Ala Glu Glu Glu Val Val Ile Arg Ser Asp Asn Phe Thr
Asn Asn Ala 435 440 445 Lys Thr Ile Ile Val Gln Leu Lys Glu Ser Val
Glu Ile Asn Cys Thr 450 455 460 Arg Pro Asn Asn Asn Thr Arg Lys Ser
Ile His Ile Gly Pro Gly Arg 465 470 475 480 Ala Phe Tyr Thr Thr Gly
Glu Ile Ile Gly Asp Ile Arg Gln Ala His 485 490 495 Cys Asn Ile Ser
Arg Ala Lys Trp Asn Asp Thr Leu Lys Gln Ile Val 500 505 510 Ile Lys
Leu Arg Glu Gln Phe Glu Asn Lys Thr Ile Val Phe Asn His 515 520 525
Ser Ser Gly Gly Asp Pro Glu Ile Val Met His Ser Phe Asn Cys Gly 530
535 540 Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gln Leu Phe Asn Ser Thr
Trp 545 550 555 560 Asn Asn Asn Thr Glu Gly Ser Asn Asn Thr Glu Gly
Asn Thr Ile Thr 565 570 575 Leu Pro Cys Arg Ile Lys Gln Leu Ala Met
Tyr Ala Pro Pro Ile Arg 580 585 590 Gly Gln Ile Arg Cys Ser Ser Asn
Ile Thr Gly Leu Leu Leu Thr Arg 595 600 605 Asp Gly Gly Ile Asn Glu
Asn Gly Thr Glu Ile Phe Arg Pro Gly Gly 610 615 620 Gly Asp Met Arg
Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val 625 630 635 640 Val
Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg Leu 645 650
655 Val Ala Ala Ala Phe Glu Ser Arg 660 <210> SEQ ID NO 68
<211> LENGTH: 2000 <212> TYPE: DNA <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 68
ggattattca taccgtccca ccatcgggcg cggatcccgg tccgaagcgc gcggaattca
60 aaggcctacg tcgacagcaa aagcagggga taattctatt aaccatgaag
actatcattg 120 ctttgagcta cattttatgt ctggttctcg ctcaaaaact
tcccggaaat gacaacaaca 180 gcgaattcat cacctccggc ttcctgggcc
ccctgctggt gctgcaggcc ggcttcttcc 240 tgctgacccg catcctgacc
atcccccagt ccctggactc ctggtggacc tccctgaact 300 tcctgggcgg
ctcccccgtg tgcctgggcc agaactccca gtcccccacc tccaaccact 360
cccccacctc ctgccccccc atctgccccg gctaccgctg gatgtgcctg cgccgcttca
420 tcatcttcct gttcatcctg ctgctgtgcc tgatcttcct gctggtgctg
ctggactacc 480 agggcatgct gcccgtgtgc cccctgatcc ccggctccac
caccacctcc accggcccct 540 gcaagacctg caccaccccc gcccagggca
actccaagtt cccctcctgc tgctgcacca 600 agcccaccga cggcaactgc
acctgcatcc ccatcccctc ctcctgggcc ttcgccaagt 660 acctgtggga
gtgggcctcc gtgcgcttct cctggctgtc cctgctggtg cccttcgtgc 720
agtggttcgt gggcctgtcc cccaccgtgt ggctgtccgc catctggatg atgtggtact
780 ggggcccctc cctgtactcc atcgtgtccc ccttcatccc cctgctgccc
atcttcttct 840 gcctgtgggt gtacatcggg gtacctgtgt ggaaagaagc
aaccaccact ctattttgtg 900 catcagatgc taaagcatat gatacagagg
tacataatgt ttgggccaca catgcctgtg 960 tacccacaga ccccaaccca
caagaagtag tattggaaaa tgtaacagaa cattttaaca 1020 tgtggaaaaa
taacatggta gaacagatgc aggaggatat aatcagttta tgggatcaaa 1080
gcctaaagcc atgtgtaaaa ttaaccccac tccaggcctg tccaaagata tcctttgagc
1140 caattcccat acattattgt gccccggctg gttttgcgat tctaaagtgt
aatgataaga 1200 cgttcaatgg aaaaggacca tgtaaaaatg tcagcacagt
acaatgtaca catggaatta 1260 ggccagtagt atcaactcaa ctgctgctaa
atggcagtct agcagaagaa gaggtagtaa 1320 ttagatctga caatttcacg
aacaatgcta aaaccataat agtacagctg aaagaatctg 1380 tagaaattaa
ttgtacaaga cccaacaaca atacaagaaa aagtatacat ataggaccag 1440
ggagagcatt ttatactaca ggagaaataa taggagatat aagacaagca cattgtaaca
1500 ttagtagagc aaaatggaat gacactttaa aacagatagt tataaaatta
agagaacaat 1560 ttgagaataa aacaatagtc tttaatcact cctcaggagg
ggacccagaa attgtaatgc 1620 acagttttaa ttgtggagga gaatttttct
actgtaattc aacacaactg tttaatagta 1680 cttggaataa taatactgaa
gggtcaaata acactgaagg aaatactatc acactcccat 1740 gcagaataaa
acagctagca atgtatgccc ctcccatcag aggacaaatt agatgttcat 1800
caaatattac agggctgcta ttaacaagag atggtggtat taatgagaat gggaccgaga
1860 tcttcagacc tggaggagga gatatgaggg acaattggag aagtgaatta
tataaatata 1920 aagtagtaaa aattgaacca ttaggagtag cacccaccaa
ggcaaagaga tgactagtcg 1980 cggccgcttt cgaatctaga 2000 <210>
SEQ ID NO 69 <211> LENGTH: 665 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 69 Ile Ile His Thr Val Pro Pro Ser Gly Ala Asp Pro Gly
Pro Lys Arg 1 5 10 15 Ala Glu Phe Lys Gly Leu Arg Arg Gln Gln Lys
Gln Gly Ile Ile Leu 20 25 30 Leu Thr Met Lys Thr Ile Ile Ala Leu
Ser Tyr Ile Leu Cys Leu Val 35 40 45 Leu Ala Gln Lys Leu Pro Gly
Asn Asp Asn Asn Ser Glu Phe Ile Thr 50 55 60 Ser Gly Phe Leu Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu 65 70 75 80 Leu Thr Arg
Ile Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr 85 90 95 Ser
Leu Asn Phe Leu Gly Gly Ser Pro Val Cys Leu Gly Gln Asn Ser 100 105
110 Gln Ser Pro Thr Ser Asn His Ser Pro Thr Ser Cys Pro Pro Ile Cys
115 120 125 Pro Gly Tyr Arg Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe 130 135 140 Ile Leu Leu Leu Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Gln 145 150 155 160 Gly Met Leu Pro Val Cys Pro Leu Ile
Pro Gly Ser Thr Thr Thr Ser 165 170 175 Thr Gly Pro Cys Lys Thr Cys
Thr Thr Pro Ala Gln Gly Asn Ser Lys 180 185 190 Phe Pro Ser Cys Cys
Cys Thr Lys Pro Thr Asp Gly Asn Cys Thr Cys 195 200 205 Ile Pro Ile
Pro Ser Ser Trp Ala Phe Ala Lys Tyr Leu Trp Glu Trp 210 215 220 Ala
Ser Val Arg Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln 225 230
235 240 Trp Phe Val Gly Leu Ser Pro Thr Val Trp Leu Ser Ala Ile Trp
Met 245 250 255 Met Trp Tyr Trp Gly Pro Ser Leu Tyr Ser Ile Val Ser
Pro Phe Ile 260 265 270 Pro Leu Leu Pro Ile Phe Phe Cys Leu Trp Val
Tyr Ile Gly Val Pro 275 280 285 Val Trp Lys Glu Ala Thr Thr Thr Leu
Phe Cys Ala Ser Asp Ala Lys 290 295 300 Ala Tyr Asp Thr Glu Val His
Asn Val Trp Ala Thr His Ala Cys Val 305 310 315 320 Pro Thr Asp Pro
Asn Pro Gln Glu Val Val Leu Glu Asn Val Thr Glu 325 330 335 Asn Phe
Asn Met Trp Lys Asn Asn Met Val Glu Gln Met His Glu Asp 340 345 350
Ile Ile Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr 355
360 365 Pro Leu Gln Ala Cys Pro Lys Val Ser Phe Glu Pro Ile Pro Ile
His 370 375 380 Tyr Cys Thr Pro Ala Gly Phe Ala Ile Leu Lys Cys Lys
Asp Lys Lys 385 390 395 400 Phe Asn Gly Thr Gly Pro Cys Lys Asn Val
Ser Thr Val Gln Cys Thr 405 410 415 His Gly Ile Arg Pro Val Val Ser
Thr Gln Leu Leu Leu Asn Gly Ser 420 425 430 Leu Ala Glu Glu Glu Val
Val Ile Arg Ser Ser Asn Phe Thr Asp Asn 435 440 445 Ala Lys Asn Ile
Ile Val Gln Leu Lys Glu Ser Val Glu Ile Asn Cys 450 455 460 Thr Arg
Pro Asn Asn Asn Thr Arg Lys Ser Ile His Ile Gly Pro Gly 465 470 475
480 Arg Ala Phe Tyr Thr Thr Gly Glu Ile Ile Gly Asp Ile Arg Gln Ala
485 490 495 His Cys Asn Ile Ser Arg Thr Lys Trp Asn Asn Thr Leu Asn
Gln Ile 500 505 510 Ala Thr Lys Leu Lys Glu Gln Phe Gly Asn Asn Lys
Thr Ile Val Phe 515 520 525 Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile
Val Met His Ser Phe Asn 530 535 540 Cys Gly Gly Glu Phe Phe Tyr Cys
Asn Ser Thr Gln Leu Phe Asn Ser 545 550 555 560 Thr Trp Asn Phe Asn
Gly Thr Trp Asn Leu Thr Gln Ser Asn Gly Thr 565 570 575 Glu Gly Asn
Asp Thr Ile Thr Leu Pro Cys Arg Ile Lys Gln Leu Ala 580 585 590 Met
Tyr Ala Pro Pro Ile Arg Gly Gln Ile Arg Cys Ser Ser Asn Ile 595 600
605 Thr Gly Leu Ile Leu Thr Arg Asp Gly Gly Asn Asn His Asn Asn Asp
610 615 620 Thr Glu Thr Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn
Trp Arg 625 630 635 640 Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile
Glu Pro Leu Gly Val 645 650 655 Ala Pro Thr Lys Ala Lys Arg Leu Val
660 665 <210> SEQ ID NO 70 <211> LENGTH: 2000
<212> TYPE: DNA <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 70 ggattattca taccgtccca ccatcgggcg
cggatcccgg tccgaagcgc gcggaattca 60 aaggcctacg tcgacagcaa
aagcagggga taattctatt aaccatgaag actatcattg 120 ctttgagcta
cattttatgt ctggttctcg ctcaaaaact tcccggaaat gacaacaaca 180
gcgaattcat cacctccggc ttcctgggcc ccctgctggt gctgcaggcc ggcttcttcc
240 tgctgacccg catcctgacc atcccccagt ccctggactc ctggtggacc
tccctgaact 300 tcctgggcgg ctcccccgtg tgcctgggcc agaactccca
gtcccccacc tccaaccact 360 cccccacctc ctgccccccc atctgccccg
gctaccgctg gatgtgcctg cgccgcttca 420 tcatcttcct gttcatcctg
ctgctgtgcc tgatcttcct gctggtgctg ctggactacc 480 agggcatgct
gcccgtgtgc cccctgatcc ccggctccac caccacctcc accggcccct 540
gcaagacctg caccaccccc gcccagggca actccaagtt cccctcctgc tgctgcacca
600 agcccaccga cggcaactgc acctgcatcc ccatcccctc ctcctgggcc
ttcgccaagt 660 acctgtggga gtgggcctcc gtgcgcttct cctggctgtc
cctgctggtg cccttcgtgc 720 agtggttcgt gggcctgtcc cccaccgtgt
ggctgtccgc catctggatg atgtggtact 780 ggggcccctc cctgtactcc
atcgtgtccc ccttcatccc cctgctgccc atcttcttct 840 gcctgtgggt
gtacatcggg gtacctgtgt ggaaagaagc aaccaccact ctattttgtg 900
catcagatgc taaagcatat gatacagagg tacataatgt ttgggccaca catgcctgtg
960 tacccacaga ccccaaccca caagaagtag tattggaaaa tgtgacagaa
aattttaaca 1020 tgtggaaaaa taacatggta gaacagatgc atgaggatat
aatcagttta tgggatcaaa 1080 gcctaaagcc atgtgtaaaa ttaaccccac
tccaggcctg tccaaaggta tcctttgagc 1140 caattcccat acattattgt
accccggctg gttttgcgat tctaaagtgt aaagacaaga 1200 agttcaatgg
aacagggcca tgtaaaaatg tcagcacagt acaatgtaca catggaatta 1260
ggccagtagt gtcaactcaa ctgctgttaa atggcagtct agcagaagaa gaggtagtaa
1320 ttagatctag taatttcaca gacaatgcaa aaaacataat agtacagttg
aaagaatctg 1380 tagaaattaa ttgtacaaga cccaacaaca atacaaggaa
aagtatacat ataggaccag 1440 gaagagcatt ttatacaaca ggagaaataa
taggagatat aagacaagca cattgcaaca 1500 ttagtagaac aaaatggaat
aacactttaa atcaaatagc tacaaaatta aaagaacaat 1560 ttgggaataa
taaaacaata gtctttaatc aatcctcagg aggggaccca gaaattgtaa 1620
tgcacagttt taattgtgga ggggaatttt tctactgtaa ttcaacacaa ctgtttaata
1680 gtacttggaa ttttaatggt acttggaatt taacacaatc gaatggtact
gaaggaaatg 1740 acactatcac actcccatgt agaataaaac agctagcaat
gtatgcccct cccatcagag 1800 gacaaattag atgctcatca aatattacag
ggctaatatt aacaagagat ggtggaaata 1860 accacaataa tgataccgag
acctttagac ctggaggagg agatatgagg gacaattgga 1920 gaagtgaatt
atataaatat aaagtagtaa aaattgaacc attaggagta gcacccacca 1980
aggcaaaaag atgactagtc 2000 <210> SEQ ID NO 71 <211>
LENGTH: 665 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 71 Ile Ile His Thr Val
Pro Pro Ser Gly Ala Asp Pro Gly Pro Lys Arg 1 5 10 15 Ala Glu Phe
Lys Gly Leu Arg Arg Gln Gln Lys Gln Gly Ile Ile Leu 20 25 30 Leu
Thr Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Val 35 40
45 Leu Ala Gln Lys Leu Pro Gly Asn Asp Asn Asn Ser Glu Phe Ile Thr
50 55 60 Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala Gly Phe
Phe Leu 65 70 75 80 Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser Leu Asp
Ser Trp Trp Thr 85 90 95 Ser Leu Asn Phe Leu Gly Gly Ser Pro Val
Cys Leu Gly Gln Asn Ser 100 105 110 Gln Ser Pro Thr Ser Asn His Ser
Pro Thr Ser Cys Pro Pro Ile Cys 115 120 125 Pro Gly Tyr Arg Trp Met
Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe 130 135 140 Ile Leu Leu Leu
Cys Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln 145 150 155 160 Gly
Met Leu Pro Val Cys Pro Leu Ile Pro Gly Ser Thr Thr Thr Ser 165 170
175 Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro Ala Gln Gly Asn Ser Lys
180 185 190 Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly Asn Cys
Thr Cys 195 200 205 Ile Pro Ile Pro Ser Ser Trp Ala Phe Ala Lys Tyr
Leu Trp Glu Trp 210 215 220 Ala Ser Val Arg Phe Ser Trp Leu Ser Leu
Leu Val Pro Phe Val Gln 225 230 235 240 Trp Phe Val Gly Leu Ser Pro
Thr Val Trp Leu Ser Ala Ile Trp Met 245 250 255 Met Trp Tyr Trp Gly
Pro Ser Leu Tyr Ser Ile Val Ser Pro Phe Ile 260 265 270 Pro Leu Leu
Pro Ile Phe Phe Cys Leu Trp Val Tyr Ile Gly Val Pro 275 280 285 Val
Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 290 295
300 Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys Val
305 310 315 320 Pro Thr Asp Pro Asn Pro Gln Glu Val Glu Leu Glu Asn
Val Thr Glu 325 330 335 Asn Phe Asn Met Trp Lys Asn Asn Met Val Glu
Gln Met His Glu Asp 340 345 350 Ile Ile Ser Leu Trp Asp Gln Ser Leu
Lys Pro Cys Val Lys Leu Thr 355 360 365 Pro Leu Gln Ala Cys Pro Lys
Ile Ser Phe Glu Pro Ile Pro Ile His 370 375 380 Tyr Cys Ala Pro Ala
Gly Phe Ala Ile Leu Lys Cys Lys Asp Lys Lys 385 390 395 400 Phe Asn
Gly Lys Gly Pro Cys Ser Asn Val Ser Thr Val Gln Cys Thr 405 410 415
His Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser 420
425 430 Leu Ala Glu Glu Glu Val Val Ile Arg Ser Glu Asn Phe Ala Asp
Asn 435 440 445 Ala Lys Thr Ile Ile Val Gln Leu Asn Glu Ser Val Glu
Ile Asn Cys 450 455 460 Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile
His Ile Gly Pro Gly 465 470 475 480 Arg Ala Leu Tyr Thr Thr Gly Glu
Ile Ile Gly Asp Ile Arg Gln Ala 485 490 495 His Cys Asn Leu Ser Arg
Ala Lys Trp Asn Asp Thr Leu Asn Lys Ile 500 505 510 Val Ile Lys Leu
Arg Glu Gln Phe Gly Asn Lys Thr Ile Val Phe Lys 515 520 525 His Ser
Ser Gly Gly Asp Pro Glu Ile Val Thr His Ser Phe Asn Cys 530 535 540
Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gln Leu Phe Asn Ser Thr 545
550 555 560 Trp Asn Val Thr Glu Glu Ser Asn Asn Thr Val Glu Asn Asn
Thr Ile 565 570 575 Thr Leu Pro Cys Arg Ile Lys Gln Leu Ala Met Tyr
Ala Pro Pro Ile 580 585 590 Arg Gly Gln Ile Arg Cys Ser Ser Asn Ile
Thr Gly Leu Leu Leu Thr 595 600 605 Arg Asp Gly Gly Pro Glu Asp Asn
Lys Thr Glu Val Phe Arg Pro Gly 610 615 620 Gly Gly Asp Met Arg Asp
Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys 625 630 635 640 Val Val Lys
Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg 645 650 655 Leu
Val Ala Ala Ala Phe Glu Ser Arg 660 665 <210> SEQ ID NO 72
<211> LENGTH: 2000 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 72 Gly
Gly Ala Thr Thr Ala Thr Thr Cys Ala Thr Ala Cys Cys Gly Thr 1 5 10
15 Cys Cys Cys Ala Cys Cys Ala Thr Cys Gly Gly Gly Cys Gly Cys Gly
20 25 30 Gly Ala Thr Cys Cys Cys Gly Gly Thr Cys Cys Gly Ala Ala
Gly Cys 35 40 45 Gly Cys Gly Cys Gly Gly Ala Ala Thr Thr Cys Ala
Ala Ala Gly Gly 50 55 60 Cys Cys Thr Ala Cys Gly Thr Cys Gly Ala
Cys Ala Gly Cys Ala Ala 65 70 75 80 Ala Ala Gly Cys Ala Gly Gly Gly
Gly Ala Thr Ala Ala Thr Thr Cys 85 90 95 Thr Ala Thr Thr Ala Ala
Cys Cys Ala Thr Gly Ala Ala Gly Ala Cys 100 105 110 Thr Ala Thr Cys
Ala Thr Thr Gly Cys Thr Thr Thr Gly Ala Gly Cys 115 120 125 Thr Ala
Cys Ala Thr Thr Thr Thr Ala Thr Gly Thr Cys Thr Gly Gly 130 135 140
Thr Thr Cys Thr Cys Gly Cys Thr Cys Ala Ala Ala Ala Ala Cys Thr 145
150 155 160 Thr Cys Cys Cys Gly Gly Ala Ala Ala Thr Gly Ala Cys Ala
Ala Cys 165 170 175 Ala Ala Cys Ala Gly Cys Gly Ala Ala Thr Thr Cys
Ala Thr Cys Ala 180 185 190 Cys Cys Thr Cys Cys Gly Gly Cys Thr Thr
Cys Cys Thr Gly Gly Gly 195 200 205 Cys Cys Cys Cys Cys Thr Gly Cys
Thr Gly Gly Thr Gly Cys Thr Gly 210 215 220 Cys Ala Gly Gly Cys Cys
Gly Gly Cys Thr Thr Cys Thr Thr Cys Cys 225 230 235 240 Thr Gly Cys
Thr Gly Ala Cys Cys Cys Gly Cys Ala Thr Cys Cys Thr 245 250 255 Gly
Ala Cys Cys Ala Thr Cys Cys Cys Cys Cys Ala Gly Thr Cys Cys 260 265
270 Cys Thr Gly Gly Ala Cys Thr Cys Cys Thr Gly Gly Thr Gly Gly Ala
275 280 285 Cys Cys Thr Cys Cys Cys Thr Gly Ala Ala Cys Thr Thr Cys
Cys Thr 290 295 300 Gly Gly Gly Cys Gly Gly Cys Thr Cys Cys Cys Cys
Cys Gly Thr Gly 305 310 315 320 Thr Gly Cys Cys Thr Gly Gly Gly Cys
Cys Ala Gly Ala Ala Cys Thr 325 330 335 Cys Cys Cys Ala Gly Thr Cys
Cys Cys Cys Cys Ala Cys Cys Thr Cys 340 345 350 Cys Ala Ala Cys Cys
Ala Cys Thr Cys Cys Cys Cys Cys Ala Cys Cys 355 360 365 Thr Cys Cys
Thr Gly Cys Cys Cys Cys Cys Cys Cys Ala Thr Cys Thr 370 375 380 Gly
Cys Cys Cys Cys Gly Gly Cys Thr Ala Cys Cys Gly Cys Thr Gly 385 390
395 400 Gly Ala Thr Gly Thr Gly Cys Cys Thr Gly Cys Gly Cys Cys Gly
Cys 405 410 415 Thr Thr Cys Ala Thr Cys Ala Thr Cys Thr Thr Cys Cys
Thr Gly Thr 420 425 430 Thr Cys Ala Thr Cys Cys Thr Gly Cys Thr Gly
Cys Thr Gly Thr Gly 435 440 445 Cys Cys Thr Gly Ala Thr Cys Thr Thr
Cys Cys Thr Gly Cys Thr Gly 450 455 460 Gly Thr Gly Cys Thr Gly Cys
Thr Gly Gly Ala Cys Thr Ala Cys Cys 465 470 475 480 Ala Gly Gly Gly
Cys Ala Thr Gly Cys Thr Gly Cys Cys Cys Gly Thr 485 490 495 Gly Thr
Gly Cys Cys Cys Cys Cys Thr Gly Ala Thr Cys Cys Cys Cys 500 505 510
Gly Gly Cys Thr Cys Cys Ala Cys Cys Ala Cys Cys Ala Cys Cys Thr 515
520 525 Cys Cys Ala Cys Cys Gly Gly Cys Cys Cys Cys Thr Gly Cys Ala
Ala 530 535 540 Gly Ala Cys Cys Thr Gly Cys Ala Cys Cys Ala Cys Cys
Cys Cys Cys 545 550 555 560 Gly Cys Cys Cys Ala Gly Gly Gly Cys Ala
Ala Cys Thr Cys Cys Ala 565 570 575 Ala Gly Thr Thr Cys Cys Cys Cys
Thr Cys Cys Thr Gly Cys Thr Gly 580 585 590 Cys Thr Gly Cys Ala Cys
Cys Ala Ala Gly Cys Cys Cys Ala Cys Cys 595 600 605 Gly Ala Cys Gly
Gly Cys Ala Ala Cys Thr Gly Cys Ala Cys Cys Thr 610 615 620 Gly Cys
Ala Thr Cys Cys Cys Cys Ala Thr Cys Cys Cys Cys Thr Cys 625 630 635
640 Cys Thr Cys Cys Thr Gly Gly Gly Cys Cys Thr Thr Cys Gly Cys Cys
645 650 655 Ala Ala Gly Thr Ala Cys Cys Thr Gly Thr Gly Gly Gly Ala
Gly Thr 660 665 670 Gly Gly Gly Cys Cys Thr Cys Cys Gly Thr Gly Cys
Gly Cys Thr Thr 675 680 685 Cys Thr Cys Cys Thr Gly Gly Cys Thr Gly
Thr Cys Cys Cys Thr Gly 690 695 700 Cys Thr Gly Gly Thr Gly Cys Cys
Cys Thr Thr Cys Gly Thr Gly Cys 705 710 715 720 Ala Gly Thr Gly Gly
Thr Thr Cys Gly Thr Gly Gly Gly Cys Cys Thr 725 730 735 Gly Thr Cys
Cys Cys Cys Cys Ala Cys Cys Gly Thr Gly Thr Gly Gly 740 745 750 Cys
Thr Gly Thr Cys Cys Gly Cys Cys Ala Thr Cys Thr Gly Gly Ala 755 760
765 Thr Gly Ala Thr Gly Thr Gly Gly Thr Ala Cys Thr Gly Gly Gly Gly
770 775 780 Cys Cys Cys Cys Thr Cys Cys Cys Thr Gly Thr Ala Cys Thr
Cys Cys 785 790 795 800 Ala Thr Cys Gly Thr Gly Thr Cys Cys Cys Cys
Cys Thr Thr Cys Ala 805 810 815 Thr Cys Cys Cys Cys Cys Thr Gly Cys
Thr Gly Cys Cys Cys Ala Thr 820 825 830 Cys Thr Thr Cys Thr Thr Cys
Thr Gly Cys Cys Thr Gly Thr Gly Gly 835 840 845 Gly Thr Gly Thr Ala
Cys Ala Thr Cys Gly Gly Gly Gly Thr Ala Cys 850 855 860 Cys Thr Gly
Thr Gly Thr Gly Gly Ala Ala Ala Gly Ala Ala Gly Cys 865 870 875 880
Ala Ala Cys Cys Ala Cys Cys Ala Cys Thr Cys Thr Ala Thr Thr Thr 885
890 895 Thr Gly Thr Gly Cys Ala Thr Cys Ala Gly Ala Thr Gly Cys Thr
Ala 900 905 910 Ala Ala Gly Cys Ala Thr Ala Thr Gly Ala Thr Ala Cys
Ala Gly Ala 915 920 925 Gly Gly Thr Ala Cys Ala Thr Ala Ala Thr Gly
Thr Thr Thr Gly Gly 930 935 940 Gly Cys Cys Ala Cys Ala Cys Ala Thr
Gly Cys Cys Thr Gly Thr Gly 945 950 955 960 Thr Ala Cys Cys Cys Ala
Cys Ala Gly Ala Cys Cys Cys Cys Ala Ala 965 970 975 Cys Cys Cys Ala
Cys Ala Ala Gly Ala Ala Gly Thr Ala Gly Ala Ala 980 985 990 Thr Thr
Gly Gly Ala Ala Ala Ala Thr Gly Thr Gly Ala Cys Ala Gly 995 1000
1005 Ala Ala Ala Ala Thr Thr Thr Thr Ala Ala Cys Ala Thr Gly Thr
1010 1015 1020 Gly Gly Ala Ala Ala Ala Ala Thr Ala Ala Cys Ala Thr
Gly Gly 1025 1030 1035 Thr Ala Gly Ala Ala Cys Ala Gly Ala Thr Gly
Cys Ala Thr Gly 1040 1045 1050 Ala Gly Gly Ala Thr Ala Thr Ala Ala
Thr Cys Ala Gly Thr Thr 1055 1060 1065 Thr Ala Thr Gly Gly Gly Ala
Thr Cys Ala Ala Ala Gly Cys Cys 1070 1075 1080 Thr Ala Ala Ala Gly
Cys Cys Ala Thr Gly Thr Gly Thr Ala Ala 1085 1090 1095 Ala Ala Thr
Thr Ala Ala Cys Thr Cys Cys Ala Cys Thr Cys Cys 1100 1105 1110 Ala
Gly Gly Cys Cys Thr Gly Thr Cys Cys Ala Ala Ala Gly Ala 1115 1120
1125 Thr Ala Thr Cys Cys Thr Thr Thr Gly Ala Gly Cys Cys Ala Ala
1130 1135 1140 Thr Thr Cys Cys Cys Ala Thr Ala Cys Ala Thr Thr Ala
Thr Thr 1145 1150 1155 Gly Thr Gly Cys Cys Cys Cys Gly Gly Cys Thr
Gly Gly Thr Thr 1160 1165 1170 Thr Thr Gly Cys Gly Ala Thr Thr Cys
Thr Ala Ala Ala Gly Thr 1175 1180 1185 Gly Thr Ala Ala Ala Gly Ala
Thr Ala Ala Gly Ala Ala Gly Thr 1190 1195 1200 Thr Cys Ala Ala Thr
Gly Gly Ala Ala Ala Ala Gly Gly Ala Cys 1205 1210 1215 Cys Ala Thr
Gly Thr Thr Cys Ala Ala Ala Thr Gly Thr Cys Ala 1220 1225 1230 Gly
Cys Ala Cys Ala Gly Thr Ala Cys Ala Ala Thr Gly Thr Ala 1235 1240
1245 Cys Ala Cys Ala Thr Gly Gly Gly Ala Thr Thr Ala Gly Gly Cys
1250 1255 1260 Cys Ala Gly Thr Ala Gly Thr Ala Thr Cys Ala Ala Cys
Thr Cys 1265 1270 1275 Ala Ala Cys Thr Gly Cys Thr Gly Thr Thr Ala
Ala Ala Thr Gly 1280 1285 1290 Gly Cys Ala Gly Thr Cys Thr Ala Gly
Cys Ala Gly Ala Ala Gly 1295 1300 1305 Ala Ala Gly Ala Gly Gly Thr
Ala Gly Thr Ala Ala Thr Thr Ala 1310 1315 1320 Gly Ala Thr Cys Cys
Gly Ala Ala Ala Ala Thr Thr Thr Cys Gly 1325 1330 1335 Cys Gly Gly
Ala Cys Ala Ala Thr Gly Cys Thr Ala Ala Ala Ala 1340 1345 1350 Cys
Cys Ala Thr Ala Ala Thr Ala Gly Thr Ala Cys Ala Gly Cys 1355 1360
1365 Thr Gly Ala Ala Thr Gly Ala Ala Thr Cys Thr Gly Thr Ala Gly
1370 1375 1380 Ala Ala Ala Thr Thr Ala Ala Thr Thr Gly Thr Ala Cys
Ala Ala 1385 1390 1395 Gly Ala Cys Cys Cys Ala Ala Cys Ala Ala Cys
Ala Ala Thr Ala 1400 1405 1410 Cys Ala Ala Gly Ala Ala Ala Ala Ala
Gly Thr Ala Thr Ala Cys 1415 1420 1425 Ala Thr Ala Thr Ala Gly Gly
Ala Cys Cys Ala Gly Gly Cys Ala 1430 1435 1440 Gly Ala Gly Cys Ala
Thr Thr Ala Thr Ala Thr Ala Cys Ala Ala 1445 1450 1455 Cys Ala Gly
Gly Ala Gly Ala Ala Ala Thr Ala Ala Thr Ala Gly 1460 1465 1470 Gly
Ala Gly Ala Thr Ala Thr Ala Ala Gly Ala Cys Ala Ala Gly 1475 1480
1485 Cys Ala Cys Ala Thr Thr Gly Thr Ala Ala Cys Cys Thr Thr Ala
1490 1495 1500 Gly Thr Ala Gly Ala Gly Cys Ala Ala Ala Ala Thr Gly
Gly Ala 1505 1510 1515 Ala Thr Gly Ala Cys Ala Cys Thr Thr Thr Ala
Ala Ala Thr Ala 1520 1525 1530 Ala Gly Ala Thr Ala Gly Thr Thr Ala
Thr Ala Ala Ala Ala Thr 1535 1540 1545 Thr Ala Ala Gly Ala Gly Ala
Ala Cys Ala Ala Thr Thr Thr Gly 1550 1555 1560 Gly Gly Ala Ala Thr
Ala Ala Ala Ala Cys Ala Ala Thr Ala Gly 1565 1570 1575 Thr Cys Thr
Thr Thr Ala Ala Gly Cys Ala Thr Thr Cys Cys Thr 1580 1585 1590 Cys
Ala Gly Gly Ala Gly Gly Gly Gly Ala Cys Cys Cys Ala Gly 1595 1600
1605 Ala Ala Ala Thr Thr Gly Thr Gly Ala Cys Gly Cys Ala Cys Ala
1610 1615 1620 Gly Thr Thr Thr Thr Ala Ala Thr Thr Gly Thr Gly Gly
Ala Gly 1625 1630 1635 Gly Gly Gly Ala Ala Thr Thr Thr Thr Thr Cys
Thr Ala Cys Thr 1640 1645 1650 Gly Thr Ala Ala Thr Thr Cys Ala Ala
Cys Ala Cys Ala Ala Cys 1655 1660 1665 Thr Gly Thr Thr Thr Ala Ala
Thr Ala Gly Thr Ala Cys Thr Thr 1670 1675 1680 Gly Gly Ala Ala Thr
Gly Thr Thr Ala Cys Thr Gly Ala Ala Gly 1685 1690 1695 Ala Gly Thr
Cys Ala Ala Ala Thr Ala Ala Cys Ala Cys Thr Gly 1700 1705 1710 Thr
Ala Gly Ala Ala Ala Ala Thr Ala Ala Cys Ala Cys Ala Ala 1715 1720
1725 Thr Cys Ala Cys Ala Cys Thr Cys Cys Cys Ala Thr Gly Cys Ala
1730 1735 1740 Gly Ala Ala Thr Ala Ala Ala Ala Cys Ala Gly Cys Thr
Ala Gly 1745 1750 1755 Cys Ala Ala Thr Gly Thr Ala Thr Gly Cys Cys
Cys Cys Thr Cys 1760 1765 1770 Cys Cys Ala Thr Cys Ala Gly Ala Gly
Gly Ala Cys Ala Ala Ala 1775 1780 1785 Thr Thr Ala Gly Ala Thr Gly
Thr Thr Cys Ala Thr Cys Ala Ala 1790 1795 1800 Ala Thr Ala Thr Thr
Ala Cys Ala Gly Gly Gly Cys Thr Gly Cys 1805 1810 1815 Thr Ala Thr
Thr Ala Ala Cys Ala Ala Gly Ala Gly Ala Thr Gly 1820 1825 1830 Gly
Thr Gly Gly Thr Cys Cys Ala Gly Ala Gly Gly Ala Cys Ala 1835 1840
1845 Ala Cys Ala Ala Gly Ala Cys Cys Gly Ala Gly Gly Thr Cys Thr
1850 1855 1860 Thr Cys Ala Gly Ala Cys Cys Thr Gly Gly Ala Gly Gly
Ala Gly 1865 1870 1875 Gly Ala Gly Ala Thr Ala Thr Gly Ala Gly Gly
Gly Ala Cys Ala 1880 1885 1890 Ala Thr Thr Gly Gly Ala Gly Ala Ala
Gly Thr Gly Ala Ala Thr 1895 1900 1905 Thr Ala Thr Ala Thr Ala Ala
Ala Thr Ala Thr Ala Ala Ala Gly 1910 1915 1920 Thr Ala Gly Thr Ala
Ala Ala Ala Ala Thr Thr Gly Ala Ala Cys 1925 1930 1935 Cys Ala Thr
Thr Ala Gly Gly Ala Gly Thr Ala Gly Cys Ala Cys 1940 1945 1950 Cys
Cys Ala Cys Cys Ala Ala Gly Gly Cys Ala Ala Ala Gly Ala 1955 1960
1965 Gly Ala Thr Gly Ala Cys Thr Ala Gly Thr Cys Gly Cys Gly Gly
1970 1975 1980 Cys Cys Gly Cys Thr Thr Thr Cys Gly Ala Ala Thr Cys
Thr Ala 1985 1990 1995 Gly Ala 2000 <210> SEQ ID NO 73
<211> LENGTH: 665 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 73 Ile Ile His
Thr Val Pro Pro Ser Gly Ala Asp Pro Gly Pro Lys Arg 1 5 10 15 Ala
Glu Phe Lys Gly Leu Arg Arg Gln Gln Lys Gln Gly Ile Ile Leu 20 25
30 Leu Thr Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Val
35 40 45 Leu Ala Gln Lys Leu Pro Gly Asn Asp Asn Asn Ser Glu Phe
Ile Thr 50 55 60 Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala
Gly Phe Phe Leu 65 70 75 80 Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser
Leu Asp Ser Trp Trp Thr 85 90 95 Ser Leu Asn Phe Leu Gly Gly Ser
Pro Val Cys Leu Gly Gln Asn Ser 100 105 110 Gln Ser Pro Thr Ser Asn
His Ser Pro Thr Ser Cys Pro Pro Ile Cys 115 120 125 Pro Gly Tyr Arg
Trp Met Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe 130 135 140 Ile Leu
Leu Leu Cys Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln 145 150 155
160 Gly Met Leu Pro Val Cys Pro Leu Ile Pro Gly Ser Thr Thr Thr Ser
165 170 175 Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro Ala Gln Gly Asn
Ser Lys 180 185 190 Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly
Asn Cys Thr Cys 195 200 205 Ile Pro Ile Pro Ser Ser Trp Ala Phe Ala
Lys Tyr Leu Trp Glu Trp 210 215 220 Ala Ser Val Arg Phe Ser Trp Leu
Ser Leu Leu Val Pro Phe Val Gln 225 230 235 240 Trp Phe Val Gly Leu
Ser Pro Thr Val Trp Leu Ser Ala Ile Trp Met 245 250 255 Met Trp Tyr
Trp Gly Pro Ser Leu Tyr Ser Ile Val Ser Pro Phe Ile 260 265 270 Pro
Leu Leu Pro Ile Phe Phe Cys Leu Trp Val Tyr Ile Gly Val Pro 275 280
285 Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys
290 295 300 Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala
Cys Val 305 310 315 320 Pro Thr Asp Pro Asn Pro Gln Glu Val Val Leu
Val Asn Val Thr Glu 325 330 335 Asn Phe Asn Met Trp Lys Asn Asp Met
Val Glu Gln Met His Glu Asp 340 345 350 Ile Ile Ser Leu Trp Asp Gln
Ser Leu Lys Pro Cys Val Lys Leu Thr 355 360 365 Pro Leu Ser Val Gln
Ala Cys Pro Lys Val Ser Phe Glu Pro Ile Pro 370 375 380 Ile His Tyr
Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn Asn 385 390 395 400
Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gln 405
410 415 Cys Thr His Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu
Asn 420 425 430 Gly Ser Leu Ala Glu Glu Glu Val Val Ile Arg Ser Val
Asn Phe Thr 435 440 445 Asp Asn Ala Lys Thr Ile Ile Val Gln Leu Asn
Thr Ser Val Glu Ile 450 455 460 Asn Cys Thr Arg Pro Ser Val Asn Phe
Thr Asp Asn Ala Lys Thr Ile 465 470 475 480 Ile Val Gln Leu Asn Thr
Ser Val Glu Ile Asn Cys Thr Arg Pro Met 485 490 495 Arg Gln Ala His
Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr Leu 500 505 510 Lys Gln
Ile Ala Ser Lys Leu Arg Glu Gln Phe Gly Asn Asn Lys Thr 515 520 525
Ile Ile Phe Lys Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Thr His 530
535 540 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gln
Leu 545 550 555 560 Phe Asn Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr
Glu Gly Ser Asn 565 570 575 Asn Thr Glu Gly Ser Asp Thr Ile Thr Leu
Pro Cys Arg Ile Lys Gln 580 585 590 Ser Ile Ala Met Tyr Ala Pro Pro
Ile Ser Gly Gln Ile Arg Cys Ser 595 600 605 Ser Asn Ile Thr Gly Leu
Leu Leu Thr Arg Asp Gly Gly Asn Ser Asn 610 615 620 Asn Glu Ser Glu
Ile Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn 625 630 635 640 Trp
Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu 645 650
655 Gly Val Ala Pro Thr Lys Ala Lys Arg 660 665 <210> SEQ ID
NO 74 <211> LENGTH: 2000 <212> TYPE: DNA <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 74
ggattattca taccgtccca ccatcgggcg cggatcccgg tccgaagcgc gcggaattca
60 aaggcctacg tcgacagcaa aagcagggga taattctatt aaccatgaag
actatcattg 120 ctttgagcta cattttatgt ctggttctcg ctcaaaaact
tcccggaaat gacaacaaca 180 gcgaattcat cacctccggc ttcctgggcc
ccctgctggt gctgcaggcc ggcttcttcc 240 tgctgacccg catcctgacc
atcccccagt ccctggactc ctggtggacc tccctgaact 300 tcctgggcgg
ctcccccgtg tgcctgggcc agaactccca gtcccccacc tccaaccact 360
cccccacctc ctgccccccc atctgccccg gctaccgctg gatgtgcctg cgccgcttca
420 tcatcttcct gttcatcctg ctgctgtgcc tgatcttcct gctggtgctg
ctggactacc 480 agggcatgct gcccgtgtgc cccctgatcc ccggctccac
caccacctcc accggcccct 540 gcaagacctg caccaccccc gcccagggca
actccaagtt cccctcctgc tgctgcacca 600 agcccaccga cggcaactgc
acctgcatcc ccatcccctc ctcctgggcc ttcgccaagt 660 acctgtggga
gtgggcctcc gtgcgcttct cctggctgtc cctgctggtg cccttcgtgc 720
agtggttcgt gggcctgtcc cccaccgtgt ggctgtccgc catctggatg atgtggtact
780 ggggcccctc cctgtactcc atcgtgtccc ccttcatccc cctgctgccc
atcttcttct 840 gcctgtgggt gtacatcggg gtacctgtgt ggaaggaagc
aaccaccact ctattttgtg 900 catcagatgc taaagcatat gatacagagg
tacataatgt ttgggccaca catgcctgtg 960 tacccacaga ccccaaccca
caagaagtag tattggtaaa tgtgacagaa aattttaaca 1020 tgtggaaaaa
tgacatggta gaacagatgc atgaggatat aatcagttta tgggatcaaa 1080
gcctaaagcc atgtgtaaaa ttaaccccac tctcggtcca ggcctgtcca aaggtatcct
1140 ttgagccaat tcccatacat tattgtgccc cggctggttt tgcgattcta
aaatgtaata 1200 ataagacgtt caatggaaca ggaccatgta caaatgtcag
cacagtacaa tgtacacatg 1260 gaattaggcc agtagtatca actcaactgc
tgttaaatgg cagtctagca gaagaagagg 1320 tagtaattag atctgtcaat
ttcacggaca atgctaaaac cataatagta cagctgaaca 1380 catctgtaga
aattaattgt acaagaccct ctgtcaattt cacggacaat gctaaaacca 1440
taatagtaca gctgaacaca tctgtagaaa ttaattgtac aagacccatg agacaagcac
1500 attgtaacat tagtagagca aaatggaata acactttaaa acagatagct
agcaaattaa 1560 gagaacaatt tggaaataat aaaacaataa tctttaagca
atcctcagga ggggacccag 1620 aaattgtaac gcacagtttt aattgtggag
gggaattttt ctactgtaat tcaacacaac 1680 tgtttaatag tacttggttt
aatagtactt ggagtactga agggtcaaat aacactgaag 1740 gaagtgacac
aatcaccctc ccatgcagaa taaaacaatc gatagcaatg tatgcccctc 1800
ccatcagtgg acaaattaga tgttcatcaa atattacagg gctgctatta acaagagatg
1860 gtggtaatag caacaatgag tccgagatct tcagacctgg aggaggagat
atgagggaca 1920 attggagaag tgaattatat aaatataaag tagtaaaaat
tgaaccatta ggagtagcac 1980 ccaccaaggc aaagagataa 2000 <210>
SEQ ID NO 75 <211> LENGTH: 50 <212> TYPE: DNA
<213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 75 cggcggccgc accggtcgcc accatggccc
agtccaagca cggcctgacc 50 <210> SEQ ID NO 76 <211>
LENGTH: 47 <212> TYPE: DNA <213> ORGANISM: Artificial
sequence <220> FEATURE: <223> OTHER INFORMATION:
Synthetic neucleic acid primer. <400> SEQUENCE: 76 tggcggccgc
tctagatccg gtggatcccg ggcccgcggt accgtcg 47 <210> SEQ ID NO
77 <211> LENGTH: 366 <212> TYPE: PRT <213>
ORGANISM: Artificial sequence <220> FEATURE: <223>
OTHER INFORMATION: Recombinant antigenic insert peptide construct.
<400> SEQUENCE: 77 Pro Gln Gly Ala Arg Met Ala Ser Thr Thr
Pro Ile Thr Met Glu Asp 1 5 10 15 Leu Gln Lys Ala Leu Glu Ala Gln
Ser Arg Ala Leu Arg Ala Asp Leu 20 25 30 Ala Ala Gly Ala Ser Gln
Ser Arg Arg Pro Arg Pro Pro Arg Gln Arg 35 40 45 Asp Ser Ser Thr
Ser Gly Asp Asp Ser Gly Arg Asp Ser Gly Gly Pro 50 55 60 Arg Arg
Arg Arg Gly Asn Arg Gly Arg Gly Gln Arg Arg Asp Trp Ser 65 70 75 80
Arg Ala Pro Pro Pro Pro Glu Glu Arg Gln Glu Ser Arg Ser Gln Thr 85
90 95 Pro Ala Pro Lys Pro Ser Arg Ala Pro Pro Gln Gln Pro Gln Pro
Pro 100 105 110 Arg Met Gln Thr Gly Arg Gly Gly Ser Ala Pro Arg Pro
Glu Leu Gly 115 120 125 Pro Pro Thr Asn Pro Phe Gln Ala Ala Val Ala
Arg Gly Leu Arg Pro 130 135 140 Pro Leu His Asp Pro Asp Thr Glu Ala
Pro Thr Glu Ala Cys Val Thr 145 150 155 160 Ser Trp Leu Trp Ser Glu
Gly Glu Gly Ala Val Phe Tyr Arg Val Asp 165 170 175 Leu His Phe Thr
Asn Leu Gly Thr Pro Pro Leu Asp Glu Asp Gly Arg 180 185 190 Trp Asp
Pro Ala Leu Met Tyr Asn Pro Cys Gly Pro Glu Pro Pro Ala 195 200 205
His Val Val Arg Ala Tyr Asn Gln Pro Ala Gly Asp Val Arg Gly Val 210
215 220 Trp Gly Lys Gly Glu Arg Thr Tyr Ala Glu Gln Asp Phe Arg Val
Gly 225 230 235 240 Gly Thr Arg Trp His Arg Leu Leu Arg Met Pro Val
Arg Gly Leu Asp 245 250 255 Gly Asp Ser Ala Pro Leu Pro Pro Tyr Thr
Thr Glu Arg Ile Glu Thr 260 265 270 Arg Ser Ala Arg His Pro Trp Arg
Ile Arg Phe Gly Ala Pro Gln Ala 275 280 285 Phe Leu Ala Gly Leu Leu
Leu Ala Thr Val Ala Val Gly Thr Ala Arg 290 295 300 Ala Gly Leu Gln
Pro Arg Ala Asp Met Ala Ala Pro Pro Thr Leu Pro 305 310 315 320 Arg
Ser Ala Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys 325 330
335 Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr
340 345 350 Ile Arg Leu Phe Ile Asp Ala Ser Thr Arg Ser Ala Arg His
355 360 365 <210> SEQ ID NO 78 <211> LENGTH: 367
<212> TYPE: PRT <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Recombinant
antigenic insert peptide construct. <400> SEQUENCE: 78 Asp
Ser Ala Pro Leu Pro Pro His Thr Thr Glu Arg Ile Glu Thr Arg 1 5 10
15 Ser Ala Arg His Pro Trp Arg Ile Arg Phe Gly Ala Pro Gln Ala Phe
20 25 30 Leu Ala Gly Leu Leu Leu Ala Thr Val Ala Val Gly Thr Ala
Arg Ala 35 40 45 Gly Pro Arg Ser Ala Gln Glu Lys Asn Glu Lys Glu
Leu Leu Glu Leu 50 55 60 Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe
Asp Ile Thr Asn Trp Leu 65 70 75 80 Trp Tyr Ile Arg Leu Phe Ile Asp
Ala Ser Ala Gly Leu Gln Pro Arg 85 90 95 Ala Asp Met Ala Ala Pro
Pro Thr Leu Pro Gln Pro Pro Cys Ala His 100 105 110 Gly Gln His Tyr
Gly His His His His Gln Leu Pro Phe Leu Gly His 115 120 125 Asp Gly
His His Gly Gly Thr Leu Arg Val Gly Gln His Tyr Arg Asn 130 135 140
Ala Ser Asp Val Leu Pro Gly His Trp Leu Gln Gly Gly Trp Gly Cys 145
150 155 160 Tyr Asn Leu Ser Asp Trp His Gln Gly Thr His Val Cys His
Thr Lys 165 170 175 His Met Asp Phe Trp Cys Val Glu His Asp Arg Pro
Pro Pro Ala Thr 180 185 190 Pro Thr Pro Leu Thr Thr Ala Ala Asn Ser
Thr Thr Ala Ala Thr Pro 195 200 205 Ala Thr Ala Pro Ala Pro Cys His
Ala Gly Leu Asn Asp Ser Cys Gly 210 215 220 Gly Phe Leu Ser Gly Cys
Gly Pro Met Arg Leu Arg His Gly Ala Asp 225 230 235 240 Thr Arg Cys
Gly Arg Leu Ile Cys Gly Leu Ser Thr Thr Ala Gln Tyr 245 250 255 Pro
Pro Thr Arg Phe Gly Cys Ala Met Arg Trp Gly Leu Pro Pro Trp 260 265
270 Glu Leu Val Val Leu Thr Ala Arg Pro Glu Asp Gly Trp Thr Cys Arg
275 280 285 Gly Val Pro Ala His Pro Gly Ala Arg Cys Pro Glu Leu Val
Ser Pro 290 295 300 Met Gly Arg Ala Thr Cys Ser Pro Ala Ser Ala Leu
Trp Leu Ala Thr 305 310 315 320 Ala Asn Ala Leu Ser Leu Asp His Ala
Leu Ala Ala Phe Val Leu Leu 325 330 335 Val Pro Trp Val Leu Ile Phe
Met Val Cys Arg Arg Ala Cys Arg Arg 340 345 350 Arg Gly Ala Ala Ala
Ala Leu Thr Ala Val Val Leu Gln Gly Tyr 355 360 365 <210> SEQ
ID NO 79 <211> LENGTH: 367 <212> TYPE: PRT <213>
ORGANISM: Artificial sequence <220> FEATURE: <223>
OTHER INFORMATION: Recombinant antigenic insert peptide construct.
<400> SEQUENCE: 79 Ala Gly Leu Leu Leu Ala Thr Val Ala Val
Gly Thr Ala Arg Ala Gly 1 5 10 15 Leu Gln Pro Arg Ala Asp Met Ala
Ala Pro Pro Thr Leu Pro Gln Pro 20 25 30 Pro Cys Ala His Gly Gln
His Tyr Gly His His His His Gln Leu Pro 35 40 45 Phe Leu Gly His
Asp Gly His His Gly Gly Thr Leu Arg Val Gly Gln 50 55 60 His Tyr
Arg Asn Ala Ser Asp Val Leu Pro Gly His Trp Leu Gln Gly 65 70 75 80
Gly Trp Gly Cys Tyr Asn Leu Ser Asp Trp His Gln Gly Thr His Val 85
90 95 Cys His Thr Lys His Met Asp Phe Trp Cys Val Glu His Asp Arg
Pro 100 105 110 Pro Pro Ala Thr Pro Thr Pro Leu Thr Thr Ala Ala Asn
Ser Thr Thr 115 120 125 Ala Ala Thr Pro Ala Thr Ala Pro Ala Pro Cys
His Ala Gly Leu Asn 130 135 140 Asp Ser Cys Gly Gly Phe Leu Ser Gly
Cys Gly Pro Met Arg Leu Arg 145 150 155 160 His Gly Ala Asp Thr Arg
Cys Gly Arg Leu Ile Cys Gly Leu Ser Thr 165 170 175 Thr Ala Gln Tyr
Pro Pro Thr Arg Phe Gly Cys Ala Met Arg Trp Gly 180 185 190 Leu Pro
Pro Trp Glu Leu Val Val Leu Thr Ala Arg Pro Glu Asp Gly 195 200 205
Trp Thr Cys Arg Gly Val Pro Ala His Pro Gly Ala Arg Cys Pro Glu 210
215 220 Leu Val Ser Pro Met Gly Arg Ala Thr Cys Ser Pro Ala Ser Ala
Leu 225 230 235 240 Trp Leu Ala Thr Ala Asn Ala Leu Ser Leu Asp His
Ala Leu Ala Ala 245 250 255 Phe Val Leu Leu Val Pro Trp Val Leu Ile
Phe Met Val Cys Arg Arg 260 265 270 Ala Cys Arg Arg Arg Gly Ala Ala
Ala Ala Leu Thr Ala Val Val Leu 275 280 285 Gln Gly Pro Arg Ser Ala
Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu 290 295 300 Leu Asp Lys Trp
Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp 305 310 315 320 Leu
Trp Tyr Ile Arg Leu Phe Ile Asp Ala Ser Arg Arg Arg Gly Ala 325 330
335 Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala
340 345 350 Tyr Gly Glu Glu Ala Phe Thr Tyr Leu Cys Thr Ala Pro Gly
Cys 355 360 365 <210> SEQ ID NO 80 <211> LENGTH: 566
<212> TYPE: PRT <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Recombinant
antigenic insert peptide construct. <400> SEQUENCE: 80 Met
Val Cys Arg Arg Ala Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu 1 5 10
15 Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly Glu Ala
20 25 30 Pro Arg Ser Ala Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu
Leu Asp 35 40 45 Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr
Asn Trp Leu Trp 50 55 60 Tyr Ile Arg Leu Phe Ile Asp Ala Ser Leu
Gln Gly Tyr Asn Pro Pro 65 70 75 80 Ala Tyr Gly Glu Glu Ala Phe Thr
Tyr Leu Cys Thr Ala Pro Gly Cys 85 90 95 Ala Thr Gln Ala Pro Val
Pro Val Arg Leu Ala Gly Val Arg Phe Glu 100 105 110 Ser Lys Ile Val
Asp Gly Gly Cys Phe Ala Pro Trp Asp Leu Glu Ala 115 120 125 Thr Gly
Ala Cys Ile Cys Glu Ile Pro Thr Asp Val Ser Cys Glu Gly 130 135 140
Leu Gly Ala Trp Val Pro Ala Ala Pro Cys Ala Arg Ile Trp Asn Gly 145
150 155 160 Thr Gln Arg Ala Cys Thr Phe Trp Ala Val Asn Ala Tyr Ser
Ser Gly 165 170 175 Gly Tyr Ala Gln Leu Ala Ser Tyr Phe Asn Pro Gly
Gly Ser Tyr Tyr 180 185 190 Lys Gln Tyr His Pro Thr Ala Cys Glu Val
Glu Pro Ala Phe Gly His 195 200 205 Ser Asp Ala Ala Cys Trp Gly Phe
Pro Thr Asp Thr Val Met Ser Val 210 215 220 Phe Ala Leu Ala Ser Tyr
Val Gln His Pro His Lys Thr Val Arg Val 225 230 235 240 Lys Phe His
Thr Glu Thr Arg Thr Val Trp Gln Leu Ser Val Ala Gly 245 250 255 Val
Ser Cys Asn Val Thr Thr Glu His Pro Phe Cys Asn Thr Pro His 260 265
270 Gly Gln Leu Glu Val Gln Val Pro Pro Asp Pro Gly Asp Leu Val Glu
275 280 285 Tyr Ile Met Asn Tyr Thr Gly Asn Gln Gln Ser Arg Trp Gly
Leu Gly 290 295 300 Ser Pro Asn Cys His Gly Pro Asp Trp Ala Ser Pro
Val Cys Gln Arg 305 310 315 320 His Ser Pro Asp Cys Ser Arg Leu Val
Gly Ala Thr Pro Glu Arg Pro 325 330 335 Arg Leu Arg Leu Val Asp Ala
Asp Asp Pro Leu Leu Arg Thr Ala Pro 340 345 350 Gly Pro Gly Glu Val
Trp Val Thr Pro Val Ile Gly Ser Gln Ala Arg 355 360 365 Lys Cys Gly
Leu His Ile Arg Ala Gly Pro Tyr Gly His Ala Thr Val 370 375 380 Glu
Met Pro Glu Trp Ile His Ala His Thr Thr Ser Asp Pro Trp His 385 390
395 400 Pro Pro Gly Pro Leu Gly Leu Lys Phe Lys Thr Val Arg Pro Val
Ala 405 410 415 Leu Pro Arg Thr Leu Ala Pro Pro Arg Asn Val Arg Val
Thr Gly Cys 420 425 430 Tyr Gln Cys Gly Thr Pro Ala Leu Val Glu Gly
Leu Ala Pro Gly Gly 435 440 445 Gly Asn Cys His Leu Thr Val Asn Gly
Glu Asp Leu Gly Ala Val Pro 450 455 460 Pro Gly Lys Phe Val Thr Ala
Ala Leu Leu Asn Thr Pro Pro Pro Tyr 465 470 475 480 Gln Val Ser Cys
Gly Gly Glu Ser Asp Arg Ala Thr Ala Arg Val Ile 485 490 495 Asp Pro
Ala Ala Gln Ser Phe Thr Gly Val Val Tyr Gly Thr His Thr 500 505 510
Thr Ala Val Ser Glu Thr Arg Gln Thr Trp Ala Glu Trp Ala Ala Ala 515
520 525 His Trp Trp Gln Leu Thr Leu Gly Ala Ile Cys Ala Leu Pro Leu
Ala 530 535 540 Gly Leu Leu Ala Cys Cys Ala Lys Cys Leu Tyr Tyr Leu
Arg Gly Ala 545 550 555 560 Ile Ala Pro Arg Trp Ala 565 <210>
SEQ ID NO 81 <211> LENGTH: 34 <212> TYPE: PRT
<213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert
peptide. <400> SEQUENCE: 81 Gln Glu Lys Asn Glu Lys Glu Leu
Leu Glu Leu Asp Lys Trp Ala Ser 1 5 10 15 Leu Trp Asn Trp Phe Asp
Ile Thr Asn Trp Leu Trp Tyr Ile Arg Leu 20 25 30 Phe Ile
<210> SEQ ID NO 82 <211> LENGTH: 39 <212> TYPE:
PRT <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert
peptide. <400> SEQUENCE: 82 Arg Glu Gly Ser Gln Lys Ile Leu
Ser Val Leu Ala Pro Leu Val Pro 1 5 10 15 Thr Gly Ser Glu Asn Leu
Lys Ser Leu Tyr Asn Thr Val Ser Val Ile 20 25 30 Trp Ser Ile His
Ala Glu Asp 35 <210> SEQ ID NO 83 <211> LENGTH: 38
<212> TYPE: PRT <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Recombinant
antigenic insert peptide. <400> SEQUENCE: 83 Phe Gln Ala Leu
Ser Glu Gly Cys Thr Pro Tyr Asp Ile Asn Gln Met 1 5 10 15 Leu Asn
Cys Val Gly Asp His Gln Ala Ala Met Gln Ile Ile Arg Asp 20 25 30
Ile Ile Asn Glu Glu Ala 35 <210> SEQ ID NO 84 <211>
LENGTH: 65 <212> TYPE: PRT <213> ORGANISM: Artificial
sequence <220> FEATURE: <223> OTHER INFORMATION:
Recombinant antigenic insert peptide. <400> SEQUENCE: 84 Leu
Pro Leu Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Leu Ile Glu 1 5 10
15 Glu Lys Lys Phe Gly Ala Glu Val Val Pro Gly Phe Gln Ala Leu Ser
20 25 30 Glu Gly Cys Thr Pro Tyr Asp Ile Asn Gln Met Leu Asn Cys
Val Gly 35 40 45 Asp His Gln Ala Ala Met Gln Ile Ile Arg Asp Ile
Ile Asn Glu Glu 50 55 60 Ala 65 <210> SEQ ID NO 85
<211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM:
Artificial sequence <220> FEATURE: <223> OTHER
INFORMATION: Recombinant antigenic insert peptide. <400>
SEQUENCE: 85 Leu Pro Leu Ser Pro Arg Thr Leu Asn Ala Trp Val Lys
Leu Ile Glu 1 5 10 15 Glu Lys Lys Phe Gly Ala Glu Val Val Pro Gly
Phe Gln Ala Leu Ser 20 25 30 Glu Gly Cys Thr Pro Tyr Asp Ile Asn
Gln Met Leu Asn Cys Val Gly 35 40 45 Asp His Gln Ala Ala Met Gln
Ile Ile Arg Asp Ile Ile Asn Glu Glu 50 55 60 Ala Thr Arg Ser Gln
Lys Ile Leu Ser Val Leu Ala Pro Leu Val Pro 65 70 75 80 Thr
<210> SEQ ID NO 86 <211> LENGTH: 79 <212> TYPE:
PRT <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert
peptide. <400> SEQUENCE: 86 Leu Pro Leu Ser Pro Arg Thr Leu
Asn Ala Trp Val Lys Leu Ile Glu 1 5 10 15 Glu Lys Lys Phe Gly Ala
Glu Val Val Pro Gly Phe Gln Ala Leu Ser 20 25 30 Glu Gly Cys Thr
Pro Tyr Asp Ile Asn Gln Met Leu Asn Cys Val Gly 35 40 45 Asp His
Gln Ala Ala Met Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu 50 55 60
Ala Thr Arg Thr Gly Ser Glu Asn Leu Lys Ser Leu Tyr Asn Thr 65 70
75 <210> SEQ ID NO 87 <211> LENGTH: 87 <212>
TYPE: PRT <213> ORGANISM: Artificial sequence <220>
FEATURE: <223> OTHER INFORMATION: Recombinant antigenic
insert peptide. <400> SEQUENCE: 87 Leu Pro Leu Ser Pro Arg
Thr Leu Asn Ala Trp Val Lys Leu Ile Glu 1 5 10 15 Glu Lys Lys Phe
Gly Ala Glu Val Val Pro Gly Phe Gln Ala Leu Ser 20 25 30 Glu Gly
Cys Thr Pro Tyr Asp Ile Asn Gln Met Leu Asn Cys Val Gly 35 40 45
Asp His Gln Ala Ala Met Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu 50
55 60 Ala Thr Arg His Thr Glu Glu Ala Lys Gln Ile Val Gln Arg His
Leu 65 70 75 80 Val Val Glu Thr Gly Thr Thr 85 <210> SEQ ID
NO 88 <211> LENGTH: 80 <212> TYPE: PRT <213>
ORGANISM: Artificial sequence <220> FEATURE: <223>
OTHER INFORMATION: Recombinant antigenic insert peptide.
<400> SEQUENCE: 88 Val Pro Thr Gly Ser Glu Asn Leu Lys Ser
Leu Tyr Asn Thr Val Thr 1 5 10 15 Arg Val Lys His Thr Glu Glu Ala
Lys Gln Ile Val Gln Arg His Leu 20 25 30 Val Val Glu Thr Gly Thr
Thr Ser Asp Ala Phe Gln Ala Leu Ser Glu 35 40 45 Gly Cys Thr Pro
Tyr Asp Ile Asn Gln Met Leu Asn Cys Val Gly Asp 50 55 60 His Gln
Ala Ala Met Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala 65 70 75 80
<210> SEQ ID NO 89 <211> LENGTH: 19 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 89 Pro Ser Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp
Tyr Ile Arg 1 5 10 15 Leu Asp Ala <210> SEQ ID NO 90
<211> LENGTH: 109 <212> TYPE: PRT <213> ORGANISM:
Artificial sequence <220> FEATURE: <223> OTHER
INFORMATION: Recombinant antigenic insert peptide. <400>
SEQUENCE: 90 Leu Asp Arg Phe Gly Leu Ala Glu Ser Leu Leu Glu Asn
Lys Glu Gly 1 5 10 15 Ser Gln Lys Ile Leu Ser Val Leu Ala Pro Leu
Val Pro Thr Gly Ser 20 25 30 Glu Asn Leu Lys Ser Leu Tyr Asn Thr
Val Thr Arg Val Lys His Thr 35 40 45 Glu Glu Ala Lys Gln Ile Val
Gln Arg His Leu Val Val Glu Thr Gly 50 55 60 Thr Thr Glu Thr Ser
Asp Ala Phe Gln Ala Leu Ser Glu Gly Cys Thr 65 70 75 80 Pro Tyr Asp
Ile Asn Gln Met Leu Asn Cys Val Gly Asp His Gln Ala 85 90 95 Ala
Met Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala 100 105 <210>
SEQ ID NO 91 <211> LENGTH: 134 <212> TYPE: PRT
<213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert
peptide. <400> SEQUENCE: 91 Leu Asp Arg Phe Gly Leu Ala Glu
Ser Leu Leu Glu Asn Lys Glu Gly 1 5 10 15 Ser Gln Lys Ile Leu Ser
Val Leu Ala Pro Leu Val Pro Thr Gly Ser 20 25 30 Glu Asn Leu Lys
Ser Leu Tyr Asn Thr Val Thr Arg Val Lys His Thr 35 40 45 Glu Glu
Ala Lys Gln Ile Val Gln Arg His Leu Val Val Glu Thr Gly 50 55 60
Thr Thr Glu Thr Arg Leu Pro Leu Ser Pro Arg Thr Leu Asn Ala Trp 65
70 75 80 Val Lys Leu Ile Glu Glu Lys Lys Phe Gly Ala Glu Val Val
Pro Gly 85 90 95 Phe Gln Ala Leu Ser Glu Gly Cys Thr Pro Tyr Asp
Ile Asn Gln Met 100 105 110 Leu Asn Cys Val Gly Asp His Gln Ala Ala
Met Gln Ile Ile Arg Asp 115 120 125 Ile Ile Asn Glu Glu Ala 130
<210> SEQ ID NO 92 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 92 Cys Thr Pro Tyr Asp Ile Asn Gln Met 1 5 <210>
SEQ ID NO 93 <211> LENGTH: 9 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 93 Gly Ser Glu Asn Leu Lys Ser Leu Tyr 1 5 <210>
SEQ ID NO 94 <211> LENGTH: 11 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 94 Lys Ile Leu Ser Val Leu Ala Pro Leu Val Pro 1 5 10
<210> SEQ ID NO 95 <211> LENGTH: 16 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 95 Thr Glu Glu Ala Lys Gln Ile Val Gln Arg His Leu Val
Val Glu Thr 1 5 10 15 <210> SEQ ID NO 96 <211> LENGTH:
11 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 96 Met Gln Ile Ile Arg
Asp Ile Ile Asn Glu Glu 1 5 10 <210> SEQ ID NO 97 <211>
LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 97 Thr Arg Ala Asn Ser
Pro Thr Arg Arg 1 5 <210> SEQ ID NO 98 <211> LENGTH: 8
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 98 Asn Ser Pro Thr Arg Arg Glu Leu 1 5
<210> SEQ ID NO 99 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 99 Pro Thr Arg Arg Glu Leu Gln Val Trp 1 5 <210>
SEQ ID NO 100 <211> LENGTH: 9 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 100 Pro Thr Ser Arg Glu Leu Gln Val Trp 1 5 <210>
SEQ ID NO 101 <211> LENGTH: 9 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 101 Ala Gly Ala Glu Arg Gln Gly Thr Leu 1 5 <210>
SEQ ID NO 102 <211> LENGTH: 9 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 102 Phe Ser Phe Pro Gln Ile Thr Leu Trp 1 5 <210>
SEQ ID NO 103 <211> LENGTH: 171 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 103 Leu Asp Arg Phe Gly Leu Ala Glu Ser Leu Leu Glu Asn
Lys Glu Gly 1 5 10 15 Cys Gln Lys Ile Leu Ser Val Leu Ala Pro Leu
Val Pro Thr Gly Ser 20 25 30 Glu Asn Leu Lys Ser Leu Tyr Asn Thr
Val Cys Val Ile Trp Cys Ile 35 40 45 His Ala Glu Glu Lys Val Lys
His Thr Glu Glu Ala Lys Gln Ile Val 50 55 60 Gln Arg His Leu Val
Val Glu Thr Gly Thr Thr Glu Thr Met Pro Lys 65 70 75 80 Thr Ser Arg
Pro Thr Ala Pro Ser Ser Gly Arg Gly Gly Asn Tyr Pro 85 90 95 Val
Gln Gln Ile Gly Gly Asn Tyr Val His Leu Pro Leu Ser Pro Arg 100 105
110 Thr Leu Asn Ala Trp Val Lys Leu Ile Glu Glu Lys Lys Phe Gly Ala
115 120 125 Glu Val Val Pro Gly Phe Gln Ala Leu Ser Glu Gly Cys Thr
Pro Tyr 130 135 140 Asp Ile Asn Gln Met Leu Asn Cys Val Gly Asp His
Gln Ala Ala Met 145 150 155 160 Gln Ile Ile Arg Asp Ile Ile Asn Glu
Glu Ala 165 170 <210> SEQ ID NO 104 <211> LENGTH: 19
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 104 gatgacgagg
cgctcatcc 19 <210> SEQ ID NO 105 <211> LENGTH: 23
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 105 gagtgccgcg
ggcgtccgag tgc 23 <210> SEQ ID NO 106 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 106 cgaactggtg
agccccatgg 20 <210> SEQ ID NO 107 <211> LENGTH: 25
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 107 gatctcgcaa
atgcaggctc cagtg 25 <210> SEQ ID NO 108 <211> LENGTH:
60 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 108 gaagcaccta
ggtcagccca agaaaagaat gaaaaagaat tattggaatt ggataaatgg 60
<210> SEQ ID NO 109 <211> LENGTH: 50 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic oligonucleotide primer
<400> SEQUENCE: 109 tgatctagat gcatctatga atagtcttat
ataccacagc cagtttgtta 50 <210> SEQ ID NO 110 <211>
LENGTH: 57 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic oligonucleotide primer <400> SEQUENCE: 110
gaacagacta gtgcccaaga aaagaatgaa aaagaattat tggaattgga taaatgg 57
<210> SEQ ID NO 111 <211> LENGTH: 59 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic oligonucleotide primer
<400> SEQUENCE: 111 ccagcagatg catcattcca caaacttgcc
catttatcca attccaataa ttctttttc 59 <210> SEQ ID NO 112
<211> LENGTH: 50 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic oligonucleotide primer <400> SEQUENCE:
112 gaacagacta gttggaattg gtttgacata acaaactggc tgtggtatat 50
<210> SEQ ID NO 113 <211> LENGTH: 47 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic oligonucleotide primer
<400> SEQUENCE: 113 ccagcagatg catctagtct tatataccac
agccagtttg ttatgtc 47 <210> SEQ ID NO 114 <211> LENGTH:
54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 114 agatagcgcc
tagggaagga agccaaaaaa tactttcggt cttagctcca ttag 54 <210> SEQ
ID NO 115 <211> LENGTH: 60 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic oligonucleotide primer <400>
SEQUENCE: 115 tggcgatgat gcatcttctg cgtgaattga ccagatgacc
gagacagtat tataaaggct 60 <210> SEQ ID NO 116 <211>
LENGTH: 40 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic oligonucleotide primer <400> SEQUENCE: 116
agatagcgcc taggtttcag gcactgtcag aaggttgcac 40 <210> SEQ ID
NO 117 <211> LENGTH: 41 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic oligonucleotide primer <400>
SEQUENCE: 117 tgtaatgatg catcagcctc ctcgtttata atatctctga t 41
<210> SEQ ID NO 118 <211> LENGTH: 42 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic oligonucleotide primer
<400> SEQUENCE: 118 agatagcgcc taggctgcca ttaagcccga
gaacattaaa tg 42 <210> SEQ ID NO 119 <211> LENGTH: 48
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 119 tggcgatgat
gcatcactag tagcctcctc gtttataata tctctgat 48 <210> SEQ ID NO
120 <211> LENGTH: 48 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic oligonucleotide primer <400>
SEQUENCE: 120 gatagcgcct aggagccaga agatcctgag cgtgctggcc cctctggt
48 <210> SEQ ID NO 121 <211> LENGTH: 47 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic oligonucleotide
primer <400> SEQUENCE: 121 tgcgatgatg catcactagt gggcaccaga
ggggccagca cgctcag 47 <210> SEQ ID NO 122 <211> LENGTH:
45 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 122 gatagcgcct
aggaccggca gcgagaacct gaagagcctg tacaa 45 <210> SEQ ID NO 123
<211> LENGTH: 47 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic oligonucleotide primer <400> SEQUENCE:
123 tgcgatgatg catcactagt gttgtacagg ctcttcaggt tctcgct 47
<210> SEQ ID NO 124 <211> LENGTH: 64 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic oligonucleotide primer
<400> SEQUENCE: 124 gatagcgcct agggtgaagc acaccgagga
ggccaagcag atcgtgcagc gccacctggt 60 ggtg 64 <210> SEQ ID NO
125 <211> LENGTH: 58 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic oligonucleotide primer <400>
SEQUENCE: 125 tgcgatgatg catcactagt ggtgccggtc tccaccacca
ggtggcgctg cacgatct 58 <210> SEQ ID NO 126 <211>
LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: MPERF
insert <400> SEQUENCE: 126 Phe Glu Glu Pro Arg Gln Glu Lys
Asn Glu Lys Glu Leu Leu Glu Leu 1 5 10 15 Asp Lys Trp Ala Ser Leu
Trp Asn Trp Phe Asp Met His Thr Leu Ala 20 25 30 Ala Phe Val Leu
Leu Val Pro Trp Val Leu Ile Phe Met Val Cys Arg 35 40 45 Arg Thr
Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val 50 55 60
Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 65 70 <210> SEQ ID NO
127 <211> LENGTH: 77 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: MPERF insert <400> SEQUENCE: 127 Gly Glu
Glu Pro Arg Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu 1 5 10 15
Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Met His Trp Trp Gln 20
25 30 Leu Thr Gly Ala Thr Cys Ala Leu Pro Leu Ala Gly Leu Leu Ala
Cys 35 40 45 Cys Ala Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala
Ala Leu Thr 50 55 60 Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala
Tyr Gly 65 70 75 <210> SEQ ID NO 128 <211> LENGTH: 19
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: MPERF insert
<400> SEQUENCE: 128 Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu
Leu Asp Lys Trp Ala Ser 1 5 10 15 Leu Trp Asn <210> SEQ ID NO
129 <211> LENGTH: 15 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: MPERE insert <400> SEQUENCE: 129 Trp Asn
Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Arg Leu 1 5 10 15
<210> SEQ ID NO 130 <211> LENGTH: 33 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: MPER insert <400> SEQUENCE:
130 Gln Glu Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu
1 5 10 15 Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Arg
Leu Phe 20 25 30 Ile <210> SEQ ID NO 131 <211> LENGTH:
86 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: MPER-HIVTM
insert <400> SEQUENCE: 131 Gly Glu Glu Pro Arg Gln Glu Lys
Asn Glu Lys Glu Leu Leu Glu Leu 1 5 10 15 Asp Lys Trp Ala Ser Leu
Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu 20 25 30 Trp Tyr Ile Arg
Leu Phe Ile Met Ile Val Gly Gly Leu Ile Gly Leu 35 40 45 Arg Ile
Val Phe Ala Val Leu Ser Ile Val Cys Arg Arg Thr Cys Arg 50 55 60
Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr 65
70 75 80 Asn Pro Pro Ala Tyr Gly 85 <210> SEQ ID NO 132
<211> LENGTH: 221 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: SIV Gag insert (sGag-E2TM amino acids 41-211)
<400> SEQUENCE: 132 Leu Asp Arg Phe Gly Leu Ala Glu Ser Leu
Leu Glu Asn Lys Glu Gly 1 5 10 15 Cys Gln Lys Ile Leu Ser Val Leu
Ala Pro Leu Val Pro Thr Gly Ser 20 25 30 Glu Asn Leu Lys Ser Leu
Tyr Asn Thr Val Cys Val Ile Trp Cys Ile 35 40 45 His Ala Glu Glu
Lys Val Lys His Thr Glu Glu Ala Lys Gln Ile Val 50 55 60 Gln Arg
His Leu Val Val Glu Thr Gly Thr Thr Glu Thr Met Pro Lys 65 70 75 80
Thr Ser Arg Pro Thr Ala Pro Ser Ser Gly Arg Gly Gly Asn Tyr Pro 85
90 95 Val Gln Gln Ile Gly Gly Asn Tyr Val His Leu Pro Leu Ser Pro
Arg 100 105 110 Thr Leu Asn Ala Trp Val Lys Leu Ile Glu Glu Lys Lys
Phe Gly Ala 115 120 125 Glu Val Val Pro Gly Phe Gln Ala Leu Ser Glu
Gly Cys Thr Pro Tyr 130 135 140 Asp Ile Asn Gln Met Leu Asn Cys Val
Gly Asp His Gln Ala Ala Met 145 150 155 160 Gln Ile Ile Arg Asp Ile
Ile Asn Glu Glu Ala Ser Leu Asp Met His 165 170 175 Thr Leu Ala Ala
Phe Val Leu Leu Val Pro Trp Val Leu Ile Phe Met 180 185 190 Val Cys
Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr 195 200 205
Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 210 215 220
<210> SEQ ID NO 133 <211> LENGTH: 184 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: SIV Gag insert (SGag-E2TM, amino
acids 135-271) <400> SEQUENCE: 133 Tyr Pro Val Gln Gln Ile
Gly Gly Asn Tyr Val His Leu Pro Leu Ser 1 5 10 15 Pro Arg Thr Leu
Asn Ala Trp Val Lys Leu Ile Glu Glu Lys Lys Phe 20 25 30 Gly Ala
Glu Val Val Pro Gly Phe Gln Ala Leu Ser Glu Gly Cys Thr 35 40 45
Pro Tyr Asp Ile Asn Gln Met Leu Asn Cys Val Gly Asp His Gln Ala 50
55 60 Ala Met Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala Ala Asp
Trp 65 70 75 80 Asp Leu Gln His Pro Gln Pro Ala Pro Gln Gln Gly Gln
Leu Arg Glu 85 90 95 Pro Ser Gly Ser Asp Ile Ala Gly Thr Thr Ser
Ser Val Asp Glu Gln 100 105 110 Ile Gln Trp Met Tyr Arg Gln Gln Asn
Pro Ile Pro Val Gly Asn Ile 115 120 125 Tyr Arg Arg Trp Ile Gln Leu
Gly Leu Met His Thr Leu Ala Ala Phe 130 135 140 Val Leu Leu Val Pro
Trp Val Leu Ile Phe Met Val Cys Arg Arg Thr 145 150 155 160 Cys Arg
Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val Leu Gln 165 170 175
Gly Tyr Asn Pro Pro Ala Tyr Gly 180 <210> SEQ ID NO 134
<211> LENGTH: 276 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: SIV Gag insert (full p28-sGag-E2TM) <400>
SEQUENCE: 134 Tyr Pro Val Gln Gln Ile Gly Gly Asn Tyr Val His Leu
Pro Leu Ser 1 5 10 15 Pro Arg Thr Leu Asn Ala Trp Val Lys Leu Ile
Glu Glu Lys Lys Phe 20 25 30 Gly Ala Glu Val Val Pro Gly Phe Gln
Ala Leu Ser Glu Gly Cys Thr 35 40 45 Pro Tyr Asp Ile Asn Gln Met
Leu Asn Cys Val Gly Asp His Gln Ala 50 55 60 Ala Met Gln Ile Ile
Arg Asp Ile Ile Asn Glu Glu Ala Ala Asp Trp 65 70 75 80 Asp Leu Gln
His Pro Gln Pro Ala Pro Gln Gln Gly Gln Leu Arg Glu 85 90 95 Pro
Ser Gly Ser Asp Ile Ala Gly Thr Thr Ser Ser Val Asp Glu Gln 100 105
110 Ile Gln Trp Met Tyr Arg Gln Gln Asn Pro Ile Pro Val Gly Asn Ile
115 120 125 Tyr Arg Arg Trp Ile Gln Leu Gly Leu Gln Lys Cys Val Arg
Met Tyr 130 135 140 Asn Pro Thr Asn Ile Leu Asp Val Lys Gln Gly Pro
Lys Glu Pro Phe 145 150 155 160 Gln Ser Tyr Val Asp Arg Phe Tyr Lys
Ser Leu Arg Ala Glu Gln Thr 165 170 175 Asp Ala Ala Val Lys Asn Trp
Met Thr Gln Thr Leu Leu Ile Gln Asn 180 185 190 Ala Asn Pro Asp Cys
Lys Leu Val Leu Lys Gly Leu Gly Val Asn Pro 195 200 205 Thr Leu Glu
Glu Met Leu Thr Ala Cys Gln Gly Val Gly Gly Pro Gly 210 215 220 Gln
Lys Ala Arg Leu Met His Thr Leu Ala Ala Phe Val Leu Leu Val 225 230
235 240 Pro Trp Val Leu Ile Phe Met Val Cys Arg Arg Thr Cys Arg Arg
Arg 245 250 255 Gly Ala Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly
Tyr Asn Pro 260 265 270 Pro Ala Tyr Gly 275 <210> SEQ ID NO
135 <211> LENGTH: 304 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: SIV Gag insert (fullp28 plus-sGag-E2TM)
<400> SEQUENCE: 135 Tyr Pro Val Gln Gln Ile Gly Gly Asn Tyr
Val His Leu Pro Leu Ser 1 5 10 15 Pro Arg Thr Leu Asn Ala Trp Val
Lys Leu Ile Glu Glu Lys Lys Phe 20 25 30 Gly Ala Glu Val Val Pro
Gly Phe Gln Ala Leu Ser Glu Gly Cys Thr 35 40 45 Pro Tyr Asp Ile
Asn Gln Met Leu Asn Cys Val Gly Asp His Gln Ala 50 55 60 Ala Met
Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala Ala Asp Trp 65 70 75 80
Asp Leu Gln His Pro Gln Pro Ala Pro Gln Gln Gly Gln Leu Arg Glu 85
90 95 Pro Ser Gly Ser Asp Ile Ala Gly Thr Thr Ser Ser Val Asp Glu
Gln 100 105 110 Ile Gln Trp Met Tyr Arg Gln Gln Asn Pro Ile Pro Val
Gly Asn Ile 115 120 125 Tyr Arg Arg Trp Ile Gln Leu Gly Leu Gln Lys
Cys Val Arg Met Tyr 130 135 140 Asn Pro Thr Asn Ile Leu Asp Val Lys
Gln Gly Pro Lys Glu Pro Phe 145 150 155 160 Gln Ser Tyr Val Asp Arg
Phe Tyr Lys Ser Leu Arg Ala Glu Gln Thr 165 170 175 Asp Ala Ala Val
Lys Asn Trp Met Thr Gln Thr Leu Leu Ile Gln Asn 180 185 190 Ala Asn
Pro Asp Cys Lys Leu Val Leu Lys Gly Leu Gly Val Asn Pro 195 200 205
Thr Leu Glu Glu Met Leu Thr Ala Cys Gln Gly Val Gly Gly Pro Gly 210
215 220 Gln Lys Ala Arg Leu Met Ala Glu Ala Leu Lys Glu Ala Leu Ala
Pro 225 230 235 240 Val Pro Ile Pro Phe Ala Ala Ala Gln Gln Arg Gly
Pro Arg Lys Pro 245 250 255 Ile Met His Thr Leu Ala Ala Phe Val Leu
Leu Val Pro Trp Val Leu 260 265 270 Ile Phe Met Val Cys Arg Arg Thr
Cys Arg Arg Arg Gly Ala Ala Ala 275 280 285 Ala Leu Thr Ala Val Val
Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 290 295 300 <210> SEQ
ID NO 136 <211> LENGTH: 367 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: variant rubella construct <400> SEQUENCE:
136 Gly Leu Gln Pro Arg Ala Asp Met Ala Ala Pro Pro Thr Leu Pro Gln
1 5 10 15 Pro Pro Arg Ala His Gly Gln His Tyr Gly His His His His
Gln Leu 20 25 30 Pro Phe Leu Gly His Asp Gly His His Gly Gly Thr
Leu Arg Val Gly 35 40 45 Gln His Tyr Arg Asn Ala Ser Asp Val Leu
Pro Gly His Trp Leu Gln 50 55 60 Gly Gly Trp Gly Cys Tyr Asn Leu
Ser Asp Trp His Gln Gly Thr His 65 70 75 80 Val Cys His Thr Lys His
Met Asp Phe Trp Cys Val Glu His Ala Arg 85 90 95 Pro Pro Pro Ala
Thr Pro Thr Pro Leu Thr Thr Ala Ala Asn Ser Thr 100 105 110 Thr Ala
Ala Thr Pro Ala Thr Ala Pro Ala Pro Cys His Ala Gly Leu 115 120 125
Asn Asp Ser Cys Gly Gly Phe Leu Ser Gly Cys Gly Pro Met Arg Leu 130
135 140 Arg His Gly Ala Asp Thr Arg Cys Gly Arg Leu Ile Cys Gly Leu
Ser 145 150 155 160 Thr Thr Ala Gln Tyr Pro Pro Thr Arg Phe Gly Cys
Ala Met Arg Trp 165 170 175 Gly Leu Pro Pro Trp Glu Leu Val Val Leu
Thr Ala Arg Pro Glu Asp 180 185 190 Gly Trp Thr Cys Arg Gly Val Pro
Ala His Pro Gly Ala Arg Cys Pro 195 200 205 Glu Leu Val Ser Pro Met
Gly Arg Ala Thr Cys Ser Pro Ala Ser Ala 210 215 220 Leu Trp Leu Ala
Thr Ala Asn Ala Leu Ser Leu Asp His Ala Leu Ala 225 230 235 240 Ala
Phe Val Leu Leu Val Pro Trp Val Leu Ile Phe Met Val Cys Arg 245 250
255 Arg Ala Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val
260 265 270 Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly Glu Glu Pro Arg
Gln Glu 275 280 285 Lys Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp
Ala Ser Leu Trp 290 295 300 Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp
Tyr Ile Arg Leu Phe Ile 305 310 315 320 Met Ile Val Gly Gly Leu Ile
Gly Leu Arg Ile Val Phe Ala Val Leu 325 330 335 Ser Ile Val Cys Arg
Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala 340 345 350 Leu Thr Ala
Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 355 360 365
<210> SEQ ID NO 137 <211> LENGTH: 142 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: MPER construct <400> SEQUENCE:
137 Pro Arg Asn Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Met Leu
1 5 10 15 Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln Ala Arg Gly
Gly Gly 20 25 30 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Trp Met Glu Trp 35 40 45 Glu Arg Glu Ile Asp Asn Tyr Thr Asp Tyr
Ile Tyr Asp Leu Leu Glu 50 55 60 Lys Ser Gln Thr Gln Gln Glu Lys
Asn Glu Lys Glu Leu Leu Glu Leu 65 70 75 80 Asp Lys Trp Ala Ser Leu
Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu 85 90 95 Trp Tyr Ile Arg
Leu Phe Ile Met Ile Val Gly Gly Leu Ile Gly Leu 100 105 110 Arg Ile
Val Phe Ala Val Leu Ser Ile Val Cys Arg Arg Thr Cys Arg 115 120 125
Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val Leu Gln 130 135 140
<210> SEQ ID NO 138 <211> LENGTH: 220 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: HIV Gag insert <400> SEQUENCE:
138 Leu Glu Arg Phe Ala Val Asn Pro Ser Leu Leu Glu Thr Ser Glu Gly
1 5 10 15 Cys Arg Gln Ile Leu Gly Gln Leu Gln Ser Ser Leu Gln Thr
Gly Ser 20 25 30 Glu Glu Leu Lys Ser Leu Tyr Asn Thr Val Ala Thr
Leu Tyr Cys Val 35 40 45 His Gln Arg Ile Glu Val Lys Asp Thr Lys
Glu Ala Leu Asp Lys Ile 50 55 60 Glu Glu Glu Gln Asn Lys Ser Lys
Lys Lys Ala Gln Gln Ala Ala Ala 65 70 75 80 Asp Thr Gly Asn Ser Ser
Gln Val Ser Gln Asn Tyr Pro Ile Val Gln 85 90 95 Asn Ile Gln Gly
Gln Met Val His Gln Ala Ile Ser Pro Arg Thr Leu 100 105 110 Asn Ala
Trp Val Lys Val Val Glu Glu Lys Ala Phe Ser Pro Glu Val 115 120 125
Ile Pro Met Phe Ser Ala Leu Ser Glu Gly Ala Thr Pro Gln Asp Leu 130
135 140 Asn Thr Met Leu Asn Thr Val Gly Gly His Gln Ala Ala Met Gln
Met 145 150 155 160 Leu Lys Glu Thr Ile Asn Glu Glu Ala Ala Glu Trp
Asp Met His Thr 165 170 175 Leu Ala Ala Phe Val Leu Leu Val Pro Trp
Val Leu Ile Phe Met Val 180 185 190 Cys Arg Arg Thr Cys Arg Arg Arg
Gly Ala Ala Ala Ala Leu Thr Ala 195 200 205 Val Val Leu Gln Gly Tyr
Asn Pro Pro Ala Tyr Gly 210 215 220 <210> SEQ ID NO 139
<211> LENGTH: 186 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: HIV Gag insert <400> SEQUENCE: 139 Tyr Pro Ile
Val Gln Asn Ile Gln Gly Gln Met Val His Gln Ala Ile 1 5 10 15 Ser
Pro Arg Thr Leu Asn Ala Trp Val Lys Val Val Glu Glu Lys Ala 20 25
30 Phe Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu Ser Glu Gly Ala
35 40 45 Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly
His Gln 50 55 60 Ala Ala Met Gln Met Leu Lys Glu Thr Ile Asn Glu
Glu Ala Ala Glu 65 70 75 80 Trp Asp Arg Leu His Pro Val Gln Ala Gly
Pro Val Ala Pro Gly Gln 85 90 95 Met Arg Glu Pro Arg Gly Ser Asp
Ile Ala Gly Thr Thr Ser Thr Leu 100 105 110 Gln Glu Gln Ile Gly Trp
Met Thr Asn Asn Pro Pro Ile Pro Val Gly 115 120 125 Glu Ile Tyr Lys
Arg Trp Ile Ile Leu Gly Leu Met His Thr Leu Ala 130 135 140 Ala Phe
Val Leu Leu Val Pro Trp Val Leu Ile Phe Met Val Cys Arg 145 150 155
160 Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val
165 170 175 Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 180 185
<210> SEQ ID NO 140 <211> LENGTH: 278 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: HIV Gag insert <400> SEQUENCE:
140 Tyr Pro Ile Val Gln Asn Ile Gln Gly Gln Met Val His Gln Ala Ile
1 5 10 15 Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Val Glu Glu
Lys Ala 20 25 30 Phe Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu
Ser Glu Gly Ala 35 40 45 Thr Pro Gln Asp Leu Asn Thr Met Leu Asn
Thr Val Gly Gly His Gln 50 55 60 Ala Ala Met Gln Met Leu Lys Glu
Thr Ile Asn Glu Glu Ala Ala Glu 65 70 75 80 Trp Asp Arg Leu His Pro
Val Gln Ala Gly Pro Val Ala Pro Gly Gln 85 90 95 Met Arg Glu Pro
Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu 100 105 110 Gln Glu
Gln Ile Gly Trp Met Thr Asn Asn Pro Pro Ile Pro Val Gly 115 120 125
Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Gln Lys Cys Val Arg 130
135 140 Met Tyr Asn Pro Thr Asn Ile Leu Asp Val Lys Gln Gly Pro Lys
Glu 145 150 155 160 Pro Phe Gln Ser Tyr Val Asp Arg Phe Tyr Lys Ser
Leu Arg Ala Glu 165 170 175 Gln Thr Asp Ala Ala Val Lys Asn Trp Met
Thr Gln Thr Leu Leu Ile 180 185 190 Gln Asn Ala Asn Pro Asp Cys Lys
Leu Val Leu Lys Gly Leu Gly Val 195 200 205 Asn Pro Thr Leu Glu Glu
Met Leu Thr Ala Cys Gln Gly Val Gly Gly 210 215 220 Pro Gly Gln Lys
Ala Arg Leu Met His Thr Leu Ala Ala Phe Val Leu 225 230 235 240 Leu
Val Pro Trp Val Leu Ile Phe Met Val Cys Arg Arg Thr Cys Arg 245 250
255 Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr
260 265 270 Asn Pro Pro Ala Tyr Gly 275 <210> SEQ ID NO 141
<211> LENGTH: 370 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: SGAG(41-363)-E2TM Gag insert <400> SEQUENCE: 141
Leu Asp Arg Phe Gly Leu Ala Glu Ser Leu Leu Glu Asn Lys Glu Gly 1 5
10 15 Cys Gln Lys Ile Leu Ser Val Leu Ala Pro Leu Val Pro Thr Gly
Ser 20 25 30 Glu Asn Leu Lys Ser Leu Tyr Asn Thr Val Cys Val Ile
Trp Cys Ile 35 40 45 His Ala Glu Glu Lys Val Lys His Thr Glu Glu
Ala Lys Gln Ile Val 50 55 60 Gln Arg His Leu Val Val Glu Thr Gly
Thr Thr Glu Thr Met Pro Lys 65 70 75 80 Thr Ser Arg Pro Thr Ala Pro
Ser Ser Gly Arg Gly Gly Asn Tyr Pro 85 90 95 Val Gln Gln Ile Gly
Gly Asn Tyr Val His Leu Pro Leu Ser Pro Arg 100 105 110 Thr Leu Asn
Ala Trp Val Lys Leu Ile Glu Glu Lys Lys Phe Gly Ala 115 120 125 Glu
Val Val Pro Gly Phe Gln Ala Leu Ser Glu Gly Cys Thr Pro Tyr 130 135
140 Asp Ile Asn Gln Met Leu Asn Cys Val Gly Asp His Gln Ala Ala Met
145 150 155 160 Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala Ala Asp
Trp Asp Leu 165 170 175 Gln His Pro Gln Pro Ala Pro Gln Gln Gly Gln
Leu Arg Glu Pro Ser 180 185 190 Gly Ser Asp Ile Ala Gly Thr Thr Ser
Ser Val Asp Glu Gln Ile Gln 195 200 205 Trp Met Tyr Arg Gln Gln Asn
Pro Ile Pro Val Gly Asn Ile Tyr Arg 210 215 220 Arg Trp Ile Gln Leu
Gly Leu Gln Lys Cys Val Arg Met Tyr Asn Pro 225 230 235 240 Thr Asn
Ile Leu Asp Val Lys Gln Gly Pro Lys Glu Pro Phe Gln Ser 245 250 255
Tyr Val Asp Arg Phe Tyr Lys Ser Leu Arg Ala Glu Gln Thr Asp Ala 260
265 270 Ala Val Lys Asn Trp Met Thr Gln Thr Leu Leu Ile Gln Asn Ala
Asn 275 280 285 Pro Asp Cys Lys Leu Val Leu Lys Gly Leu Gly Val Asn
Pro Thr Leu 290 295 300 Glu Glu Met Leu Thr Ala Cys Gln Gly Val Gly
Gly Pro Gly Gln Lys 305 310 315 320 Ala Arg Leu Met His Thr Leu Ala
Ala Phe Val Leu Leu Val Pro Trp 325 330 335 Val Leu Ile Phe Met Val
Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala 340 345 350 Ala Ala Ala Leu
Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala 355 360 365 Tyr Gly
370 <210> SEQ ID NO 142 <211> LENGTH: 398 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: SGAG(41-391)-E2TM Gag
insert <400> SEQUENCE: 142 Leu Asp Arg Phe Gly Leu Ala Glu
Ser Leu Leu Glu Asn Lys Glu Gly 1 5 10 15 Cys Gln Lys Ile Leu Ser
Val Leu Ala Pro Leu Val Pro Thr Gly Ser 20 25 30 Glu Asn Leu Lys
Ser Leu Tyr Asn Thr Val Cys Val Ile Trp Cys Ile 35 40 45 His Ala
Glu Glu Lys Val Lys His Thr Glu Glu Ala Lys Gln Ile Val 50 55 60
Gln Arg His Leu Val Val Glu Thr Gly Thr Thr Glu Thr Met Pro Lys 65
70 75 80 Thr Ser Arg Pro Thr Ala Pro Ser Ser Gly Arg Gly Gly Asn
Tyr Pro 85 90 95 Val Gln Gln Ile Gly Gly Asn Tyr Val His Leu Pro
Leu Ser Pro Arg 100 105 110 Thr Leu Asn Ala Trp Val Lys Leu Ile Glu
Glu Lys Lys Phe Gly Ala 115 120 125 Glu Val Val Pro Gly Phe Gln Ala
Leu Ser Glu Gly Cys Thr Pro Tyr 130 135 140 Asp Ile Asn Gln Met Leu
Asn Cys Val Gly Asp His Gln Ala Ala Met 145 150 155 160 Gln Ile Ile
Arg Asp Ile Ile Asn Glu Glu Ala Ala Asp Trp Asp Leu 165 170 175 Gln
His Pro Gln Pro Ala Pro Gln Gln Gly Gln Leu Arg Glu Pro Ser 180 185
190 Gly Ser Asp Ile Ala Gly Thr Thr Ser Ser Val Asp Glu Gln Ile Gln
195 200 205 Trp Met Tyr Arg Gln Gln Asn Pro Ile Pro Val Gly Asn Ile
Tyr Arg 210 215 220 Arg Trp Ile Gln Leu Gly Leu Gln Lys Cys Val Arg
Met Tyr Asn Pro 225 230 235 240 Thr Asn Ile Leu Asp Val Lys Gln Gly
Pro Lys Glu Pro Phe Gln Ser 245 250 255 Tyr Val Asp Arg Phe Tyr Lys
Ser Leu Arg Ala Glu Gln Thr Asp Ala 260 265 270 Ala Val Lys Asn Trp
Met Thr Gln Thr Leu Leu Ile Gln Asn Ala Asn 275 280 285 Pro Asp Cys
Lys Leu Val Leu Lys Gly Leu Gly Val Asn Pro Thr Leu 290 295 300 Glu
Glu Met Leu Thr Ala Cys Gln Gly Val Gly Gly Pro Gly Gln Lys 305 310
315 320 Ala Arg Leu Met Ala Glu Ala Leu Lys Glu Ala Leu Ala Pro Val
Pro 325 330 335 Ile Pro Phe Ala Ala Ala Gln Gln Arg Gly Pro Arg Lys
Pro Ile Met 340 345 350 His Thr Leu Ala Ala Phe Val Leu Leu Val Pro
Trp Val Leu Ile Phe 355 360 365 Met Val Cys Arg Arg Thr Cys Arg Arg
Arg Gly Ala Ala Ala Ala Leu 370 375 380 Thr Ala Val Val Leu Gln Gly
Tyr Asn Pro Pro Ala Tyr Gly 385 390 395 <210> SEQ ID NO 143
<211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: MPER-E2TM <400> SEQUENCE: 143 Glu Glu Pro Arg
Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu Asp 1 5 10 15 Lys Trp
Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp 20 25 30
Tyr Ile Arg Met His Thr Leu Ala Ala Phe Val Leu Leu Val Pro Trp 35
40 45 Val Leu Ile Phe Met Val Cys Arg Arg Thr Cys Arg Arg Arg Gly
Ala 50 55 60 Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr Asn
Pro Pro Ala 65 70 75 80 Tyr Gly <210> SEQ ID NO 144
<211> LENGTH: 86 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: MPER-E1TM insert <400> SEQUENCE: 144 Glu Glu Pro
Arg Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu Asp 1 5 10 15 Lys
Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp 20 25
30 Tyr Ile Arg Met His Trp Trp Gln Leu Thr Leu Gly Ala Thr Cys Ala
35 40 45 Leu Pro Leu Ala Gly Leu Leu Ala Cys Cys Ala Arg Arg Thr
Cys Arg 50 55 60 Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val
Leu Gln Gly Tyr 65 70 75 80 Asn Pro Pro Ala Tyr Gly 85 <210>
SEQ ID NO 145 <211> LENGTH: 89 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: MPER-HIVTM-E2SP <400>
SEQUENCE: 145 Glu Glu Pro Arg Gln Glu Lys Asn Glu Lys Glu Leu Leu
Glu Leu Asp 1 5 10 15 Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile
Thr Asn Trp Leu Trp 20 25 30 Tyr Ile Arg Leu Phe Ile Met Ile Val
Gly Gly Leu Ile Gly Leu Arg 35 40 45 Ile Val Phe Ala Val Leu Ser
Ile Val Cys Arg Arg Thr Cys Arg Arg 50 55 60 Arg Phe Gly Ala Pro
Gln Ala Phe Leu Ala Gly Leu Leu Leu Ala Ala 65 70 75 80 Val Ala Val
Gly Thr Ala Arg Ala Gly 85 <210> SEQ ID NO 146 <211>
LENGTH: 165 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
BC-SGAG2-MPER-HIVTM insert <400> SEQUENCE: 146 Glu Glu Pro
Arg Val Pro Thr Gly Ser Glu Asn Leu Lys Ser Leu Tyr 1 5 10 15 Asn
Thr Val Thr Arg Val Lys His Thr Glu Glu Ala Lys Gln Ile Val 20 25
30 Gln Arg His Leu Val Val Glu Thr Gly Thr Thr Ser Asp Ala Phe Gln
35 40 45 Ala Leu Ser Glu Gly Cys Thr Pro Tyr Asp Ile Asn Gln Met
Leu Asn 50 55 60 Cys Val Gly Asp His Gln Ala Ala Met Gln Ile Ile
Arg Asp Ile Ile 65 70 75 80 Asn Glu Glu Ala Gln Glu Lys Asn Glu Lys
Glu Leu Leu Glu Leu Asp 85 90 95 Lys Trp Ala Ser Leu Trp Asn Trp
Phe Asp Ile Thr Asn Trp Leu Trp 100 105 110 Tyr Ile Arg Leu Phe Ile
Met Ile Val Gly Gly Leu Ile Gly Leu Arg 115 120 125 Ile Val Phe Ala
Val Leu Ser Ile Val Cys Arg Arg Thr Cys Arg Arg 130 135 140 Arg Gly
Ala Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr Asn 145 150 155
160 Pro Pro Ala Tyr Gly 165 <210> SEQ ID NO 147 <211>
LENGTH: 161 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
MPER-BC-SGAG2-E2TM insert <400> SEQUENCE: 147 Glu Glu Pro Arg
Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu Asp 1 5 10 15 Lys Trp
Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Val 20 25 30
Pro Thr Gly Ser Glu Asn Leu Lys Ser Leu Tyr Asn Thr Val Thr Arg 35
40 45 Val Lys His Thr Glu Glu Ala Lys Gln Ile Val Gln Arg His Leu
Val 50 55 60 Val Glu Thr Gly Thr Thr Ser Asp Ala Phe Gln Ala Leu
Ser Glu Gly 65 70 75 80 Cys Thr Pro Tyr Asp Ile Asn Gln Met Leu Asn
Cys Val Gly Asp His 85 90 95 Gln Ala Ala Met Gln Ile Ile Arg Asp
Ile Ile Asn Glu Glu Ala Ser 100 105 110 Leu Asp Leu His Thr Leu Ala
Ala Phe Val Leu Leu Val Pro Trp Val 115 120 125 Leu Ile Phe Met Val
Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala 130 135 140 Ala Ala Leu
Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr 145 150 155 160
Gly <210> SEQ ID NO 148 <211> LENGTH: 98 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: 10e8-MPER-HIVTM insert
<400> SEQUENCE: 148 Glu Glu Pro Ser Leu Trp Asn Trp Phe Asp
Ile Thr Asn Trp Leu Trp 1 5 10 15 Tyr Ile Arg Leu Asn Glu Lys Glu
Leu Leu Glu Leu Asp Lys Trp Ala 20 25 30 Ser Leu Trp Asn Trp Phe
Asp Ile Thr Asn Trp Leu Trp Tyr Ile Arg 35 40 45 Leu Phe Ile Met
Ile Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe 50 55 60 Ala Val
Leu Ser Ile Val Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala 65 70 75 80
Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala 85
90 95 Tyr Gly <210> SEQ ID NO 149 <211> LENGTH: 95
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: 10e8-MPER-E2TM
insert <400> SEQUENCE: 149 Glu Glu Pro Ser Leu Trp Asn Trp
Phe Asp Ile Thr Asn Trp Leu Trp 1 5 10 15 Tyr Ile Arg Leu Asn Glu
Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala 20 25 30 Ser Leu Trp Asn
Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Arg 35 40 45 Met His
Thr Leu Ala Ala Phe Val Leu Leu Val Pro Trp Val Leu Ile 50 55 60
Phe Met Val Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala 65
70 75 80 Leu Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr
Gly 85 90 95 <210> SEQ ID NO 150 <211> LENGTH: 93
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION:
MPERF-MPER-HIVTM <400> SEQUENCE: 150 Glu Glu Lys Glu Leu Leu
Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Glu Lys Glu Leu
Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp 20 25 30 Phe Asp
Ile Thr Asn Trp Leu Trp Tyr Ile Arg Leu Phe Ile Met Ile 35 40 45
Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe Ala Val Leu Ser Ile 50
55 60 Val Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu
Thr 65 70 75 80 Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly
85 90 <210> SEQ ID NO 151 <211> LENGTH: 90 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: MPERF-MPER-E2TM <400>
SEQUENCE: 151 Glu Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser
Leu Trp Asn 1 5 10 15 Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala
Ser Leu Trp Asn Trp 20 25 30 Phe Asp Ile Thr Asn Trp Leu Trp Tyr
Ile Arg Met His Thr Leu Ala 35 40 45 Ala Phe Val Leu Leu Val Pro
Trp Val Leu Ile Phe Met Val Cys Arg 50 55 60 Arg Thr Cys Arg Arg
Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val 65 70 75 80 Leu Gln Gly
Tyr Asn Pro Pro Ala Tyr Gly 85 90 <210> SEQ ID NO 152
<211> LENGTH: 344 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: HIV gp120 insert <400> SEQUENCE: 152 Glu Glu Pro
Arg Asn Pro Gln Glu Val Val Leu Glu Asn Val Thr Glu 1 5 10 15 Asn
Phe Asn Met Trp Lys Asn Asn Met Val Asp Gln Met His Glu Asp 20 25
30 Ile Ile Ser Leu Trp Asp Glu Ser Leu Lys Pro Cys Val Lys Leu Thr
35 40 45 Pro Leu Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln Pro
Ile Ser 50 55 60 Ile Gly Gly Gly Ile Arg Pro Val Val Ser Thr Gln
Leu Leu Leu Asn 65 70 75 80 Gly Ser Leu Ala Glu Glu Asp Ile Val Ile
Arg Ser Glu Asn Phe Thr 85 90 95 Asp Asn Ala Lys Thr Ile Ile Val
Gln Leu Asn Glu Ser Val Val Ile 100 105 110 Asn Cys Thr Arg Pro Asn
Asn Asn Thr Arg Gly Arg Arg Gly Asp Ile 115 120 125 Arg Gln Ala His
Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr Leu 130 135 140 Gln Gln
Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn Lys Thr Ile 145 150 155
160 Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met His Ser
165 170 175 Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr Ala Gln
Leu Phe 180 185 190 Asn Ser Thr Trp Asn Val Thr Gly Gly Thr Asn Gly
Thr Glu Gly Asn 195 200 205 Asp Ile Ile Thr Leu Gln Cys Arg Ile Lys
Gln Leu Ala Met Tyr Ala 210 215 220 Pro Pro Ile Thr Gly Gln Ile Arg
Cys Ser Ser Asn Ile Thr Gly Leu 225 230 235 240 Leu Leu Thr Arg Asp
Gly Gly Asn Ser Thr Glu Thr Glu Thr Glu Ile 245 250 255 Phe Arg Pro
Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu 260 265 270 Tyr
Lys Tyr Lys Val Val Arg Ile Glu Pro Ile Gly Val Ala Pro Thr 275 280
285 Arg Ala Lys Arg Gly Gly Gly Gly Ser Met His Thr Leu Ala Ala Phe
290 295 300 Val Leu Leu Val Pro Trp Val Leu Ile Phe Met Val Cys Arg
Arg Thr 305 310 315 320 Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr
Ala Val Val Leu Gln 325 330 335 Gly Tyr Asn Pro Pro Ala Tyr Gly 340
<210> SEQ ID NO 153 <211> LENGTH: 352 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: HIV gp120 insert <400>
SEQUENCE: 153 Glu Glu Pro Arg Asn Pro Gln Glu Val Val Leu Glu Asn
Val Thr Glu 1 5 10 15 Asn Phe Asn Met Trp Lys Asn Asn Met Val Asp
Gln Met His Glu Asp 20 25 30 Ile Ile Ser Leu Trp Asp Glu Ser Leu
Lys Pro Cys Val Lys Leu Thr 35 40 45 Pro Leu Ser Val Gln Ala Cys
Pro Lys Val Ser Phe Gln Pro Ile Ser 50 55 60 Ile Gly Gly Gly Ile
Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn 65 70 75 80 Gly Ser Leu
Ala Glu Glu Asp Ile Val Ile Arg Ser Glu Asn Phe Thr 85 90 95 Asp
Asn Ala Lys Thr Ile Ile Val Gln Leu Asn Glu Ser Val Val Ile 100 105
110 Asn Cys Thr Arg Pro Asn Asn Asn Thr Arg Gly Arg Arg Gly Asp Ile
115 120 125 Arg Gln Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn
Thr Leu 130 135 140 Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg
Asn Lys Thr Ile 145 150 155 160 Ala Phe Asn Gln Ser Ser Gly Gly Asp
Pro Glu Ile Val Met His Ser 165 170 175 Phe Asn Cys Gly Gly Glu Phe
Phe Tyr Cys Asn Thr Ala Gln Leu Phe 180 185 190 Asn Ser Thr Trp Asn
Val Thr Gly Gly Thr Asn Gly Thr Glu Gly Asn 195 200 205 Asp Ile Ile
Thr Leu Gln Cys Arg Ile Lys Gln Leu Ala Met Tyr Ala 210 215 220 Pro
Pro Ile Thr Gly Gln Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu 225 230
235 240 Leu Leu Thr Arg Asp Gly Gly Asn Ser Thr Glu Thr Glu Thr Glu
Ile 245 250 255 Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg
Ser Glu Leu 260 265 270 Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile
Gly Val Ala Pro Thr 275 280 285 Arg Ala Lys Arg Gly Gly Gly Gly Ser
Met His Val Tyr Thr Ile Leu 290 295 300 Ala Val Ala Ser Ala Thr Val
Ala Met Met Ile Gly Val Thr Val Ala 305 310 315 320 Val Leu Cys Ala
Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala 325 330 335 Ala Leu
Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 340 345 350
<210> SEQ ID NO 154 <211> LENGTH: 349 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: HIV gp120 insert <400>
SEQUENCE: 154 Glu Glu Pro Arg Asn Pro Gln Glu Val Val Leu Glu Asn
Val Thr Glu 1 5 10 15 Asn Phe Asn Met Trp Lys Asn Asn Met Val Asp
Gln Met His Glu Asp 20 25 30 Ile Ile Ser Leu Trp Asp Glu Ser Leu
Lys Pro Cys Val Lys Leu Thr 35 40 45 Pro Leu Ser Val Gln Ala Cys
Pro Lys Val Ser Phe Gln Pro Ile Ser 50 55 60 Ile Gly Gly Gly Ile
Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn 65 70 75 80 Gly Ser Leu
Ala Glu Glu Asp Ile Val Ile Arg Ser Glu Asn Phe Thr 85 90 95 Asp
Asn Ala Lys Thr Ile Ile Val Gln Leu Asn Glu Ser Val Val Ile 100 105
110 Asn Cys Thr Arg Pro Asn Asn Asn Thr Arg Gly Arg Arg Gly Asp Ile
115 120 125 Arg Gln Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn
Thr Leu 130 135 140 Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg
Asn Lys Thr Ile 145 150 155 160 Ala Phe Asn Gln Ser Ser Gly Gly Asp
Pro Glu Ile Val Met His Ser 165 170 175 Phe Asn Cys Gly Gly Glu Phe
Phe Tyr Cys Asn Thr Ala Gln Leu Phe 180 185 190 Asn Ser Thr Trp Asn
Val Thr Gly Gly Thr Asn Gly Thr Glu Gly Asn 195 200 205 Asp Ile Ile
Thr Leu Gln Cys Arg Ile Lys Gln Leu Ala Met Tyr Ala 210 215 220 Pro
Pro Ile Thr Gly Gln Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu 225 230
235 240 Leu Leu Thr Arg Asp Gly Gly Asn Ser Thr Glu Thr Glu Thr Glu
Ile 245 250 255 Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg
Ser Glu Leu 260 265 270 Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile
Gly Val Ala Pro Thr 275 280 285 Arg Ala Lys Arg Gly Gly Gly Gly Ser
Met His Leu Phe Ile Met Ile 290 295 300 Val Gly Gly Leu Ile Gly Leu
Arg Ile Val Phe Ala Val Leu Ser Ile 305 310 315 320 Val Cys Arg Arg
Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr 325 330 335 Ala Val
Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 340 345 <210> SEQ
ID NO 155 <211> LENGTH: 347 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HIV gp120 insert <400> SEQUENCE: 155 Glu
Glu Pro Arg Asn Pro Gln Glu Val Val Leu Glu Asn Val Thr Glu 1 5 10
15 Asn Phe Asn Met Trp Lys Asn Asn Met Val Asp Gln Met His Glu Asp
20 25 30 Ile Ile Ser Leu Trp Asp Glu Ser Leu Lys Pro Cys Val Lys
Leu Thr 35 40 45 Pro Leu Ser Val Gln Ala Cys Pro Lys Val Ser Phe
Gln Pro Ile Ser 50 55 60 Ile Gly Gly Gly Ile Arg Pro Val Val Ser
Thr Gln Leu Leu Leu Asn 65 70 75 80 Gly Ser Leu Ala Glu Glu Asp Ile
Val Ile Arg Ser Glu Asn Phe Thr 85 90 95 Asp Asn Ala Lys Thr Ile
Ile Val Gln Leu Asn Glu Ser Val Val Ile 100 105 110 Asn Cys Thr Arg
Pro Asn Asn Asn Thr Arg Gly Arg Arg Gly Asp Ile 115 120 125 Arg Gln
Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr Leu 130 135 140
Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn Lys Thr Ile 145
150 155 160 Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met
His Ser 165 170 175 Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr
Ala Gln Leu Phe 180 185 190 Asn Ser Thr Trp Asn Val Thr Gly Gly Thr
Asn Gly Thr Glu Gly Asn 195 200 205 Asp Ile Ile Thr Leu Gln Cys Arg
Ile Lys Gln Leu Ala Met Tyr Ala 210 215 220 Pro Pro Ile Thr Gly Gln
Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu 225 230 235 240 Leu Leu Thr
Arg Asp Gly Gly Asn Ser Thr Glu Thr Glu Thr Glu Ile 245 250 255 Phe
Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu 260 265
270 Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile Gly Val Ala Pro Thr
275 280 285 Arg Ala Lys Arg Gly Gly Gly Gly Ser Met His Ser Ser Ile
Ala Ser 290 295 300 Phe Phe Phe Ile Ile Gly Leu Ile Ile Gly Leu Phe
Leu Val Leu Cys 305 310 315 320 Arg Arg Thr Cys Arg Arg Arg Gly Ala
Ala Ala Ala Leu Thr Ala Val 325 330 335 Val Leu Gln Gly Tyr Asn Pro
Pro Ala Tyr Gly 340 345 <210> SEQ ID NO 156 <211>
LENGTH: 377 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: HIV
gp120 insert <400> SEQUENCE: 156 Glu Glu Pro Arg Asn Pro Gln
Glu Val Val Leu Glu Asn Val Thr Glu 1 5 10 15 Asn Phe Asn Met Trp
Lys Asn Asn Met Val Asp Gln Met His Glu Asp 20 25 30 Ile Ile Ser
Leu Trp Asp Glu Ser Leu Lys Pro Cys Val Lys Leu Thr 35 40 45 Pro
Leu Thr Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln Pro Ile 50 55
60 Pro Ile His Tyr Cys Val Pro Ala Gly Phe Ala Met Leu Lys Cys Asn
65 70 75 80 Asp Lys Lys Phe Asn Gly Ser Gly Pro Cys Lys Asn Val Ser
Thr Val 85 90 95 Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr
Gln Leu Leu Leu 100 105 110 Asn Gly Ser Leu Ala Glu Glu Asp Ile Val
Ile Arg Ser Glu Asn Phe 115 120 125 Thr Asp Asn Ala Lys Thr Ile Ile
Val Gln Leu Asn Glu Ser Val Val 130 135 140 Ile Asn Cys Thr Arg Pro
Asn Asn Asn Thr Arg Gly Arg Arg Gly Asp 145 150 155 160 Ile Arg Gln
Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr 165 170 175 Leu
Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn Lys Thr 180 185
190 Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met His
195 200 205 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr Ala
Gln Leu 210 215 220 Phe Asn Ser Thr Trp Asn Val Thr Gly Gly Thr Asn
Gly Thr Glu Gly 225 230 235 240 Asn Asp Ile Ile Thr Leu Gln Cys Arg
Ile Lys Gln Leu Ala Met Tyr 245 250 255 Ala Pro Pro Ile Thr Gly Gln
Ile Arg Cys Ser Ser Asn Ile Thr Gly 260 265 270 Leu Leu Leu Thr Arg
Asp Gly Gly Asn Ser Thr Glu Thr Glu Thr Glu 275 280 285 Ile Phe Arg
Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu 290 295 300 Leu
Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile Gly Val Ala Pro 305 310
315 320 Thr Arg Ala Lys Arg Gly Gly Gly Gly Ser Met His Thr Leu Ala
Ala 325 330 335 Phe Val Leu Leu Val Pro Trp Val Leu Ile Phe Met Val
Cys Arg Arg 340 345 350 Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu
Thr Ala Val Val Leu 355 360 365 Gln Gly Tyr Asn Pro Pro Ala Tyr Gly
370 375 <210> SEQ ID NO 157 <211> LENGTH: 1131
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: nucleotide
sequence for Seq_156 HIV gp120 insert <400> SEQUENCE: 157
gaagaaccta ggaacccaca agaagtagta ttggagaatg tgacagaaaa ttttaacatg
60 tggaaaaata acatggtaga tcagatgcac gaggatataa tcagtttatg
ggacgaaagt 120 cttaagccat gtgtaaaatt aaccccgctc actagtgtcc
aggcctgtcc aaaggtatcc 180 tttcagccaa ttcccataca ttattgtgtc
ccagcagggt tcgcgatgct aaagtgtaac 240 gataagaaat tcaatggatc
aggaccatgc aagaatgtga gcacagtaca atgtacccat 300 ggaattaggc
cagtggtgtc aactcagctg ctgttaaatg gcagtctagc agaagaagac 360
atagtaatta gatctgaaaa tttcacagac aatgctaaaa ccataatagt acagctaaat
420 gaatctgtag taattaattg tacaagaccc aacaacaata caagaggaag
aaggggagat 480 ataagacaag cacattgtaa catttcccgg gcaaaatgga
ataacacttt acaacagata 540 gttataaaat taagagaaaa atttaggaat
aaaacaatag cctttaatca atcctcagga 600 ggggacccag aaattgtaat
gcacagtttt aattgtggag gggaattttt ctactgtaat 660 acagcacaac
tgtttaatag cacgtggaat gttactggag ggacaaatgg cactgaagga 720
aatgacataa tcacactcca atgcagaata aaacagctag caatgtatgc ccctcccatc
780 accggtcaaa ttagatgttc atcaaatatt acagggctgc tactaacgcg
tgatggaggt 840 aatagtactg agactgagac tgagatcttc agacctggag
gaggagatat gagggacaat 900 tggagaagtg agctctataa atataaagta
gtaagaattg aaccaatagg agtagcaccc 960 accagggcaa agagaggagg
cggaggaagc atgcataccc tggccgcgtt cgtgctcctc 1020 gtgccatggg
tgctcatctt tatggtctgt cggaggacct gcagacggag gggagctgcc 1080
gctgccctta cagcagtggt cctgcagggg tacaaccccc ccgcctatgg c 1131
<210> SEQ ID NO 158 <211> LENGTH: 368 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: HIV gp120 insert <400>
SEQUENCE: 158 Glu Glu Pro Arg Val Thr Glu Asn Phe Asn Met Trp Lys
Asn Asn Met 1 5 10 15 Val Asp Gln Met His Glu Asp Ile Ile Ser Leu
Trp Asp Glu Ser Leu 20 25 30 Lys Pro Cys Val Lys Leu Thr Pro Leu
Thr Ser Val Gln Ala Cys Pro 35 40 45 Lys Val Ser Phe Gln Pro Ile
Pro Ile His Tyr Cys Val Pro Ala Gly 50 55 60 Phe Ala Met Leu Lys
Cys Asn Asp Lys Lys Phe Asn Gly Ser Gly Pro 65 70 75 80 Cys Lys Asn
Val Ser Thr Val Gln Cys Thr His Gly Ile Arg Pro Val 85 90 95 Val
Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu Ala Glu Glu Asp Ile 100 105
110 Val Ile Arg Ser Glu Asn Phe Thr Asp Asn Ala Lys Thr Ile Ile Val
115 120 125 Gln Leu Asn Glu Ser Val Val Ile Asn Cys Thr Arg Pro Asn
Asn Asn 130 135 140 Thr Arg Gly Arg Arg Gly Asp Ile Arg Gln Ala His
Cys Asn Ile Ser 145 150 155 160 Arg Ala Lys Trp Asn Asn Thr Leu Gln
Gln Ile Val Ile Lys Leu Arg 165 170 175 Glu Lys Phe Arg Asn Lys Thr
Ile Ala Phe Asn Gln Ser Ser Gly Gly 180 185 190 Asp Pro Glu Ile Val
Met His Ser Phe Asn Cys Gly Gly Glu Phe Phe 195 200 205 Tyr Cys Asn
Thr Ala Gln Leu Phe Asn Ser Thr Trp Asn Val Thr Gly 210 215 220 Gly
Thr Asn Gly Thr Glu Gly Asn Asp Ile Ile Thr Leu Gln Cys Arg 225 230
235 240 Ile Lys Gln Leu Ala Met Tyr Ala Pro Pro Ile Thr Gly Gln Ile
Arg 245 250 255 Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp
Gly Gly Asn 260 265 270 Ser Thr Glu Thr Glu Thr Glu Ile Phe Arg Pro
Gly Gly Gly Asp Met 275 280 285 Arg Asp Asn Trp Arg Ser Glu Leu Tyr
Lys Tyr Lys Val Val Arg Ile 290 295 300 Glu Pro Ile Gly Val Ala Pro
Thr Arg Ala Lys Arg Gly Gly Gly Gly 305 310 315 320 Ser Met His Thr
Leu Ala Ala Phe Val Leu Leu Val Pro Trp Val Leu 325 330 335 Ile Phe
Met Val Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala 340 345 350
Ala Leu Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 355
360 365 <210> SEQ ID NO 159 <211> LENGTH: 363
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: HIV gp120
insert <400> SEQUENCE: 159 Glu Glu Pro Arg Asn Met Trp Lys
Asn Asn Met Val Asp Gln Met His 1 5 10 15 Glu Asp Ile Ile Ser Leu
Trp Asp Glu Ser Leu Lys Pro Cys Val Lys 20 25 30 Leu Thr Pro Leu
Thr Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln 35 40 45 Pro Ile
Pro Ile His Tyr Cys Val Pro Ala Gly Phe Ala Met Leu Lys 50 55 60
Cys Asn Asp Lys Lys Phe Asn Gly Ser Gly Pro Cys Lys Asn Val Ser 65
70 75 80 Thr Val Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr
Gln Leu 85 90 95 Leu Leu Asn Gly Ser Leu Ala Glu Glu Asp Ile Val
Ile Arg Ser Glu 100 105 110 Asn Phe Thr Asp Asn Ala Lys Thr Ile Ile
Val Gln Leu Asn Glu Ser 115 120 125 Val Val Ile Asn Cys Thr Arg Pro
Asn Asn Asn Thr Arg Gly Arg Arg 130 135 140 Gly Asp Ile Arg Gln Ala
His Cys Asn Ile Ser Arg Ala Lys Trp Asn 145 150 155 160 Asn Thr Leu
Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn 165 170 175 Lys
Thr Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val 180 185
190 Met His Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr Ala
195 200 205 Gln Leu Phe Asn Ser Thr Trp Asn Val Thr Gly Gly Thr Asn
Gly Thr 210 215 220 Glu Gly Asn Asp Ile Ile Thr Leu Gln Cys Arg Ile
Lys Gln Leu Ala 225 230 235 240 Met Tyr Ala Pro Pro Ile Thr Gly Gln
Ile Arg Cys Ser Ser Asn Ile 245 250 255 Thr Gly Leu Leu Leu Thr Arg
Asp Gly Gly Asn Ser Thr Glu Thr Glu 260 265 270 Thr Glu Ile Phe Arg
Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg 275 280 285 Ser Glu Leu
Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile Gly Val 290 295 300 Ala
Pro Thr Arg Ala Lys Arg Gly Gly Gly Gly Ser Met His Thr Leu 305 310
315 320 Ala Ala Phe Val Leu Leu Val Pro Trp Val Leu Ile Phe Met Val
Cys 325 330 335 Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu
Thr Ala Val 340 345 350 Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly
355 360 <210> SEQ ID NO 160 <211> LENGTH: 344
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: HIV gp120
insert <400> SEQUENCE: 160 Glu Glu Pro Arg Asn Met Trp Lys
Asn Asn Met Val Asp Gln Met His 1 5 10 15 Glu Asp Ile Ile Ser Leu
Trp Asp Glu Ser Leu Lys Pro Cys Val Lys 20 25 30 Leu Thr Pro Leu
Thr Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln 35 40 45 Pro Ile
Pro Ile His Tyr Cys Val Pro Ala Gly Phe Ala Met Leu Lys 50 55 60
Cys Asn Asp Lys Lys Phe Asn Gly Ser Gly Pro Cys Lys Asn Val Ser 65
70 75 80 Thr Val Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr
Gln Leu 85 90 95 Leu Leu Asn Gly Ser Leu Ala Glu Glu Asp Ile Val
Ile Arg Ser Glu 100 105 110 Asn Phe Thr Asp Asn Ala Lys Thr Ile Ile
Val Gln Leu Asn Glu Ser 115 120 125 Val Val Ile Asn Cys Thr Arg Pro
Asn Asn Asn Thr Arg Gly Arg Arg 130 135 140 Gly Asp Ile Arg Gln Ala
His Cys Asn Ile Ser Arg Ala Lys Trp Asn 145 150 155 160 Asn Thr Leu
Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn 165 170 175 Lys
Thr Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val 180 185
190 Met His Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr Ala
195 200 205 Gln Leu Phe Asn Ser Thr Trp Asn Val Thr Gly Gly Thr Asn
Gly Thr 210 215 220 Glu Gly Asn Asp Ile Ile Thr Leu Gln Cys Arg Ile
Lys Gln Leu Ala 225 230 235 240 Met Tyr Ala Pro Pro Ile Thr Gly Gln
Ile Arg Cys Ser Ser Asn Ile 245 250 255 Thr Gly Leu Leu Leu Thr Arg
Asp Gly Gly Asn Ser Thr Glu Thr Glu 260 265 270 Thr Glu Ile Phe Arg
Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg 275 280 285 Ser Glu Leu
Tyr Gly Gly Gly Gly Ser Met His Thr Leu Ala Ala Phe 290 295 300 Val
Leu Leu Val Pro Trp Val Leu Ile Phe Met Val Cys Arg Arg Thr 305 310
315 320 Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val Leu
Gln 325 330 335 Gly Tyr Asn Pro Pro Ala Tyr Gly 340 <210> SEQ
ID NO 161 <211> LENGTH: 429 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: antigenic insert Seamless E1 or E2 sequence at
amino end of gp120 <400> SEQUENCE: 161 Glu Glu Ala Phe Thr
Tyr Leu Cys Thr Ala Pro Gly Cys Ala Thr Gln 1 5 10 15 Ala Pro Val
Pro Val Trp Arg Glu Ala Thr Thr Thr Leu Phe Cys Ala 20 25 30 Ser
Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr 35 40
45 His Ala Cys Val Pro Thr Asp Pro Asn Pro Gln Glu Val Val Leu Glu
50 55 60 Asn Val Thr Glu Asn Phe Asn Met Trp Lys Asn Asn Met Val
Asp Gln 65 70 75 80 Met His Glu Asp Ile Ile Ser Leu Trp Asp Glu Ser
Leu Lys Pro Cys 85 90 95 Val Lys Leu Thr Pro Leu Thr Ser Val Gln
Ala Cys Pro Lys Val Ser 100 105 110 Phe Gln Pro Ile Pro Ile His Tyr
Cys Val Pro Ala Gly Phe Ala Met 115 120 125 Leu Lys Cys Asn Asp Lys
Lys Phe Asn Gly Ser Gly Pro Cys Lys Asn 130 135 140 Val Ser Thr Val
Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr 145 150 155 160 Gln
Leu Leu Leu Asn Gly Ser Leu Ala Glu Glu Asp Ile Val Ile Arg 165 170
175 Ser Glu Asn Phe Thr Asp Asn Ala Lys Thr Ile Ile Val Gln Leu Asn
180 185 190 Glu Ser Val Val Ile Asn Cys Thr Arg Pro Asn Asn Asn Thr
Arg Gly 195 200 205 Arg Arg Gly Asp Ile Arg Gln Ala His Cys Asn Ile
Ser Arg Ala Lys 210 215 220 Trp Asn Asn Thr Leu Gln Gln Ile Val Ile
Lys Leu Arg Glu Lys Phe 225 230 235 240 Arg Asn Lys Thr Ile Ala Phe
Asn Gln Ser Ser Gly Gly Asp Pro Glu 245 250 255 Ile Val Met His Ser
Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn 260 265 270 Thr Ala Gln
Leu Phe Asn Ser Thr Trp Asn Val Thr Gly Gly Thr Asn 275 280 285 Gly
Thr Glu Gly Asn Asp Ile Ile Thr Leu Gln Cys Arg Ile Lys Gln 290 295
300 Leu Ala Met Tyr Ala Pro Pro Ile Thr Gly Gln Ile Arg Cys Ser Ser
305 310 315 320 Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Asn
Ser Thr Glu 325 330 335 Thr Glu Thr Glu Ile Phe Arg Pro Gly Gly Gly
Asp Met Arg Asp Asn 340 345 350 Trp Arg Ser Glu Leu Tyr Lys Tyr Lys
Val Val Arg Ile Glu Pro Ile 355 360 365 Gly Val Ala Pro Thr Arg Ala
Lys Arg Gly Gly Gly Gly Ser Met His 370 375 380 Thr Leu Ala Ala Phe
Val Leu Leu Val Pro Trp Val Leu Ile Phe Met 385 390 395 400 Val Cys
Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr 405 410 415
Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 420 425
<210> SEQ ID NO 162 <211> LENGTH: 383 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Non-HIV envelope glycoprotein
<400> SEQUENCE: 162 Glu Glu Pro Arg Phe Asn Cys Leu Gly Met
Ser Asn Arg Asp Phe Leu 1 5 10 15 Glu Gly Val Ser Gly Ala Thr Trp
Val Asp Leu Val Leu Glu Gly Asp 20 25 30 Ser Cys Val Thr Ile Met
Ser Lys Asp Lys Pro Thr Ile Asp Val Lys 35 40 45 Met Met Asn Met
Glu Ala Ala Asn Leu Ala Glu Val Arg Ser Tyr Cys 50 55 60 Tyr Leu
Ala Thr Val Ser Asp Leu Ser Thr Lys Ala Ala Cys Pro Thr 65 70 75 80
Met Gly Glu Ala His Asn Asp Lys Arg Ala Asp Pro Ala Phe Val Cys 85
90 95 Arg Gln Gly Val Val Asp Arg Gly Trp Gly Asn Gly Cys Gly Phe
Phe 100 105 110 Gly Lys Gly Ser Ile Asp Thr Cys Ala Lys Phe Ala Cys
Ser Thr Lys 115 120 125 Ala Ile Gly Arg Thr Ile Leu Lys Glu Asn Ile
Lys Tyr Glu Val Ala 130 135 140 Ile Phe Val His Gly Pro Thr Thr Val
Glu Ser His Gly Asn Tyr Ser 145 150 155 160 Thr Gln Val Gly Ala Thr
Gln Ala Gly Arg Leu Ser Ile Thr Pro Ala 165 170 175 Ala Pro Ser Tyr
Thr Leu Lys Leu Gly Glu Tyr Gly Glu Val Thr Val 180 185 190 Asp Cys
Glu Pro Arg Ser Gly Ile Asp Thr Asn Ala Tyr Tyr Val Met 195 200 205
Thr Val Gly Thr Lys Thr Phe Leu Val His Arg Glu Trp Phe Met Asp 210
215 220 Leu Asn Leu Pro Trp Ser Ser Ala Gly Ser Thr Val Trp Arg Asn
Arg 225 230 235 240 Glu Thr Leu Met Glu Phe Glu Glu Pro His Ala Thr
Lys Gln Ser Val 245 250 255 Ile Ala Leu Gly Ser Gln Glu Gly Ala Leu
His Gln Ala Leu Ala Gly 260 265 270 Ala Ile Pro Val Glu Phe Ser Ser
Asn Thr Val Lys Leu Thr Ser Gly 275 280 285 His Leu Lys Cys Arg Val
Lys Met Glu Lys Leu Gln Leu Lys Gly Thr 290 295 300 Thr Tyr Gly Val
Cys Ser Lys Ala Phe Lys Phe Leu Gly Thr Pro Val 305 310 315 320 Asp
Thr Gly His Gly Thr Val Val Leu Glu Leu Gln Tyr Thr Gly Thr 325 330
335 Asp Gly Pro Cys Lys Val Pro Ile Ser Ser Val Ala Ser Leu Asn Asp
340 345 350 Leu Thr Pro Val Gly Arg Leu Val Thr Val Asn Pro Phe Val
Ser Val 355 360 365 Ala Thr Ala Asn Ala Lys Val Leu Ile Glu Leu Glu
Pro Pro Phe 370 375 380
1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 162
<210> SEQ ID NO 1 <211> LENGTH: 16 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <220>
FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION:
(3)..(4) <223> OTHER INFORMATION: Xaa can be any naturally
occurring amino acid <220> FEATURE: <221> NAME/KEY:
misc_feature <222> LOCATION: (7)..(7) <223> OTHER
INFORMATION: Xaa can be any naturally occurring amino acid
<400> SEQUENCE: 1 Asn Glu Xaa Xaa Leu Leu Xaa Leu Asp Lys Trp
Ala Ser Leu Trp Asn 1 5 10 15 <210> SEQ ID NO 2 <211>
LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 2 Asn Glu Gln Glu Leu
Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp Phe Asp
Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 3
<211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 3 Asn Glu Gln
Asp Leu Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp
Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ
ID NO 4 <211> LENGTH: 28 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 4 Asn
Glu Gln Asp Leu Leu Ala Leu Asp Lys Trp Ala Asn Leu Trp Asn 1 5 10
15 Trp Phe Asp Ile Ser Asn Trp Leu Trp Tyr Ile Lys 20 25
<210> SEQ ID NO 5 <211> LENGTH: 28 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 5 Asn Glu Gln Asp Leu Leu Ala Leu Asp Lys Trp Ala Asn Leu
Trp Asn 1 5 10 15 Trp Phe Asn Ile Thr Asn Trp Leu Trp Tyr Ile Arg
20 25 <210> SEQ ID NO 6 <211> LENGTH: 28 <212>
TYPE: PRT <213> ORGANISM: Human immunodeficiency virus
<400> SEQUENCE: 6 Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp
Ala Ser Leu Trp Asn 1 5 10 15 Trp Phe Asp Ile Thr Asn Trp Leu Trp
Tyr Ile Lys 20 25 <210> SEQ ID NO 7 <211> LENGTH: 28
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 7 Asn Glu Lys Asp Leu Leu Ala Leu Asp
Ser Trp Lys Asn Leu Trp Asn 1 5 10 15 Trp Phe Asp Ile Thr Asn Trp
Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 8 <211>
LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 8 Asn Glu Gln Asp Leu
Leu Ala Leu Asp Ser Trp Glu Asn Leu Trp Asn 1 5 10 15 Trp Phe Asp
Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 9
<211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 9 Asn Glu Gln
Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp
Phe Ser Ile Thr Gln Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ
ID NO 10 <211> LENGTH: 28 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 10 Asn
Glu Gln Glu Leu Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10
15 Trp Phe Asp Ile Ser Asn Trp Leu Trp Tyr Ile Lys 20 25
<210> SEQ ID NO 11 <211> LENGTH: 28 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 11 Asn Glu Gln Asp Leu Leu Ala Leu Asp Lys Trp Asp Asn
Leu Trp Ser 1 5 10 15 Trp Phe Thr Ile Thr Asn Trp Leu Trp Tyr Ile
Lys 20 25 <210> SEQ ID NO 12 <211> LENGTH: 28
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 12 Asn Glu Gln Asp Leu Leu Ala Leu Asp
Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp Phe Asp Ile Thr Lys Trp
Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 13 <211>
LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 13 Asn Glu Gln Asp Leu
Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp Phe Ser
Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 14
<211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 14 Asn Glu Lys
Asp Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp
Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ
ID NO 15 <211> LENGTH: 28 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 15 Asn
Glu Gln Glu Ile Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10
15 Trp Phe Asp Ile Ser Lys Trp Leu Trp Tyr Ile Lys 20 25
<210> SEQ ID NO 16 <211> LENGTH: 28 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 16 Asn Glu Gln Asp Leu Leu Ala Leu Asp Lys Trp Ala Asn
Leu Trp Asn 1 5 10 15 Trp Phe Asn Ile Ser Asn Trp Leu Trp Tyr Ile
Lys 20 25 <210> SEQ ID NO 17 <211> LENGTH: 28
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 17 Asn Glu Gln Asp Leu Leu Ala Leu Asp
Lys Trp Ala Ser Leu Trp Ser 1 5 10 15 Trp Phe Asp Ile Ser Asn Trp
Leu Trp Tyr Ile Lys 20 25
<210> SEQ ID NO 18 <211> LENGTH: 28 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 18 Asn Glu Lys Asp Leu Leu Ala Leu Asp Ser Trp Lys Asn
Leu Trp Ser 1 5 10 15 Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile
Lys 20 25 <210> SEQ ID NO 19 <211> LENGTH: 28
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 19 Asn Glu Gln Glu Leu Leu Gln Leu Asp
Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp Phe Ser Ile Thr Asn Trp
Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 20 <211>
LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 20 Asn Glu Gln Asp Leu
Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp Phe Asp
Ile Ser Asn Trp Leu Trp Tyr Ile Lys 20 25 <210> SEQ ID NO 21
<211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 21 Asn Glu Gln
Glu Leu Leu Ala Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Trp
Phe Asp Ile Ser Asn Trp Leu Trp Tyr Ile Arg 20 25 <210> SEQ
ID NO 22 <211> LENGTH: 28 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 22 Asn
Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10
15 Trp Phe Asn Ile Thr Asn Trp Leu Trp Tyr Ile Lys 20 25
<210> SEQ ID NO 23 <211> LENGTH: 23 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 23 Cys Cys Ala Thr Thr Ala Ala Gly Cys Gly Gly Thr Thr
Cys Cys Thr 1 5 10 15 Cys Gly Gly Thr Ala Gly Cys 20 <210>
SEQ ID NO 24 <211> LENGTH: 23 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 24 Gly Ala Gly Thr Gly Cys Cys Gly Cys Gly Ala Gly Cys
Gly Thr Cys 1 5 10 15 Cys Gly Ala Gly Thr Gly Cys 20 <210>
SEQ ID NO 25 <211> LENGTH: 22 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <220>
FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION:
(1)..(1) <223> OTHER INFORMATION: Xaa can be any naturally
occurring amino acid <220> FEATURE: <221> NAME/KEY:
MISC_FEATURE <222> LOCATION: (3)..(3) <223> OTHER
INFORMATION: Xaa can be any hydrophobic amino acid. <220>
FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION:
(10)..(10) <223> OTHER INFORMATION: Xaa can be any
hydrophobic amino acid. <220> FEATURE: <221> NAME/KEY:
MISC_FEATURE <222> LOCATION: (18)..(18) <223> OTHER
INFORMATION: Xaa can be any hydrophobic amino acid. <400>
SEQUENCE: 25 Xaa Phe Ile Met Ile Val Gly Gly Leu Xaa Gly Leu Arg
Ile Val Phe 1 5 10 15 Thr Xaa Leu Ser Ile Val 20 <210> SEQ ID
NO 26 <211> LENGTH: 22 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 26 Ile
Phe Ile Met Ile Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe 1 5 10
15 Thr Val Leu Ser Ile Val 20 <210> SEQ ID NO 27 <211>
LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 27 Leu Phe Ile Met Ile
Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe 1 5 10 15 Thr Ala Leu
Ser Ile Val 20 <210> SEQ ID NO 28 <211> LENGTH: 22
<212> TYPE: PRT <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 28 Ile Phe Ile Met Ile Val Gly Gly Leu
Val Gly Leu Arg Ile Val Phe 1 5 10 15 Thr Ala Leu Ser Ile Val 20
<210> SEQ ID NO 29 <211> LENGTH: 276 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 29 Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Phe Cys Leu
Val Phe Ala 1 5 10 15 Gln Asp Leu Pro Gly Asn Asp Asn Asn Ser Glu
Phe Asn Glu Lys Glu 20 25 30 Leu Leu Glu Leu Asp Lys Trp Ala Ser
Leu Trp Asn Trp Phe Asp Ile 35 40 45 Thr Asn Trp Leu Trp Tyr Ile
Arg Leu Phe Ile Met Ile Val Gly Gly 50 55 60 Leu Ile Gly Leu Arg
Ile Val Phe Ala Val Leu Ser Ile Pro Gln Ser 65 70 75 80 Leu Asp Ser
Trp Trp Thr Ser Leu Asn Phe Leu Gly Gly Ser Pro Val 85 90 95 Cys
Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn His Ser Pro Thr 100 105
110 Ser Cys Pro Pro Ile Cys Pro Gly Tyr Arg Trp Met Cys Leu Arg Arg
115 120 125 Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu Cys Leu Ile Phe
Leu Leu 130 135 140 Val Leu Leu Asp Tyr Gln Gly Met Leu Pro Val Cys
Pro Leu Ile Pro 145 150 155 160 Gly Ser Thr Thr Thr Ser Thr Gly Pro
Cys Lys Thr Cys Thr Thr Pro 165 170 175 Ala Gln Gly Asn Ser Lys Phe
Pro Ser Cys Cys Cys Thr Lys Pro Thr 180 185 190 Asp Gly Asn Cys Thr
Cys Ile Pro Ile Pro Ser Ser Trp Ala Phe Ala 195 200 205 Lys Tyr Leu
Trp Glu Trp Ala Ser Val Arg Phe Ser Trp Leu Ser Leu 210 215 220 Leu
Val Pro Phe Val Gln Trp Phe Val Gly Leu Ser Pro Thr Val Trp 225 230
235 240 Leu Ser Ala Ile Trp Met Met Trp Tyr Trp Gly Pro Ser Leu Tyr
Ser 245 250 255 Ile Val Ser Pro Phe Ile Pro Leu Leu Pro Ile Phe Phe
Cys Leu Trp 260 265 270 Val Tyr Ile Gly 275 <210> SEQ ID NO
30 <211> LENGTH: 22 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 30 Pro
Ser Ala Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys 1 5 10
15 Trp Ala Ser Leu Trp Asn 20 <210> SEQ ID NO 31 <211>
LENGTH: 226 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 31 Glu Phe Ile Thr Ser Gly Phe Leu Gly Pro Leu Leu Val
Leu Gln Ala 1 5 10 15 Gly Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile
Pro Gln Ser Leu Asp 20 25 30 Ser Trp Trp Thr Ser Leu Asn Phe Leu
Gly Gly Ser Pro Val Cys Leu 35 40 45 Gly Gln Asn Ser Gln Ser Pro
Thr Ser Asn His Ser Pro Thr Ser Cys 50 55 60 Pro Pro Ile Cys Pro
Gly Tyr Arg Trp Met Cys Leu Arg Arg Phe Ile 65 70 75 80 Ile Phe Leu
Phe Ile Leu Leu Leu Cys Leu Ile Phe Leu Leu Val Leu 85 90 95 Leu
Asp Tyr Gln Gly Met Leu Pro Val Cys Pro Leu Ile Pro Gly Ser 100 105
110 Thr Thr Thr Ser Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro Ala Gln
115 120 125 Gly Asn Ser Lys Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr
Asp Gly 130 135 140 Asn Cys Thr Cys Ile Ser Ile Pro Ser Ser Trp Ala
Phe Ala Lys Tyr 145 150 155 160 Leu Trp Glu Trp Ala Ser Val Arg Phe
Ser Trp Leu Ser Leu Leu Val 165 170 175 Pro Phe Val Gln Trp Phe Val
Gly Leu Ser Pro Thr Val Trp Leu Ser 180 185 190 Ala Ile Trp Met Met
Trp Tyr Trp Gly Pro Ser Leu Tyr Ser Ile Val 195 200 205 Ser Pro Phe
Ile Pro Leu Leu Pro Ile Phe Phe Cys Leu Trp Val Tyr 210 215 220 Ile
Gly 225 <210> SEQ ID NO 32 <211> LENGTH: 15 <212>
TYPE: PRT <213> ORGANISM: Human immunodeficiency virus
<400> SEQUENCE: 32 Ala Ser Leu Trp Asn Trp Phe Asn Ile Thr
Asn Trp Leu Trp Tyr 1 5 10 15 <210> SEQ ID NO 33 <211>
LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 33 Ile Lys Leu Phe Ile
Met Ile Val Gly Gly Leu Val Gly Leu Arg 1 5 10 15 <210> SEQ
ID NO 34 <211> LENGTH: 4 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <220> FEATURE:
<221> NAME/KEY: misc_feature <222> LOCATION: (4)..(4)
<223> OTHER INFORMATION: Xaa can be any naturally occurring
amino acid <400> SEQUENCE: 34 Cys Ala Ala Xaa 1 <210>
SEQ ID NO 35 <211> LENGTH: 7 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 35 Glu Leu Asp Lys Trp Ala Ser 1 5 <210> SEQ ID NO
36 <211> LENGTH: 6 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 36 Asn
Trp Phe Asp Ile Thr 1 5 <210> SEQ ID NO 37 <211>
LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 37 Gly Pro Gly Pro 1
<210> SEQ ID NO 38 <211> LENGTH: 18 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 38 ggagctcgtc gacagcaa 18 <210> SEQ ID
NO 39 <211> LENGTH: 23 <212> TYPE: DNA <213>
ORGANISM: Artificial sequence <220> FEATURE: <223>
OTHER INFORMATION: Synthetic neucleic acid primer. <400>
SEQUENCE: 39 gctctagacc cgatgtacac cca 23 <210> SEQ ID NO 40
<211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM:
Artificial sequence <220> FEATURE: <223> OTHER
INFORMATION: Synthetic neucleic acid primer. <400> SEQUENCE:
40 gctctagaaa cgagcaggag ctgctg 26 <210> SEQ ID NO 41
<211> LENGTH: 36 <212> TYPE: DNA <213> ORGANISM:
Artificial sequence <220> FEATURE: <223> OTHER
INFORMATION: Synthetic neucleic acid primer. <400> SEQUENCE:
41 cgcggatcct caccccttga tgtaccacag ccactt 36 <210> SEQ ID NO
42 <211> LENGTH: 33 <212> TYPE: DNA <213>
ORGANISM: Artificial sequence <220> FEATURE: <223>
OTHER INFORMATION: Synthetic neucleic acid primer. <400>
SEQUENCE: 42 cgcggatcct caatggtgat ggtgatggtg ggg 33 <210>
SEQ ID NO 43 <211> LENGTH: 26 <212> TYPE: DNA
<213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 43 gctctagagc cgtggagcgg tacctg 26
<210> SEQ ID NO 44 <211> LENGTH: 33 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 44 ctcggatcct caaatcatga tgaaaatctt gat 33
<210> SEQ ID NO 45 <211> LENGTH: 30 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 45 ctcggatcct cacaccaggc caccaacaat 30
<210> SEQ ID NO 46 <211> LENGTH: 30 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 46 ctcggatcct cacaccagcc tcaggcccac 30
<210> SEQ ID NO 47 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 47 ctcggatcct caggcgggcg c 21 <210> SEQ
ID NO 48 <211> LENGTH: 48 <212> TYPE: DNA <213>
ORGANISM: Artificial sequence <220> FEATURE: <223>
OTHER INFORMATION: Synthetic neucleic acid primer. <400>
SEQUENCE: 48 ccctgcaaga cctgcaccac caccggtcag ggcaactcca agttcccc
48
<210> SEQ ID NO 49 <211> LENGTH: 48 <212> TYPE:
DNA <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic neucleic acid primer.
<400> SEQUENCE: 49 ggggaacttg gagttgccct gaccggtggt
ggtgcaggtc ttgcaggg 48 <210> SEQ ID NO 50 <211> LENGTH:
27 <212> TYPE: DNA <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Synthetic
neucleic acid primer. <400> SEQUENCE: 50 ggcaccggta
acgagcagga gctgctg 27 <210> SEQ ID NO 51 <211> LENGTH:
33 <212> TYPE: DNA <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Synthetic
neucleic acid primer. <400> SEQUENCE: 51 ggcaccggtc
cccttgatgt accacagcca ctt 33 <210> SEQ ID NO 52 <211>
LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial
sequence <220> FEATURE: <223> OTHER INFORMATION:
Synthetic neucleic acid primer. <400> SEQUENCE: 52 agcgaattca
acgagcagga gctgctg 27 <210> SEQ ID NO 53 <211> LENGTH:
27 <212> TYPE: DNA <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Synthetic
neucleic acid primer. <400> SEQUENCE: 53 cgcggatcct
cacccgatgt acaccca 27 <210> SEQ ID NO 54 <211> LENGTH:
45 <212> TYPE: DNA <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Synthetic
neucleic acid primer. <400> SEQUENCE: 54 caggaagccg
gaggtgatga accccttgat gtaccacagc cactt 45 <210> SEQ ID NO 55
<211> LENGTH: 45 <212> TYPE: DNA <213> ORGANISM:
Artificial sequence <220> FEATURE: <223> OTHER
INFORMATION: Synthetic neucleic acid primer. <400> SEQUENCE:
55 aagtggctgt ggtacatcaa ggggttcatc acctccggct tcctg 45 <210>
SEQ ID NO 56 <211> LENGTH: 515 <212> TYPE: DNA
<213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Neucleic acid sequence for
recombinant antigenic insert peptide. <400> SEQUENCE: 56
attagataga tttggattag cagaaagcct gttggagaac aaagaaggat gtcaaaaaat
60 actttcggtc ttagctccat tagtgccaac aggctcagaa aatttaaaaa
gcctttataa 120 tactgtctgc gtcatctggt gcattcacgc agaagagaaa
gtgaaacaca ctgaggaagc 180 aaaacagata gtgcagagac acctagtggt
ggaaacagga acaacagaaa ctatgccaaa 240 aacaagtaga ccaacagcac
catctagcgg cagaggagga aattacccag tacaacaaat 300 aggtggtaac
tatgtccacc tgccattaag cccgagaaca ttaaatgcct gggtaaaatt 360
gatagaggaa aagaaatttg gagcagaagt agtgccagga tttcaggcac tgtcagaagg
420 ttgcaccccc tatgacatta atcagatgtt aaattgtgtg ggagaccatc
aagcggctat 480 gcagattatc agagatatta taaacgagga ggctg 515
<210> SEQ ID NO 57 <211> LENGTH: 295 <212> TYPE:
PRT <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert peptide
construct. <400> SEQUENCE: 57 Met Lys Thr Ile Ile Ala Leu Ser
Tyr Ile Phe Cys Leu Val Phe Ala 1 5 10 15 Gln Asp Leu Pro Gly Asn
Asp Asn Asn Ser Glu Phe Asn Glu Lys Glu 20 25 30 Leu Leu Glu Leu
Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile 35 40 45 Thr Asn
Trp Leu Trp Tyr Ile Arg Leu Phe Ile Met Ile Val Gly Gly 50 55 60
Leu Ile Gly Leu Arg Ile Val Phe Ala Val Leu Ser Ile Pro Gln Ser 65
70 75 80 Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly Gly Ser
Pro Val 85 90 95 Cys Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn
His Ser Pro Thr 100 105 110 Ser Cys Pro Pro Ile Cys Pro Gly Tyr Arg
Trp Met Cys Leu Arg Arg 115 120 125 Phe Ile Ile Phe Leu Phe Ile Leu
Leu Leu Cys Leu Ile Phe Leu Leu 130 135 140 Val Leu Leu Asp Tyr Gln
Gly Met Leu Pro Val Cys Pro Leu Ile Pro 145 150 155 160 Gly Ser Thr
Thr Thr Ser Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro 165 170 175 Ala
Gln Gly Asn Ser Lys Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr 180 185
190 Asp Gly Asn Cys Thr Cys Ile Pro Ile Asn Glu Lys Glu Leu Leu Glu
195 200 205 Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr
Asn Trp 210 215 220 Leu Trp Tyr Ile Arg Leu Phe Ile Met Ile Val Gly
Gly Leu Ile Gly 225 230 235 240 Leu Arg Ile Val Phe Ala Val Leu Ser
Ile Val Val Gly Leu Ser Pro 245 250 255 Thr Val Trp Leu Ser Ala Ile
Trp Met Met Trp Tyr Trp Gly Pro Ser 260 265 270 Leu Tyr Ser Ile Val
Ser Pro Phe Ile Pro Leu Leu Pro Ile Phe Phe 275 280 285 Cys Leu Trp
Val Tyr Ile Gly 290 295 <210> SEQ ID NO 58 <211>
LENGTH: 1730 <212> TYPE: DNA <213> ORGANISM: Artificial
sequence <220> FEATURE: <223> OTHER INFORMATION:
Recombinant antigenic insert peptide. <400> SEQUENCE: 58
ggtaccgtcg acagcaaaag caggggataa ttctattaac catgaagact atcattgctt
60 ccatggcagc tgtcgttttc gtcccctatt aagataattg gtacttctga
tagtaacgaa 120 tgagctacat tttctgtctg gttttcgccc aagaccttcc
aggaaatgac aacaacagcg 180 actcgatgta aaagacagac caaaagcggg
ttctggaagg tcctttactg ttgttgtcgc 240 aattcatcac ctccggcttc
ctgggccccc tgctggtcct gcaggccggg ttcttcctgc 300 ttaagtagtg
gaggccgaag gacccggggg acgaccagga cgtccggccc aagaaggacg 360
tgacccgcat cctcaccatc ccccagtccc tggactcgtg gtggacctcc ctcaactttc
420 actgggcgta ggagtggtag ggggtcaggg acctgagcac cacctggagg
gagttgaaag 480 tggggggctc ccccgtgtgt ctgggccaga actcccagtc
ccccacctcc aaccactccc 540 accccccgag ggggcacaca gacccggtct
tgagggtcag ggggtggagg ttggtgaggg 600 ccacctcctg cccccccatc
tgccccggct accgctggat gtgcctgcgc cgcttcatca 660 ggtggaggac
gggggggtag acggggccga tggcgaccta cacggacgcg gcgaagtagt 720
tcttcctgtt catcctgctg ctgtgcctga tcttcctgct ggtgctgctg gactaccagg
780 agaaggacaa gtaggacgac gacacggact agaaggacga ccacgacgac
ctgatggtcc 840 gcatgctgcc cgtgtgcccc ctgatccccg gctccaccac
cacctccacc ggcccctgca 900 cgtacgacgg gcacacgggg gactaggggc
cgaggtggtg gtggaggtgg ccggggacgt 960 agacctgcac cacccccgcc
cagggcaact ccaagttccc ctcctgctgc tgcaccaagc 1020 tctggacgtg
gtgggggcgg gtcccgttga ggttcaaggg gaggacgacg acgtggttcg 1080
ccaccgacgg caactgcacc tgcatcaata ttaatgaaaa agaattattg gaattggata
1140 ggtggctgcc gttgacgtgg acgtagttat aattactttt tcttaataac
cttaacctat 1200 aatgggcaag tttgtggaat tggtttgaca taacaaactg
gctgtggtat ataagattat 1260 ttacccgttc aaacacctta accaaactgt
attgtttgac cgacaccata tattctaata 1320 tcataatgat agtaggaggc
ttgataggtt taagaatagt ttttgctgta ctttctatag 1380 agtattacta
tcatcctccg aactatccaa attcttatca aaaacgacat gaaagatatc 1440
tagtgggcct gtcccccacc gtgtggctgt ccgccatctg gatgatgtgg tactggggcc
1500 atcacccgga cagggggtgg cacaccgaca ggcggtagac ctactacacc
atgaccccgg 1560 cctccctgta ctccatcgtg tcccccttca tccccctgct
gcccatcttc ttctgcctgt 1620 ggagggacat gaggtagcac agggggaagt
agggggacga cgggtagaag aagacggaca 1680 gggtgtacat ctgactagtg
agctccccac atgtagactg atcactcgag 1730
<210> SEQ ID NO 59 <211> LENGTH: 271 <212> TYPE:
PRT <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert peptide
construct. <400> SEQUENCE: 59 Met Lys Thr Ile Ile Ala Leu Ser
Tyr Ile Phe Cys Leu Val Phe Ala 1 5 10 15 Gln Asp Leu Pro Gly Asn
Asp Asn Asn Ser Glu Phe Ile Thr Ser Gly 20 25 30 Phe Leu Gly Pro
Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr 35 40 45 Arg Ile
Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu 50 55 60
Asn Phe Leu Gly Gly Ser Pro Val Cys Leu Gly Gln Asn Ser Gln Ser 65
70 75 80 Pro Thr Ser Asn His Ser Pro Thr Ser Cys Pro Pro Ile Cys
Pro Gly 85 90 95 Tyr Arg Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu 100 105 110 Leu Leu Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Gln Gly Met 115 120 125 Leu Pro Val Cys Pro Leu Ile Pro
Gly Ser Thr Thr Thr Ser Thr Gly 130 135 140 Pro Cys Lys Thr Cys Thr
Thr Pro Ala Gln Gly Asn Ser Lys Phe Pro 145 150 155 160 Ser Cys Cys
Cys Thr Lys Pro Thr Asp Gly Asn Cys Thr Cys Ile Asn 165 170 175 Ile
Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp 180 185
190 Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Arg Leu Phe Ile
195 200 205 Met Ile Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe Ala
Val Leu 210 215 220 Ser Ile Val Val Gly Leu Ser Pro Thr Val Trp Leu
Ser Ala Ile Trp 225 230 235 240 Met Met Trp Tyr Trp Gly Pro Ser Leu
Tyr Ser Ile Val Ser Pro Phe 245 250 255 Ile Pro Leu Leu Pro Ile Phe
Phe Cys Leu Trp Val Tyr Ile Gly 260 265 270 <210> SEQ ID NO
60 <211> LENGTH: 15 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 60 Asn
Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp 1 5 10 15
<210> SEQ ID NO 61 <211> LENGTH: 25 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 61 Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser
Leu Trp Asn 1 5 10 15 Trp Phe Asp Ile Thr Asn Trp Leu Trp 20 25
<210> SEQ ID NO 62 <211> LENGTH: 300 <212> TYPE:
PRT <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert peptide
construct. <400> SEQUENCE: 62 Met Lys Thr Ile Ile Ala Leu Ser
Tyr Ile Phe Cys Leu Val Phe Ala 1 5 10 15 Gln Asp Leu Pro Gly Asn
Asp Asn Asn Ser Glu Phe Asn Glu Lys Glu 20 25 30 Leu Leu Glu Leu
Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile 35 40 45 Thr Asn
Trp Leu Trp Tyr Ile Arg Leu Phe Ile Met Ile Val Gly Gly 50 55 60
Leu Ile Gly Leu Arg Ile Val Phe Ala Val Leu Ser Ile Pro Gln Ser 65
70 75 80 Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly Gly Ser
Pro Val 85 90 95 Cys Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn
His Ser Pro Thr 100 105 110 Ser Cys Pro Pro Ile Cys Pro Gly Tyr Arg
Trp Met Cys Leu Arg Arg 115 120 125 Phe Ile Ile Phe Leu Phe Ile Leu
Leu Leu Cys Leu Ile Phe Leu Leu 130 135 140 Val Leu Leu Asp Tyr Gln
Gly Met Leu Pro Val Cys Pro Leu Ile Pro 145 150 155 160 Gly Ser Thr
Thr Thr Ser Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro 165 170 175 Ala
Gln Gly Asn Ser Lys Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr 180 185
190 Asp Gly Asn Cys Thr Cys Ile Ser Ile Asn Glu Lys Glu Leu Leu Glu
195 200 205 Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr
Asn Trp 210 215 220 Leu Trp Ser Ser Leu Trp Ala Ile Lys Tyr Leu Trp
Glu Trp Ala Ser 225 230 235 240 Val Arg Phe Ser Trp Leu Ser Leu Leu
Val Pro Phe Val Gln Trp Phe 245 250 255 Val Gly Leu Ser Pro Thr Val
Trp Leu Ser Ala Ile Trp Met Met Trp 260 265 270 Tyr Trp Gly Pro Ser
Leu Tyr Ser Ile Val Ser Pro Phe Ile Pro Leu 275 280 285 Leu Pro Ile
Phe Phe Cys Leu Trp Val Tyr Ile Gly 290 295 300 <210> SEQ ID
NO 63 <211> LENGTH: 382 <212> TYPE: PRT <213>
ORGANISM: Artificial sequence <220> FEATURE: <223>
OTHER INFORMATION: Recombinant antigenic insert peptide construct.
<400> SEQUENCE: 63 Val Pro Val Trp Arg Glu Ala Thr Thr Thr
Leu Phe Cys Ala Ser Asp 1 5 10 15 Ala Lys Ala Tyr Asp Thr Glu Val
His Asn Val Trp Ala Thr His Ala 20 25 30 Cys Val Pro Thr Asp Pro
Asn Pro Gln Glu Val Val Leu Gly Asn Val 35 40 45 Thr Glu Asn Phe
Asn Met Trp Lys Asn Asn Met Val Asp Gln Met His 50 55 60 Glu Asp
Ile Ile Ser Leu Trp Asp Glu Ser Leu Lys Pro Cys Val Lys 65 70 75 80
Leu Thr Pro Leu Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln Pro 85
90 95 Ile Pro Ile His Tyr Cys Val Pro Ala Gly Phe Ala Met Leu Lys
Cys 100 105 110 Asn Asn Lys Thr Phe Asn Gly Ser Gly Pro Cys Thr Asn
Val Ser Thr 115 120 125 Val Gln Cys Thr His Gly Ile Arg Pro Val Val
Ser Thr Gln Leu Leu 130 135 140 Leu Asn Gly Ser Leu Ala Glu Glu Asp
Ile Val Ile Arg Ser Glu Asn 145 150 155 160 Phe Thr Asp Asn Ala Lys
Thr Ile Ile Val Gln Leu Asn Glu Ser Val 165 170 175 Val Ile Asn Cys
Thr Arg Pro Asn Asn Asn Thr Arg Arg Arg Leu Ser 180 185 190 Ile Gly
Pro Gly Arg Ala Phe Tyr Ala Arg Arg Asn Ile Ile Gly Asp 195 200 205
Ile Arg Gln Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr 210
215 220 Leu Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn Lys
Thr 225 230 235 240 Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu
Ile Val Met His 245 250 255 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr
Cys Asn Thr Ala Gln Leu 260 265 270 Phe Asn Ser Thr Trp Asn Val Thr
Gly Gly Thr Asn Gly Thr Glu Gly 275 280 285 Asn Asp Ile Ile Thr Leu
Gln Cys Arg Ile Lys Gln Ile Ile Asn Met 290 295 300 Trp Gln Lys Val
Gly Lys Ala Met Tyr Ala Pro Pro Ile Thr Gly Gln 305 310 315 320 Ile
Arg Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly 325 330
335 Gly Asn Ser Thr Glu Thr Glu Thr Glu Ile Phe Arg Pro Gly Gly Gly
340 345 350 Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys
Val Val 355 360 365 Arg Ile Glu Pro Ile Gly Val Ala Pro Thr Arg Ala
Lys Arg 370 375 380 <210> SEQ ID NO 64 <211> LENGTH:
337 <212> TYPE: PRT <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Recombinant
antigenic insert peptide construct. <400> SEQUENCE: 64 Met
Lys Thr Ile Ile Ala Leu Ser Tyr Ile Phe Cys Leu Val Phe Ala 1 5 10
15
Gln Asp Leu Pro Gly Asn Asp Asn Asn Ser Glu Phe Asn Glu Lys Glu 20
25 30 Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp
Ile 35 40 45 Thr Asn Trp Leu Trp Tyr Ile Arg Leu Phe Ile Met Ile
Val Gly Gly 50 55 60 Leu Ile Gly Leu Arg Ile Val Phe Ala Val Leu
Ser Ile Pro Gln Ser 65 70 75 80 Leu Asp Ser Trp Trp Thr Ser Leu Asn
Phe Leu Gly Gly Ser Pro Val 85 90 95 Cys Leu Gly Gln Asn Ser Gln
Ser Pro Thr Ser Asn His Ser Pro Thr 100 105 110 Ser Cys Pro Pro Ile
Cys Pro Gly Tyr Arg Trp Met Cys Leu Arg Arg 115 120 125 Phe Ile Ile
Phe Leu Phe Ile Leu Leu Leu Cys Leu Ile Phe Leu Leu 130 135 140 Val
Leu Leu Asp Tyr Gln Gly Met Leu Pro Val Cys Pro Leu Ile Pro 145 150
155 160 Gly Ser Thr Thr Thr Ser Thr Gly Pro Cys Lys Thr Cys Thr Thr
Pro 165 170 175 Ala Gln Gly Asn Ser Lys Phe Pro Ser Cys Cys Cys Thr
Lys Pro Thr 180 185 190 Asp Gly Asn Cys Thr Cys Ile Ser Ile Asn Glu
Lys Glu Leu Leu Glu 195 200 205 Leu Asp Lys Trp Ala Ser Leu Trp Ala
Ile Asn Glu Lys Glu Leu Leu 210 215 220 Glu Leu Asp Lys Trp Ala Ser
Leu Trp Ala Ile Asn Glu Lys Glu Leu 225 230 235 240 Leu Glu Leu Asp
Lys Trp Ala Ser Leu Trp Ala Ile Asn Glu Lys Glu 245 250 255 Leu Leu
Glu Leu Asp Lys Trp Ala Ser Leu Trp Ala Ile Lys Tyr Leu 260 265 270
Trp Glu Trp Ala Ser Val Arg Phe Ser Trp Leu Ser Leu Leu Val Pro 275
280 285 Phe Val Gln Trp Phe Val Gly Leu Ser Pro Thr Val Trp Leu Ser
Ala 290 295 300 Ile Trp Met Met Trp Tyr Trp Gly Pro Ser Leu Tyr Ser
Ile Val Ser 305 310 315 320 Pro Phe Ile Pro Leu Leu Pro Ile Phe Phe
Cys Leu Trp Val Tyr Ile 325 330 335 Gly <210> SEQ ID NO 65
<211> LENGTH: 313 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 65 Met Lys Thr
Ile Ile Ala Leu Ser Tyr Ile Phe Cys Leu Val Phe Ala 1 5 10 15 Gln
Asp Leu Pro Gly Asn Asp Asn Asn Ser Glu Phe Ile Thr Ser Gly 20 25
30 Phe Leu Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr
35 40 45 Arg Ile Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr
Ser Leu 50 55 60 Asn Phe Leu Gly Gly Ser Pro Val Cys Leu Gly Gln
Asn Ser Gln Ser 65 70 75 80 Pro Thr Ser Asn His Ser Pro Thr Ser Cys
Pro Pro Ile Cys Pro Gly 85 90 95 Tyr Arg Trp Met Cys Leu Arg Arg
Phe Ile Ile Phe Leu Phe Ile Leu 100 105 110 Leu Leu Cys Leu Ile Phe
Leu Leu Val Leu Leu Asp Tyr Gln Gly Met 115 120 125 Leu Pro Val Cys
Pro Leu Ile Pro Gly Ser Thr Thr Thr Ser Thr Gly 130 135 140 Pro Cys
Lys Thr Cys Thr Thr Pro Ala Gln Gly Asn Ser Lys Phe Pro 145 150 155
160 Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly Asn Cys Thr Cys Ile Ser
165 170 175 Ile Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser
Leu Trp 180 185 190 Ala Ile Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys
Trp Ala Ser Leu 195 200 205 Trp Ala Ile Asn Glu Lys Glu Leu Leu Glu
Leu Asp Lys Trp Ala Ser 210 215 220 Leu Trp Ala Ile Asn Glu Lys Glu
Leu Leu Glu Leu Asp Lys Trp Ala 225 230 235 240 Ser Leu Trp Ala Ile
Lys Tyr Leu Trp Glu Trp Ala Ser Val Arg Phe 245 250 255 Ser Trp Leu
Ser Leu Leu Val Pro Phe Val Gln Trp Phe Val Gly Leu 260 265 270 Ser
Pro Thr Val Trp Leu Ser Ala Ile Trp Met Met Trp Tyr Trp Gly 275 280
285 Pro Ser Leu Tyr Ser Ile Val Ser Pro Phe Ile Pro Leu Leu Pro Ile
290 295 300 Phe Phe Cys Leu Trp Val Tyr Ile Gly 305 310 <210>
SEQ ID NO 66 <211> LENGTH: 373 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 66 Val Pro Val Trp Arg Glu Ala Thr Thr Thr Leu Phe Cys
Ala Ser Asp 1 5 10 15 Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val
Trp Ala Thr His Ala 20 25 30 Cys Val Pro Thr Asp Pro Asn Pro Gln
Glu Val Val Leu Gly Asn Val 35 40 45 Thr Glu Asn Phe Asn Met Trp
Lys Asn Asn Met Val Asp Gln Met His 50 55 60 Glu Asp Ile Ile Ser
Leu Trp Asp Glu Ser Leu Lys Pro Cys Val Lys 65 70 75 80 Leu Thr Pro
Leu Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln Pro 85 90 95 Ile
Pro Ile His Tyr Cys Val Pro Ala Gly Phe Ala Met Leu Lys Cys 100 105
110 Asn Asn Lys Thr Phe Asn Gly Ser Gly Pro Cys Thr Asn Val Ser Thr
115 120 125 Val Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr Gln
Leu Leu 130 135 140 Leu Asn Gly Ser Leu Ala Glu Glu Asp Ile Val Ile
Arg Ser Glu Asn 145 150 155 160 Phe Thr Asp Asn Ala Lys Thr Ile Ile
Val Gln Leu Asn Glu Ser Val 165 170 175 Val Ile Asn Cys Thr Arg Pro
Asn Asn Asn Thr Arg Arg Arg Leu Ser 180 185 190 Ile Gly Pro Gly Arg
Ala Phe Tyr Ala Arg Arg Asn Ile Ile Gly Asp 195 200 205 Ile Arg Gln
Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr 210 215 220 Leu
Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn Lys Thr 225 230
235 240 Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met
His 245 250 255 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr
Ala Gln Leu 260 265 270 Phe Asn Ser Thr Trp Asn Val Thr Gly Gly Thr
Asn Gly Thr Glu Gly 275 280 285 Asn Asp Ile Ile Thr Leu Gln Cys Arg
Ile Lys Gln Leu Ala Met Tyr 290 295 300 Ala Pro Pro Ile Thr Gly Gln
Ile Arg Cys Ser Ser Asn Ile Thr Gly 305 310 315 320 Leu Leu Leu Thr
Arg Asp Gly Gly Asn Ser Thr Glu Thr Glu Thr Glu 325 330 335 Ile Phe
Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu 340 345 350
Leu Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile Gly Val Ala Pro 355
360 365 Thr Arg Ala Lys Arg 370 <210> SEQ ID NO 67
<211> LENGTH: 664 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 67 Ile Ile His
Thr Val Pro Pro Ser Gly Ala Asp Pro Gly Pro Lys Arg 1 5 10 15 Ala
Glu Phe Lys Gly Leu Arg Arg Gln Gln Lys Gln Gly Ile Ile Leu 20 25
30 Leu Thr Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Val
35 40 45 Leu Ala Gln Lys Leu Pro Gly Asn Asp Asn Asn Ser Glu Phe
Ile Thr 50 55 60 Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala
Gly Phe Phe Leu 65 70 75 80 Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser
Leu Asp Ser Trp Trp Thr 85 90 95 Ser Leu Asn Phe Leu Gly Gly Ser
Pro Val Cys Leu Gly Gln Asn Ser 100 105 110 Gln Ser Pro Thr Ser Asn
His Ser Pro Thr Ser Cys Pro Pro Ile Cys 115 120 125 Pro Gly Tyr Arg
Met Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile 130 135 140 Leu Leu
Leu Cys Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln Gly 145 150 155
160 Met Leu Pro Val Cys Pro Leu Ile Pro Gly Ser Thr Thr Thr Ser Thr
165 170 175 Gly Pro Cys Lys Thr Cys Thr Thr Pro Ala Gln Gly Asn Ser
Lys Phe 180 185 190
Pro Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly Asn Cys Thr Cys Ile 195
200 205 Pro Ile Pro Ser Ser Trp Ala Phe Ala Lys Tyr Leu Trp Glu Trp
Ala 210 215 220 Ser Val Arg Phe Ser Trp Leu Ser Leu Leu Val Pro Phe
Val Gln Trp 225 230 235 240 Phe Val Gly Leu Ser Pro Thr Val Trp Leu
Ser Ala Ile Trp Met Met 245 250 255 Trp Tyr Trp Gly Pro Ser Leu Tyr
Ser Ile Val Ser Pro Phe Ile Pro 260 265 270 Leu Leu Pro Ile Phe Phe
Cys Leu Trp Val Tyr Ile Gly Val Pro Val 275 280 285 Trp Lys Glu Ala
Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala 290 295 300 Tyr Asp
Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys Val Pro 305 310 315
320 Thr Asp Pro Asn Pro Gln Glu Val Val Leu Glu Asn Val Thr Glu His
325 330 335 Phe Asn Met Trp Lys Asn Asn Met Val Glu Gln Met Gln Glu
Asp Ile 340 345 350 Ile Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val
Lys Leu Thr Pro 355 360 365 Leu Gln Ala Cys Pro Lys Ile Ser Phe Glu
Pro Ile Pro Ile His Tyr 370 375 380 Cys Ala Pro Ala Gly Phe Ala Ile
Leu Lys Cys Asn Asp Lys Thr Phe 385 390 395 400 Asn Gly Lys Gly Pro
Cys Lys Asn Val Ser Thr Val Gln Cys Thr His 405 410 415 Gly Ile Arg
Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu 420 425 430 Ala
Glu Glu Glu Val Val Ile Arg Ser Asp Asn Phe Thr Asn Asn Ala 435 440
445 Lys Thr Ile Ile Val Gln Leu Lys Glu Ser Val Glu Ile Asn Cys Thr
450 455 460 Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile His Ile Gly Pro
Gly Arg 465 470 475 480 Ala Phe Tyr Thr Thr Gly Glu Ile Ile Gly Asp
Ile Arg Gln Ala His 485 490 495 Cys Asn Ile Ser Arg Ala Lys Trp Asn
Asp Thr Leu Lys Gln Ile Val 500 505 510 Ile Lys Leu Arg Glu Gln Phe
Glu Asn Lys Thr Ile Val Phe Asn His 515 520 525 Ser Ser Gly Gly Asp
Pro Glu Ile Val Met His Ser Phe Asn Cys Gly 530 535 540 Gly Glu Phe
Phe Tyr Cys Asn Ser Thr Gln Leu Phe Asn Ser Thr Trp 545 550 555 560
Asn Asn Asn Thr Glu Gly Ser Asn Asn Thr Glu Gly Asn Thr Ile Thr 565
570 575 Leu Pro Cys Arg Ile Lys Gln Leu Ala Met Tyr Ala Pro Pro Ile
Arg 580 585 590 Gly Gln Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu Leu
Leu Thr Arg 595 600 605 Asp Gly Gly Ile Asn Glu Asn Gly Thr Glu Ile
Phe Arg Pro Gly Gly 610 615 620 Gly Asp Met Arg Asp Asn Trp Arg Ser
Glu Leu Tyr Lys Tyr Lys Val 625 630 635 640 Val Lys Ile Glu Pro Leu
Gly Val Ala Pro Thr Lys Ala Lys Arg Leu 645 650 655 Val Ala Ala Ala
Phe Glu Ser Arg 660 <210> SEQ ID NO 68 <211> LENGTH:
2000 <212> TYPE: DNA <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 68 ggattattca
taccgtccca ccatcgggcg cggatcccgg tccgaagcgc gcggaattca 60
aaggcctacg tcgacagcaa aagcagggga taattctatt aaccatgaag actatcattg
120 ctttgagcta cattttatgt ctggttctcg ctcaaaaact tcccggaaat
gacaacaaca 180 gcgaattcat cacctccggc ttcctgggcc ccctgctggt
gctgcaggcc ggcttcttcc 240 tgctgacccg catcctgacc atcccccagt
ccctggactc ctggtggacc tccctgaact 300 tcctgggcgg ctcccccgtg
tgcctgggcc agaactccca gtcccccacc tccaaccact 360 cccccacctc
ctgccccccc atctgccccg gctaccgctg gatgtgcctg cgccgcttca 420
tcatcttcct gttcatcctg ctgctgtgcc tgatcttcct gctggtgctg ctggactacc
480 agggcatgct gcccgtgtgc cccctgatcc ccggctccac caccacctcc
accggcccct 540 gcaagacctg caccaccccc gcccagggca actccaagtt
cccctcctgc tgctgcacca 600 agcccaccga cggcaactgc acctgcatcc
ccatcccctc ctcctgggcc ttcgccaagt 660 acctgtggga gtgggcctcc
gtgcgcttct cctggctgtc cctgctggtg cccttcgtgc 720 agtggttcgt
gggcctgtcc cccaccgtgt ggctgtccgc catctggatg atgtggtact 780
ggggcccctc cctgtactcc atcgtgtccc ccttcatccc cctgctgccc atcttcttct
840 gcctgtgggt gtacatcggg gtacctgtgt ggaaagaagc aaccaccact
ctattttgtg 900 catcagatgc taaagcatat gatacagagg tacataatgt
ttgggccaca catgcctgtg 960 tacccacaga ccccaaccca caagaagtag
tattggaaaa tgtaacagaa cattttaaca 1020 tgtggaaaaa taacatggta
gaacagatgc aggaggatat aatcagttta tgggatcaaa 1080 gcctaaagcc
atgtgtaaaa ttaaccccac tccaggcctg tccaaagata tcctttgagc 1140
caattcccat acattattgt gccccggctg gttttgcgat tctaaagtgt aatgataaga
1200 cgttcaatgg aaaaggacca tgtaaaaatg tcagcacagt acaatgtaca
catggaatta 1260 ggccagtagt atcaactcaa ctgctgctaa atggcagtct
agcagaagaa gaggtagtaa 1320 ttagatctga caatttcacg aacaatgcta
aaaccataat agtacagctg aaagaatctg 1380 tagaaattaa ttgtacaaga
cccaacaaca atacaagaaa aagtatacat ataggaccag 1440 ggagagcatt
ttatactaca ggagaaataa taggagatat aagacaagca cattgtaaca 1500
ttagtagagc aaaatggaat gacactttaa aacagatagt tataaaatta agagaacaat
1560 ttgagaataa aacaatagtc tttaatcact cctcaggagg ggacccagaa
attgtaatgc 1620 acagttttaa ttgtggagga gaatttttct actgtaattc
aacacaactg tttaatagta 1680 cttggaataa taatactgaa gggtcaaata
acactgaagg aaatactatc acactcccat 1740 gcagaataaa acagctagca
atgtatgccc ctcccatcag aggacaaatt agatgttcat 1800 caaatattac
agggctgcta ttaacaagag atggtggtat taatgagaat gggaccgaga 1860
tcttcagacc tggaggagga gatatgaggg acaattggag aagtgaatta tataaatata
1920 aagtagtaaa aattgaacca ttaggagtag cacccaccaa ggcaaagaga
tgactagtcg 1980 cggccgcttt cgaatctaga 2000 <210> SEQ ID NO 69
<211> LENGTH: 665 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 69 Ile Ile His
Thr Val Pro Pro Ser Gly Ala Asp Pro Gly Pro Lys Arg 1 5 10 15 Ala
Glu Phe Lys Gly Leu Arg Arg Gln Gln Lys Gln Gly Ile Ile Leu 20 25
30 Leu Thr Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Val
35 40 45 Leu Ala Gln Lys Leu Pro Gly Asn Asp Asn Asn Ser Glu Phe
Ile Thr 50 55 60 Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala
Gly Phe Phe Leu 65 70 75 80 Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser
Leu Asp Ser Trp Trp Thr 85 90 95 Ser Leu Asn Phe Leu Gly Gly Ser
Pro Val Cys Leu Gly Gln Asn Ser 100 105 110 Gln Ser Pro Thr Ser Asn
His Ser Pro Thr Ser Cys Pro Pro Ile Cys 115 120 125 Pro Gly Tyr Arg
Trp Met Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe 130 135 140 Ile Leu
Leu Leu Cys Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln 145 150 155
160 Gly Met Leu Pro Val Cys Pro Leu Ile Pro Gly Ser Thr Thr Thr Ser
165 170 175 Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro Ala Gln Gly Asn
Ser Lys 180 185 190 Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly
Asn Cys Thr Cys 195 200 205 Ile Pro Ile Pro Ser Ser Trp Ala Phe Ala
Lys Tyr Leu Trp Glu Trp 210 215 220 Ala Ser Val Arg Phe Ser Trp Leu
Ser Leu Leu Val Pro Phe Val Gln 225 230 235 240 Trp Phe Val Gly Leu
Ser Pro Thr Val Trp Leu Ser Ala Ile Trp Met 245 250 255 Met Trp Tyr
Trp Gly Pro Ser Leu Tyr Ser Ile Val Ser Pro Phe Ile 260 265 270 Pro
Leu Leu Pro Ile Phe Phe Cys Leu Trp Val Tyr Ile Gly Val Pro 275 280
285 Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys
290 295 300 Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala
Cys Val 305 310 315 320 Pro Thr Asp Pro Asn Pro Gln Glu Val Val Leu
Glu Asn Val Thr Glu 325 330 335 Asn Phe Asn Met Trp Lys Asn Asn Met
Val Glu Gln Met His Glu Asp 340 345 350 Ile Ile Ser Leu Trp Asp Gln
Ser Leu Lys Pro Cys Val Lys Leu Thr 355 360 365 Pro Leu Gln Ala Cys
Pro Lys Val Ser Phe Glu Pro Ile Pro Ile His 370 375 380 Tyr Cys Thr
Pro Ala Gly Phe Ala Ile Leu Lys Cys Lys Asp Lys Lys 385 390 395 400
Phe Asn Gly Thr Gly Pro Cys Lys Asn Val Ser Thr Val Gln Cys Thr
405 410 415 His Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn
Gly Ser 420 425 430 Leu Ala Glu Glu Glu Val Val Ile Arg Ser Ser Asn
Phe Thr Asp Asn 435 440 445 Ala Lys Asn Ile Ile Val Gln Leu Lys Glu
Ser Val Glu Ile Asn Cys 450 455 460 Thr Arg Pro Asn Asn Asn Thr Arg
Lys Ser Ile His Ile Gly Pro Gly 465 470 475 480 Arg Ala Phe Tyr Thr
Thr Gly Glu Ile Ile Gly Asp Ile Arg Gln Ala 485 490 495 His Cys Asn
Ile Ser Arg Thr Lys Trp Asn Asn Thr Leu Asn Gln Ile 500 505 510 Ala
Thr Lys Leu Lys Glu Gln Phe Gly Asn Asn Lys Thr Ile Val Phe 515 520
525 Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met His Ser Phe Asn
530 535 540 Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gln Leu Phe
Asn Ser 545 550 555 560 Thr Trp Asn Phe Asn Gly Thr Trp Asn Leu Thr
Gln Ser Asn Gly Thr 565 570 575 Glu Gly Asn Asp Thr Ile Thr Leu Pro
Cys Arg Ile Lys Gln Leu Ala 580 585 590 Met Tyr Ala Pro Pro Ile Arg
Gly Gln Ile Arg Cys Ser Ser Asn Ile 595 600 605 Thr Gly Leu Ile Leu
Thr Arg Asp Gly Gly Asn Asn His Asn Asn Asp 610 615 620 Thr Glu Thr
Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg 625 630 635 640
Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val 645
650 655 Ala Pro Thr Lys Ala Lys Arg Leu Val 660 665 <210> SEQ
ID NO 70 <211> LENGTH: 2000 <212> TYPE: DNA <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 70
ggattattca taccgtccca ccatcgggcg cggatcccgg tccgaagcgc gcggaattca
60 aaggcctacg tcgacagcaa aagcagggga taattctatt aaccatgaag
actatcattg 120 ctttgagcta cattttatgt ctggttctcg ctcaaaaact
tcccggaaat gacaacaaca 180 gcgaattcat cacctccggc ttcctgggcc
ccctgctggt gctgcaggcc ggcttcttcc 240 tgctgacccg catcctgacc
atcccccagt ccctggactc ctggtggacc tccctgaact 300 tcctgggcgg
ctcccccgtg tgcctgggcc agaactccca gtcccccacc tccaaccact 360
cccccacctc ctgccccccc atctgccccg gctaccgctg gatgtgcctg cgccgcttca
420 tcatcttcct gttcatcctg ctgctgtgcc tgatcttcct gctggtgctg
ctggactacc 480 agggcatgct gcccgtgtgc cccctgatcc ccggctccac
caccacctcc accggcccct 540 gcaagacctg caccaccccc gcccagggca
actccaagtt cccctcctgc tgctgcacca 600 agcccaccga cggcaactgc
acctgcatcc ccatcccctc ctcctgggcc ttcgccaagt 660 acctgtggga
gtgggcctcc gtgcgcttct cctggctgtc cctgctggtg cccttcgtgc 720
agtggttcgt gggcctgtcc cccaccgtgt ggctgtccgc catctggatg atgtggtact
780 ggggcccctc cctgtactcc atcgtgtccc ccttcatccc cctgctgccc
atcttcttct 840 gcctgtgggt gtacatcggg gtacctgtgt ggaaagaagc
aaccaccact ctattttgtg 900 catcagatgc taaagcatat gatacagagg
tacataatgt ttgggccaca catgcctgtg 960 tacccacaga ccccaaccca
caagaagtag tattggaaaa tgtgacagaa aattttaaca 1020 tgtggaaaaa
taacatggta gaacagatgc atgaggatat aatcagttta tgggatcaaa 1080
gcctaaagcc atgtgtaaaa ttaaccccac tccaggcctg tccaaaggta tcctttgagc
1140 caattcccat acattattgt accccggctg gttttgcgat tctaaagtgt
aaagacaaga 1200 agttcaatgg aacagggcca tgtaaaaatg tcagcacagt
acaatgtaca catggaatta 1260 ggccagtagt gtcaactcaa ctgctgttaa
atggcagtct agcagaagaa gaggtagtaa 1320 ttagatctag taatttcaca
gacaatgcaa aaaacataat agtacagttg aaagaatctg 1380 tagaaattaa
ttgtacaaga cccaacaaca atacaaggaa aagtatacat ataggaccag 1440
gaagagcatt ttatacaaca ggagaaataa taggagatat aagacaagca cattgcaaca
1500 ttagtagaac aaaatggaat aacactttaa atcaaatagc tacaaaatta
aaagaacaat 1560 ttgggaataa taaaacaata gtctttaatc aatcctcagg
aggggaccca gaaattgtaa 1620 tgcacagttt taattgtgga ggggaatttt
tctactgtaa ttcaacacaa ctgtttaata 1680 gtacttggaa ttttaatggt
acttggaatt taacacaatc gaatggtact gaaggaaatg 1740 acactatcac
actcccatgt agaataaaac agctagcaat gtatgcccct cccatcagag 1800
gacaaattag atgctcatca aatattacag ggctaatatt aacaagagat ggtggaaata
1860 accacaataa tgataccgag acctttagac ctggaggagg agatatgagg
gacaattgga 1920 gaagtgaatt atataaatat aaagtagtaa aaattgaacc
attaggagta gcacccacca 1980 aggcaaaaag atgactagtc 2000 <210>
SEQ ID NO 71 <211> LENGTH: 665 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 71 Ile Ile His Thr Val Pro Pro Ser Gly Ala Asp Pro Gly
Pro Lys Arg 1 5 10 15 Ala Glu Phe Lys Gly Leu Arg Arg Gln Gln Lys
Gln Gly Ile Ile Leu 20 25 30 Leu Thr Met Lys Thr Ile Ile Ala Leu
Ser Tyr Ile Leu Cys Leu Val 35 40 45 Leu Ala Gln Lys Leu Pro Gly
Asn Asp Asn Asn Ser Glu Phe Ile Thr 50 55 60 Ser Gly Phe Leu Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu 65 70 75 80 Leu Thr Arg
Ile Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr 85 90 95 Ser
Leu Asn Phe Leu Gly Gly Ser Pro Val Cys Leu Gly Gln Asn Ser 100 105
110 Gln Ser Pro Thr Ser Asn His Ser Pro Thr Ser Cys Pro Pro Ile Cys
115 120 125 Pro Gly Tyr Arg Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe 130 135 140 Ile Leu Leu Leu Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Gln 145 150 155 160 Gly Met Leu Pro Val Cys Pro Leu Ile
Pro Gly Ser Thr Thr Thr Ser 165 170 175 Thr Gly Pro Cys Lys Thr Cys
Thr Thr Pro Ala Gln Gly Asn Ser Lys 180 185 190 Phe Pro Ser Cys Cys
Cys Thr Lys Pro Thr Asp Gly Asn Cys Thr Cys 195 200 205 Ile Pro Ile
Pro Ser Ser Trp Ala Phe Ala Lys Tyr Leu Trp Glu Trp 210 215 220 Ala
Ser Val Arg Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln 225 230
235 240 Trp Phe Val Gly Leu Ser Pro Thr Val Trp Leu Ser Ala Ile Trp
Met 245 250 255 Met Trp Tyr Trp Gly Pro Ser Leu Tyr Ser Ile Val Ser
Pro Phe Ile 260 265 270 Pro Leu Leu Pro Ile Phe Phe Cys Leu Trp Val
Tyr Ile Gly Val Pro 275 280 285 Val Trp Lys Glu Ala Thr Thr Thr Leu
Phe Cys Ala Ser Asp Ala Lys 290 295 300 Ala Tyr Asp Thr Glu Val His
Asn Val Trp Ala Thr His Ala Cys Val 305 310 315 320 Pro Thr Asp Pro
Asn Pro Gln Glu Val Glu Leu Glu Asn Val Thr Glu 325 330 335 Asn Phe
Asn Met Trp Lys Asn Asn Met Val Glu Gln Met His Glu Asp 340 345 350
Ile Ile Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr 355
360 365 Pro Leu Gln Ala Cys Pro Lys Ile Ser Phe Glu Pro Ile Pro Ile
His 370 375 380 Tyr Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys Cys Lys
Asp Lys Lys 385 390 395 400 Phe Asn Gly Lys Gly Pro Cys Ser Asn Val
Ser Thr Val Gln Cys Thr 405 410 415 His Gly Ile Arg Pro Val Val Ser
Thr Gln Leu Leu Leu Asn Gly Ser 420 425 430 Leu Ala Glu Glu Glu Val
Val Ile Arg Ser Glu Asn Phe Ala Asp Asn 435 440 445 Ala Lys Thr Ile
Ile Val Gln Leu Asn Glu Ser Val Glu Ile Asn Cys 450 455 460 Thr Arg
Pro Asn Asn Asn Thr Arg Lys Ser Ile His Ile Gly Pro Gly 465 470 475
480 Arg Ala Leu Tyr Thr Thr Gly Glu Ile Ile Gly Asp Ile Arg Gln Ala
485 490 495 His Cys Asn Leu Ser Arg Ala Lys Trp Asn Asp Thr Leu Asn
Lys Ile 500 505 510 Val Ile Lys Leu Arg Glu Gln Phe Gly Asn Lys Thr
Ile Val Phe Lys 515 520 525 His Ser Ser Gly Gly Asp Pro Glu Ile Val
Thr His Ser Phe Asn Cys 530 535 540 Gly Gly Glu Phe Phe Tyr Cys Asn
Ser Thr Gln Leu Phe Asn Ser Thr 545 550 555 560 Trp Asn Val Thr Glu
Glu Ser Asn Asn Thr Val Glu Asn Asn Thr Ile 565 570 575 Thr Leu Pro
Cys Arg Ile Lys Gln Leu Ala Met Tyr Ala Pro Pro Ile 580 585 590 Arg
Gly Gln Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu Thr 595 600
605 Arg Asp Gly Gly Pro Glu Asp Asn Lys Thr Glu Val Phe Arg Pro Gly
610 615 620
Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys 625
630 635 640 Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala
Lys Arg 645 650 655 Leu Val Ala Ala Ala Phe Glu Ser Arg 660 665
<210> SEQ ID NO 72 <211> LENGTH: 2000 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 72 Gly Gly Ala Thr Thr Ala Thr Thr Cys Ala Thr Ala Cys
Cys Gly Thr 1 5 10 15 Cys Cys Cys Ala Cys Cys Ala Thr Cys Gly Gly
Gly Cys Gly Cys Gly 20 25 30 Gly Ala Thr Cys Cys Cys Gly Gly Thr
Cys Cys Gly Ala Ala Gly Cys 35 40 45 Gly Cys Gly Cys Gly Gly Ala
Ala Thr Thr Cys Ala Ala Ala Gly Gly 50 55 60 Cys Cys Thr Ala Cys
Gly Thr Cys Gly Ala Cys Ala Gly Cys Ala Ala 65 70 75 80 Ala Ala Gly
Cys Ala Gly Gly Gly Gly Ala Thr Ala Ala Thr Thr Cys 85 90 95 Thr
Ala Thr Thr Ala Ala Cys Cys Ala Thr Gly Ala Ala Gly Ala Cys 100 105
110 Thr Ala Thr Cys Ala Thr Thr Gly Cys Thr Thr Thr Gly Ala Gly Cys
115 120 125 Thr Ala Cys Ala Thr Thr Thr Thr Ala Thr Gly Thr Cys Thr
Gly Gly 130 135 140 Thr Thr Cys Thr Cys Gly Cys Thr Cys Ala Ala Ala
Ala Ala Cys Thr 145 150 155 160 Thr Cys Cys Cys Gly Gly Ala Ala Ala
Thr Gly Ala Cys Ala Ala Cys 165 170 175 Ala Ala Cys Ala Gly Cys Gly
Ala Ala Thr Thr Cys Ala Thr Cys Ala 180 185 190 Cys Cys Thr Cys Cys
Gly Gly Cys Thr Thr Cys Cys Thr Gly Gly Gly 195 200 205 Cys Cys Cys
Cys Cys Thr Gly Cys Thr Gly Gly Thr Gly Cys Thr Gly 210 215 220 Cys
Ala Gly Gly Cys Cys Gly Gly Cys Thr Thr Cys Thr Thr Cys Cys 225 230
235 240 Thr Gly Cys Thr Gly Ala Cys Cys Cys Gly Cys Ala Thr Cys Cys
Thr 245 250 255 Gly Ala Cys Cys Ala Thr Cys Cys Cys Cys Cys Ala Gly
Thr Cys Cys 260 265 270 Cys Thr Gly Gly Ala Cys Thr Cys Cys Thr Gly
Gly Thr Gly Gly Ala 275 280 285 Cys Cys Thr Cys Cys Cys Thr Gly Ala
Ala Cys Thr Thr Cys Cys Thr 290 295 300 Gly Gly Gly Cys Gly Gly Cys
Thr Cys Cys Cys Cys Cys Gly Thr Gly 305 310 315 320 Thr Gly Cys Cys
Thr Gly Gly Gly Cys Cys Ala Gly Ala Ala Cys Thr 325 330 335 Cys Cys
Cys Ala Gly Thr Cys Cys Cys Cys Cys Ala Cys Cys Thr Cys 340 345 350
Cys Ala Ala Cys Cys Ala Cys Thr Cys Cys Cys Cys Cys Ala Cys Cys 355
360 365 Thr Cys Cys Thr Gly Cys Cys Cys Cys Cys Cys Cys Ala Thr Cys
Thr 370 375 380 Gly Cys Cys Cys Cys Gly Gly Cys Thr Ala Cys Cys Gly
Cys Thr Gly 385 390 395 400 Gly Ala Thr Gly Thr Gly Cys Cys Thr Gly
Cys Gly Cys Cys Gly Cys 405 410 415 Thr Thr Cys Ala Thr Cys Ala Thr
Cys Thr Thr Cys Cys Thr Gly Thr 420 425 430 Thr Cys Ala Thr Cys Cys
Thr Gly Cys Thr Gly Cys Thr Gly Thr Gly 435 440 445 Cys Cys Thr Gly
Ala Thr Cys Thr Thr Cys Cys Thr Gly Cys Thr Gly 450 455 460 Gly Thr
Gly Cys Thr Gly Cys Thr Gly Gly Ala Cys Thr Ala Cys Cys 465 470 475
480 Ala Gly Gly Gly Cys Ala Thr Gly Cys Thr Gly Cys Cys Cys Gly Thr
485 490 495 Gly Thr Gly Cys Cys Cys Cys Cys Thr Gly Ala Thr Cys Cys
Cys Cys 500 505 510 Gly Gly Cys Thr Cys Cys Ala Cys Cys Ala Cys Cys
Ala Cys Cys Thr 515 520 525 Cys Cys Ala Cys Cys Gly Gly Cys Cys Cys
Cys Thr Gly Cys Ala Ala 530 535 540 Gly Ala Cys Cys Thr Gly Cys Ala
Cys Cys Ala Cys Cys Cys Cys Cys 545 550 555 560 Gly Cys Cys Cys Ala
Gly Gly Gly Cys Ala Ala Cys Thr Cys Cys Ala 565 570 575 Ala Gly Thr
Thr Cys Cys Cys Cys Thr Cys Cys Thr Gly Cys Thr Gly 580 585 590 Cys
Thr Gly Cys Ala Cys Cys Ala Ala Gly Cys Cys Cys Ala Cys Cys 595 600
605 Gly Ala Cys Gly Gly Cys Ala Ala Cys Thr Gly Cys Ala Cys Cys Thr
610 615 620 Gly Cys Ala Thr Cys Cys Cys Cys Ala Thr Cys Cys Cys Cys
Thr Cys 625 630 635 640 Cys Thr Cys Cys Thr Gly Gly Gly Cys Cys Thr
Thr Cys Gly Cys Cys 645 650 655 Ala Ala Gly Thr Ala Cys Cys Thr Gly
Thr Gly Gly Gly Ala Gly Thr 660 665 670 Gly Gly Gly Cys Cys Thr Cys
Cys Gly Thr Gly Cys Gly Cys Thr Thr 675 680 685 Cys Thr Cys Cys Thr
Gly Gly Cys Thr Gly Thr Cys Cys Cys Thr Gly 690 695 700 Cys Thr Gly
Gly Thr Gly Cys Cys Cys Thr Thr Cys Gly Thr Gly Cys 705 710 715 720
Ala Gly Thr Gly Gly Thr Thr Cys Gly Thr Gly Gly Gly Cys Cys Thr 725
730 735 Gly Thr Cys Cys Cys Cys Cys Ala Cys Cys Gly Thr Gly Thr Gly
Gly 740 745 750 Cys Thr Gly Thr Cys Cys Gly Cys Cys Ala Thr Cys Thr
Gly Gly Ala 755 760 765 Thr Gly Ala Thr Gly Thr Gly Gly Thr Ala Cys
Thr Gly Gly Gly Gly 770 775 780 Cys Cys Cys Cys Thr Cys Cys Cys Thr
Gly Thr Ala Cys Thr Cys Cys 785 790 795 800 Ala Thr Cys Gly Thr Gly
Thr Cys Cys Cys Cys Cys Thr Thr Cys Ala 805 810 815 Thr Cys Cys Cys
Cys Cys Thr Gly Cys Thr Gly Cys Cys Cys Ala Thr 820 825 830 Cys Thr
Thr Cys Thr Thr Cys Thr Gly Cys Cys Thr Gly Thr Gly Gly 835 840 845
Gly Thr Gly Thr Ala Cys Ala Thr Cys Gly Gly Gly Gly Thr Ala Cys 850
855 860 Cys Thr Gly Thr Gly Thr Gly Gly Ala Ala Ala Gly Ala Ala Gly
Cys 865 870 875 880 Ala Ala Cys Cys Ala Cys Cys Ala Cys Thr Cys Thr
Ala Thr Thr Thr 885 890 895 Thr Gly Thr Gly Cys Ala Thr Cys Ala Gly
Ala Thr Gly Cys Thr Ala 900 905 910 Ala Ala Gly Cys Ala Thr Ala Thr
Gly Ala Thr Ala Cys Ala Gly Ala 915 920 925 Gly Gly Thr Ala Cys Ala
Thr Ala Ala Thr Gly Thr Thr Thr Gly Gly 930 935 940 Gly Cys Cys Ala
Cys Ala Cys Ala Thr Gly Cys Cys Thr Gly Thr Gly 945 950 955 960 Thr
Ala Cys Cys Cys Ala Cys Ala Gly Ala Cys Cys Cys Cys Ala Ala 965 970
975 Cys Cys Cys Ala Cys Ala Ala Gly Ala Ala Gly Thr Ala Gly Ala Ala
980 985 990 Thr Thr Gly Gly Ala Ala Ala Ala Thr Gly Thr Gly Ala Cys
Ala Gly 995 1000 1005 Ala Ala Ala Ala Thr Thr Thr Thr Ala Ala Cys
Ala Thr Gly Thr 1010 1015 1020 Gly Gly Ala Ala Ala Ala Ala Thr Ala
Ala Cys Ala Thr Gly Gly 1025 1030 1035 Thr Ala Gly Ala Ala Cys Ala
Gly Ala Thr Gly Cys Ala Thr Gly 1040 1045 1050 Ala Gly Gly Ala Thr
Ala Thr Ala Ala Thr Cys Ala Gly Thr Thr 1055 1060 1065 Thr Ala Thr
Gly Gly Gly Ala Thr Cys Ala Ala Ala Gly Cys Cys 1070 1075 1080 Thr
Ala Ala Ala Gly Cys Cys Ala Thr Gly Thr Gly Thr Ala Ala 1085 1090
1095 Ala Ala Thr Thr Ala Ala Cys Thr Cys Cys Ala Cys Thr Cys Cys
1100 1105 1110 Ala Gly Gly Cys Cys Thr Gly Thr Cys Cys Ala Ala Ala
Gly Ala 1115 1120 1125 Thr Ala Thr Cys Cys Thr Thr Thr Gly Ala Gly
Cys Cys Ala Ala 1130 1135 1140 Thr Thr Cys Cys Cys Ala Thr Ala Cys
Ala Thr Thr Ala Thr Thr 1145 1150 1155 Gly Thr Gly Cys Cys Cys Cys
Gly Gly Cys Thr Gly Gly Thr Thr 1160 1165 1170 Thr Thr Gly Cys Gly
Ala Thr Thr Cys Thr Ala Ala Ala Gly Thr 1175 1180 1185 Gly Thr Ala
Ala Ala Gly Ala Thr Ala Ala Gly Ala Ala Gly Thr 1190 1195 1200 Thr
Cys Ala Ala Thr Gly Gly Ala Ala Ala Ala Gly Gly Ala Cys 1205 1210
1215 Cys Ala Thr Gly Thr Thr Cys Ala Ala Ala Thr Gly Thr Cys Ala
1220 1225 1230
Gly Cys Ala Cys Ala Gly Thr Ala Cys Ala Ala Thr Gly Thr Ala 1235
1240 1245 Cys Ala Cys Ala Thr Gly Gly Gly Ala Thr Thr Ala Gly Gly
Cys 1250 1255 1260 Cys Ala Gly Thr Ala Gly Thr Ala Thr Cys Ala Ala
Cys Thr Cys 1265 1270 1275 Ala Ala Cys Thr Gly Cys Thr Gly Thr Thr
Ala Ala Ala Thr Gly 1280 1285 1290 Gly Cys Ala Gly Thr Cys Thr Ala
Gly Cys Ala Gly Ala Ala Gly 1295 1300 1305 Ala Ala Gly Ala Gly Gly
Thr Ala Gly Thr Ala Ala Thr Thr Ala 1310 1315 1320 Gly Ala Thr Cys
Cys Gly Ala Ala Ala Ala Thr Thr Thr Cys Gly 1325 1330 1335 Cys Gly
Gly Ala Cys Ala Ala Thr Gly Cys Thr Ala Ala Ala Ala 1340 1345 1350
Cys Cys Ala Thr Ala Ala Thr Ala Gly Thr Ala Cys Ala Gly Cys 1355
1360 1365 Thr Gly Ala Ala Thr Gly Ala Ala Thr Cys Thr Gly Thr Ala
Gly 1370 1375 1380 Ala Ala Ala Thr Thr Ala Ala Thr Thr Gly Thr Ala
Cys Ala Ala 1385 1390 1395 Gly Ala Cys Cys Cys Ala Ala Cys Ala Ala
Cys Ala Ala Thr Ala 1400 1405 1410 Cys Ala Ala Gly Ala Ala Ala Ala
Ala Gly Thr Ala Thr Ala Cys 1415 1420 1425 Ala Thr Ala Thr Ala Gly
Gly Ala Cys Cys Ala Gly Gly Cys Ala 1430 1435 1440 Gly Ala Gly Cys
Ala Thr Thr Ala Thr Ala Thr Ala Cys Ala Ala 1445 1450 1455 Cys Ala
Gly Gly Ala Gly Ala Ala Ala Thr Ala Ala Thr Ala Gly 1460 1465 1470
Gly Ala Gly Ala Thr Ala Thr Ala Ala Gly Ala Cys Ala Ala Gly 1475
1480 1485 Cys Ala Cys Ala Thr Thr Gly Thr Ala Ala Cys Cys Thr Thr
Ala 1490 1495 1500 Gly Thr Ala Gly Ala Gly Cys Ala Ala Ala Ala Thr
Gly Gly Ala 1505 1510 1515 Ala Thr Gly Ala Cys Ala Cys Thr Thr Thr
Ala Ala Ala Thr Ala 1520 1525 1530 Ala Gly Ala Thr Ala Gly Thr Thr
Ala Thr Ala Ala Ala Ala Thr 1535 1540 1545 Thr Ala Ala Gly Ala Gly
Ala Ala Cys Ala Ala Thr Thr Thr Gly 1550 1555 1560 Gly Gly Ala Ala
Thr Ala Ala Ala Ala Cys Ala Ala Thr Ala Gly 1565 1570 1575 Thr Cys
Thr Thr Thr Ala Ala Gly Cys Ala Thr Thr Cys Cys Thr 1580 1585 1590
Cys Ala Gly Gly Ala Gly Gly Gly Gly Ala Cys Cys Cys Ala Gly 1595
1600 1605 Ala Ala Ala Thr Thr Gly Thr Gly Ala Cys Gly Cys Ala Cys
Ala 1610 1615 1620 Gly Thr Thr Thr Thr Ala Ala Thr Thr Gly Thr Gly
Gly Ala Gly 1625 1630 1635 Gly Gly Gly Ala Ala Thr Thr Thr Thr Thr
Cys Thr Ala Cys Thr 1640 1645 1650 Gly Thr Ala Ala Thr Thr Cys Ala
Ala Cys Ala Cys Ala Ala Cys 1655 1660 1665 Thr Gly Thr Thr Thr Ala
Ala Thr Ala Gly Thr Ala Cys Thr Thr 1670 1675 1680 Gly Gly Ala Ala
Thr Gly Thr Thr Ala Cys Thr Gly Ala Ala Gly 1685 1690 1695 Ala Gly
Thr Cys Ala Ala Ala Thr Ala Ala Cys Ala Cys Thr Gly 1700 1705 1710
Thr Ala Gly Ala Ala Ala Ala Thr Ala Ala Cys Ala Cys Ala Ala 1715
1720 1725 Thr Cys Ala Cys Ala Cys Thr Cys Cys Cys Ala Thr Gly Cys
Ala 1730 1735 1740 Gly Ala Ala Thr Ala Ala Ala Ala Cys Ala Gly Cys
Thr Ala Gly 1745 1750 1755 Cys Ala Ala Thr Gly Thr Ala Thr Gly Cys
Cys Cys Cys Thr Cys 1760 1765 1770 Cys Cys Ala Thr Cys Ala Gly Ala
Gly Gly Ala Cys Ala Ala Ala 1775 1780 1785 Thr Thr Ala Gly Ala Thr
Gly Thr Thr Cys Ala Thr Cys Ala Ala 1790 1795 1800 Ala Thr Ala Thr
Thr Ala Cys Ala Gly Gly Gly Cys Thr Gly Cys 1805 1810 1815 Thr Ala
Thr Thr Ala Ala Cys Ala Ala Gly Ala Gly Ala Thr Gly 1820 1825 1830
Gly Thr Gly Gly Thr Cys Cys Ala Gly Ala Gly Gly Ala Cys Ala 1835
1840 1845 Ala Cys Ala Ala Gly Ala Cys Cys Gly Ala Gly Gly Thr Cys
Thr 1850 1855 1860 Thr Cys Ala Gly Ala Cys Cys Thr Gly Gly Ala Gly
Gly Ala Gly 1865 1870 1875 Gly Ala Gly Ala Thr Ala Thr Gly Ala Gly
Gly Gly Ala Cys Ala 1880 1885 1890 Ala Thr Thr Gly Gly Ala Gly Ala
Ala Gly Thr Gly Ala Ala Thr 1895 1900 1905 Thr Ala Thr Ala Thr Ala
Ala Ala Thr Ala Thr Ala Ala Ala Gly 1910 1915 1920 Thr Ala Gly Thr
Ala Ala Ala Ala Ala Thr Thr Gly Ala Ala Cys 1925 1930 1935 Cys Ala
Thr Thr Ala Gly Gly Ala Gly Thr Ala Gly Cys Ala Cys 1940 1945 1950
Cys Cys Ala Cys Cys Ala Ala Gly Gly Cys Ala Ala Ala Gly Ala 1955
1960 1965 Gly Ala Thr Gly Ala Cys Thr Ala Gly Thr Cys Gly Cys Gly
Gly 1970 1975 1980 Cys Cys Gly Cys Thr Thr Thr Cys Gly Ala Ala Thr
Cys Thr Ala 1985 1990 1995 Gly Ala 2000 <210> SEQ ID NO 73
<211> LENGTH: 665 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 73 Ile Ile His
Thr Val Pro Pro Ser Gly Ala Asp Pro Gly Pro Lys Arg 1 5 10 15 Ala
Glu Phe Lys Gly Leu Arg Arg Gln Gln Lys Gln Gly Ile Ile Leu 20 25
30 Leu Thr Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Val
35 40 45 Leu Ala Gln Lys Leu Pro Gly Asn Asp Asn Asn Ser Glu Phe
Ile Thr 50 55 60 Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala
Gly Phe Phe Leu 65 70 75 80 Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser
Leu Asp Ser Trp Trp Thr 85 90 95 Ser Leu Asn Phe Leu Gly Gly Ser
Pro Val Cys Leu Gly Gln Asn Ser 100 105 110 Gln Ser Pro Thr Ser Asn
His Ser Pro Thr Ser Cys Pro Pro Ile Cys 115 120 125 Pro Gly Tyr Arg
Trp Met Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe 130 135 140 Ile Leu
Leu Leu Cys Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln 145 150 155
160 Gly Met Leu Pro Val Cys Pro Leu Ile Pro Gly Ser Thr Thr Thr Ser
165 170 175 Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro Ala Gln Gly Asn
Ser Lys 180 185 190 Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly
Asn Cys Thr Cys 195 200 205 Ile Pro Ile Pro Ser Ser Trp Ala Phe Ala
Lys Tyr Leu Trp Glu Trp 210 215 220 Ala Ser Val Arg Phe Ser Trp Leu
Ser Leu Leu Val Pro Phe Val Gln 225 230 235 240 Trp Phe Val Gly Leu
Ser Pro Thr Val Trp Leu Ser Ala Ile Trp Met 245 250 255 Met Trp Tyr
Trp Gly Pro Ser Leu Tyr Ser Ile Val Ser Pro Phe Ile 260 265 270 Pro
Leu Leu Pro Ile Phe Phe Cys Leu Trp Val Tyr Ile Gly Val Pro 275 280
285 Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys
290 295 300 Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala
Cys Val 305 310 315 320 Pro Thr Asp Pro Asn Pro Gln Glu Val Val Leu
Val Asn Val Thr Glu 325 330 335 Asn Phe Asn Met Trp Lys Asn Asp Met
Val Glu Gln Met His Glu Asp 340 345 350 Ile Ile Ser Leu Trp Asp Gln
Ser Leu Lys Pro Cys Val Lys Leu Thr 355 360 365 Pro Leu Ser Val Gln
Ala Cys Pro Lys Val Ser Phe Glu Pro Ile Pro 370 375 380 Ile His Tyr
Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn Asn 385 390 395 400
Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gln 405
410 415 Cys Thr His Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu
Asn 420 425 430 Gly Ser Leu Ala Glu Glu Glu Val Val Ile Arg Ser Val
Asn Phe Thr 435 440 445 Asp Asn Ala Lys Thr Ile Ile Val Gln Leu Asn
Thr Ser Val Glu Ile 450 455 460
Asn Cys Thr Arg Pro Ser Val Asn Phe Thr Asp Asn Ala Lys Thr Ile 465
470 475 480 Ile Val Gln Leu Asn Thr Ser Val Glu Ile Asn Cys Thr Arg
Pro Met 485 490 495 Arg Gln Ala His Cys Asn Ile Ser Arg Ala Lys Trp
Asn Asn Thr Leu 500 505 510 Lys Gln Ile Ala Ser Lys Leu Arg Glu Gln
Phe Gly Asn Asn Lys Thr 515 520 525 Ile Ile Phe Lys Gln Ser Ser Gly
Gly Asp Pro Glu Ile Val Thr His 530 535 540 Ser Phe Asn Cys Gly Gly
Glu Phe Phe Tyr Cys Asn Ser Thr Gln Leu 545 550 555 560 Phe Asn Ser
Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu Gly Ser Asn 565 570 575 Asn
Thr Glu Gly Ser Asp Thr Ile Thr Leu Pro Cys Arg Ile Lys Gln 580 585
590 Ser Ile Ala Met Tyr Ala Pro Pro Ile Ser Gly Gln Ile Arg Cys Ser
595 600 605 Ser Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Asn
Ser Asn 610 615 620 Asn Glu Ser Glu Ile Phe Arg Pro Gly Gly Gly Asp
Met Arg Asp Asn 625 630 635 640 Trp Arg Ser Glu Leu Tyr Lys Tyr Lys
Val Val Lys Ile Glu Pro Leu 645 650 655 Gly Val Ala Pro Thr Lys Ala
Lys Arg 660 665 <210> SEQ ID NO 74 <211> LENGTH: 2000
<212> TYPE: DNA <213> ORGANISM: Human immunodeficiency
virus <400> SEQUENCE: 74 ggattattca taccgtccca ccatcgggcg
cggatcccgg tccgaagcgc gcggaattca 60 aaggcctacg tcgacagcaa
aagcagggga taattctatt aaccatgaag actatcattg 120 ctttgagcta
cattttatgt ctggttctcg ctcaaaaact tcccggaaat gacaacaaca 180
gcgaattcat cacctccggc ttcctgggcc ccctgctggt gctgcaggcc ggcttcttcc
240 tgctgacccg catcctgacc atcccccagt ccctggactc ctggtggacc
tccctgaact 300 tcctgggcgg ctcccccgtg tgcctgggcc agaactccca
gtcccccacc tccaaccact 360 cccccacctc ctgccccccc atctgccccg
gctaccgctg gatgtgcctg cgccgcttca 420 tcatcttcct gttcatcctg
ctgctgtgcc tgatcttcct gctggtgctg ctggactacc 480 agggcatgct
gcccgtgtgc cccctgatcc ccggctccac caccacctcc accggcccct 540
gcaagacctg caccaccccc gcccagggca actccaagtt cccctcctgc tgctgcacca
600 agcccaccga cggcaactgc acctgcatcc ccatcccctc ctcctgggcc
ttcgccaagt 660 acctgtggga gtgggcctcc gtgcgcttct cctggctgtc
cctgctggtg cccttcgtgc 720 agtggttcgt gggcctgtcc cccaccgtgt
ggctgtccgc catctggatg atgtggtact 780 ggggcccctc cctgtactcc
atcgtgtccc ccttcatccc cctgctgccc atcttcttct 840 gcctgtgggt
gtacatcggg gtacctgtgt ggaaggaagc aaccaccact ctattttgtg 900
catcagatgc taaagcatat gatacagagg tacataatgt ttgggccaca catgcctgtg
960 tacccacaga ccccaaccca caagaagtag tattggtaaa tgtgacagaa
aattttaaca 1020 tgtggaaaaa tgacatggta gaacagatgc atgaggatat
aatcagttta tgggatcaaa 1080 gcctaaagcc atgtgtaaaa ttaaccccac
tctcggtcca ggcctgtcca aaggtatcct 1140 ttgagccaat tcccatacat
tattgtgccc cggctggttt tgcgattcta aaatgtaata 1200 ataagacgtt
caatggaaca ggaccatgta caaatgtcag cacagtacaa tgtacacatg 1260
gaattaggcc agtagtatca actcaactgc tgttaaatgg cagtctagca gaagaagagg
1320 tagtaattag atctgtcaat ttcacggaca atgctaaaac cataatagta
cagctgaaca 1380 catctgtaga aattaattgt acaagaccct ctgtcaattt
cacggacaat gctaaaacca 1440 taatagtaca gctgaacaca tctgtagaaa
ttaattgtac aagacccatg agacaagcac 1500 attgtaacat tagtagagca
aaatggaata acactttaaa acagatagct agcaaattaa 1560 gagaacaatt
tggaaataat aaaacaataa tctttaagca atcctcagga ggggacccag 1620
aaattgtaac gcacagtttt aattgtggag gggaattttt ctactgtaat tcaacacaac
1680 tgtttaatag tacttggttt aatagtactt ggagtactga agggtcaaat
aacactgaag 1740 gaagtgacac aatcaccctc ccatgcagaa taaaacaatc
gatagcaatg tatgcccctc 1800 ccatcagtgg acaaattaga tgttcatcaa
atattacagg gctgctatta acaagagatg 1860 gtggtaatag caacaatgag
tccgagatct tcagacctgg aggaggagat atgagggaca 1920 attggagaag
tgaattatat aaatataaag tagtaaaaat tgaaccatta ggagtagcac 1980
ccaccaaggc aaagagataa 2000 <210> SEQ ID NO 75 <211>
LENGTH: 50 <212> TYPE: DNA <213> ORGANISM: Artificial
sequence <220> FEATURE: <223> OTHER INFORMATION:
Synthetic neucleic acid primer. <400> SEQUENCE: 75 cggcggccgc
accggtcgcc accatggccc agtccaagca cggcctgacc 50 <210> SEQ ID
NO 76 <211> LENGTH: 47 <212> TYPE: DNA <213>
ORGANISM: Artificial sequence <220> FEATURE: <223>
OTHER INFORMATION: Synthetic neucleic acid primer. <400>
SEQUENCE: 76 tggcggccgc tctagatccg gtggatcccg ggcccgcggt accgtcg 47
<210> SEQ ID NO 77 <211> LENGTH: 366 <212> TYPE:
PRT <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert peptide
construct. <400> SEQUENCE: 77 Pro Gln Gly Ala Arg Met Ala Ser
Thr Thr Pro Ile Thr Met Glu Asp 1 5 10 15 Leu Gln Lys Ala Leu Glu
Ala Gln Ser Arg Ala Leu Arg Ala Asp Leu 20 25 30 Ala Ala Gly Ala
Ser Gln Ser Arg Arg Pro Arg Pro Pro Arg Gln Arg 35 40 45 Asp Ser
Ser Thr Ser Gly Asp Asp Ser Gly Arg Asp Ser Gly Gly Pro 50 55 60
Arg Arg Arg Arg Gly Asn Arg Gly Arg Gly Gln Arg Arg Asp Trp Ser 65
70 75 80 Arg Ala Pro Pro Pro Pro Glu Glu Arg Gln Glu Ser Arg Ser
Gln Thr 85 90 95 Pro Ala Pro Lys Pro Ser Arg Ala Pro Pro Gln Gln
Pro Gln Pro Pro 100 105 110 Arg Met Gln Thr Gly Arg Gly Gly Ser Ala
Pro Arg Pro Glu Leu Gly 115 120 125 Pro Pro Thr Asn Pro Phe Gln Ala
Ala Val Ala Arg Gly Leu Arg Pro 130 135 140 Pro Leu His Asp Pro Asp
Thr Glu Ala Pro Thr Glu Ala Cys Val Thr 145 150 155 160 Ser Trp Leu
Trp Ser Glu Gly Glu Gly Ala Val Phe Tyr Arg Val Asp 165 170 175 Leu
His Phe Thr Asn Leu Gly Thr Pro Pro Leu Asp Glu Asp Gly Arg 180 185
190 Trp Asp Pro Ala Leu Met Tyr Asn Pro Cys Gly Pro Glu Pro Pro Ala
195 200 205 His Val Val Arg Ala Tyr Asn Gln Pro Ala Gly Asp Val Arg
Gly Val 210 215 220 Trp Gly Lys Gly Glu Arg Thr Tyr Ala Glu Gln Asp
Phe Arg Val Gly 225 230 235 240 Gly Thr Arg Trp His Arg Leu Leu Arg
Met Pro Val Arg Gly Leu Asp 245 250 255 Gly Asp Ser Ala Pro Leu Pro
Pro Tyr Thr Thr Glu Arg Ile Glu Thr 260 265 270 Arg Ser Ala Arg His
Pro Trp Arg Ile Arg Phe Gly Ala Pro Gln Ala 275 280 285 Phe Leu Ala
Gly Leu Leu Leu Ala Thr Val Ala Val Gly Thr Ala Arg 290 295 300 Ala
Gly Leu Gln Pro Arg Ala Asp Met Ala Ala Pro Pro Thr Leu Pro 305 310
315 320 Arg Ser Ala Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu Asp
Lys 325 330 335 Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp
Leu Trp Tyr 340 345 350 Ile Arg Leu Phe Ile Asp Ala Ser Thr Arg Ser
Ala Arg His 355 360 365 <210> SEQ ID NO 78 <211>
LENGTH: 367 <212> TYPE: PRT <213> ORGANISM: Artificial
sequence <220> FEATURE: <223> OTHER INFORMATION:
Recombinant antigenic insert peptide construct. <400>
SEQUENCE: 78 Asp Ser Ala Pro Leu Pro Pro His Thr Thr Glu Arg Ile
Glu Thr Arg 1 5 10 15 Ser Ala Arg His Pro Trp Arg Ile Arg Phe Gly
Ala Pro Gln Ala Phe 20 25 30 Leu Ala Gly Leu Leu Leu Ala Thr Val
Ala Val Gly Thr Ala Arg Ala 35 40 45 Gly Pro Arg Ser Ala Gln Glu
Lys Asn Glu Lys Glu Leu Leu Glu Leu 50 55 60 Asp Lys Trp Ala Ser
Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu 65 70 75 80 Trp Tyr Ile
Arg Leu Phe Ile Asp Ala Ser Ala Gly Leu Gln Pro Arg 85 90 95 Ala
Asp Met Ala Ala Pro Pro Thr Leu Pro Gln Pro Pro Cys Ala His 100 105
110
Gly Gln His Tyr Gly His His His His Gln Leu Pro Phe Leu Gly His 115
120 125 Asp Gly His His Gly Gly Thr Leu Arg Val Gly Gln His Tyr Arg
Asn 130 135 140 Ala Ser Asp Val Leu Pro Gly His Trp Leu Gln Gly Gly
Trp Gly Cys 145 150 155 160 Tyr Asn Leu Ser Asp Trp His Gln Gly Thr
His Val Cys His Thr Lys 165 170 175 His Met Asp Phe Trp Cys Val Glu
His Asp Arg Pro Pro Pro Ala Thr 180 185 190 Pro Thr Pro Leu Thr Thr
Ala Ala Asn Ser Thr Thr Ala Ala Thr Pro 195 200 205 Ala Thr Ala Pro
Ala Pro Cys His Ala Gly Leu Asn Asp Ser Cys Gly 210 215 220 Gly Phe
Leu Ser Gly Cys Gly Pro Met Arg Leu Arg His Gly Ala Asp 225 230 235
240 Thr Arg Cys Gly Arg Leu Ile Cys Gly Leu Ser Thr Thr Ala Gln Tyr
245 250 255 Pro Pro Thr Arg Phe Gly Cys Ala Met Arg Trp Gly Leu Pro
Pro Trp 260 265 270 Glu Leu Val Val Leu Thr Ala Arg Pro Glu Asp Gly
Trp Thr Cys Arg 275 280 285 Gly Val Pro Ala His Pro Gly Ala Arg Cys
Pro Glu Leu Val Ser Pro 290 295 300 Met Gly Arg Ala Thr Cys Ser Pro
Ala Ser Ala Leu Trp Leu Ala Thr 305 310 315 320 Ala Asn Ala Leu Ser
Leu Asp His Ala Leu Ala Ala Phe Val Leu Leu 325 330 335 Val Pro Trp
Val Leu Ile Phe Met Val Cys Arg Arg Ala Cys Arg Arg 340 345 350 Arg
Gly Ala Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr 355 360 365
<210> SEQ ID NO 79 <211> LENGTH: 367 <212> TYPE:
PRT <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert peptide
construct. <400> SEQUENCE: 79 Ala Gly Leu Leu Leu Ala Thr Val
Ala Val Gly Thr Ala Arg Ala Gly 1 5 10 15 Leu Gln Pro Arg Ala Asp
Met Ala Ala Pro Pro Thr Leu Pro Gln Pro 20 25 30 Pro Cys Ala His
Gly Gln His Tyr Gly His His His His Gln Leu Pro 35 40 45 Phe Leu
Gly His Asp Gly His His Gly Gly Thr Leu Arg Val Gly Gln 50 55 60
His Tyr Arg Asn Ala Ser Asp Val Leu Pro Gly His Trp Leu Gln Gly 65
70 75 80 Gly Trp Gly Cys Tyr Asn Leu Ser Asp Trp His Gln Gly Thr
His Val 85 90 95 Cys His Thr Lys His Met Asp Phe Trp Cys Val Glu
His Asp Arg Pro 100 105 110 Pro Pro Ala Thr Pro Thr Pro Leu Thr Thr
Ala Ala Asn Ser Thr Thr 115 120 125 Ala Ala Thr Pro Ala Thr Ala Pro
Ala Pro Cys His Ala Gly Leu Asn 130 135 140 Asp Ser Cys Gly Gly Phe
Leu Ser Gly Cys Gly Pro Met Arg Leu Arg 145 150 155 160 His Gly Ala
Asp Thr Arg Cys Gly Arg Leu Ile Cys Gly Leu Ser Thr 165 170 175 Thr
Ala Gln Tyr Pro Pro Thr Arg Phe Gly Cys Ala Met Arg Trp Gly 180 185
190 Leu Pro Pro Trp Glu Leu Val Val Leu Thr Ala Arg Pro Glu Asp Gly
195 200 205 Trp Thr Cys Arg Gly Val Pro Ala His Pro Gly Ala Arg Cys
Pro Glu 210 215 220 Leu Val Ser Pro Met Gly Arg Ala Thr Cys Ser Pro
Ala Ser Ala Leu 225 230 235 240 Trp Leu Ala Thr Ala Asn Ala Leu Ser
Leu Asp His Ala Leu Ala Ala 245 250 255 Phe Val Leu Leu Val Pro Trp
Val Leu Ile Phe Met Val Cys Arg Arg 260 265 270 Ala Cys Arg Arg Arg
Gly Ala Ala Ala Ala Leu Thr Ala Val Val Leu 275 280 285 Gln Gly Pro
Arg Ser Ala Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu 290 295 300 Leu
Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp 305 310
315 320 Leu Trp Tyr Ile Arg Leu Phe Ile Asp Ala Ser Arg Arg Arg Gly
Ala 325 330 335 Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr Asn
Pro Pro Ala 340 345 350 Tyr Gly Glu Glu Ala Phe Thr Tyr Leu Cys Thr
Ala Pro Gly Cys 355 360 365 <210> SEQ ID NO 80 <211>
LENGTH: 566 <212> TYPE: PRT <213> ORGANISM: Artificial
sequence <220> FEATURE: <223> OTHER INFORMATION:
Recombinant antigenic insert peptide construct. <400>
SEQUENCE: 80 Met Val Cys Arg Arg Ala Cys Arg Arg Arg Gly Ala Ala
Ala Ala Leu 1 5 10 15 Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro
Ala Tyr Gly Glu Ala 20 25 30 Pro Arg Ser Ala Gln Glu Lys Asn Glu
Lys Glu Leu Leu Glu Leu Asp 35 40 45 Lys Trp Ala Ser Leu Trp Asn
Trp Phe Asp Ile Thr Asn Trp Leu Trp 50 55 60 Tyr Ile Arg Leu Phe
Ile Asp Ala Ser Leu Gln Gly Tyr Asn Pro Pro 65 70 75 80 Ala Tyr Gly
Glu Glu Ala Phe Thr Tyr Leu Cys Thr Ala Pro Gly Cys 85 90 95 Ala
Thr Gln Ala Pro Val Pro Val Arg Leu Ala Gly Val Arg Phe Glu 100 105
110 Ser Lys Ile Val Asp Gly Gly Cys Phe Ala Pro Trp Asp Leu Glu Ala
115 120 125 Thr Gly Ala Cys Ile Cys Glu Ile Pro Thr Asp Val Ser Cys
Glu Gly 130 135 140 Leu Gly Ala Trp Val Pro Ala Ala Pro Cys Ala Arg
Ile Trp Asn Gly 145 150 155 160 Thr Gln Arg Ala Cys Thr Phe Trp Ala
Val Asn Ala Tyr Ser Ser Gly 165 170 175 Gly Tyr Ala Gln Leu Ala Ser
Tyr Phe Asn Pro Gly Gly Ser Tyr Tyr 180 185 190 Lys Gln Tyr His Pro
Thr Ala Cys Glu Val Glu Pro Ala Phe Gly His 195 200 205 Ser Asp Ala
Ala Cys Trp Gly Phe Pro Thr Asp Thr Val Met Ser Val 210 215 220 Phe
Ala Leu Ala Ser Tyr Val Gln His Pro His Lys Thr Val Arg Val 225 230
235 240 Lys Phe His Thr Glu Thr Arg Thr Val Trp Gln Leu Ser Val Ala
Gly 245 250 255 Val Ser Cys Asn Val Thr Thr Glu His Pro Phe Cys Asn
Thr Pro His 260 265 270 Gly Gln Leu Glu Val Gln Val Pro Pro Asp Pro
Gly Asp Leu Val Glu 275 280 285 Tyr Ile Met Asn Tyr Thr Gly Asn Gln
Gln Ser Arg Trp Gly Leu Gly 290 295 300 Ser Pro Asn Cys His Gly Pro
Asp Trp Ala Ser Pro Val Cys Gln Arg 305 310 315 320 His Ser Pro Asp
Cys Ser Arg Leu Val Gly Ala Thr Pro Glu Arg Pro 325 330 335 Arg Leu
Arg Leu Val Asp Ala Asp Asp Pro Leu Leu Arg Thr Ala Pro 340 345 350
Gly Pro Gly Glu Val Trp Val Thr Pro Val Ile Gly Ser Gln Ala Arg 355
360 365 Lys Cys Gly Leu His Ile Arg Ala Gly Pro Tyr Gly His Ala Thr
Val 370 375 380 Glu Met Pro Glu Trp Ile His Ala His Thr Thr Ser Asp
Pro Trp His 385 390 395 400 Pro Pro Gly Pro Leu Gly Leu Lys Phe Lys
Thr Val Arg Pro Val Ala 405 410 415 Leu Pro Arg Thr Leu Ala Pro Pro
Arg Asn Val Arg Val Thr Gly Cys 420 425 430 Tyr Gln Cys Gly Thr Pro
Ala Leu Val Glu Gly Leu Ala Pro Gly Gly 435 440 445 Gly Asn Cys His
Leu Thr Val Asn Gly Glu Asp Leu Gly Ala Val Pro 450 455 460 Pro Gly
Lys Phe Val Thr Ala Ala Leu Leu Asn Thr Pro Pro Pro Tyr 465 470 475
480 Gln Val Ser Cys Gly Gly Glu Ser Asp Arg Ala Thr Ala Arg Val Ile
485 490 495 Asp Pro Ala Ala Gln Ser Phe Thr Gly Val Val Tyr Gly Thr
His Thr 500 505 510 Thr Ala Val Ser Glu Thr Arg Gln Thr Trp Ala Glu
Trp Ala Ala Ala 515 520 525 His Trp Trp Gln Leu Thr Leu Gly Ala Ile
Cys Ala Leu Pro Leu Ala 530 535 540 Gly Leu Leu Ala Cys Cys Ala Lys
Cys Leu Tyr Tyr Leu Arg Gly Ala 545 550 555 560 Ile Ala Pro Arg Trp
Ala 565 <210> SEQ ID NO 81 <211> LENGTH: 34 <212>
TYPE: PRT
<213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert
peptide. <400> SEQUENCE: 81 Gln Glu Lys Asn Glu Lys Glu Leu
Leu Glu Leu Asp Lys Trp Ala Ser 1 5 10 15 Leu Trp Asn Trp Phe Asp
Ile Thr Asn Trp Leu Trp Tyr Ile Arg Leu 20 25 30 Phe Ile
<210> SEQ ID NO 82 <211> LENGTH: 39 <212> TYPE:
PRT <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert
peptide. <400> SEQUENCE: 82 Arg Glu Gly Ser Gln Lys Ile Leu
Ser Val Leu Ala Pro Leu Val Pro 1 5 10 15 Thr Gly Ser Glu Asn Leu
Lys Ser Leu Tyr Asn Thr Val Ser Val Ile 20 25 30 Trp Ser Ile His
Ala Glu Asp 35 <210> SEQ ID NO 83 <211> LENGTH: 38
<212> TYPE: PRT <213> ORGANISM: Artificial sequence
<220> FEATURE: <223> OTHER INFORMATION: Recombinant
antigenic insert peptide. <400> SEQUENCE: 83 Phe Gln Ala Leu
Ser Glu Gly Cys Thr Pro Tyr Asp Ile Asn Gln Met 1 5 10 15 Leu Asn
Cys Val Gly Asp His Gln Ala Ala Met Gln Ile Ile Arg Asp 20 25 30
Ile Ile Asn Glu Glu Ala 35 <210> SEQ ID NO 84 <211>
LENGTH: 65 <212> TYPE: PRT <213> ORGANISM: Artificial
sequence <220> FEATURE: <223> OTHER INFORMATION:
Recombinant antigenic insert peptide. <400> SEQUENCE: 84 Leu
Pro Leu Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Leu Ile Glu 1 5 10
15 Glu Lys Lys Phe Gly Ala Glu Val Val Pro Gly Phe Gln Ala Leu Ser
20 25 30 Glu Gly Cys Thr Pro Tyr Asp Ile Asn Gln Met Leu Asn Cys
Val Gly 35 40 45 Asp His Gln Ala Ala Met Gln Ile Ile Arg Asp Ile
Ile Asn Glu Glu 50 55 60 Ala 65 <210> SEQ ID NO 85
<211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM:
Artificial sequence <220> FEATURE: <223> OTHER
INFORMATION: Recombinant antigenic insert peptide. <400>
SEQUENCE: 85 Leu Pro Leu Ser Pro Arg Thr Leu Asn Ala Trp Val Lys
Leu Ile Glu 1 5 10 15 Glu Lys Lys Phe Gly Ala Glu Val Val Pro Gly
Phe Gln Ala Leu Ser 20 25 30 Glu Gly Cys Thr Pro Tyr Asp Ile Asn
Gln Met Leu Asn Cys Val Gly 35 40 45 Asp His Gln Ala Ala Met Gln
Ile Ile Arg Asp Ile Ile Asn Glu Glu 50 55 60 Ala Thr Arg Ser Gln
Lys Ile Leu Ser Val Leu Ala Pro Leu Val Pro 65 70 75 80 Thr
<210> SEQ ID NO 86 <211> LENGTH: 79 <212> TYPE:
PRT <213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert
peptide. <400> SEQUENCE: 86 Leu Pro Leu Ser Pro Arg Thr Leu
Asn Ala Trp Val Lys Leu Ile Glu 1 5 10 15 Glu Lys Lys Phe Gly Ala
Glu Val Val Pro Gly Phe Gln Ala Leu Ser 20 25 30 Glu Gly Cys Thr
Pro Tyr Asp Ile Asn Gln Met Leu Asn Cys Val Gly 35 40 45 Asp His
Gln Ala Ala Met Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu 50 55 60
Ala Thr Arg Thr Gly Ser Glu Asn Leu Lys Ser Leu Tyr Asn Thr 65 70
75 <210> SEQ ID NO 87 <211> LENGTH: 87 <212>
TYPE: PRT <213> ORGANISM: Artificial sequence <220>
FEATURE: <223> OTHER INFORMATION: Recombinant antigenic
insert peptide. <400> SEQUENCE: 87 Leu Pro Leu Ser Pro Arg
Thr Leu Asn Ala Trp Val Lys Leu Ile Glu 1 5 10 15 Glu Lys Lys Phe
Gly Ala Glu Val Val Pro Gly Phe Gln Ala Leu Ser 20 25 30 Glu Gly
Cys Thr Pro Tyr Asp Ile Asn Gln Met Leu Asn Cys Val Gly 35 40 45
Asp His Gln Ala Ala Met Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu 50
55 60 Ala Thr Arg His Thr Glu Glu Ala Lys Gln Ile Val Gln Arg His
Leu 65 70 75 80 Val Val Glu Thr Gly Thr Thr 85 <210> SEQ ID
NO 88 <211> LENGTH: 80 <212> TYPE: PRT <213>
ORGANISM: Artificial sequence <220> FEATURE: <223>
OTHER INFORMATION: Recombinant antigenic insert peptide.
<400> SEQUENCE: 88 Val Pro Thr Gly Ser Glu Asn Leu Lys Ser
Leu Tyr Asn Thr Val Thr 1 5 10 15 Arg Val Lys His Thr Glu Glu Ala
Lys Gln Ile Val Gln Arg His Leu 20 25 30 Val Val Glu Thr Gly Thr
Thr Ser Asp Ala Phe Gln Ala Leu Ser Glu 35 40 45 Gly Cys Thr Pro
Tyr Asp Ile Asn Gln Met Leu Asn Cys Val Gly Asp 50 55 60 His Gln
Ala Ala Met Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala 65 70 75 80
<210> SEQ ID NO 89 <211> LENGTH: 19 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 89 Pro Ser Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp
Tyr Ile Arg 1 5 10 15 Leu Asp Ala <210> SEQ ID NO 90
<211> LENGTH: 109 <212> TYPE: PRT <213> ORGANISM:
Artificial sequence <220> FEATURE: <223> OTHER
INFORMATION: Recombinant antigenic insert peptide. <400>
SEQUENCE: 90 Leu Asp Arg Phe Gly Leu Ala Glu Ser Leu Leu Glu Asn
Lys Glu Gly 1 5 10 15 Ser Gln Lys Ile Leu Ser Val Leu Ala Pro Leu
Val Pro Thr Gly Ser 20 25 30 Glu Asn Leu Lys Ser Leu Tyr Asn Thr
Val Thr Arg Val Lys His Thr 35 40 45 Glu Glu Ala Lys Gln Ile Val
Gln Arg His Leu Val Val Glu Thr Gly 50 55 60 Thr Thr Glu Thr Ser
Asp Ala Phe Gln Ala Leu Ser Glu Gly Cys Thr 65 70 75 80 Pro Tyr Asp
Ile Asn Gln Met Leu Asn Cys Val Gly Asp His Gln Ala 85 90 95 Ala
Met Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala 100 105 <210>
SEQ ID NO 91 <211> LENGTH: 134 <212> TYPE: PRT
<213> ORGANISM: Artificial sequence <220> FEATURE:
<223> OTHER INFORMATION: Recombinant antigenic insert
peptide. <400> SEQUENCE: 91 Leu Asp Arg Phe Gly Leu Ala Glu
Ser Leu Leu Glu Asn Lys Glu Gly 1 5 10 15 Ser Gln Lys Ile Leu Ser
Val Leu Ala Pro Leu Val Pro Thr Gly Ser 20 25 30 Glu Asn Leu Lys
Ser Leu Tyr Asn Thr Val Thr Arg Val Lys His Thr 35 40 45 Glu Glu
Ala Lys Gln Ile Val Gln Arg His Leu Val Val Glu Thr Gly 50 55 60
Thr Thr Glu Thr Arg Leu Pro Leu Ser Pro Arg Thr Leu Asn Ala Trp 65
70 75 80
Val Lys Leu Ile Glu Glu Lys Lys Phe Gly Ala Glu Val Val Pro Gly 85
90 95 Phe Gln Ala Leu Ser Glu Gly Cys Thr Pro Tyr Asp Ile Asn Gln
Met 100 105 110 Leu Asn Cys Val Gly Asp His Gln Ala Ala Met Gln Ile
Ile Arg Asp 115 120 125 Ile Ile Asn Glu Glu Ala 130 <210> SEQ
ID NO 92 <211> LENGTH: 9 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 92 Cys
Thr Pro Tyr Asp Ile Asn Gln Met 1 5 <210> SEQ ID NO 93
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 93 Gly Ser Glu
Asn Leu Lys Ser Leu Tyr 1 5 <210> SEQ ID NO 94 <211>
LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 94 Lys Ile Leu Ser Val
Leu Ala Pro Leu Val Pro 1 5 10 <210> SEQ ID NO 95 <211>
LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 95 Thr Glu Glu Ala Lys
Gln Ile Val Gln Arg His Leu Val Val Glu Thr 1 5 10 15 <210>
SEQ ID NO 96 <211> LENGTH: 11 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 96 Met Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu 1 5 10
<210> SEQ ID NO 97 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 97 Thr Arg Ala Asn Ser Pro Thr Arg Arg 1 5 <210>
SEQ ID NO 98 <211> LENGTH: 8 <212> TYPE: PRT
<213> ORGANISM: Human immunodeficiency virus <400>
SEQUENCE: 98 Asn Ser Pro Thr Arg Arg Glu Leu 1 5 <210> SEQ ID
NO 99 <211> LENGTH: 9 <212> TYPE: PRT <213>
ORGANISM: Human immunodeficiency virus <400> SEQUENCE: 99 Pro
Thr Arg Arg Glu Leu Gln Val Trp 1 5 <210> SEQ ID NO 100
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Human immunodeficiency virus <400> SEQUENCE: 100 Pro Thr Ser
Arg Glu Leu Gln Val Trp 1 5 <210> SEQ ID NO 101 <211>
LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 101 Ala Gly Ala Glu
Arg Gln Gly Thr Leu 1 5 <210> SEQ ID NO 102 <211>
LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 102 Phe Ser Phe Pro
Gln Ile Thr Leu Trp 1 5 <210> SEQ ID NO 103 <211>
LENGTH: 171 <212> TYPE: PRT <213> ORGANISM: Human
immunodeficiency virus <400> SEQUENCE: 103 Leu Asp Arg Phe
Gly Leu Ala Glu Ser Leu Leu Glu Asn Lys Glu Gly 1 5 10 15 Cys Gln
Lys Ile Leu Ser Val Leu Ala Pro Leu Val Pro Thr Gly Ser 20 25 30
Glu Asn Leu Lys Ser Leu Tyr Asn Thr Val Cys Val Ile Trp Cys Ile 35
40 45 His Ala Glu Glu Lys Val Lys His Thr Glu Glu Ala Lys Gln Ile
Val 50 55 60 Gln Arg His Leu Val Val Glu Thr Gly Thr Thr Glu Thr
Met Pro Lys 65 70 75 80 Thr Ser Arg Pro Thr Ala Pro Ser Ser Gly Arg
Gly Gly Asn Tyr Pro 85 90 95 Val Gln Gln Ile Gly Gly Asn Tyr Val
His Leu Pro Leu Ser Pro Arg 100 105 110 Thr Leu Asn Ala Trp Val Lys
Leu Ile Glu Glu Lys Lys Phe Gly Ala 115 120 125 Glu Val Val Pro Gly
Phe Gln Ala Leu Ser Glu Gly Cys Thr Pro Tyr 130 135 140 Asp Ile Asn
Gln Met Leu Asn Cys Val Gly Asp His Gln Ala Ala Met 145 150 155 160
Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala 165 170 <210> SEQ
ID NO 104 <211> LENGTH: 19 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic oligonucleotide primer <400>
SEQUENCE: 104 gatgacgagg cgctcatcc 19 <210> SEQ ID NO 105
<211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic oligonucleotide primer <400> SEQUENCE:
105 gagtgccgcg ggcgtccgag tgc 23 <210> SEQ ID NO 106
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic oligonucleotide primer <400> SEQUENCE:
106 cgaactggtg agccccatgg 20 <210> SEQ ID NO 107 <211>
LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic oligonucleotide primer <400> SEQUENCE: 107
gatctcgcaa atgcaggctc cagtg 25 <210> SEQ ID NO 108
<211> LENGTH: 60 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic oligonucleotide primer <400> SEQUENCE:
108 gaagcaccta ggtcagccca agaaaagaat gaaaaagaat tattggaatt
ggataaatgg 60 <210> SEQ ID NO 109 <211> LENGTH: 50
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 109 tgatctagat
gcatctatga atagtcttat ataccacagc cagtttgtta 50 <210> SEQ ID
NO 110 <211> LENGTH: 57 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic oligonucleotide primer
<400> SEQUENCE: 110 gaacagacta gtgcccaaga aaagaatgaa
aaagaattat tggaattgga taaatgg 57 <210> SEQ ID NO 111
<211> LENGTH: 59 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic oligonucleotide primer <400> SEQUENCE:
111 ccagcagatg catcattcca caaacttgcc catttatcca attccaataa
ttctttttc 59 <210> SEQ ID NO 112 <211> LENGTH: 50
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 112 gaacagacta
gttggaattg gtttgacata acaaactggc tgtggtatat 50 <210> SEQ ID
NO 113 <211> LENGTH: 47 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic oligonucleotide primer <400>
SEQUENCE: 113 ccagcagatg catctagtct tatataccac agccagtttg ttatgtc
47 <210> SEQ ID NO 114 <211> LENGTH: 54 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic oligonucleotide
primer <400> SEQUENCE: 114 agatagcgcc tagggaagga agccaaaaaa
tactttcggt cttagctcca ttag 54 <210> SEQ ID NO 115 <211>
LENGTH: 60 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic oligonucleotide primer <400> SEQUENCE: 115
tggcgatgat gcatcttctg cgtgaattga ccagatgacc gagacagtat tataaaggct
60 <210> SEQ ID NO 116 <211> LENGTH: 40 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic oligonucleotide
primer <400> SEQUENCE: 116 agatagcgcc taggtttcag gcactgtcag
aaggttgcac 40 <210> SEQ ID NO 117 <211> LENGTH: 41
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 117 tgtaatgatg
catcagcctc ctcgtttata atatctctga t 41 <210> SEQ ID NO 118
<211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic oligonucleotide primer <400> SEQUENCE:
118 agatagcgcc taggctgcca ttaagcccga gaacattaaa tg 42 <210>
SEQ ID NO 119 <211> LENGTH: 48 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic oligonucleotide primer
<400> SEQUENCE: 119 tggcgatgat gcatcactag tagcctcctc
gtttataata tctctgat 48 <210> SEQ ID NO 120 <211>
LENGTH: 48 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic oligonucleotide primer <400> SEQUENCE: 120
gatagcgcct aggagccaga agatcctgag cgtgctggcc cctctggt 48 <210>
SEQ ID NO 121 <211> LENGTH: 47 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic oligonucleotide primer
<400> SEQUENCE: 121 tgcgatgatg catcactagt gggcaccaga
ggggccagca cgctcag 47 <210> SEQ ID NO 122 <211> LENGTH:
45 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
oligonucleotide primer <400> SEQUENCE: 122 gatagcgcct
aggaccggca gcgagaacct gaagagcctg tacaa 45 <210> SEQ ID NO 123
<211> LENGTH: 47 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic oligonucleotide primer <400> SEQUENCE:
123 tgcgatgatg catcactagt gttgtacagg ctcttcaggt tctcgct 47
<210> SEQ ID NO 124 <211> LENGTH: 64 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic oligonucleotide primer
<400> SEQUENCE: 124 gatagcgcct agggtgaagc acaccgagga
ggccaagcag atcgtgcagc gccacctggt 60 ggtg 64 <210> SEQ ID NO
125 <211> LENGTH: 58 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic oligonucleotide primer <400>
SEQUENCE: 125 tgcgatgatg catcactagt ggtgccggtc tccaccacca
ggtggcgctg cacgatct 58 <210> SEQ ID NO 126 <211>
LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: MPERF
insert <400> SEQUENCE: 126 Phe Glu Glu Pro Arg Gln Glu Lys
Asn Glu Lys Glu Leu Leu Glu Leu 1 5 10 15 Asp Lys Trp Ala Ser Leu
Trp Asn Trp Phe Asp Met His Thr Leu Ala 20 25 30 Ala Phe Val Leu
Leu Val Pro Trp Val Leu Ile Phe Met Val Cys Arg 35 40 45 Arg Thr
Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val 50 55 60
Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 65 70 <210> SEQ ID NO
127 <211> LENGTH: 77 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: MPERF insert <400> SEQUENCE: 127 Gly Glu
Glu Pro Arg Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu 1 5 10 15
Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Met His Trp Trp Gln 20
25 30 Leu Thr Gly Ala Thr Cys Ala Leu Pro Leu Ala Gly Leu Leu Ala
Cys 35 40 45 Cys Ala Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala
Ala Leu Thr 50 55 60 Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala
Tyr Gly 65 70 75 <210> SEQ ID NO 128 <211> LENGTH: 19
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: MPERF insert
<400> SEQUENCE: 128 Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu
Leu Asp Lys Trp Ala Ser 1 5 10 15
Leu Trp Asn <210> SEQ ID NO 129 <211> LENGTH: 15
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: MPERE insert
<400> SEQUENCE: 129 Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu
Trp Tyr Ile Arg Leu 1 5 10 15 <210> SEQ ID NO 130 <211>
LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: MPER
insert <400> SEQUENCE: 130 Gln Glu Asn Glu Lys Glu Leu Leu
Glu Leu Asp Lys Trp Ala Ser Leu 1 5 10 15 Trp Asn Trp Phe Asp Ile
Thr Asn Trp Leu Trp Tyr Ile Arg Leu Phe 20 25 30 Ile <210>
SEQ ID NO 131 <211> LENGTH: 86 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: MPER-HIVTM insert <400>
SEQUENCE: 131 Gly Glu Glu Pro Arg Gln Glu Lys Asn Glu Lys Glu Leu
Leu Glu Leu 1 5 10 15 Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp
Ile Thr Asn Trp Leu 20 25 30 Trp Tyr Ile Arg Leu Phe Ile Met Ile
Val Gly Gly Leu Ile Gly Leu 35 40 45 Arg Ile Val Phe Ala Val Leu
Ser Ile Val Cys Arg Arg Thr Cys Arg 50 55 60 Arg Arg Gly Ala Ala
Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr 65 70 75 80 Asn Pro Pro
Ala Tyr Gly 85 <210> SEQ ID NO 132 <211> LENGTH: 221
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: SIV Gag insert
(sGag-E2TM amino acids 41-211) <400> SEQUENCE: 132 Leu Asp
Arg Phe Gly Leu Ala Glu Ser Leu Leu Glu Asn Lys Glu Gly 1 5 10 15
Cys Gln Lys Ile Leu Ser Val Leu Ala Pro Leu Val Pro Thr Gly Ser 20
25 30 Glu Asn Leu Lys Ser Leu Tyr Asn Thr Val Cys Val Ile Trp Cys
Ile 35 40 45 His Ala Glu Glu Lys Val Lys His Thr Glu Glu Ala Lys
Gln Ile Val 50 55 60 Gln Arg His Leu Val Val Glu Thr Gly Thr Thr
Glu Thr Met Pro Lys 65 70 75 80 Thr Ser Arg Pro Thr Ala Pro Ser Ser
Gly Arg Gly Gly Asn Tyr Pro 85 90 95 Val Gln Gln Ile Gly Gly Asn
Tyr Val His Leu Pro Leu Ser Pro Arg 100 105 110 Thr Leu Asn Ala Trp
Val Lys Leu Ile Glu Glu Lys Lys Phe Gly Ala 115 120 125 Glu Val Val
Pro Gly Phe Gln Ala Leu Ser Glu Gly Cys Thr Pro Tyr 130 135 140 Asp
Ile Asn Gln Met Leu Asn Cys Val Gly Asp His Gln Ala Ala Met 145 150
155 160 Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala Ser Leu Asp Met
His 165 170 175 Thr Leu Ala Ala Phe Val Leu Leu Val Pro Trp Val Leu
Ile Phe Met 180 185 190 Val Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala
Ala Ala Ala Leu Thr 195 200 205 Ala Val Val Leu Gln Gly Tyr Asn Pro
Pro Ala Tyr Gly 210 215 220 <210> SEQ ID NO 133 <211>
LENGTH: 184 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: SIV
Gag insert (SGag-E2TM, amino acids 135-271) <400> SEQUENCE:
133 Tyr Pro Val Gln Gln Ile Gly Gly Asn Tyr Val His Leu Pro Leu Ser
1 5 10 15 Pro Arg Thr Leu Asn Ala Trp Val Lys Leu Ile Glu Glu Lys
Lys Phe 20 25 30 Gly Ala Glu Val Val Pro Gly Phe Gln Ala Leu Ser
Glu Gly Cys Thr 35 40 45 Pro Tyr Asp Ile Asn Gln Met Leu Asn Cys
Val Gly Asp His Gln Ala 50 55 60 Ala Met Gln Ile Ile Arg Asp Ile
Ile Asn Glu Glu Ala Ala Asp Trp 65 70 75 80 Asp Leu Gln His Pro Gln
Pro Ala Pro Gln Gln Gly Gln Leu Arg Glu 85 90 95 Pro Ser Gly Ser
Asp Ile Ala Gly Thr Thr Ser Ser Val Asp Glu Gln 100 105 110 Ile Gln
Trp Met Tyr Arg Gln Gln Asn Pro Ile Pro Val Gly Asn Ile 115 120 125
Tyr Arg Arg Trp Ile Gln Leu Gly Leu Met His Thr Leu Ala Ala Phe 130
135 140 Val Leu Leu Val Pro Trp Val Leu Ile Phe Met Val Cys Arg Arg
Thr 145 150 155 160 Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala
Val Val Leu Gln 165 170 175 Gly Tyr Asn Pro Pro Ala Tyr Gly 180
<210> SEQ ID NO 134 <211> LENGTH: 276 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: SIV Gag insert (full p28-sGag-E2TM)
<400> SEQUENCE: 134 Tyr Pro Val Gln Gln Ile Gly Gly Asn Tyr
Val His Leu Pro Leu Ser 1 5 10 15 Pro Arg Thr Leu Asn Ala Trp Val
Lys Leu Ile Glu Glu Lys Lys Phe 20 25 30 Gly Ala Glu Val Val Pro
Gly Phe Gln Ala Leu Ser Glu Gly Cys Thr 35 40 45 Pro Tyr Asp Ile
Asn Gln Met Leu Asn Cys Val Gly Asp His Gln Ala 50 55 60 Ala Met
Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala Ala Asp Trp 65 70 75 80
Asp Leu Gln His Pro Gln Pro Ala Pro Gln Gln Gly Gln Leu Arg Glu 85
90 95 Pro Ser Gly Ser Asp Ile Ala Gly Thr Thr Ser Ser Val Asp Glu
Gln 100 105 110 Ile Gln Trp Met Tyr Arg Gln Gln Asn Pro Ile Pro Val
Gly Asn Ile 115 120 125 Tyr Arg Arg Trp Ile Gln Leu Gly Leu Gln Lys
Cys Val Arg Met Tyr 130 135 140 Asn Pro Thr Asn Ile Leu Asp Val Lys
Gln Gly Pro Lys Glu Pro Phe 145 150 155 160 Gln Ser Tyr Val Asp Arg
Phe Tyr Lys Ser Leu Arg Ala Glu Gln Thr 165 170 175 Asp Ala Ala Val
Lys Asn Trp Met Thr Gln Thr Leu Leu Ile Gln Asn 180 185 190 Ala Asn
Pro Asp Cys Lys Leu Val Leu Lys Gly Leu Gly Val Asn Pro 195 200 205
Thr Leu Glu Glu Met Leu Thr Ala Cys Gln Gly Val Gly Gly Pro Gly 210
215 220 Gln Lys Ala Arg Leu Met His Thr Leu Ala Ala Phe Val Leu Leu
Val 225 230 235 240 Pro Trp Val Leu Ile Phe Met Val Cys Arg Arg Thr
Cys Arg Arg Arg 245 250 255 Gly Ala Ala Ala Ala Leu Thr Ala Val Val
Leu Gln Gly Tyr Asn Pro 260 265 270 Pro Ala Tyr Gly 275 <210>
SEQ ID NO 135 <211> LENGTH: 304 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: SIV Gag insert (fullp28
plus-sGag-E2TM) <400> SEQUENCE: 135 Tyr Pro Val Gln Gln Ile
Gly Gly Asn Tyr Val His Leu Pro Leu Ser 1 5 10 15 Pro Arg Thr Leu
Asn Ala Trp Val Lys Leu Ile Glu Glu Lys Lys Phe 20 25 30 Gly Ala
Glu Val Val Pro Gly Phe Gln Ala Leu Ser Glu Gly Cys Thr 35 40 45
Pro Tyr Asp Ile Asn Gln Met Leu Asn Cys Val Gly Asp His Gln Ala 50
55 60 Ala Met Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala Ala Asp
Trp 65 70 75 80 Asp Leu Gln His Pro Gln Pro Ala Pro Gln Gln Gly Gln
Leu Arg Glu
85 90 95 Pro Ser Gly Ser Asp Ile Ala Gly Thr Thr Ser Ser Val Asp
Glu Gln 100 105 110 Ile Gln Trp Met Tyr Arg Gln Gln Asn Pro Ile Pro
Val Gly Asn Ile 115 120 125 Tyr Arg Arg Trp Ile Gln Leu Gly Leu Gln
Lys Cys Val Arg Met Tyr 130 135 140 Asn Pro Thr Asn Ile Leu Asp Val
Lys Gln Gly Pro Lys Glu Pro Phe 145 150 155 160 Gln Ser Tyr Val Asp
Arg Phe Tyr Lys Ser Leu Arg Ala Glu Gln Thr 165 170 175 Asp Ala Ala
Val Lys Asn Trp Met Thr Gln Thr Leu Leu Ile Gln Asn 180 185 190 Ala
Asn Pro Asp Cys Lys Leu Val Leu Lys Gly Leu Gly Val Asn Pro 195 200
205 Thr Leu Glu Glu Met Leu Thr Ala Cys Gln Gly Val Gly Gly Pro Gly
210 215 220 Gln Lys Ala Arg Leu Met Ala Glu Ala Leu Lys Glu Ala Leu
Ala Pro 225 230 235 240 Val Pro Ile Pro Phe Ala Ala Ala Gln Gln Arg
Gly Pro Arg Lys Pro 245 250 255 Ile Met His Thr Leu Ala Ala Phe Val
Leu Leu Val Pro Trp Val Leu 260 265 270 Ile Phe Met Val Cys Arg Arg
Thr Cys Arg Arg Arg Gly Ala Ala Ala 275 280 285 Ala Leu Thr Ala Val
Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 290 295 300 <210>
SEQ ID NO 136 <211> LENGTH: 367 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: variant rubella construct
<400> SEQUENCE: 136 Gly Leu Gln Pro Arg Ala Asp Met Ala Ala
Pro Pro Thr Leu Pro Gln 1 5 10 15 Pro Pro Arg Ala His Gly Gln His
Tyr Gly His His His His Gln Leu 20 25 30 Pro Phe Leu Gly His Asp
Gly His His Gly Gly Thr Leu Arg Val Gly 35 40 45 Gln His Tyr Arg
Asn Ala Ser Asp Val Leu Pro Gly His Trp Leu Gln 50 55 60 Gly Gly
Trp Gly Cys Tyr Asn Leu Ser Asp Trp His Gln Gly Thr His 65 70 75 80
Val Cys His Thr Lys His Met Asp Phe Trp Cys Val Glu His Ala Arg 85
90 95 Pro Pro Pro Ala Thr Pro Thr Pro Leu Thr Thr Ala Ala Asn Ser
Thr 100 105 110 Thr Ala Ala Thr Pro Ala Thr Ala Pro Ala Pro Cys His
Ala Gly Leu 115 120 125 Asn Asp Ser Cys Gly Gly Phe Leu Ser Gly Cys
Gly Pro Met Arg Leu 130 135 140 Arg His Gly Ala Asp Thr Arg Cys Gly
Arg Leu Ile Cys Gly Leu Ser 145 150 155 160 Thr Thr Ala Gln Tyr Pro
Pro Thr Arg Phe Gly Cys Ala Met Arg Trp 165 170 175 Gly Leu Pro Pro
Trp Glu Leu Val Val Leu Thr Ala Arg Pro Glu Asp 180 185 190 Gly Trp
Thr Cys Arg Gly Val Pro Ala His Pro Gly Ala Arg Cys Pro 195 200 205
Glu Leu Val Ser Pro Met Gly Arg Ala Thr Cys Ser Pro Ala Ser Ala 210
215 220 Leu Trp Leu Ala Thr Ala Asn Ala Leu Ser Leu Asp His Ala Leu
Ala 225 230 235 240 Ala Phe Val Leu Leu Val Pro Trp Val Leu Ile Phe
Met Val Cys Arg 245 250 255 Arg Ala Cys Arg Arg Arg Gly Ala Ala Ala
Ala Leu Thr Ala Val Val 260 265 270 Leu Gln Gly Tyr Asn Pro Pro Ala
Tyr Gly Glu Glu Pro Arg Gln Glu 275 280 285 Lys Asn Glu Lys Glu Leu
Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp 290 295 300 Asn Trp Phe Asp
Ile Thr Asn Trp Leu Trp Tyr Ile Arg Leu Phe Ile 305 310 315 320 Met
Ile Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe Ala Val Leu 325 330
335 Ser Ile Val Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala
340 345 350 Leu Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr
Gly 355 360 365 <210> SEQ ID NO 137 <211> LENGTH: 142
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: MPER construct
<400> SEQUENCE: 137 Pro Arg Asn Asn Leu Leu Arg Ala Ile Glu
Ala Gln Gln His Met Leu 1 5 10 15 Gln Leu Thr Val Trp Gly Ile Lys
Gln Leu Gln Ala Arg Gly Gly Gly 20 25 30 Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Trp Met Glu Trp 35 40 45 Glu Arg Glu Ile
Asp Asn Tyr Thr Asp Tyr Ile Tyr Asp Leu Leu Glu 50 55 60 Lys Ser
Gln Thr Gln Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu 65 70 75 80
Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu 85
90 95 Trp Tyr Ile Arg Leu Phe Ile Met Ile Val Gly Gly Leu Ile Gly
Leu 100 105 110 Arg Ile Val Phe Ala Val Leu Ser Ile Val Cys Arg Arg
Thr Cys Arg 115 120 125 Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val
Val Leu Gln 130 135 140 <210> SEQ ID NO 138 <211>
LENGTH: 220 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: HIV
Gag insert <400> SEQUENCE: 138 Leu Glu Arg Phe Ala Val Asn
Pro Ser Leu Leu Glu Thr Ser Glu Gly 1 5 10 15 Cys Arg Gln Ile Leu
Gly Gln Leu Gln Ser Ser Leu Gln Thr Gly Ser 20 25 30 Glu Glu Leu
Lys Ser Leu Tyr Asn Thr Val Ala Thr Leu Tyr Cys Val 35 40 45 His
Gln Arg Ile Glu Val Lys Asp Thr Lys Glu Ala Leu Asp Lys Ile 50 55
60 Glu Glu Glu Gln Asn Lys Ser Lys Lys Lys Ala Gln Gln Ala Ala Ala
65 70 75 80 Asp Thr Gly Asn Ser Ser Gln Val Ser Gln Asn Tyr Pro Ile
Val Gln 85 90 95 Asn Ile Gln Gly Gln Met Val His Gln Ala Ile Ser
Pro Arg Thr Leu 100 105 110 Asn Ala Trp Val Lys Val Val Glu Glu Lys
Ala Phe Ser Pro Glu Val 115 120 125 Ile Pro Met Phe Ser Ala Leu Ser
Glu Gly Ala Thr Pro Gln Asp Leu 130 135 140 Asn Thr Met Leu Asn Thr
Val Gly Gly His Gln Ala Ala Met Gln Met 145 150 155 160 Leu Lys Glu
Thr Ile Asn Glu Glu Ala Ala Glu Trp Asp Met His Thr 165 170 175 Leu
Ala Ala Phe Val Leu Leu Val Pro Trp Val Leu Ile Phe Met Val 180 185
190 Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala
195 200 205 Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 210 215
220 <210> SEQ ID NO 139 <211> LENGTH: 186 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: HIV Gag insert <400>
SEQUENCE: 139 Tyr Pro Ile Val Gln Asn Ile Gln Gly Gln Met Val His
Gln Ala Ile 1 5 10 15 Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val
Val Glu Glu Lys Ala 20 25 30 Phe Ser Pro Glu Val Ile Pro Met Phe
Ser Ala Leu Ser Glu Gly Ala 35 40 45 Thr Pro Gln Asp Leu Asn Thr
Met Leu Asn Thr Val Gly Gly His Gln 50 55 60 Ala Ala Met Gln Met
Leu Lys Glu Thr Ile Asn Glu Glu Ala Ala Glu 65 70 75 80 Trp Asp Arg
Leu His Pro Val Gln Ala Gly Pro Val Ala Pro Gly Gln 85 90 95 Met
Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu 100 105
110 Gln Glu Gln Ile Gly Trp Met Thr Asn Asn Pro Pro Ile Pro Val Gly
115 120 125 Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Met His Thr
Leu Ala 130 135 140 Ala Phe Val Leu Leu Val Pro Trp Val Leu Ile Phe
Met Val Cys Arg 145 150 155 160 Arg Thr Cys Arg Arg Arg Gly Ala Ala
Ala Ala Leu Thr Ala Val Val 165 170 175
Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 180 185 <210> SEQ ID
NO 140 <211> LENGTH: 278 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HIV Gag insert <400> SEQUENCE: 140 Tyr Pro
Ile Val Gln Asn Ile Gln Gly Gln Met Val His Gln Ala Ile 1 5 10 15
Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Val Glu Glu Lys Ala 20
25 30 Phe Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu Ser Glu Gly
Ala 35 40 45 Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly
Gly His Gln 50 55 60 Ala Ala Met Gln Met Leu Lys Glu Thr Ile Asn
Glu Glu Ala Ala Glu 65 70 75 80 Trp Asp Arg Leu His Pro Val Gln Ala
Gly Pro Val Ala Pro Gly Gln 85 90 95 Met Arg Glu Pro Arg Gly Ser
Asp Ile Ala Gly Thr Thr Ser Thr Leu 100 105 110 Gln Glu Gln Ile Gly
Trp Met Thr Asn Asn Pro Pro Ile Pro Val Gly 115 120 125 Glu Ile Tyr
Lys Arg Trp Ile Ile Leu Gly Leu Gln Lys Cys Val Arg 130 135 140 Met
Tyr Asn Pro Thr Asn Ile Leu Asp Val Lys Gln Gly Pro Lys Glu 145 150
155 160 Pro Phe Gln Ser Tyr Val Asp Arg Phe Tyr Lys Ser Leu Arg Ala
Glu 165 170 175 Gln Thr Asp Ala Ala Val Lys Asn Trp Met Thr Gln Thr
Leu Leu Ile 180 185 190 Gln Asn Ala Asn Pro Asp Cys Lys Leu Val Leu
Lys Gly Leu Gly Val 195 200 205 Asn Pro Thr Leu Glu Glu Met Leu Thr
Ala Cys Gln Gly Val Gly Gly 210 215 220 Pro Gly Gln Lys Ala Arg Leu
Met His Thr Leu Ala Ala Phe Val Leu 225 230 235 240 Leu Val Pro Trp
Val Leu Ile Phe Met Val Cys Arg Arg Thr Cys Arg 245 250 255 Arg Arg
Gly Ala Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr 260 265 270
Asn Pro Pro Ala Tyr Gly 275 <210> SEQ ID NO 141 <211>
LENGTH: 370 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
SGAG(41-363)-E2TM Gag insert <400> SEQUENCE: 141 Leu Asp Arg
Phe Gly Leu Ala Glu Ser Leu Leu Glu Asn Lys Glu Gly 1 5 10 15 Cys
Gln Lys Ile Leu Ser Val Leu Ala Pro Leu Val Pro Thr Gly Ser 20 25
30 Glu Asn Leu Lys Ser Leu Tyr Asn Thr Val Cys Val Ile Trp Cys Ile
35 40 45 His Ala Glu Glu Lys Val Lys His Thr Glu Glu Ala Lys Gln
Ile Val 50 55 60 Gln Arg His Leu Val Val Glu Thr Gly Thr Thr Glu
Thr Met Pro Lys 65 70 75 80 Thr Ser Arg Pro Thr Ala Pro Ser Ser Gly
Arg Gly Gly Asn Tyr Pro 85 90 95 Val Gln Gln Ile Gly Gly Asn Tyr
Val His Leu Pro Leu Ser Pro Arg 100 105 110 Thr Leu Asn Ala Trp Val
Lys Leu Ile Glu Glu Lys Lys Phe Gly Ala 115 120 125 Glu Val Val Pro
Gly Phe Gln Ala Leu Ser Glu Gly Cys Thr Pro Tyr 130 135 140 Asp Ile
Asn Gln Met Leu Asn Cys Val Gly Asp His Gln Ala Ala Met 145 150 155
160 Gln Ile Ile Arg Asp Ile Ile Asn Glu Glu Ala Ala Asp Trp Asp Leu
165 170 175 Gln His Pro Gln Pro Ala Pro Gln Gln Gly Gln Leu Arg Glu
Pro Ser 180 185 190 Gly Ser Asp Ile Ala Gly Thr Thr Ser Ser Val Asp
Glu Gln Ile Gln 195 200 205 Trp Met Tyr Arg Gln Gln Asn Pro Ile Pro
Val Gly Asn Ile Tyr Arg 210 215 220 Arg Trp Ile Gln Leu Gly Leu Gln
Lys Cys Val Arg Met Tyr Asn Pro 225 230 235 240 Thr Asn Ile Leu Asp
Val Lys Gln Gly Pro Lys Glu Pro Phe Gln Ser 245 250 255 Tyr Val Asp
Arg Phe Tyr Lys Ser Leu Arg Ala Glu Gln Thr Asp Ala 260 265 270 Ala
Val Lys Asn Trp Met Thr Gln Thr Leu Leu Ile Gln Asn Ala Asn 275 280
285 Pro Asp Cys Lys Leu Val Leu Lys Gly Leu Gly Val Asn Pro Thr Leu
290 295 300 Glu Glu Met Leu Thr Ala Cys Gln Gly Val Gly Gly Pro Gly
Gln Lys 305 310 315 320 Ala Arg Leu Met His Thr Leu Ala Ala Phe Val
Leu Leu Val Pro Trp 325 330 335 Val Leu Ile Phe Met Val Cys Arg Arg
Thr Cys Arg Arg Arg Gly Ala 340 345 350 Ala Ala Ala Leu Thr Ala Val
Val Leu Gln Gly Tyr Asn Pro Pro Ala 355 360 365 Tyr Gly 370
<210> SEQ ID NO 142 <211> LENGTH: 398 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: SGAG(41-391)-E2TM Gag insert
<400> SEQUENCE: 142 Leu Asp Arg Phe Gly Leu Ala Glu Ser Leu
Leu Glu Asn Lys Glu Gly 1 5 10 15 Cys Gln Lys Ile Leu Ser Val Leu
Ala Pro Leu Val Pro Thr Gly Ser 20 25 30 Glu Asn Leu Lys Ser Leu
Tyr Asn Thr Val Cys Val Ile Trp Cys Ile 35 40 45 His Ala Glu Glu
Lys Val Lys His Thr Glu Glu Ala Lys Gln Ile Val 50 55 60 Gln Arg
His Leu Val Val Glu Thr Gly Thr Thr Glu Thr Met Pro Lys 65 70 75 80
Thr Ser Arg Pro Thr Ala Pro Ser Ser Gly Arg Gly Gly Asn Tyr Pro 85
90 95 Val Gln Gln Ile Gly Gly Asn Tyr Val His Leu Pro Leu Ser Pro
Arg 100 105 110 Thr Leu Asn Ala Trp Val Lys Leu Ile Glu Glu Lys Lys
Phe Gly Ala 115 120 125 Glu Val Val Pro Gly Phe Gln Ala Leu Ser Glu
Gly Cys Thr Pro Tyr 130 135 140 Asp Ile Asn Gln Met Leu Asn Cys Val
Gly Asp His Gln Ala Ala Met 145 150 155 160 Gln Ile Ile Arg Asp Ile
Ile Asn Glu Glu Ala Ala Asp Trp Asp Leu 165 170 175 Gln His Pro Gln
Pro Ala Pro Gln Gln Gly Gln Leu Arg Glu Pro Ser 180 185 190 Gly Ser
Asp Ile Ala Gly Thr Thr Ser Ser Val Asp Glu Gln Ile Gln 195 200 205
Trp Met Tyr Arg Gln Gln Asn Pro Ile Pro Val Gly Asn Ile Tyr Arg 210
215 220 Arg Trp Ile Gln Leu Gly Leu Gln Lys Cys Val Arg Met Tyr Asn
Pro 225 230 235 240 Thr Asn Ile Leu Asp Val Lys Gln Gly Pro Lys Glu
Pro Phe Gln Ser 245 250 255 Tyr Val Asp Arg Phe Tyr Lys Ser Leu Arg
Ala Glu Gln Thr Asp Ala 260 265 270 Ala Val Lys Asn Trp Met Thr Gln
Thr Leu Leu Ile Gln Asn Ala Asn 275 280 285 Pro Asp Cys Lys Leu Val
Leu Lys Gly Leu Gly Val Asn Pro Thr Leu 290 295 300 Glu Glu Met Leu
Thr Ala Cys Gln Gly Val Gly Gly Pro Gly Gln Lys 305 310 315 320 Ala
Arg Leu Met Ala Glu Ala Leu Lys Glu Ala Leu Ala Pro Val Pro 325 330
335 Ile Pro Phe Ala Ala Ala Gln Gln Arg Gly Pro Arg Lys Pro Ile Met
340 345 350 His Thr Leu Ala Ala Phe Val Leu Leu Val Pro Trp Val Leu
Ile Phe 355 360 365 Met Val Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala
Ala Ala Ala Leu 370 375 380 Thr Ala Val Val Leu Gln Gly Tyr Asn Pro
Pro Ala Tyr Gly 385 390 395 <210> SEQ ID NO 143 <211>
LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
MPER-E2TM <400> SEQUENCE: 143 Glu Glu Pro Arg Gln Glu Lys Asn
Glu Lys Glu Leu Leu Glu Leu Asp 1 5 10 15 Lys Trp Ala Ser Leu Trp
Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp 20 25 30
Tyr Ile Arg Met His Thr Leu Ala Ala Phe Val Leu Leu Val Pro Trp 35
40 45 Val Leu Ile Phe Met Val Cys Arg Arg Thr Cys Arg Arg Arg Gly
Ala 50 55 60 Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr Asn
Pro Pro Ala 65 70 75 80 Tyr Gly <210> SEQ ID NO 144
<211> LENGTH: 86 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: MPER-E1TM insert <400> SEQUENCE: 144 Glu Glu Pro
Arg Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu Asp 1 5 10 15 Lys
Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp 20 25
30 Tyr Ile Arg Met His Trp Trp Gln Leu Thr Leu Gly Ala Thr Cys Ala
35 40 45 Leu Pro Leu Ala Gly Leu Leu Ala Cys Cys Ala Arg Arg Thr
Cys Arg 50 55 60 Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val
Leu Gln Gly Tyr 65 70 75 80 Asn Pro Pro Ala Tyr Gly 85 <210>
SEQ ID NO 145 <211> LENGTH: 89 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: MPER-HIVTM-E2SP <400>
SEQUENCE: 145 Glu Glu Pro Arg Gln Glu Lys Asn Glu Lys Glu Leu Leu
Glu Leu Asp 1 5 10 15 Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile
Thr Asn Trp Leu Trp 20 25 30 Tyr Ile Arg Leu Phe Ile Met Ile Val
Gly Gly Leu Ile Gly Leu Arg 35 40 45 Ile Val Phe Ala Val Leu Ser
Ile Val Cys Arg Arg Thr Cys Arg Arg 50 55 60 Arg Phe Gly Ala Pro
Gln Ala Phe Leu Ala Gly Leu Leu Leu Ala Ala 65 70 75 80 Val Ala Val
Gly Thr Ala Arg Ala Gly 85 <210> SEQ ID NO 146 <211>
LENGTH: 165 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
BC-SGAG2-MPER-HIVTM insert <400> SEQUENCE: 146 Glu Glu Pro
Arg Val Pro Thr Gly Ser Glu Asn Leu Lys Ser Leu Tyr 1 5 10 15 Asn
Thr Val Thr Arg Val Lys His Thr Glu Glu Ala Lys Gln Ile Val 20 25
30 Gln Arg His Leu Val Val Glu Thr Gly Thr Thr Ser Asp Ala Phe Gln
35 40 45 Ala Leu Ser Glu Gly Cys Thr Pro Tyr Asp Ile Asn Gln Met
Leu Asn 50 55 60 Cys Val Gly Asp His Gln Ala Ala Met Gln Ile Ile
Arg Asp Ile Ile 65 70 75 80 Asn Glu Glu Ala Gln Glu Lys Asn Glu Lys
Glu Leu Leu Glu Leu Asp 85 90 95 Lys Trp Ala Ser Leu Trp Asn Trp
Phe Asp Ile Thr Asn Trp Leu Trp 100 105 110 Tyr Ile Arg Leu Phe Ile
Met Ile Val Gly Gly Leu Ile Gly Leu Arg 115 120 125 Ile Val Phe Ala
Val Leu Ser Ile Val Cys Arg Arg Thr Cys Arg Arg 130 135 140 Arg Gly
Ala Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr Asn 145 150 155
160 Pro Pro Ala Tyr Gly 165 <210> SEQ ID NO 147 <211>
LENGTH: 161 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
MPER-BC-SGAG2-E2TM insert <400> SEQUENCE: 147 Glu Glu Pro Arg
Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu Asp 1 5 10 15 Lys Trp
Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Val 20 25 30
Pro Thr Gly Ser Glu Asn Leu Lys Ser Leu Tyr Asn Thr Val Thr Arg 35
40 45 Val Lys His Thr Glu Glu Ala Lys Gln Ile Val Gln Arg His Leu
Val 50 55 60 Val Glu Thr Gly Thr Thr Ser Asp Ala Phe Gln Ala Leu
Ser Glu Gly 65 70 75 80 Cys Thr Pro Tyr Asp Ile Asn Gln Met Leu Asn
Cys Val Gly Asp His 85 90 95 Gln Ala Ala Met Gln Ile Ile Arg Asp
Ile Ile Asn Glu Glu Ala Ser 100 105 110 Leu Asp Leu His Thr Leu Ala
Ala Phe Val Leu Leu Val Pro Trp Val 115 120 125 Leu Ile Phe Met Val
Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala 130 135 140 Ala Ala Leu
Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr 145 150 155 160
Gly <210> SEQ ID NO 148 <211> LENGTH: 98 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: 10e8-MPER-HIVTM insert
<400> SEQUENCE: 148 Glu Glu Pro Ser Leu Trp Asn Trp Phe Asp
Ile Thr Asn Trp Leu Trp 1 5 10 15 Tyr Ile Arg Leu Asn Glu Lys Glu
Leu Leu Glu Leu Asp Lys Trp Ala 20 25 30 Ser Leu Trp Asn Trp Phe
Asp Ile Thr Asn Trp Leu Trp Tyr Ile Arg 35 40 45 Leu Phe Ile Met
Ile Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe 50 55 60 Ala Val
Leu Ser Ile Val Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala 65 70 75 80
Ala Ala Ala Leu Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala 85
90 95 Tyr Gly <210> SEQ ID NO 149 <211> LENGTH: 95
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: 10e8-MPER-E2TM
insert <400> SEQUENCE: 149 Glu Glu Pro Ser Leu Trp Asn Trp
Phe Asp Ile Thr Asn Trp Leu Trp 1 5 10 15 Tyr Ile Arg Leu Asn Glu
Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala 20 25 30 Ser Leu Trp Asn
Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Arg 35 40 45 Met His
Thr Leu Ala Ala Phe Val Leu Leu Val Pro Trp Val Leu Ile 50 55 60
Phe Met Val Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala 65
70 75 80 Leu Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr
Gly 85 90 95 <210> SEQ ID NO 150 <211> LENGTH: 93
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION:
MPERF-MPER-HIVTM <400> SEQUENCE: 150 Glu Glu Lys Glu Leu Leu
Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn 1 5 10 15 Glu Lys Glu Leu
Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp 20 25 30 Phe Asp
Ile Thr Asn Trp Leu Trp Tyr Ile Arg Leu Phe Ile Met Ile 35 40 45
Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe Ala Val Leu Ser Ile 50
55 60 Val Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu
Thr 65 70 75 80 Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly
85 90 <210> SEQ ID NO 151 <211> LENGTH: 90 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: MPERF-MPER-E2TM <400>
SEQUENCE: 151 Glu Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser
Leu Trp Asn 1 5 10 15 Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala
Ser Leu Trp Asn Trp
20 25 30 Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Arg Met His Thr
Leu Ala 35 40 45 Ala Phe Val Leu Leu Val Pro Trp Val Leu Ile Phe
Met Val Cys Arg 50 55 60 Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala
Ala Leu Thr Ala Val Val 65 70 75 80 Leu Gln Gly Tyr Asn Pro Pro Ala
Tyr Gly 85 90 <210> SEQ ID NO 152 <211> LENGTH: 344
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: HIV gp120
insert <400> SEQUENCE: 152 Glu Glu Pro Arg Asn Pro Gln Glu
Val Val Leu Glu Asn Val Thr Glu 1 5 10 15 Asn Phe Asn Met Trp Lys
Asn Asn Met Val Asp Gln Met His Glu Asp 20 25 30 Ile Ile Ser Leu
Trp Asp Glu Ser Leu Lys Pro Cys Val Lys Leu Thr 35 40 45 Pro Leu
Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln Pro Ile Ser 50 55 60
Ile Gly Gly Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn 65
70 75 80 Gly Ser Leu Ala Glu Glu Asp Ile Val Ile Arg Ser Glu Asn
Phe Thr 85 90 95 Asp Asn Ala Lys Thr Ile Ile Val Gln Leu Asn Glu
Ser Val Val Ile 100 105 110 Asn Cys Thr Arg Pro Asn Asn Asn Thr Arg
Gly Arg Arg Gly Asp Ile 115 120 125 Arg Gln Ala His Cys Asn Ile Ser
Arg Ala Lys Trp Asn Asn Thr Leu 130 135 140 Gln Gln Ile Val Ile Lys
Leu Arg Glu Lys Phe Arg Asn Lys Thr Ile 145 150 155 160 Ala Phe Asn
Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met His Ser 165 170 175 Phe
Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr Ala Gln Leu Phe 180 185
190 Asn Ser Thr Trp Asn Val Thr Gly Gly Thr Asn Gly Thr Glu Gly Asn
195 200 205 Asp Ile Ile Thr Leu Gln Cys Arg Ile Lys Gln Leu Ala Met
Tyr Ala 210 215 220 Pro Pro Ile Thr Gly Gln Ile Arg Cys Ser Ser Asn
Ile Thr Gly Leu 225 230 235 240 Leu Leu Thr Arg Asp Gly Gly Asn Ser
Thr Glu Thr Glu Thr Glu Ile 245 250 255 Phe Arg Pro Gly Gly Gly Asp
Met Arg Asp Asn Trp Arg Ser Glu Leu 260 265 270 Tyr Lys Tyr Lys Val
Val Arg Ile Glu Pro Ile Gly Val Ala Pro Thr 275 280 285 Arg Ala Lys
Arg Gly Gly Gly Gly Ser Met His Thr Leu Ala Ala Phe 290 295 300 Val
Leu Leu Val Pro Trp Val Leu Ile Phe Met Val Cys Arg Arg Thr 305 310
315 320 Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val Leu
Gln 325 330 335 Gly Tyr Asn Pro Pro Ala Tyr Gly 340 <210> SEQ
ID NO 153 <211> LENGTH: 352 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HIV gp120 insert <400> SEQUENCE: 153 Glu
Glu Pro Arg Asn Pro Gln Glu Val Val Leu Glu Asn Val Thr Glu 1 5 10
15 Asn Phe Asn Met Trp Lys Asn Asn Met Val Asp Gln Met His Glu Asp
20 25 30 Ile Ile Ser Leu Trp Asp Glu Ser Leu Lys Pro Cys Val Lys
Leu Thr 35 40 45 Pro Leu Ser Val Gln Ala Cys Pro Lys Val Ser Phe
Gln Pro Ile Ser 50 55 60 Ile Gly Gly Gly Ile Arg Pro Val Val Ser
Thr Gln Leu Leu Leu Asn 65 70 75 80 Gly Ser Leu Ala Glu Glu Asp Ile
Val Ile Arg Ser Glu Asn Phe Thr 85 90 95 Asp Asn Ala Lys Thr Ile
Ile Val Gln Leu Asn Glu Ser Val Val Ile 100 105 110 Asn Cys Thr Arg
Pro Asn Asn Asn Thr Arg Gly Arg Arg Gly Asp Ile 115 120 125 Arg Gln
Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr Leu 130 135 140
Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn Lys Thr Ile 145
150 155 160 Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met
His Ser 165 170 175 Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr
Ala Gln Leu Phe 180 185 190 Asn Ser Thr Trp Asn Val Thr Gly Gly Thr
Asn Gly Thr Glu Gly Asn 195 200 205 Asp Ile Ile Thr Leu Gln Cys Arg
Ile Lys Gln Leu Ala Met Tyr Ala 210 215 220 Pro Pro Ile Thr Gly Gln
Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu 225 230 235 240 Leu Leu Thr
Arg Asp Gly Gly Asn Ser Thr Glu Thr Glu Thr Glu Ile 245 250 255 Phe
Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu 260 265
270 Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile Gly Val Ala Pro Thr
275 280 285 Arg Ala Lys Arg Gly Gly Gly Gly Ser Met His Val Tyr Thr
Ile Leu 290 295 300 Ala Val Ala Ser Ala Thr Val Ala Met Met Ile Gly
Val Thr Val Ala 305 310 315 320 Val Leu Cys Ala Cys Arg Arg Thr Cys
Arg Arg Arg Gly Ala Ala Ala 325 330 335 Ala Leu Thr Ala Val Val Leu
Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 340 345 350 <210> SEQ ID
NO 154 <211> LENGTH: 349 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HIV gp120 insert <400> SEQUENCE: 154 Glu
Glu Pro Arg Asn Pro Gln Glu Val Val Leu Glu Asn Val Thr Glu 1 5 10
15 Asn Phe Asn Met Trp Lys Asn Asn Met Val Asp Gln Met His Glu Asp
20 25 30 Ile Ile Ser Leu Trp Asp Glu Ser Leu Lys Pro Cys Val Lys
Leu Thr 35 40 45 Pro Leu Ser Val Gln Ala Cys Pro Lys Val Ser Phe
Gln Pro Ile Ser 50 55 60 Ile Gly Gly Gly Ile Arg Pro Val Val Ser
Thr Gln Leu Leu Leu Asn 65 70 75 80 Gly Ser Leu Ala Glu Glu Asp Ile
Val Ile Arg Ser Glu Asn Phe Thr 85 90 95 Asp Asn Ala Lys Thr Ile
Ile Val Gln Leu Asn Glu Ser Val Val Ile 100 105 110 Asn Cys Thr Arg
Pro Asn Asn Asn Thr Arg Gly Arg Arg Gly Asp Ile 115 120 125 Arg Gln
Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr Leu 130 135 140
Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn Lys Thr Ile 145
150 155 160 Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met
His Ser 165 170 175 Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr
Ala Gln Leu Phe 180 185 190 Asn Ser Thr Trp Asn Val Thr Gly Gly Thr
Asn Gly Thr Glu Gly Asn 195 200 205 Asp Ile Ile Thr Leu Gln Cys Arg
Ile Lys Gln Leu Ala Met Tyr Ala 210 215 220 Pro Pro Ile Thr Gly Gln
Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu 225 230 235 240 Leu Leu Thr
Arg Asp Gly Gly Asn Ser Thr Glu Thr Glu Thr Glu Ile 245 250 255 Phe
Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu 260 265
270 Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile Gly Val Ala Pro Thr
275 280 285 Arg Ala Lys Arg Gly Gly Gly Gly Ser Met His Leu Phe Ile
Met Ile 290 295 300 Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe Ala
Val Leu Ser Ile 305 310 315 320 Val Cys Arg Arg Thr Cys Arg Arg Arg
Gly Ala Ala Ala Ala Leu Thr 325 330 335 Ala Val Val Leu Gln Gly Tyr
Asn Pro Pro Ala Tyr Gly 340 345 <210> SEQ ID NO 155
<211> LENGTH: 347 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: HIV gp120 insert <400> SEQUENCE: 155
Glu Glu Pro Arg Asn Pro Gln Glu Val Val Leu Glu Asn Val Thr Glu 1 5
10 15 Asn Phe Asn Met Trp Lys Asn Asn Met Val Asp Gln Met His Glu
Asp 20 25 30 Ile Ile Ser Leu Trp Asp Glu Ser Leu Lys Pro Cys Val
Lys Leu Thr 35 40 45 Pro Leu Ser Val Gln Ala Cys Pro Lys Val Ser
Phe Gln Pro Ile Ser 50 55 60 Ile Gly Gly Gly Ile Arg Pro Val Val
Ser Thr Gln Leu Leu Leu Asn 65 70 75 80 Gly Ser Leu Ala Glu Glu Asp
Ile Val Ile Arg Ser Glu Asn Phe Thr 85 90 95 Asp Asn Ala Lys Thr
Ile Ile Val Gln Leu Asn Glu Ser Val Val Ile 100 105 110 Asn Cys Thr
Arg Pro Asn Asn Asn Thr Arg Gly Arg Arg Gly Asp Ile 115 120 125 Arg
Gln Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr Leu 130 135
140 Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn Lys Thr Ile
145 150 155 160 Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val
Met His Ser 165 170 175 Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn
Thr Ala Gln Leu Phe 180 185 190 Asn Ser Thr Trp Asn Val Thr Gly Gly
Thr Asn Gly Thr Glu Gly Asn 195 200 205 Asp Ile Ile Thr Leu Gln Cys
Arg Ile Lys Gln Leu Ala Met Tyr Ala 210 215 220 Pro Pro Ile Thr Gly
Gln Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu 225 230 235 240 Leu Leu
Thr Arg Asp Gly Gly Asn Ser Thr Glu Thr Glu Thr Glu Ile 245 250 255
Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu 260
265 270 Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile Gly Val Ala Pro
Thr 275 280 285 Arg Ala Lys Arg Gly Gly Gly Gly Ser Met His Ser Ser
Ile Ala Ser 290 295 300 Phe Phe Phe Ile Ile Gly Leu Ile Ile Gly Leu
Phe Leu Val Leu Cys 305 310 315 320 Arg Arg Thr Cys Arg Arg Arg Gly
Ala Ala Ala Ala Leu Thr Ala Val 325 330 335 Val Leu Gln Gly Tyr Asn
Pro Pro Ala Tyr Gly 340 345 <210> SEQ ID NO 156 <211>
LENGTH: 377 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: HIV
gp120 insert <400> SEQUENCE: 156 Glu Glu Pro Arg Asn Pro Gln
Glu Val Val Leu Glu Asn Val Thr Glu 1 5 10 15 Asn Phe Asn Met Trp
Lys Asn Asn Met Val Asp Gln Met His Glu Asp 20 25 30 Ile Ile Ser
Leu Trp Asp Glu Ser Leu Lys Pro Cys Val Lys Leu Thr 35 40 45 Pro
Leu Thr Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln Pro Ile 50 55
60 Pro Ile His Tyr Cys Val Pro Ala Gly Phe Ala Met Leu Lys Cys Asn
65 70 75 80 Asp Lys Lys Phe Asn Gly Ser Gly Pro Cys Lys Asn Val Ser
Thr Val 85 90 95 Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr
Gln Leu Leu Leu 100 105 110 Asn Gly Ser Leu Ala Glu Glu Asp Ile Val
Ile Arg Ser Glu Asn Phe 115 120 125 Thr Asp Asn Ala Lys Thr Ile Ile
Val Gln Leu Asn Glu Ser Val Val 130 135 140 Ile Asn Cys Thr Arg Pro
Asn Asn Asn Thr Arg Gly Arg Arg Gly Asp 145 150 155 160 Ile Arg Gln
Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Asn Thr 165 170 175 Leu
Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn Lys Thr 180 185
190 Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met His
195 200 205 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr Ala
Gln Leu 210 215 220 Phe Asn Ser Thr Trp Asn Val Thr Gly Gly Thr Asn
Gly Thr Glu Gly 225 230 235 240 Asn Asp Ile Ile Thr Leu Gln Cys Arg
Ile Lys Gln Leu Ala Met Tyr 245 250 255 Ala Pro Pro Ile Thr Gly Gln
Ile Arg Cys Ser Ser Asn Ile Thr Gly 260 265 270 Leu Leu Leu Thr Arg
Asp Gly Gly Asn Ser Thr Glu Thr Glu Thr Glu 275 280 285 Ile Phe Arg
Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu 290 295 300 Leu
Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile Gly Val Ala Pro 305 310
315 320 Thr Arg Ala Lys Arg Gly Gly Gly Gly Ser Met His Thr Leu Ala
Ala 325 330 335 Phe Val Leu Leu Val Pro Trp Val Leu Ile Phe Met Val
Cys Arg Arg 340 345 350 Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu
Thr Ala Val Val Leu 355 360 365 Gln Gly Tyr Asn Pro Pro Ala Tyr Gly
370 375 <210> SEQ ID NO 157 <211> LENGTH: 1131
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: nucleotide
sequence for Seq_156 HIV gp120 insert <400> SEQUENCE: 157
gaagaaccta ggaacccaca agaagtagta ttggagaatg tgacagaaaa ttttaacatg
60 tggaaaaata acatggtaga tcagatgcac gaggatataa tcagtttatg
ggacgaaagt 120 cttaagccat gtgtaaaatt aaccccgctc actagtgtcc
aggcctgtcc aaaggtatcc 180 tttcagccaa ttcccataca ttattgtgtc
ccagcagggt tcgcgatgct aaagtgtaac 240 gataagaaat tcaatggatc
aggaccatgc aagaatgtga gcacagtaca atgtacccat 300 ggaattaggc
cagtggtgtc aactcagctg ctgttaaatg gcagtctagc agaagaagac 360
atagtaatta gatctgaaaa tttcacagac aatgctaaaa ccataatagt acagctaaat
420 gaatctgtag taattaattg tacaagaccc aacaacaata caagaggaag
aaggggagat 480 ataagacaag cacattgtaa catttcccgg gcaaaatgga
ataacacttt acaacagata 540 gttataaaat taagagaaaa atttaggaat
aaaacaatag cctttaatca atcctcagga 600 ggggacccag aaattgtaat
gcacagtttt aattgtggag gggaattttt ctactgtaat 660 acagcacaac
tgtttaatag cacgtggaat gttactggag ggacaaatgg cactgaagga 720
aatgacataa tcacactcca atgcagaata aaacagctag caatgtatgc ccctcccatc
780 accggtcaaa ttagatgttc atcaaatatt acagggctgc tactaacgcg
tgatggaggt 840 aatagtactg agactgagac tgagatcttc agacctggag
gaggagatat gagggacaat 900 tggagaagtg agctctataa atataaagta
gtaagaattg aaccaatagg agtagcaccc 960 accagggcaa agagaggagg
cggaggaagc atgcataccc tggccgcgtt cgtgctcctc 1020 gtgccatggg
tgctcatctt tatggtctgt cggaggacct gcagacggag gggagctgcc 1080
gctgccctta cagcagtggt cctgcagggg tacaaccccc ccgcctatgg c 1131
<210> SEQ ID NO 158 <211> LENGTH: 368 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: HIV gp120 insert <400>
SEQUENCE: 158 Glu Glu Pro Arg Val Thr Glu Asn Phe Asn Met Trp Lys
Asn Asn Met 1 5 10 15 Val Asp Gln Met His Glu Asp Ile Ile Ser Leu
Trp Asp Glu Ser Leu 20 25 30 Lys Pro Cys Val Lys Leu Thr Pro Leu
Thr Ser Val Gln Ala Cys Pro 35 40 45 Lys Val Ser Phe Gln Pro Ile
Pro Ile His Tyr Cys Val Pro Ala Gly 50 55 60 Phe Ala Met Leu Lys
Cys Asn Asp Lys Lys Phe Asn Gly Ser Gly Pro 65 70 75 80 Cys Lys Asn
Val Ser Thr Val Gln Cys Thr His Gly Ile Arg Pro Val 85 90 95 Val
Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu Ala Glu Glu Asp Ile 100 105
110 Val Ile Arg Ser Glu Asn Phe Thr Asp Asn Ala Lys Thr Ile Ile Val
115 120 125 Gln Leu Asn Glu Ser Val Val Ile Asn Cys Thr Arg Pro Asn
Asn Asn 130 135 140 Thr Arg Gly Arg Arg Gly Asp Ile Arg Gln Ala His
Cys Asn Ile Ser 145 150 155 160 Arg Ala Lys Trp Asn Asn Thr Leu Gln
Gln Ile Val Ile Lys Leu Arg 165 170 175 Glu Lys Phe Arg Asn Lys Thr
Ile Ala Phe Asn Gln Ser Ser Gly Gly 180 185 190 Asp Pro Glu Ile Val
Met His Ser Phe Asn Cys Gly Gly Glu Phe Phe 195 200 205 Tyr Cys Asn
Thr Ala Gln Leu Phe Asn Ser Thr Trp Asn Val Thr Gly 210 215 220 Gly
Thr Asn Gly Thr Glu Gly Asn Asp Ile Ile Thr Leu Gln Cys Arg
225 230 235 240 Ile Lys Gln Leu Ala Met Tyr Ala Pro Pro Ile Thr Gly
Gln Ile Arg 245 250 255 Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu Thr
Arg Asp Gly Gly Asn 260 265 270 Ser Thr Glu Thr Glu Thr Glu Ile Phe
Arg Pro Gly Gly Gly Asp Met 275 280 285 Arg Asp Asn Trp Arg Ser Glu
Leu Tyr Lys Tyr Lys Val Val Arg Ile 290 295 300 Glu Pro Ile Gly Val
Ala Pro Thr Arg Ala Lys Arg Gly Gly Gly Gly 305 310 315 320 Ser Met
His Thr Leu Ala Ala Phe Val Leu Leu Val Pro Trp Val Leu 325 330 335
Ile Phe Met Val Cys Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala 340
345 350 Ala Leu Thr Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr
Gly 355 360 365 <210> SEQ ID NO 159 <211> LENGTH: 363
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: HIV gp120
insert <400> SEQUENCE: 159 Glu Glu Pro Arg Asn Met Trp Lys
Asn Asn Met Val Asp Gln Met His 1 5 10 15 Glu Asp Ile Ile Ser Leu
Trp Asp Glu Ser Leu Lys Pro Cys Val Lys 20 25 30 Leu Thr Pro Leu
Thr Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln 35 40 45 Pro Ile
Pro Ile His Tyr Cys Val Pro Ala Gly Phe Ala Met Leu Lys 50 55 60
Cys Asn Asp Lys Lys Phe Asn Gly Ser Gly Pro Cys Lys Asn Val Ser 65
70 75 80 Thr Val Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr
Gln Leu 85 90 95 Leu Leu Asn Gly Ser Leu Ala Glu Glu Asp Ile Val
Ile Arg Ser Glu 100 105 110 Asn Phe Thr Asp Asn Ala Lys Thr Ile Ile
Val Gln Leu Asn Glu Ser 115 120 125 Val Val Ile Asn Cys Thr Arg Pro
Asn Asn Asn Thr Arg Gly Arg Arg 130 135 140 Gly Asp Ile Arg Gln Ala
His Cys Asn Ile Ser Arg Ala Lys Trp Asn 145 150 155 160 Asn Thr Leu
Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn 165 170 175 Lys
Thr Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val 180 185
190 Met His Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr Ala
195 200 205 Gln Leu Phe Asn Ser Thr Trp Asn Val Thr Gly Gly Thr Asn
Gly Thr 210 215 220 Glu Gly Asn Asp Ile Ile Thr Leu Gln Cys Arg Ile
Lys Gln Leu Ala 225 230 235 240 Met Tyr Ala Pro Pro Ile Thr Gly Gln
Ile Arg Cys Ser Ser Asn Ile 245 250 255 Thr Gly Leu Leu Leu Thr Arg
Asp Gly Gly Asn Ser Thr Glu Thr Glu 260 265 270 Thr Glu Ile Phe Arg
Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg 275 280 285 Ser Glu Leu
Tyr Lys Tyr Lys Val Val Arg Ile Glu Pro Ile Gly Val 290 295 300 Ala
Pro Thr Arg Ala Lys Arg Gly Gly Gly Gly Ser Met His Thr Leu 305 310
315 320 Ala Ala Phe Val Leu Leu Val Pro Trp Val Leu Ile Phe Met Val
Cys 325 330 335 Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu
Thr Ala Val 340 345 350 Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly
355 360 <210> SEQ ID NO 160 <211> LENGTH: 344
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: HIV gp120
insert <400> SEQUENCE: 160 Glu Glu Pro Arg Asn Met Trp Lys
Asn Asn Met Val Asp Gln Met His 1 5 10 15 Glu Asp Ile Ile Ser Leu
Trp Asp Glu Ser Leu Lys Pro Cys Val Lys 20 25 30 Leu Thr Pro Leu
Thr Ser Val Gln Ala Cys Pro Lys Val Ser Phe Gln 35 40 45 Pro Ile
Pro Ile His Tyr Cys Val Pro Ala Gly Phe Ala Met Leu Lys 50 55 60
Cys Asn Asp Lys Lys Phe Asn Gly Ser Gly Pro Cys Lys Asn Val Ser 65
70 75 80 Thr Val Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr
Gln Leu 85 90 95 Leu Leu Asn Gly Ser Leu Ala Glu Glu Asp Ile Val
Ile Arg Ser Glu 100 105 110 Asn Phe Thr Asp Asn Ala Lys Thr Ile Ile
Val Gln Leu Asn Glu Ser 115 120 125 Val Val Ile Asn Cys Thr Arg Pro
Asn Asn Asn Thr Arg Gly Arg Arg 130 135 140 Gly Asp Ile Arg Gln Ala
His Cys Asn Ile Ser Arg Ala Lys Trp Asn 145 150 155 160 Asn Thr Leu
Gln Gln Ile Val Ile Lys Leu Arg Glu Lys Phe Arg Asn 165 170 175 Lys
Thr Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val 180 185
190 Met His Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr Ala
195 200 205 Gln Leu Phe Asn Ser Thr Trp Asn Val Thr Gly Gly Thr Asn
Gly Thr 210 215 220 Glu Gly Asn Asp Ile Ile Thr Leu Gln Cys Arg Ile
Lys Gln Leu Ala 225 230 235 240 Met Tyr Ala Pro Pro Ile Thr Gly Gln
Ile Arg Cys Ser Ser Asn Ile 245 250 255 Thr Gly Leu Leu Leu Thr Arg
Asp Gly Gly Asn Ser Thr Glu Thr Glu 260 265 270 Thr Glu Ile Phe Arg
Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg 275 280 285 Ser Glu Leu
Tyr Gly Gly Gly Gly Ser Met His Thr Leu Ala Ala Phe 290 295 300 Val
Leu Leu Val Pro Trp Val Leu Ile Phe Met Val Cys Arg Arg Thr 305 310
315 320 Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr Ala Val Val Leu
Gln 325 330 335 Gly Tyr Asn Pro Pro Ala Tyr Gly 340 <210> SEQ
ID NO 161 <211> LENGTH: 429 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: antigenic insert Seamless E1 or E2 sequence at
amino end of gp120 <400> SEQUENCE: 161 Glu Glu Ala Phe Thr
Tyr Leu Cys Thr Ala Pro Gly Cys Ala Thr Gln 1 5 10 15 Ala Pro Val
Pro Val Trp Arg Glu Ala Thr Thr Thr Leu Phe Cys Ala 20 25 30 Ser
Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr 35 40
45 His Ala Cys Val Pro Thr Asp Pro Asn Pro Gln Glu Val Val Leu Glu
50 55 60 Asn Val Thr Glu Asn Phe Asn Met Trp Lys Asn Asn Met Val
Asp Gln 65 70 75 80 Met His Glu Asp Ile Ile Ser Leu Trp Asp Glu Ser
Leu Lys Pro Cys 85 90 95 Val Lys Leu Thr Pro Leu Thr Ser Val Gln
Ala Cys Pro Lys Val Ser 100 105 110 Phe Gln Pro Ile Pro Ile His Tyr
Cys Val Pro Ala Gly Phe Ala Met 115 120 125 Leu Lys Cys Asn Asp Lys
Lys Phe Asn Gly Ser Gly Pro Cys Lys Asn 130 135 140 Val Ser Thr Val
Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr 145 150 155 160 Gln
Leu Leu Leu Asn Gly Ser Leu Ala Glu Glu Asp Ile Val Ile Arg 165 170
175 Ser Glu Asn Phe Thr Asp Asn Ala Lys Thr Ile Ile Val Gln Leu Asn
180 185 190 Glu Ser Val Val Ile Asn Cys Thr Arg Pro Asn Asn Asn Thr
Arg Gly 195 200 205 Arg Arg Gly Asp Ile Arg Gln Ala His Cys Asn Ile
Ser Arg Ala Lys 210 215 220 Trp Asn Asn Thr Leu Gln Gln Ile Val Ile
Lys Leu Arg Glu Lys Phe 225 230 235 240 Arg Asn Lys Thr Ile Ala Phe
Asn Gln Ser Ser Gly Gly Asp Pro Glu 245 250 255 Ile Val Met His Ser
Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn 260 265 270 Thr Ala Gln
Leu Phe Asn Ser Thr Trp Asn Val Thr Gly Gly Thr Asn 275 280 285 Gly
Thr Glu Gly Asn Asp Ile Ile Thr Leu Gln Cys Arg Ile Lys Gln 290 295
300 Leu Ala Met Tyr Ala Pro Pro Ile Thr Gly Gln Ile Arg Cys Ser
Ser
305 310 315 320 Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Asn
Ser Thr Glu 325 330 335 Thr Glu Thr Glu Ile Phe Arg Pro Gly Gly Gly
Asp Met Arg Asp Asn 340 345 350 Trp Arg Ser Glu Leu Tyr Lys Tyr Lys
Val Val Arg Ile Glu Pro Ile 355 360 365 Gly Val Ala Pro Thr Arg Ala
Lys Arg Gly Gly Gly Gly Ser Met His 370 375 380 Thr Leu Ala Ala Phe
Val Leu Leu Val Pro Trp Val Leu Ile Phe Met 385 390 395 400 Val Cys
Arg Arg Thr Cys Arg Arg Arg Gly Ala Ala Ala Ala Leu Thr 405 410 415
Ala Val Val Leu Gln Gly Tyr Asn Pro Pro Ala Tyr Gly 420 425
<210> SEQ ID NO 162 <211> LENGTH: 383 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Non-HIV envelope glycoprotein
<400> SEQUENCE: 162 Glu Glu Pro Arg Phe Asn Cys Leu Gly Met
Ser Asn Arg Asp Phe Leu 1 5 10 15 Glu Gly Val Ser Gly Ala Thr Trp
Val Asp Leu Val Leu Glu Gly Asp 20 25 30 Ser Cys Val Thr Ile Met
Ser Lys Asp Lys Pro Thr Ile Asp Val Lys 35 40 45 Met Met Asn Met
Glu Ala Ala Asn Leu Ala Glu Val Arg Ser Tyr Cys 50 55 60 Tyr Leu
Ala Thr Val Ser Asp Leu Ser Thr Lys Ala Ala Cys Pro Thr 65 70 75 80
Met Gly Glu Ala His Asn Asp Lys Arg Ala Asp Pro Ala Phe Val Cys 85
90 95 Arg Gln Gly Val Val Asp Arg Gly Trp Gly Asn Gly Cys Gly Phe
Phe 100 105 110 Gly Lys Gly Ser Ile Asp Thr Cys Ala Lys Phe Ala Cys
Ser Thr Lys 115 120 125 Ala Ile Gly Arg Thr Ile Leu Lys Glu Asn Ile
Lys Tyr Glu Val Ala 130 135 140 Ile Phe Val His Gly Pro Thr Thr Val
Glu Ser His Gly Asn Tyr Ser 145 150 155 160 Thr Gln Val Gly Ala Thr
Gln Ala Gly Arg Leu Ser Ile Thr Pro Ala 165 170 175 Ala Pro Ser Tyr
Thr Leu Lys Leu Gly Glu Tyr Gly Glu Val Thr Val 180 185 190 Asp Cys
Glu Pro Arg Ser Gly Ile Asp Thr Asn Ala Tyr Tyr Val Met 195 200 205
Thr Val Gly Thr Lys Thr Phe Leu Val His Arg Glu Trp Phe Met Asp 210
215 220 Leu Asn Leu Pro Trp Ser Ser Ala Gly Ser Thr Val Trp Arg Asn
Arg 225 230 235 240 Glu Thr Leu Met Glu Phe Glu Glu Pro His Ala Thr
Lys Gln Ser Val 245 250 255 Ile Ala Leu Gly Ser Gln Glu Gly Ala Leu
His Gln Ala Leu Ala Gly 260 265 270 Ala Ile Pro Val Glu Phe Ser Ser
Asn Thr Val Lys Leu Thr Ser Gly 275 280 285 His Leu Lys Cys Arg Val
Lys Met Glu Lys Leu Gln Leu Lys Gly Thr 290 295 300 Thr Tyr Gly Val
Cys Ser Lys Ala Phe Lys Phe Leu Gly Thr Pro Val 305 310 315 320 Asp
Thr Gly His Gly Thr Val Val Leu Glu Leu Gln Tyr Thr Gly Thr 325 330
335 Asp Gly Pro Cys Lys Val Pro Ile Ser Ser Val Ala Ser Leu Asn Asp
340 345 350 Leu Thr Pro Val Gly Arg Leu Val Thr Val Asn Pro Phe Val
Ser Val 355 360 365 Ala Thr Ala Asn Ala Lys Val Leu Ile Glu Leu Glu
Pro Pro Phe 370 375 380
* * * * *